WO2009100872A1 - Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use - Google Patents

Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use Download PDF

Info

Publication number
WO2009100872A1
WO2009100872A1 PCT/EP2009/000905 EP2009000905W WO2009100872A1 WO 2009100872 A1 WO2009100872 A1 WO 2009100872A1 EP 2009000905 W EP2009000905 W EP 2009000905W WO 2009100872 A1 WO2009100872 A1 WO 2009100872A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
oxo
alkyloxy
piperazin
carbonyl
Prior art date
Application number
PCT/EP2009/000905
Other languages
French (fr)
Other versions
WO2009100872A8 (en
Inventor
Matthias Eckhardt
Frank Himmelsbach
Bradford Hamilton
Stefan Peters
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Priority to AT09709660T priority Critical patent/ATE531696T1/en
Priority to CA2711757A priority patent/CA2711757C/en
Priority to US12/866,125 priority patent/US20110028445A1/en
Priority to EP09709660A priority patent/EP2245014B1/en
Priority to JP2010546254A priority patent/JP5538239B2/en
Publication of WO2009100872A1 publication Critical patent/WO2009100872A1/en
Publication of WO2009100872A8 publication Critical patent/WO2009100872A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/26—Benzomorphans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Definitions

  • the present invention relates to compounds derived from the following chemical scaffold which is structurally defined by the formula I
  • the invention further relates to pharmaceutical compositions containing a compound of formula I according to the invention as well as the use of a compound according to the invention for preparing a pharmaceutical composition for the treatment of metabolic disorders.
  • the invention relates to processes for preparing a pharmaceutical composition as well as a compound according to the invention.
  • HSD ⁇ - hydroxysteroid dehydrogenase
  • R 1 , R 2 , R 3 , X and Y are as defined therein, are described as non-toxic analgesics having an activity of the same order of magnitude as codeine or morphine and as being free of addictive properties.
  • R-i, R 2 , R3, R 4 , R 5 and X are as defined therein, are described as analgesics free of addictive properties and having antitussive action.
  • R 4 and R 5 together with the adjacent nitrogen atom represent a saturated heterocycle, in which the nitrogen atom is the only hetero atom, having at most 7 carbon atoms, or a morpholino radical.
  • the following compound is mentioned therein:
  • the aim of the present invention is to find new benzomorphanes or related compounds, particularly those which are active with regard to the enzyme 11 ⁇ - hydroxysteroid dehydrogenase (HSD) 1.
  • a further aim of the present invention is to discover benzomorphanes or related compounds which have an inhibitory effect on the enzyme 11 ⁇ -hydroxysteroid dehydrogenase (HSD) 1 in vitro and/or in vivo and possess suitable pharmacological and pharmacokinetic properties to use them as medicaments.
  • a further aim of the present invention is to provide new pharmaceutical compositions which are suitable for the prevention and/or treatment of metabolic disorders, particularly diabetes and dyslipidemia.
  • the present invention relates to compounds derived from the following chemical scaffold which is structurally defined by the formula I
  • X denotes CH or N
  • n, o independently of each other denote 0, 1 or 2
  • Cs+ m +n-azacycloalkene core structure of general formula I including the bridging group -(CH 2 ) 0 - is optionally substituted with 1 , 2 or more substituents independently of each other selected from the group consisting of R 11 and R 12
  • A denotes a benzo, pyrido, pyrrolo, furo, thieno, pyridazino, pyrimido, or pyrazino ring wherein each of said rings is optionally substituted with one or more substituents independently of each other selected from R 1 , and wherein 2 adjacent C-atoms of each of said rings are optionally substituted with R 2 and R 3 ; or
  • B denotes a 3- to 8-membered monocylic, 7- to 12-membered spirocyclic, 6- to
  • R N independently of each other denotes hydrogen, d- 6 -alkyl, C 3 - 6 -alkenyl, C 3- 6- alkynyl, (het)aryl, Ci -4 -alkylcarbonyl, C- M -alkylsulfonyl, (het)arylcarbonyl, (het)arylsulfonyl,
  • each alkyl, alkenyl, and alkynyl group may be mono- or polysubstituted with fluorine, and may be monosubstitued with hydroxy, d-4-alkoxy, Ci -4 -alkylsulfanyl, Ci -4 -alkylsulfinyl, C 1-4 -alkylsulfonyl, amino, Ci- 4 -alkylamino, di-(Ci -4 -alkyl)amino, Ci- 4 -alkylcarbonylamino, cyano, carboxy, Ci -4 -alkoxycarbonyl, aminocarbonyl, C- M -alkylaminocarbonyl, di- (Ci- 4 -alkyl)aminocarbonyl, or (het)aryl,
  • Ci -4 -alkylamino di-(Ci_ 4 -alkyl)amino, pyrrolidin-1-yl, 2-oxo-pyrrolidin-1 - yl, piperidin-1-yl, 2-oxo-piperidin-i -yl, morpholin-4-yl, 3-oxo-morpholin-4-yl, piperazin-1 -yl, 2-oxo-piperazin-1-yl, 3-oxo-piperazin-1-yl, 4-(Ci- 4 -alkyl)-pi- perazin-1-yl, 4-(Ci -4 -alkylcarbonyl)-piperazin-1-yl, 4-(C 3 - 6 -cycloalkylcarbonyl)- piperazin-1-yl, 4-(Ci -4 -alkyloxycarbonyl)-piperazin-1 -yl, 4-(Ci -4 -alkylsulfonyl)- pipe
  • carboxy-Ci- 4 -alkyl Ci ⁇ -alkyloxy-carbonyl-C- M -alkyl, cyano-Ci -4 -alkyl, aminocarbonyl-Ci- 4 -alkyl, C-i ⁇ -alkyl-aminocarbonyl-C- M -alkyl, di-(Ci -4 -alkyl)- aminocarbonyl-Ci -4 -alkyl, pyrrolidin-i-yl-carbonyl-Ci- 4 -alkyl, piperidin-1-yl- morpholin-4-yl-carbonyl-Ci- 4 -alkyl, piperazin-1-yl-carbonyl- Ci- 4 -alkyl, 4-(Ci. 4 -alkyl)-piperazin-1-yl-carbonyl-Ci. 4 -alkyl,
  • aminosulfonyl di-(Ci- 4 -alkyl)-aminosulfonyl, pyrroli- din-1 -yl-sulfonyl, piperidin-1 -yl-sulfonyl, morpholin-4-yl-sulfonyl, piperazin-1 -yl- sulfonyl, or 4-(Ci- 4 -alkyl)-piperazin-1 -yl-sulfonyl,
  • saturated heterocycles and cycloalkyl-rings are optionally substituted with one or two groups selected from fluorine, Ci -3 -alkyl, C- ⁇ - 3 -alkoxy, C-i-a-alkoxy-C-i-s-alkyl, or hydroxy,
  • R 2 , R 3 are linked to each other to form a methylenedioxy, ethylenedioxy or 0 3 . 5 - alkylene bridging group, which may be mono- or disubstituted with methyl, and which may be mono- or polyfluorinated; or
  • R 2 , R 3 form combined with the carbon atoms to which they are attached a benzo, pyrido, pyrimido, pyrazino, pyridazino, pyrrolo, furano, thieno, pyrazolo, imidazo, triazolo, oxazolo, thiazolo, isoxazolo, or isothiazolo ring, wherein each of said rings may be substituted with one or more, preferably one to three, substituents independently selected from R p ;
  • R p denotes halogen, d- ⁇ -alkyl, hydroxy-d-4-alkyl, Ci -3 -alkyloxy-Ci -3 -alkyl, C 3-6 - cycloalkyl, hydroxy-C 4-6 -cycloalkyl, d-s-alkyloxy-Cs-e-cycloalkyl, azetidinyl, 1- (Ci -3 -alkyl)-azetidinyl, 1-(Ci -3 -alkylcarbonyl)-azetidinyl, pyrrolidinyl, 1 -(Ci -3 - alkyl)-pyrrolidinyl, 1-(Ci -3 -alkylcarbonyl)-pyrrolidinyl, piperidinyl, 1-(Ci -3 -alkyl)- piperidinyl, 1-(Ci -3 -alkylcarbonyl)piperidinyl, tetrahydr
  • each of the aromatic or heteroaromatic groups mentioned above is optionally substituted with one or two groups independently selected from fluorine, chlorine, Ci -3 -alkyl, difluoromethyl, trifluoromethyl, cyano, amino, acetylamino, methylsulfonylamino, carboxy, Ci -4 -alkyloxycarbonyl, aminocar- bonyl, Ci -3 -alkylaminocarbonyl, di-(Ci -3 -alkyl)-aminocarbonyl, hydroxy, Ci -3 - alkyloxy, difluoromethoxy, and trifluoromethoxy,
  • R 10 independently of each other enotes halogen, Ci -3 -alkyl, difluoromethyl, trifluoromethyl, cyano, nitro, amino, Ci -3 -alkylamino, di-(Ci -3 -alkyl)amino, acetylamino, methylsulfonylamino, carboxy, C- M -alkyloxycarbonyl, aminocar- bonyl, Ci- 3 -alkylaminocarbonyl, di-(Ci. 3 -alkyl)-aminocarbonyl, aminosulfonyl, methylsulfanyl, methylsulfinyl, methylsulfonyl, hydroxy, Ci. 3 -alkyloxy, difluoromethoxy, trifluoromethoxy, or phenyl optionally substituted with 1 or 2 substituents independently of each other selected from fluorine, methyl, methoxy, cyano, or hydroxy,
  • R 11 independently of each other denotes fluorine, Ci -4 -alkyl, (het)aryl, hydroxy, Ci- 4 -alkyloxy, cyano, carboxy, Ci -4 -alkyloxycarbonyl, aminocarbonyl, Ci- 4 -alkylamino-carbonyl, di-(Ci- 4 -alkyl)-aminocarbonyl, hydroxy-Ci -4 -alkyl or d-a-alkyloxy-C- M -alkyl,
  • R 12 independently of each other denotes fluorine or Ci -4 -alkyl
  • L 1 independently of each other denotes halogen, Ci -4 -alkyl, trifluoromethyl, hydroxy, Ci -4 -alkyloxy, or cyano;
  • L 2 independently of each other denotes fluorine, chlorine, bromine, iodine, nitro, cyano, hydroxy, C 3 - 6 -cycloalkyl, Cs- 6 -cycloalkyloxy, tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy, tetrahydrofuranyl-C- ⁇ -3 - alkyloxy, tetrahydropyranyl-C- ⁇ - 3 -alkyloxy, (het)aryl, (het)aryloxy,
  • Ci- 3 -alkylamino di-(Ci -3 -alkyl)amino, pyrrolidin-1 -yl, 2-oxo-pyrrolidin-1 - yl, piperidin-1 -yl, 2-oxo-piperidin-1 -yl, morpholin-4-yl, 3-oxo-morpholin-4-yl, piperazin-1 -yl, 2-oxo-piperazin-1 -yl, 3-oxo-piperazin-1-yl, 4-(Ci- 3 -alkyl)- piperazin-1 -yl, 4-(Ci -4 -alkylcarbonyl)-piperazin-1 -yl, 4-(C 3-6 -cycloalkylcarbonyl)- piperazin-1 -yl, 4-(Ci- 4 -alkyloxycarbonyl)-piperazin-1-yl, 4-(Ci -4 -alkylsulfonyl)- piperazin-1
  • Ci- 3 -alkyl-aminosulfonyl di-(Ci -3 -alkyl)-aminosulfonyl, pyrroli- din-1-yl-sulfonyl, piperidin-1 -yl-sulfonyl, morpholin-4-yl-sulfonyl, piperazin-1-yl- sulfonyl, 4-(C 1-3 -alkyl)-piperazin-1 -yl-sulfonyl,
  • saturated heterocycles and cycloalkyl-rings are optionally substituted with one or two groups selected from fluorine, d- 3 -alkyl, C- ⁇ - 3 -alkoxy, Ci. 3 -alkoxy-Ci- 3 -alkyl, or hydroxy, and
  • L 3 and L 4 are linked to each other and
  • L 5 and L 6 are linked to each other, such that independently of each other and in each case together with the 2 adjacent C-atoms to which they are attached an aryl- or heteroaryl-group is formed which is fused to the cyclic group B, and which aryl- or heteroaryl-group is optionally substituted with 1 , 2 or 3 identical or different R 10 ,
  • aryl phenyl or naphthtyl
  • heteroaryl is meant pyrrolyl, furanyl, thienyl, pyridyl, indolyl, benzofuranyl, benzothiophenyl, quinolinyl, isoquinolinyl, or pyrrolyl, furanyl, thienyl, pyridyl wherein in said pyrrolyl, furanyl, thienyl, pyridyl 1 or 2 CH groups are each replaced by N, or indolyl, benzofuranyl, benzothiophenyl, quinolinyl, isoquinolinyl wherein in said indolyl, benzofuranyl, benzothiophenyl, quinolinyl, isoquinolinyl 1 to 3 CH groups are each replaced by N, or tetrazolyl,
  • the above-mentioned (het)aryl is an aryl group as defined hereinbefore, or a heteroaryl group as defined hereinbefore, or a ring selected from the group consisting of 1 ,2-dihydro-2-oxo-pyridinyl, 1 ,4-dihydro-4-oxo-pyridinyl, 2,3-dihydro-3- oxo-pyridazinyl, 1 ,2,3,6-tetrahydro-3,6-dioxo-pyridazinyl, 1 ,2-dihydro-2-oxo-pyrimi- dinyl, 3,4-dihydro-4-oxo-pyrimidinyl, 1 ,2,3,4-tetrahydro-2,4-dioxo-pyrimidinyl, 1 ,2- dihydro-2-oxo-pyrazinyl, 1 ,2,3,4-tetrahydro-2,3-dioxo-pyra
  • alkyl or alkylene moieties may be branched or unbranched
  • the compounds of general formula I according to the invention and the physiologically acceptable salts thereof have valuable pharmacological properties, particularly an inhibitory effect on the enzyme 11 ⁇ -hydroxysteroid dehydrogenase (HSD) 1.
  • HSD ⁇ -hydroxysteroid dehydrogenase
  • a further aspect of the invention also relates to the physiologically acceptable salts of the compounds of general formula I according to this invention with inorganic or organic acids.
  • this invention relates to pharmaceutical compositions, containing at least one compound of general formula I or a physiologically acceptable salt according to the invention, optionally together with one or more inert carriers and/or diluents.
  • this invention relates to the compounds according to general formula I, including the compounds (M1 ), (M2), (M3) and (M4), or the physiologically acceptable salts thereof, for treatment or prevention of diseases or conditions which can be influenced by inhibiting the enzyme 11 ⁇ -hydroxysteroid dehydrogenase (HSD) 1 , such as metabolic disorders.
  • HSD ⁇ -hydroxysteroid dehydrogenase
  • this invention relates to the use of at least one compound according to general formula I, including the compounds (M1 ), (M2), (M3) and (M4), or one of the physiologically acceptable salts thereof for preparing a pharmaceutical composition which is suitable for the treatment or prevention of diseases or conditions which can be influenced by inhibiting the enzyme 11 ⁇ -hydroxysteroid dehydrogenase (HSD) 1 , such as metabolic disorders.
  • HSD ⁇ -hydroxysteroid dehydrogenase
  • the present invention relates to a process for preparing the compounds of general formula I, characterized in that
  • V I V which is optionally isolated and optionally purified, and the intermediate of the formula IV or V is reacted with the other amine of the formula III or Il to yield the compound of- the formula I, wherein Y is a leaving group and in particular denotes fluorine, chlorine, bromine, cyano, Ci -4 -alkoxy, C 2-4 -alkenyloxy, C2-4-alkynyloxy, partially or fully fluorinated
  • aryl groups mentioned in the definition of the above groups denote phenyl or naphthyl
  • heteroaryl groups mentioned in the definition of the above groups denote pyridinyl, pyrimidinyl, triazinyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl
  • both the aryl and heteroaryl groups optionally are substituted with one or more substituents independently of each other selected from fluorine, chlorine, bromine, d- 3 -alkyl, Ci -3 -alkyloxy, nitro, cyano, or di-(C- ⁇ - 3 -alkyl)amino groups
  • the second Y to be replaced may also be transformed to a more reactive Y after the first Y is replaced with one of the two amines
  • an organic base such as an amine, e.g. ethyldiisopropylamine, triethylamine, imidazole or pyridine, or an inorganic base, e.g. potassium carbonate or calcium oxide, and/or an additive such as 4- dimethylaminopyridine or 1-hydroxybenzotriazol; wherein the reactions are preferably conducted between 0 and 120 0 C; wherein preferred solvents are selected from tetrahydrofuran, 1 ,2-dimethoxyethane, ether, 1 ,4-dioxane, dimethylformamide, N 1 N- dimethylacetamide, N-methylpyrrolidinone, acetonitrile, dichloromethane, 1 ,2- dichloroethane, toluene, benzene, hexanes, ethyl acetate, but also aqueous and alcoholic solutions may be usable for some of the combinations listed above;
  • an organic base such as an amine
  • a compound of general formula I thus obtained is resolved into its stereoisomers; if desired a compound of general formula I thus obtained is converted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts thereof.
  • the groups, residues, and substituents particularly A, B, R N , R 1 , R 2 , R 3 , R 10 , R 11 , R 12 , R p , L 1 , L 2 , L 3 , L 4 , L 5 , L 6 , X 1 m, n, and o are defined as above and hereinafter. If residues, substituents, or groups occur several times in a compound they may have the same or different meanings. Some preferred meanings of individual scaffolds, groups, and substituents of the compounds according to the invention will be given hereinafter.
  • indexes m, n and o each denote independently of each other 0, 1 or 2.
  • m, n and o are chosen such that the sum of m + n + o is 2, 3 or 4.
  • Cs +m + n -azacycloalkene core structure of general formulae 1.1 to 1.10 including the bridging group -(CH 2 ) 0 - is optionally substituted with 1 , 2 or more substituents independently of each other selected from the group consisting of R 11 and R 12 , and
  • rings A and B are defined as hereinbefore and hereinafter, their tautomers, their stereoisomers, mixtures thereof and the salts thereof, while the compounds (M1 ), (M2), (M3) and (M4) as defined hereinbefore, are excluded.
  • 2,6-methano-azocin core structure with the stereochemical configuration as depicted is optionally substituted with 1 , 2 or more substituents independently of each other selected from the group consisting of R 11 and R 12 , and wherein the rings A, B and R 11 , R 12 are defined as hereinbefore and hereinafter, their tautomers, their stereoisomers, mixtures thereof and the salts thereof.
  • 2,6-methano-azocin core structure with the stereochemical configuration as depicted is optionally substituted with 1 , 2 or more substituents independently of each other selected from the group consisting of R 11 and R 12 , and wherein the rings A, B and R 11 , R 12 are defined as hereinbefore and hereinafter, their tautomers, their stereoisomers, mixtures thereof and the salts thereof.
  • the nitrogen containing ring B preferably denotes azetidin-1-yl, pyrrolidin-1 -yl, piperidin-1-yl, azepan-1-yl, azocan-1-yl,
  • azetidin-1-yl wherein one -CH 2 - group is replaced by O, S, NR N , carbonyl, or sulfonyl, or
  • pyrrolidin-1-yl piperidin-1-yl, azepan-1-yl, azocan-1-yl, which may be partially or fully unsaturated and wherein one or two -CH 2 - groups are independently of each other replaced by O, S, carbonyl, or sulfonyl, and wherein one -CH 2 - group may be replaced by -NR N -,
  • each of the above rings B may be substituted with one or more substituents independently of each other selected from L 1 , wherein each of the above rings B may be substituted with 1 or 2 substituents independently of each other selected from L 2 , wherein 2 adjacent C-atoms of each of the above rings B may be substituted with L 3 and L 4 , and wherein 2 adjacent C-atoms of each of the above rings B may be substituted with L 5 and L 6 .
  • the ring B denotes pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, azocan-1-yl, which may be partially or fully unsaturated, and wherein one or two -CH 2 - groups may be independently of each other replaced by O, S, carbonyl, or sulfonyl, and wherein one -CH 2 - group may be replaced by -NR N -,
  • each of the above rings B may be substituted with one or more substituents independently of each other selected from L 1 , wherein each of the above rings B may be substituted with 1 or 2 substituents independently of each other selected from L 2 , wherein 2 adjacent C-atoms of each of the above rings B may be substituted with L 3 and L 4 , and wherein 2 adjacent C-atorhs of each of the above rings B may be substituted with L 5 and L 6 .
  • the ring B denotes pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, azocan-1-yl, 2-oxo-pyrrolidin-1-yl, 2-oxo-imidazolidin-1-yl, 2-oxo-piperidin-1-yl, piperazin-1-yl, morpholin-4-yl, 2-oxo-piperazin-1-yl, 3-oxo-piperazin-1-yl, 2-oxo- morpholin-4-yl, 3-oxo-morpholin-4-yl, 2,3-dihydro-indol-1-yl, 5,6-dihydro-8H- [1 ,2,4]triazolo[4,3-a]pyrazin-7-yl, 1 ,2,3,4-tetrahydro-isoquinolin-2-yl, 2,3-dihydro- benzo[1 ,4]oxazin-4-yl,
  • each of the above rings B may be substituted with one or more substituents independently of each other selected from L 1 , wherein each of the above rings B may be substituted with 1 or 2 substituents independently of each other selected from L 2 , wherein 2 adjacent C-atoms of each of the above rings B may be substituted with L 3 and L 4 , and wherein 2 adjacent C-atoms of each of the above rings B may be substituted with L 5 and L 6 .
  • the ring A denotes a benzo, pyrido, pyrrolo, furo, thieno, pyridazino, pyrimido, or pyrazino ring wherein each of said rings is optionally substituted with one or more substituents independently of each other selected from R 1 , and wherein 2 adjacent C-atoms of each of said rings are optionally substituted with R 2 and R 3 ; or a pyrazolo, oxazolo, thiazolo, or imidazo ring each of which is optionally substituted with R 1 .
  • the ring A denotes a benzo or pyrido ring, most preferably a benzo ring, wherein each of said rings is optionally substituted with one or more substituents independently of each other selected from R 1 , and wherein 2 adjacent C-atoms of each of said rings are optionally substituted with R 2 and R 3 .
  • R N denotes hydrogen, d- ⁇ -alkyl, C 3 - 6 -alkenyl, phenyl, d- 4 -alkylcarbonyl, Ci -4 -alkylsulfonyl, phenylcarbonyl, phenylsulfonyl, wherein each alkyl group may be mono- or polysubstituted with fluorine and may be monosubstituted with hydroxy, Ci.
  • Ci -4 -alkylcarbonylamino cyano, carboxy, C-i -4 -alkoxycarbonyl, aminocarbonyl, Ci- 4 -alkylaminocarbonyl, di-(Ci -4 -alkyl)aminocarbonyl or phenyl, and wherein each phenyl group may be monosubstitued with R 10 .
  • R N denotes hydrogen, d- 6 -alkyl, phenyl, Ci -4 -alkylcarbonyl, d -4 -alkylsulfonyl, wherein each alkyl group may be mono- or polysubstituted with fluorine and may be monosubstitued with hydroxy, Ci -4 -alkoxy, or phenyl, and wherein each phenyl group may be monosubstitued with R 10 .
  • R N denotes hydrogen, methyl, ethyl, isopropyl, phenyl, acetyl, methylsulfonyl.
  • the one or more substituents L 1 which may be identical or different, denote fluorine, chlorine, d- 4 -alkyl, trifluoromethyl, hydroxy, Ci-4-alkoxy, cyano, more preferably fluorine, methyl, ethyl, trifluoromethyl, hydroxy, methoxy, ethoxy, cyano, particularly fluorine, methyl, trifluoromethyl, hydroxy, and methoxy.
  • the one or more substituents L 2 which may be identical or different, denote fluorine, chlorine, bromine, cyano, hydroxy, d- 6 -alkyl, C2-6-alkenyl, C2-6- alkynyl, Ci -4 -alkyloxy, difluoromethyl, trifluoromethyl, difluoromethoxy, thfluoromethoxy, C 3 - 6 -cycloalkyl, Cs-e-cycloalkyloxy, C 3 .
  • N-(Ci-3-alkyl)-Ci -3 -alkyl-sulfonylamino N-(Ci. 3 -alkyl)-(het)arylsulfonylamino, N-(Ci -3 -alkyl)-(het)aryl-Ci- 3 -alkyl-sulfonylamino,
  • Ci -3 -alkylsulfanyl Ci_ 3 -alkylsulfinyl, Ci -3 -alkylsulfonyl, (het)arylsulfonyl, trifluoro- methylsulfanyl, trifluoromethylsulfinyl, trifluoromethylsulfonyl,
  • saturated heterocycles and cycloalkyl-rings are optionally substituted with one or two groups independently of each other selected from Ci. 3 -alkyl, Ci -3 -alkoxy, Ci -3 -alkoxy-Ci -3 -alkyl, or hydroxy, and
  • (het)aryl is phenyl, naphthyl, pyrrolyl, furanyl, thienyl, pyridyl, indolyl, benzofuranyl, benzothiophenyl, quinolinyl, isoquinolinyl, or pyrrolyl, furanyl, thienyl, pyridyl in which 1 or 2 CH are each replaced by N, or indolyl, benzofuranyl, benzothiophenyl, quinolinyl, isoquinolinyl in which 1 to 3 CH are each replaced by N, or tetrazolyl, and
  • the one or more substituents L 2 which may be identical or different, denote fluorine, chlorine, bromine, cyano, C- ⁇ - 6 -alkyl, C2- 6 -alkenyl, C 2 - 6 -alkynyl, hydroxy, C- ⁇ - 4 -alkyloxy, trifluoromethyl, difluoromethoxy, trifluoromethoxy, C 3- 6- cycloalkyl, Cs- ⁇ -cycloalkyloxy, phenyl, phenoxy, tetrazolyl, benzimidazolyl,
  • Ci -3 -alkylamino di-(Ci -3 -alkyl)amino, Ci- 3 -alkyl-carbonylamino, phenyl- carbonylamino, Ci -3 -alkyl-sulfonylamino, N ⁇ Ci-s-alkylJ-Ci-s-alkyl-carbonylamino, N- (C-i-s-alkylJ-phenylcarbonylamino, N-(Ci -3 -alkyl)-Ci -3 -alkyl-sulfonylamino,
  • Ci -3 -alkyloxy-carbonyl aminocarbonyl, C-i-s-alkyl-aminocarbonyl, di-(Ci -3 - alkyl)-aminocarbonyl, phenylaminocarbonyl, N-(Ci_ 3 -alkyl)-phenylaminocarbonyl,
  • Ci-s-alkylcarbonylamino-Ci-s-alkyl Ci-s-alkylcarbonylamino-Ci-s-alkyl
  • Ci-s-alkyloxy-Ci-3-alkyloxy amino-Ci -3 -alkyloxy
  • Ci -3 - alkylamino-Ci- 3 -alkyloxy di-(Ci -3 -alkyl)-amino-Ci -3 -alkyloxy
  • C- ⁇ -3-alkylsulfanyl d- 3 -alkylsulfinyl
  • Ci- 3 -alkylsulfonyl
  • the one or more substituents L 2 which may be identical or different, denote fluorine, C 1-4 -alkyl, hydroxy, d- 3 -alkoxy, hydroxy-C- ⁇ - 3 -alkyl, C-i. 3 -alkyloxy-C-i.
  • L 3 and L 4 which are linked to each other, form with the atoms to which they are linked an aryl- or heteroaryl-group which is fused to the cyclic group B, and which is optionally substituted with 1 , 2 or 3 identical or different R 10 , while said aryl- or heteroaryl group is selected from the group consisting of phenyl, pyrrolyl, furanyl, thienyl, pyridyl, indolyl, benzofuranyl, benzothio- phenyl, quinolinyl, isoquinolinyl, and
  • L 3 and L 4 which are linked to each other, form with the atoms to which they are linked an aryl- or heteroaryl-group which is fused to the cyclic group B, wherein said fused aryl- or heteroaryl-group is selected from the group consisting of benzo, pyhdo, pyrimido, pyrazino, pyridazino, pyrrolo, furano, thieno, imidazo, pyrazolo, oxazolo, isoxazolo, thiazolo, isothiazolo, each of which is optionally substituted with one to three identical or different R 10 .
  • L 3 and L 4 which are linked to each other, form with the atoms to which they are linked an aryl- or heteroaryl-group which is fused to the cyclic group B, wherein said fused aryl- or heteroaryl-group is selected from the group consisting of benzo, pyrido, pyrimido, pyrazino, pyridazino, pyrrolo, furano, thieno, imidazo, pyrazolo, oxazolo, isoxazolo, thiazolo and isothiazolo, each of which is optionally substituted with 1 , 2 or 3 identical or different R 10 .
  • L 3 and L 4 which are linked to each other, form with the atoms to which they are linked an aryl- or heteroaryl-group which is fused to the cyclic group B, wherein said fused aryl- or heteroaryl-group is selected from the group consisting of benzo, pyrido, pyrimido, pyrrolo, furano, thieno, imidazo and oxazolo group, each of which is optionally substituted with 1 , 2 or 3 identical or different R 10 , particularly benzo, thieno, and imidazo, each of which is optionally substituted with 1 , 2 or 3 identical or different R 10 .
  • L 5 and L 6 which are linked to each other, form with the atoms to which they are linked an aryl- or heteroaryl-group which is fused to the cyclic group B, wherein said fused aryl- or heteroaryl-group is selected from the group consisting of benzo, pyrido, pyrimido, pyrazino, pyridazino, pyrrolo, furano, thieno, imidazo, pyrazolo, oxazolo, isoxazolo, thiazolo, and isothiazolo, each of which is optionally substituted with 1 , 2 or 3 identical or different R 10 , more preferably selected from the group consisting of benzo, pyrido, pyrimido, pyrazino, and pyridazino, each of which is optionally substituted with one to three identical or different R 10 , most preferably benzo, which is optinally substituted with 1 , 2
  • a tautomeric amide substructure may be formed and is part of the invention.
  • Examples of substructures of the ring B wherein two adjacent C-atoms are substituted with L 3 and L 4 , wherein a tautomeric amide is formed are depicted in the following table:
  • the substituent R 1 denotes fluorine, chlorine, cyano, C- M -alkyl, hydroxy, C- ⁇ - 4 -alkyloxy, difluoromethyl, trifluoromethyl, trifluoromethyl-hydroxy-C- ⁇ - 2 -alkyl, difluoromethoxy, trifluoromethoxy, C 3-6 -cycloalkyl, Ca- ⁇ -cycloalkyloxy, C 3-6 -cycloalkyl- Ci- 3 -alkyl, Ca-e-cycloalkyl-d-a-alkyloxy, tetrahydrofuran-3-yloxy, tetrahydropyran-3- yloxy, tetrahydropyran-4-yloxy, tetrahydrofuranyl-C- ⁇ - 3 -alkyloxy, tetrahydropyranyl-Ci.
  • N-CCi.s-alkyO-Ci.s-alkyl-carbonylamino N-(Ci -3 -alkyl)-(het)arylcarbonylamino, N-(Ci -3 - alkyl)-Ci -3 -alkyloxy-carbonylamino, N-(Ci -3 -alkyl-aminocarbonyl)-Ci -3 -alkylamino, N- ⁇ (-(Ci-s-alkyOaminocarbonylJ-Ci-s-alkylamino,
  • Ci.a-alkyloxy-Ci.s-alkyl amino-Ci -3 -alkyl
  • Ci -3 -alkylamino-Ci -3 - alkyl di-(C 1-3 -alkyl)-amino-Ci -3 -alkyl
  • pyrrolidin-1 -yl-Ci -3 -alkyl 2-oxo-pyrrolidin-i-yl-Ci.
  • Ci.a-alkyloxy-d.a-alkyloxy Ci ⁇ -alkylsulfinyl-Ci-s-alkyloxy, Ci -3 - alkylsulfonyl-C- ⁇ - 3 -alkyloxy, di-(Ci -3 -alkyl)-amino-Ci -3 -alkyloxy, 2-oxo-pyrrolidin-1-yl-Ci. 3 -alkyloxy, 2-oxo-piperidin-1-yl-Ci. 3 -alkyloxy, morpholin-4-yl-Ci- 3 -alkyloxy, 3-oxo- morpholin-4-yl-Ci-3-alkyloxy,
  • R 1 denotes fluorine, chlorine, cyano, C- M -alkyl, hydroxy, Ci -4 - alkyloxy, trifluoromethyl, trifluoromethyl-hydroxy-Ci- 2 -alkyl, difluoromethoxy, trifluoromethoxy, Cs- 6 -cycloalkyloxy, tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy, tetrahydrofuranyl-Ci -3 -alkyloxy, tetrahydropyranyl-Ci -3 - alkyloxy, (het)aryl, (het)aryloxy, (het)aryl-Ci- 3 -alkyloxy, Ci- 3 -alkyl-carbonyl, or
  • Ci- 3 -alkyl-carbonylamino (het)aryl-carbonylamino
  • Ci_ 3 -alkyl- sulfonylamino N-(Ci. 3 -alkyl)-Ci- 3 -alkyl-carbonylamino, N-(Ci- 3 -alkyl)- (het)arylcarbonylamino,
  • Ci-s-alkyloxy-Ci-s-alkyl Ci ⁇ -alkylcarbonyl-amino-Ci-s-alkyl, N-(Ci- s-alkyO-Ci ⁇ -alkylcarbonyl-amino-Ci-s-alkyl, 2-oxo-pyrrolidin-1-yl-Ci- 3 -alkyl, 2-oxo- piperidin-1 -yl-Ci- 3 -alkyl, S-oxo-morpholin ⁇ -yl-Ci-s-alkyl,
  • the above-mentioned (het)aryl groups are selected from the group consisting of phenyl, furanyl, thienyl, oxazolyl, thiazolyl, isoxazolyl, imidazolyl, pyrazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, 1 ,2- dihydro-1 -methyl-2-oxo-pyridinyl, 2,3-dihydro-2-methyl-3-oxo-pyridazinyl, and triazinyl, wherein each group is optionally mono- or disubstituted with identical or different R 10 .
  • R 1 denotes fluorine, chlorine, Ci- 3 -alkyl, hydroxy, Ci- 3 -alkyloxy, amino, Ci- 3 -alkyl-carbonylamino, Ci -3 -alkyl-sulfonylamino, cyano, carboxy, C1-3- alkyloxy-carbonyl, aminocarbonyl, Ci- 3 -alkyl-aminocarbonyl, di-(Ci- 3 -alkyl)- aminocarbonyl, hydroxy-d- 3 -alkyl, trifluoromethyl-hydroxy-Ci- 2 -alkyl, Ci- 3 -alkyloxy-Ci- 3-alkyl, Ci-s-alkyl-carbonyl-amino-Ci-s-alkyl, cyano-Ci -3 -alkyloxy, hydroxy-Ci -3 - alkyloxy, trifluoromethyl, difluoromethoxy, trifluoromethoxy, Ci
  • R 1 denotes fluorine, chlorine, methyl, hydroxy, methoxy, amino, acetylamino, methylsulfonylamino, cyano, methoxycarbonyl, ethoxycarbonyl, acetyl, 1-hydroxyethyl, 1-hydroxy-1 -methyl-ethyl, 2,2,2-trifluoro-1-hydroxy-1 -methyl-ethyl, methylsulfonyl, aminosulfonyl, methylaminosulfonyl, dimethylaminosulfonyl, cyanomethoxy, benzyloxy, phenoxy, phenyl, pyridin-3-yl, pyridin-4-yl, 1 ,2-dihydro-1- methyl-2-oxo-pyridin-5-yl, 1 ,2-dihydro-1-methyl-2-oxo-pyhdin-4-yl, pyrimidin-4-yl, 2- methyl-pyhmidin
  • R 2 and R 3 are linked to each other to form a bridging group they are preferably selected from the group consisting of methylenedioxy, difluoromethylenedioxy, ethylenedioxy and C 3 - 5 -alkylene bridging group, even more preferably consisting of methylenedioxy, ethylenedioxy, propylene, and butylene, most preferably methylenedioxy or ethylenedioxy.
  • R 2 and R 3 may form combined with the carbon atoms to which they are attached a group preferably selected from the group consisting of a benzo, pyrazino, pyrazolo, imidazo, N-(Ci- 3 -alkyl)-pyrazolo, N-(Ci- 3 -alkyl)-imidazo, oxazolo, thiazolo, isoxazolo, and isothiazolo ring, wherein each of the five-membered rings is optionally monosubstituted with R p and each of the six-membered rings is optionally substituted with one or two substituents independently of each other selected from R p , or N-(Ci- 3 -alkyl)-thazolo or thazolo.
  • R 2 and R 3 combined with the carbon atoms to which they are attached form a group as described hereinbefore said group is even more preferably selected from the group consisting of a benzo, pyrazino, pyrazolo, imidazo, N-(Ci- 3 -alkyl)-pyrazolo, N-(Ci- 3 -alkyl)-imidazo, oxazolo, thiazolo, isoxazolo, and isothiazolo ring, wherein each of the five-membered rings is optionally monosubstituted with R p and each of the six-membered rings is optionally substituted with one or two substituents independently of each other selected from R p , or N-(Ci -3 -alkyl)-triazolo or triazolo.
  • R 2 and R 3 combined with the carbon atoms to which they are attached form a group as described hereinbefore said group is most preferably selected from the group consisting of a benzo, pyrazino, imidazo, N-(Ci -3 -alkyl)-imidazo, N-(Ci -3 -alkyl)- triazolo, oxazolo, or thiazolo ring, wherein the benzo and pyrazino ring are optionally substituted with one or two substituents independently of each other selected from R p and the imidazo, N-(Ci- 3 -alkyl)-imidazo, oxazolo, and thiazolo ring are optionally additionally monosubstituted with R p .
  • R 2 and R 3 together denote methylenedioxy or together with the carbon atoms to which they are attached form an optionally additionally with methyl, tert-butyl, cyclopropyl, tetrahydrofuran-2-yl, 1 -acetyl-piperidin-4-yl, pyridin-3-yl, 1 ,2- dihydro-1-methyl-2-oxo-pyridin-5-yl, pyridazin-4-yl, pyrazinyl, or 5-methyl-pyrazin-2-yl substituted oxazolo, imidazo, or N-methyl-imidazo group, an optionally with methyl substituted triazolo group, or an optionally methyl or dimethyl substituted benzo or pyrazino ring.
  • R p preferably is fluorine, Ci -4 -alkyl, C 3 - 6 -cycloalkyl, pyrrolidinyl, 1-methyl-pyrrolidinyl, 1-acetyl-pyrrolidinyl, piperidinyl, 1-methyl-piperidinyl, 1-acetyl-piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, trifluoromethyl, cyano, amino, acetylamino, methylsulfonylamino, carboxy, d- 3 -alkyloxycarbonyl, aminocarbonyl, methylamino- carbonyl, dimethylaminocarbonyl, aminosulfonyl, hydroxy, C- ⁇ - 3 -alkyloxy, or phenyl, pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, 1 ,2-dihydro-2-oxo
  • R p is fluorine, methyl, ethyl, tert-butyl, C 3-6 -cycloalkyl, pyrrolidinyl, 1- methyl-pyrrolidinyl, 1-acetyl-pyrrolidinyl, piperidinyl, 1-methyl-piperidinyl, 1-acetyl- piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, trifluoromethyl, cyano, amino, acetylamino, methylsulfonylamino, carboxy, methoxycarbonyl, ethoxycarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, aminosulfonyl, hydroxy, methoxy, or phenyl, pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, 1 ,2-dihydro-2-oxo
  • R p is fluorine, methyl, cyclopropyl, 1-acetyl-piperidinyl, tetrahydrofuranyl, acetylamino, methylsulfonylamino, carboxy, hydroxy, methoxy, or pyridyl, pyridazinyl, pyrazinyl, 1 ,2-dihydro-2-oxo-pyhdinyl, which are optionally substituted with one or two methyl groups; particularly, L is methyl, tert-butyl, cyclopropyl, tetrahydrofuran-2-yl, 1-acetyl-piperidin-4-yl, pyrid-3-yl, pyridazin-3-yl, pyrazinyl, 5-methylpyrazin-2-yl, 1 ,2-dihydro-2-oxo-pyridin-5-yl.
  • the one or more substituents R 10 independently of each other denote fluorine, chlorine, bromine, d- 3 -alkyl, difluoromethyl, trifluoromethyl, cyano, nitro, amino, acetylamino, methylsulfonylamino, carboxy, C- M -alkyloxycarbonyl, aminocarbonyl, Ci-3-alkylaminocarbonyl, di-(Ci- 3 -alkyl)-aminocarbonyl, aminosulfonyl, methylsulfanyl, methylsulfinyl, methylsulfonyl, phenyl, hydroxy, Ci- 3 -alkyloxy, difluoromethoxy, or thfluoromethoxy.
  • R 10 denotes fluorine, chlorine, methyl, difluoromethyl, trifluoromethyl, cyano, hydroxy, methoxy, difluoromethoxy, or trifluoromethoxy. Most preferably, R 10 denotes fluorine or methyl.
  • the one or more substituents R 11 independently of each other denote fluorine, Ci -3 -alkyl, phenyl, hydroxy, Ci -3 -alkyloxy, cyano, carboxy, Ci -4 -alkyloxy- carbonyl, aminocarbonyl, Ci -4 -alkylamino-carbonyl, di-(Ci -4 -alkyl)-aminocarbonyl, hydroxy-d- 4 -alkyl, or More preferably R 11 denotes fluorine, d- 3 -alkyl, hydroxy, or d- 3 -alkyloxy. Most preferably, R 11 denotes methyl, ethyl, propyl, hydroxy, or methoxy, particularly methyl or hydroxy.
  • the one or more substituents R 12 independently of each other denote fluorine, or Ci- 3 -alkyl, more preferably methyl or ethyl.
  • the C 5+m+n -azacycloalkene core structure of general formulae 1.1a to 1.10a including the bridging group -(CH2) 0 - is optionally substituted with 1 , 2 or more substituents independently of each other selected from the group consisting of R 11 and R 12 , and wherein the ring B and R 1 , R 2 , R 3 , R 11 , R 12 are defined as hereinbefore and hereinafter, their tautomers, their stereoisomers, mixtures thereof and the salts thereof, while the compounds (M1 ), (M2), (M3) and (M4) as defined hereinbefore, are excluded.
  • 2,6-methano-azocin core structure with the stereochemical configuration as depicted is optionally substituted with 1 , 2 or more substituents independently of each other selected from the group consisting of R 11 and R 12 , and wherein the ring B and R 1 , R 2 , R 3 , R 11 , R 12 are defined as hereinbefore and hereinafter, their tautomers, their stereoisomers, mixtures thereof and the salts thereof.
  • 2,6-methano-azocin core structure with the stereochemical configuration as depicted is optionally substituted with 1 , 2 or more substituents independently of each other selected from the group consisting of R 11 and R 12 , and wherein the ring B and R 1 , R 2 , R 3 , R 11 , R 12 are defined as hereinbefore and hereinafter, their tautomers, their stereoisomers, mixtures thereof and the salts thereof.
  • the invention relates to compounds of the formula I 1 in particular of the formulae M to MO, most preferably of the formulae M a to M Oa, in particular of the formula 1.5 and 1.5a, defined as hereinbefore wherein compounds of the formula l.5a-1
  • R 1 is hydrogen, hydroxy or Ci -4 -alkyloxy
  • R 11 is C 1-4 -alkyl or phenyl
  • the ring B is morpholin-4-yl, piperidin-1-yl or pyrrolidin-1-yl, and all remaining substituents are hydrogen, are excluded.
  • the invention relates to compounds of the formula I, in particular of the formulae 1.1 to M O, most preferably of the formulae M a to MOa, in particular of the formula 1.1 and Ma, defined as hereinbefore wherein compounds of the formula Ma-1
  • R 1 is hydrogen, hydroxy or Ci -4 -alkyloxy
  • R 11 is hydrogen, C 1-4 -alkyl, 2- methoxy-ethyl, or phenyl, wherein said phenyl is optionally substituted with halogen, hydroxy or C- ⁇ -3-alkyloxy
  • R 12 is hydrogen, or Ci -4 -alkyl
  • the ring B is a 3- to 8- membered monocytic azacycloalk-1-yl group or morpholin-4-yl, and all remaining substituents are hydrogen, and their salts, are excluded.
  • substituted means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valence is not exceeded, and that the substitution results in a stable compound.
  • partially unsaturated means that in the designated group or moiety 1 , 2 or more, preferably 1 or 2, double bonds are present.
  • the term “partially unsaturated” does not cover fully unsaturated groups or moieties.
  • halogen denotes an atom selected from the group consisting of F, Cl, Br and I.
  • Ci -n -alkyl wherein n may have a value of 1 to 18, denotes a saturated, branched or unbranched hydrocarbon group with 1 to n C atoms.
  • examples of such groups include methyl, ethyl, n-propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, neo-pentyl, tert-pentyl, n-hexyl, iso-hexyl, etc.
  • groups include ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2- butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2- hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl etc.
  • C 2-n -alkynyl wherein n has a value of 3 to 6, denotes a branched or unbranched hydrocarbon group with 2 to n C atoms and a C ⁇ C triple bond.
  • groups include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3- butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 3- hexynyl, 4-hexynyl, 5-hexynyl etc.
  • alkynyl groups are connected to the remainder of the molecule via the C atom in position 1. Therefore terms such as 1-propynyl, 2-propynyl, 1 -butynyl, etc. are equivalent to the terms 1- propyn-1-yl, 2-propyn-1-yl, 1-butyn-1-yl, etc.. This also applies analogously to C2 -n - alkenyl groups.
  • Ci -n -alkoxy denotes a C- ⁇ . n -alkyl-0 group, wherein Ci -n -alkyl is as hereinbefore defined.
  • groups include methoxy, ethoxy, n-propoxy, iso- propoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, iso-pentoxy, neo- pentoxy, tert-pentoxy, n-hexoxy, iso-hexoxy, etc.
  • groups include methylcarbonyl, ethylcarbo- nyl, n-propylcarbonyl, iso-propylcarbonyl, n-butylcarbonyl, iso-butylcarbonyl, sec-bu- tylcarbonyl, tert-butylcarbonyl, n-pentylcarbonyl, iso-pentylcarbonyl, neo-pentylcar- bonyl, tert-pentylcarbonyl, n-hexylcarbonyl, iso-hexylcarbonyl, etc.
  • C 3-n -cycloalkyl denotes a saturated mono-, bi-, tri- or spirocarbocyclic group with 3 to n C atoms.
  • groups include cyclopropyl, cyclobutyl, cyclo- pentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclododecyl, bicyclo[3.2.1.]oc- tyl, spiro[4.5]decyl, norpinyl, norbonyl, norcaryl, adamantyl, etc.
  • C 3-7 -cycloalkyl denotes saturated monocyclic groups.
  • tri-(Ci -4 -alkyl)silyl comprises silyl groups which have identical or two or three different alkyl groups.
  • di-(Ci- 3 -alkyl)amino comprises amino groups which have identical or two different alkyl groups.
  • alkyl group is optionally mono- or polyfluorinated this comprises also alkyl residues which are part of larger groups, e.g. alkyloxy, alkylcarbonyl, alkoxyalkyl, etc., or if a (het)aryl group is optionally mono- or polysubstituted with a certain substituent or a set of substituents this also includes (het)aryl groups which are part of larger groups, e.g.
  • a CH 2 group is optionally replaced with O, S, NR, CO, or SO 2 .
  • a residue having inter alia the meaning hydroxy-Ci- 3 -alkyl, in which a CH 2 group is optionally replaced by CO this also comprises carboxy, carboxymethyl, hydroxymethylcarbonyl, carboxyethyl, hydroxyl-methylcarbonylmethyl, and hydroxyethylcarbonyl.
  • the compounds according to the invention may be obtained using methods of synthesis known in principle.
  • the compounds are obtained by the following methods according to the invention which are described in more detail hereinafter.
  • a general strategy to access compounds of the invention is delineated in Scheme 1 ;
  • A, X, m, n, and 0 have the meanings as defined hereinbefore and hereinafter.
  • the key reaction to assemble the bicyclic framework is an intramolecular reaction of an amino functionality with a carboxy group that results in the formation of an amide linkage.
  • the fusion of the carboxylic acid function and the amino group may be carried out with or without an additive at elevated temperatures, preferably between 20 and 200 0 C.
  • Additives that remove the water forming during the reaction such as molecular sieves or orthoesters, or other additives such as bases, e.g. hexamethyldisilazides, or boronic acids may facilitate the reaction.
  • acyl halides or pseudohalides are acyl chloride, acyl fluoride, and acylcyanide.
  • esters and thioesters are derived from e.g.
  • mixed anhydrides are derived from alkylcarboxylic acids, e.g. pivalic acid, carbonates, e.g. methyl and ethyl carbonate, carbamates, e.g. N,N-dimethyl carbamate, phosphoric acids, e.g.
  • N acylated derivatives derived from azaheteroaromatics such as imidazole, triazole, tetrazole, or pyridine such as e.g. 4-dimethylaminopyridine may be used as well.
  • Some of the more popular reagents used for the activation of the carboxylic acid function are N,N'-carbonyldiimidazol, dicyclohexylcarbodiimide, (benzotriazol-1- yloxy)dipiperidinocarbenium hexafluorophosphate or tetrafluoroborate, (benzotriazol- 1-yloxy)dipyrrolidinocarbenium hexafluorophosphate or tetrafluoroborate, 1-(3- dimethylaminopropyl)-3-ethylcarbodiimide methiodide, POCI 3 , SOCI 2 , (COCI) 2 , COCI 2 , arylboronic acid, TiCI 4 , (MeO) 2 POCI, cyanuric chloride, 1 -hydroxybenzotriazol, 1-hydroxy-7-azabenzothazol, benzoltriazol-1-yloxytris(dimethylamino)phospho
  • ethyldiisopro- pylamine triethylamine
  • alkali metal carbonate pyridine, 4-dimethylaminopyridine, imidazole, dimethylaluminum amides, lithium amides, alkali metal cyanide, or alkali metal hexamethyldisilazide.
  • the reactions are preferably conducted in organic solvents but may also be carried out in aqueous solvents.
  • organic solvents ordinarily used are dimethylformamide, N.N-dimethylacetamide, N-methyl- pyrrolidinone, dimethylsulfoxide, tetrahydrofuran, hexane, ether, 1 ,4-dioxane, 1 ,2- dimethoxyethane, dichloromethane, dichloroethane, toluene, benzene, ethyl acetate, quinoline, pyridine, or mixtures thereof.
  • the reactions may be carried out at -80 0 C to 220 0 C, preferably between -10 0 C and 120 0 C. Subsequently, the lactam group is reduced to give the secondary amine.
  • This transformation is a well established reaction that may be carried out, for example, using LiAIH 4 , hydrogen in the presence of a catalyst, NaBH 4 in the presence of e.g. iodine, LiBH 4 , borane, sodium in propanol, CI 3 SiH, silanes, e.g. Et 3 SiH, in the presence of a transition metal such as rhenium, 9-BBN, LiBH 3 NMe 2 , or Et 3 SiH combined with LiEt 3 BH.
  • Solvents such as e.g.
  • tetrahydrofuran, ether, 1 ,2-dimethoxyethane, 1 ,4-dioxane, hexane, benzene, toluene, dichloromethane, alcohols, water, or mixtures thereof may be employed at - 78 0 C to 200 0 C, preferably between -10 0 C and 120 0 C; though, in combination with some reducing reagents only a few of these solvents are usable. This strategy is well suited for the synthesis of the scaffolds 1.1 to 1.10.
  • A, X, m, n, and o have the meanings as defined hereinbefore and hereinafter.
  • the bicyclic framework is formed via an intramolecular reductive amination reaction of a primary amine with a ketone functionality. Reductive aminations have large precedence in organic chemistry and may be carried out e.g. using hydrogen in the presence of a transition metal catalyst such as one derived from Ni, Rh, Pd, or Pt, borohydride reagents, e.g.
  • Some of these reagents are preferably used in combination with an additive such as acid, e.g. acetic acid or mineral acid.
  • the reactions are preferably conducted in organic solvents or aqueous mixtures, e.g.
  • the reactions may be carried out at -80 0 C to 200 0 C, preferably between -10 0 C and 100 0 C.
  • Scheme 4 shows another approach to assemble the bicyclic framework.
  • This approach is an intramolecular alkylation of the nitrogen group with an appropriate electrophile of the side-chain.
  • the nitrogen group may be an amino group, i.e. R a denotes e.g. hydrogen, methyl, allyl, benzyl, or dimethoxybenzyl, or an amide group, i.e. R a denotes e.g.
  • a base such as e.g. triethylamine, ethyldiisopropylamine, diazabicycloundecene, alkali metal carbonate, alkali metal tertbutoxide, alkali metal diisopropylamide, butyllithium, or sodium hydride.
  • a base such as e.g. triethylamine, ethyldiisopropylamine, diazabicycloundecene, alkali metal carbonate, alkali metal tertbutoxide, alkali metal diisopropylamide, butyllithium, or sodium hydride.
  • the stronger bases among them are preferably used in combination with the amides in e.g.
  • N-methylpyrrolidinone dimethylsulfoxide, tetrahydrofuran, hexane, ether, 1 ,4-dioxane, 1 ,2-dimethoxyethane, toluene, benzene, terfoutanol, isopropanol, or mixtures thereof at temperatures between -70 and 100 0 C, preferably between -30 and 60 0 C.
  • the milder bases listed are preferably used in combination with the amines in dichloromethane, dimethylformamide, N-methylpyrrolidinone, dimethylsulfoxide, tetrahydrofuran, hexane, ether, 1 ,4-dioxane, 1 ,2-dimethoxyethane, toluene, benzene, methanol, ethanol, tertbutanol, isopropanol, water, or mixtures thereof at temperatures between 0 and 140 0 C, preferably between 20 and 120 0 C.
  • the conditions originally reported by Mitsunobu may be used as well.
  • a phosphine e.g. triphenylphosphine or thbutylphosphine
  • an azodicarboxylate e.g. diethyl azodicarboxylate, diisopropyl azodicarboxylate, or azodicarboxylic dipiperidide.
  • Suited solvents may be selected from among dimethylformamide, N-methylpyrrolidinone, dichloromethane, tetrahydrofuran, hexane, ether, 1 ,4-dioxane, 1 ,2-dimethoxyethane, toluene, benzene, and mixtures thereof.
  • the reaction is preferably conducted at temperatures between 0 and 100 °C.
  • LG denotes NHR a and NHR a denotes LG, may be applicable as well. Reaction conditions are equivalent to the original way around.
  • a further generally applicable approach is based on an electrophilic aromatic substitution reaction (Scheme 5);
  • A, X 1 m, n, and o have the meanings as defined hereinbefore and hereinafter.
  • the aromatic part of the molecule reacts with an activated carbon atom of the azacycle to form the bicyclic framework.
  • the reactive intermediate bears a (partially) positively charged carbon atom in the azacycle that may be generated by the addition of an acid to an olefinic bond or by the activation of an appropriately positioned leaving group.
  • a huge number of Bronstedt and Lewis acids have been described for this classical reaction that may also be used here.
  • hydrobromic acid hydroiodic acid, hydrochloric acid, sulfuric acid, phosphoric acid, P 4 Oi O , trifluoroacetic acid, methanesulfonic acid, toluenesulfonic acid, trifluorme- thanesulfonic acid, Sc(OSO 2 CFs) 31 SnCI 4 , FeCI 3 , AIBr 3 , AICI 3 , SbCI 5 , BCI 3 , BF 3 , ZnCI 2 , montmorillonites, POCI 3 , and PCI 5 .
  • a more or less powerful acid catalyst has to be used.
  • silver salts e.g. AgOSO 2 CF 3
  • Preferred solvents are hydrocarbons such as hexanes or cyclohexane, chlorinated hydrocarbons such as dichloromethane or dichloroethane, perfluorinated hydrocarbons, nitrobenzene, chlorinated benzenes, heteroaromatics such as quinoline, 1 ,2-dimethoxyethane, 1 ,4-dioxane, ether, ionic liquids, or mixtures thereof.
  • the reactions may be carried out between -10 0 C and 220 0 C, preferably between 20 0 C and 180 °C.
  • the reactions may also be conducted under microwave irradiation.
  • This synthetic strategy is particularly suited for the scaffolds 1.1 and 1.3 to 1.10 bearing an electron rich aromatic.
  • Scheme 5 Strategy 5 to build the bicyclic skeleton
  • LG e.g. OH, OSO 2 Me, OSO 2 ToI, OSO 2 CF 3 , Cl, Br, I, OC ⁇ -alkyl, OCOC ⁇ -alkyl, ...
  • a compound of general formula I which contains a carboxy or ester group, this may be converted by reaction with an amine into a corresponding amide of general formula I. If a compound of general formula I is obtained which contains an aromatic substructure, this may be derivatized with a chlorine, bromine, or iodine atom or a nitro, sulfonic acid, chlorosulfonyl, or acyl group to a corresponding compound of general formula I by an electrophilic substitution reaction.
  • a compound of general formula I which contains an aromatic amino group
  • this may be transformed into a corresponding cyano, fluoro, chloro, bromo, iodo, hydroxy, mercapto, or azido compound of general formula I by diazotization and subsequent replacement of the diazo group with cyanide, fluoride, chloride, bromide, iodide, hydroxide, alkyl or hydrogen sulfide, or azide, respectively.
  • a compound of general formula I which contains an aromatic amino group, this may be converted into a corresponding aryl derivatized aromatic compound of general formula I by diazotization and subsequent replacement of the diazo group with an appropriate aryl nucleophile mediated by a suited transition metal species.
  • a compound of general formula I which contains an aromatic chloro, bromo, iodo, trifluoromethylsulfonyloxy, mesyloxy, or tosyloxy group, this may be converted into a corresponding aryl, alkenyl, alkynyl, or alkyl derivatized compound of general formula I by replacement of the respective group by aryl, alkenyl, alkynyl, or alkyl using a transition metal species mediated process.
  • a compound of general formula I which contains two adjacent hetero- atoms that are amino and hydroxy, amino, or mercapto, these heteroatoms may be linked via a carboxy carbon atom to form a cyclic amidine, imino ester, or imino thioester substructure that may be part of an aromatic ring. If a compound of general formula I is obtained which contains a cyano group, this may be converted into an amino alkyl derivatized compound of general formula I by reduction.
  • the subsequent esterification is optionally carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chloro- benzene, tetrahydrofuran, benzene/tetrahydrofuran or 1 ,4-dioxane or particularly advantageously in the corresponding alcohol optionally in the presence of an acid such as hydrochloric acid or in the presence of a dehydrating agent, lsobutyl chloroformate, thionyl chloride, trimethylchlorosilane, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, phosphorus trichloride, phosphorus pentoxide, N,N'-di- cyclohexylcarbodiimide, N,N'-dicyclohexylcarbodiimide/N-hydroxysuccinimide, N,N'-carbonyldiimidazo
  • 1-hydroxy-benzotriazole are among the routinely used reagents to accomplish this transformation.
  • the reactions are conducted between 0 and 150 0 C, preferably between 0 and 80 0 C.
  • the subsequent ester formation may also be carried out by reacting a compound which contains a carboxy group with a corresponding alkyl halide.
  • the subsequent acylation or sulfonylation is optionally carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran, or 1 ,4-dioxane with a corresponding acyl or sulfonyl derivative optionally in the presence of a tertiary organic base or in the presence of an inorganic base or in the presence of a dehydrating agent.
  • solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran, or 1 ,4-dioxane with a corresponding acyl or sulfonyl derivative optionally in the presence of a tertiary organic base or in the presence of
  • the subsequent alkylation is optionally carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran, or 1 ,4-dioxane with an alkylating agent such as a corresponding halide or sulfonic acid ester, e.g.
  • methyl iodide ethyl bromide, dimethylsulfate, or benzyl chloride, optionally in the presence of a tertiary organic base or in the presence of an inorganic base at temperatures between 0 and 150 0 C, preferably between 0 and 100 0 C.
  • the subsequent reductive alkylation is carried out with a corresponding carbonyl compound such as e.g. formaldehyde, acetaldehyde, propionaldehyde, acetone, or butyraldehyde in the presence of a complex metal hydride such as sodium borohy- dride, lithium borohydride, sodium triacetoxyborohydhde, or sodium cyanoborohydhde conveniently at a pH of 6-7 and at ambient temperature or using hydrogen in the presence of a transition metal catalyst, e.g. palladium/charcoal at a hydrogen pressure of 1 to 5 bar.
  • Methylation may also be carried out in the presence of formic acid as reducing agent at elevated temperature, e.g.
  • the subsequent reduction of a nitro group is carried out, for example, with hydrogen and a catalyst such as palladium on carbon, platinum dioxide, or Raney nickel, or using other reducing agents such as iron or zinc in the presence of an acid such as acetic acid.
  • a catalyst such as palladium on carbon, platinum dioxide, or Raney nickel
  • other reducing agents such as iron or zinc in the presence of an acid such as acetic acid.
  • the subsequent nitrosation of an imino group followed by reduction to obtain the N- amino-imino compound is carried out, for example, with an alkyl nitrite such as isoamyl nitrite to form the N-nitroso-imino compound that is then reduced to the N- amino-imino compound using, for example, zinc in the presence of an acid such as acetic acid.
  • an alkyl nitrite such as isoamyl nitrite
  • the subsequent cleaving of a Ci- 3 -alkyloxycarbony! group to obtain the carboxy group is carried out, for example, by hydrolysis with an acid such as hydrochloric acid or sulfuric acid or an alkali metal hydroxide such as lithium hydroxide, sodium hydroxide, or potassium hydroxide.
  • an acid such as hydrochloric acid or sulfuric acid
  • an alkali metal hydroxide such as lithium hydroxide, sodium hydroxide, or potassium hydroxide.
  • the subsequent amide formation is carried out by reacting a corresponding reactive carboxylic acid derivative with a corresponding amine optionally in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or 1 ,4-dioxane, while the amine used may also serve as solvent, optionally in the presence of a tertiary organic base or in the presence of an inorganic base or with a corresponding carboxylic acid in the presence of a dehydrating agent, lsobutyl chloroformate, thionyl chloride, trimethylchlorosilane, phosphorus trichloride, phosphorus pentoxide,
  • a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran
  • chlorine and bromine electrophiles may be e.g. N-halosuccinimide, HOCI 1 HOBr, ferfBuOCI, terfBuOBr, chlorine, bromine, dibromoisocyanuric acid, pyridinium dichlorobromate, pyridinium tribromide, or sulfu- ryl chloride that may be used alone or in combination with an acid, e.g.
  • hydrochloric acid hydrobromic acid, tetrafluoroboric acid, triflic acid, sulfuric acid, or acetic acid, or a Lewis acid, e.g. iron(lll) halide, borontrifluoride hydrate, borontrifluoride etherate, or aluminum halide.
  • Lewis acid e.g. iron(lll) halide, borontrifluoride hydrate, borontrifluoride etherate, or aluminum halide.
  • Further useful combinations may be LiBr and eerie ammonium nitrate, KCI or KBr with Oxone ® , or KBr and sodium perborate.
  • Suited iodine electro- philes may be generated from iodine combined with an oxidizing agent such as nitric acid, sulfur trioxide, manganese dioxide, HIO3, hydrogen peroxide, sodium periodate, peroxydisulfates, and Oxone ® .
  • an oxidizing agent such as nitric acid, sulfur trioxide, manganese dioxide, HIO3, hydrogen peroxide, sodium periodate, peroxydisulfates, and Oxone ® .
  • Further suited iodine electrophiles may be e.g. iodine chloride, dichloroiodates, and N-iodosuccinimide. These iodine electrophiles may be used without an additive or in the presence of an acid such as e.g. acetic acid, trifluoroacetic acid, or sulfuric acid, or a Lewis acid such as borontrifluoride hydrate, or copper salts.
  • nitro electrophiles may be generated from, for example, nitric acid, acetyl nitrate, eerie ammonium nitrate, sodium nitrate, N 2 Os, alkyl nitrate, and nitronium tetrafluoroborate.
  • Some of these reagents may be used without an additive, though, several of them are better used in combination with an acid, e.g. sulfuric acid or triflic acid, acetic anhydride, trifluoroacetic anhydride, Lewis acid, e.g. ytterbium triflate or iron acetate, P2O 5 , or a base.
  • the SO 3 H group may be introduced by reacting the aromatic compound with, for example, concentrated sulfuric acid, SO 3 , CISO 3 H, or CISO 2 NMe 2 combined with indium triflate. Reacting the aromatic compound with CISO 3 H gives the corresponding chlorosulfonylated derivative that may be hydrolyzed to the sulfonic acid. Acylating the aromatic part is conducted using an acyl electrophile that may be generated from the respective acyl halide, e.g. chloride, or acyl anhydride and a Lewis acid such as e.g.
  • Preferred solvents for the electrophilic substitutions described may differ depending on the electrophile employed; in the following some more generally applicable are mentioned: methylene chloride, dichloroethane, chlorobenzene, dichlorobenzene, ether, fluorinated hydrocarbons, hexanes, quinoline, or acetonitrile.
  • the temperatures preferably applied range from 0 to 180 0 C.
  • a nitrous acid or nitrosonium source or equivalent such as a nitrite salt combined with an acid, e.g. sodium nitrite and hydrochloric acid, nitrosonium tetrafluoroborate, or an alkylnitrite, e.g. terfbutylnitrite or /soamyl nitrite.
  • the diazotization is optionally carried out in methylene chloride, dichloroethane, dimethyl- formamide, N-methylpyrrolidinone, benzene, toluene, chlorobenzene, tetrahydro- furan, water, ethyl acetate, alcohol, ether, 1 ,2-dimethoxyethane, 1 ,4-dioxane, or mixtures thereof at temperatures between -10 0 C and 100 0 C (diazotization of amino groups is detailed in, for example, Angew. Chem. Int. Ed. 1976, 15, 251 ).
  • the subsequent displacement of the diazo group for a cyano group, chlorine, or bromine using cuprous cyanide, chloride, or bromide, respectively, is known as the Sandmeyer reaction (see e.g. March's Advanced Organic Chemistry, Michael B. Smith and Jerry March, John Wiley & Sons Inc., 6. Ed., New Jersey, 2007 and references quoted therein); the reaction is optionally conducted between -10 °C and 120 0 C in one of the solvents or mixtures mentioned above.
  • the replacement of the diazo group for a fluorine atom may be achieved with a tetrafluoroborate salt or tetrafluoroboric acid and heating to 20 to 160 0 C; the reaction is known as the
  • Iodine may be introduced by treatment of the diazo compound with an iodide salt, e.g. sodium iodide, preferably using water or an aqueous solvent mixture at temperatures between 0 and 120 0 C.
  • the diazo group is replaced for hydroxy using water or an aqueous solvent mixture at temperatures between 0 and 180 0 C.
  • the reaction usually works without further additives but the addition of cuprous oxide or strong acid may be advantageous.
  • Mercapto or alkylmercapto may be introduced via their corresponding disulfide salts or dialkyldisulfides at temperatures between 0 and 120 0 C; depending on the sulfur species used an inert solvent or aqueous solvent system may be preferred (see e.g. Synth. Commun. 2001 , 31, 1857 and references quoted therein).
  • the subsequent replacement of an aromatic amino group by an aryl group may be carried out via the corresponding diazo compound obtainable as described above.
  • the reaction with an aryl nucleophile, preferably an aryl boronic acid, boronic ester, trifluoroborate, zinc halide, or stannane is conducted in the presence of a transition metal species derived from palladium, nickel, rhodium, copper, or iron, preferably palladium.
  • the active catalyst may be a complex of the transition metal with ligands such as e.g.
  • phosphines phosphites, imdiazole carbenes, imidazolidine carbenes, dibenzylideneacetone, ally!, or nitriles, an elemental form of the transition metal such as palladium on carbon or nanoparticles, or salts such as chloride, bromide, acetate, or trifluoroacetate.
  • the diazo compound is preferably employed as its tetrafluoroborate salt optionally in methylene chloride, dimethylformamide, N-me- thylpyrrolidinone, benzene, toluene, tetrahydrofuran, water, ethyl acetate, alcohol, ether, 1 ,2-dimethoxyethane, 1 ,4-dioxane, or mixtures thereof at temperatures between 10 0 C and 180 0 C, preferably between 20 0 C and 140 0 C.
  • the subsequent replacement of an aromatic chloro, bromo, iodo atom or an aromatic trifluoromethylsulfonyloxy, mesyloxy, or tosyloxy group for an aryl, alkenyl, alkynyl, or alkyl residue is preferably mediated by a transition metal species derived from palladium, nickel, rhodium, copper, or iron.
  • the active catalyst may be a complex of the transition metal with ligands such as e.g. phosphines (e.g.
  • triterfbutylphosphine tricyclohexylphosphine, substituted biphenyldicyclohexylphosphines, substituted biphenylditerfbutylphosphines, triphenylphosphine, tritolylphosphine, trifurylphos- phine, 1 ,1 '-bis(diphenylphosphino)ferrocene), phosphites, imdiazole carbenes, imidazolidine carbenes, dibenzylideneacetone, allyl, or nitriles, an elemental form of the transition metal such as palladium on carbon or nanoparticles of iron or palladium, or a salt such as fluoride, chloride, bromide, acetate, thflate, or trifluoroacetate.
  • the replacement is preferably conducted with a trifluoroborate, boronic acid, or boronic ester (Suzuki or Suzuki-type reaction), zinc halide (Negishi or Negishi-type reaction), stannane (Stille reaction), silane (Hiyama or Hiyama-type reaction), magnesium halide (Kumada or Kumada-type reaction) of the aryl, alkenyl, or alkyl residue to be introduced.
  • the terminal alkyne is preferably used as it is or as the zinc acetylide derivative.
  • additives such as halide salts, e.g.
  • Copper iodide is a preferred additive in the coupling with a terminal alkyne group (Sonogashira reaction).
  • the coupling reactions are optionally conducted in methylene chloride, dimethylformamide, N-methylpyrrolidinone, benzene, toluene, tetrahydrofuran, water, ethyl acetate, alcohol, ether, dimethylsulfoxide, 1 ,2- dimethoxyethane, 1 ,4-dioxane, or mixtures thereof, though, depending on the nucleophile some of them are less or not suited at all.
  • Preferred temperatures are in the range from -10 0 C to 180 0 C.
  • the subsequent replacement of an aromatic chlorine, bromine, or iodine atom or an aromatic trifluoromethylsulfonyloxy, mesyloxy, or tosyloxy group for a hydrogen atom is preferably mediated by a transition metal species derived from palladium, nickel, platinum, or rhodium.
  • the active catalyst may be a complex of the transition metal with ligands, an elemental form, or a salt of the transition metal as mentioned above. Raney nickel or palladium on carbon are among the preferred catalyst species.
  • Suited hydrogen sources may be hydrogen, preferably at pressures of 1 to 5 bar, silanes, e.g. trialkoxysilane, boranes, hydrides, e.g.
  • alkali metal borohydride formic acid, or formates, e.g. ammonium formate.
  • the reactions are preferably carried out in methylene chloride, dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, benzene, toluene, tetrahydrofuran, water, ethyl acetate, alcohol, ether, 1 ,2-dimethoxyethane, 1 ,4-dioxane, or mixtures thereof at -10 0 C to 180 0 C, more preferably at 20 0 C to 140 0 C.
  • the subsequent cyclization of two adjacent heteroatoms is optionally conducted with a carboxy equivalent such as nitrile, carboxylic chloride or fluoride, carboxylic acid, ketene, carboxylic ester, or carboxylic thioester.
  • the overall transformation consists of two reaction steps: attachment of the carboxy equivalent to one of the two heteroatoms followed by cyclization with the other heteroatom.
  • the first step is an amide formation with the amino functionality that may be carried out as described hereinbefore.
  • the ensuing reaction step, cyclization with the second heteroatom may be accomplished by heating in the presence of an acid, e.g. acetic acid, trifluoroacetic acid, sulfuric acid, or hydrochloric acid, or a base, e.g.
  • dehydrating reagents such as anhydrides, e.g. acetic anhydride, orthoesters, e.g. trimethylorthoformate, thionylchloride, phosgene, diphosgene, triphosgene, phosphorous oxychloride, phosphorous penta- chloride, dialkylcarbodiimides, combinations of phosphines, e.g. triphenylphosphine or trialkylphosphine with dialkyl azodicarboxylates, bromine, iodine, or 1 ,2-dihalo- ethanes, e.g.
  • 1 ,2-dibromotetrafluoroethane may be advantageous.
  • the reactions are preferably carried out in inert solvents or mixtures such as methylene chloride, dichlo- roethane, benzene, toluene, tetrahydrofuran, ether, or combinations thereof, though, cyclization in the presence of an acid or a base may also be conducted in water or an alcohol, e.g. methanol, ethanol, /sopropanol, or terfoutanol, or combinations with these solvents.
  • the reactions are carried out at temperatures between 0 0 C and 200 0 C, preferably between 20 0 C and 140 0 C.
  • transition metal species may be derived from palladium, nickel, platinum, rhodium, or ruthenium such as, for example, palladium on charcoal, palladium hydroxide, platinum oxide, or Raney nickel that may be used in solvents such as ethyl acetate, alcohols, e.g.
  • methanol or ethanol dichloromethane, tetrahydrofuran, ether, benzene, toluene, dimethylformamide, or N-methylpyrrolidinone at hydrogen pressures between 1 and 10 bar, preferably between 1 and 5 bar, and at temperatures between 0 and 180 0 C 1 preferably between 20 and 120 0 C.
  • Additives such as acids, e.g. hydrochloric acid, methanesulfonic acid, sulfuric acid, or acetic acid, may be beneficial for the hydrogenation.
  • Appropriate hydride sources may be selected from e.g. borohydrides, e.g.
  • Some of these reagents are best used in combination with nickel chloride or cobalt chloride as sodium borohydride.
  • These reagents may be used in e.g. tetrahydrofuran, ether, 1 ,4-dioxane, 1 ,2- dimethoxyethane, dichloromethane, 1 ,2-dichloroethane, benzene, or toluene; some are also compatible with alcoholic solutions.
  • Preferred reaction temperatures range from -80 0 C to 160 0 C, more preferred from -40 0 C to 80 0 C.
  • the subsequent formation of a N-hydroxycarbamimidoyl group from a cyano group may be carried out by the treatment of the cyano compound with hydroxylamine.
  • the reaction is preferably conducted in aqueous or alcoholic solvents at temperatures between 0 0 C and 140 0 C.
  • the subsequent formation of an oxadiazole from an N-hydroxycarbamimidoyl is optionally conducted with a carboxy equivalent such as nitrile, carboxylic chloride or fluoride, carboxylic acid, ketene, carboxylic ester, or carboxylic thioester.
  • the transformation is related to the formation of a ring starting from two adjacent heteroatoms described above and may be carried out analogously.
  • a dehydrating reagent such as e.g. anhydride, e.g. acetic anhydride, trifluoroacetic anhydride, or triflic anhydride, phosgene, thionyl chloride, oxalyl chloride, POCb, PCI 5 , P 4 Oio, triphenylphosphite, or triphenyl- or trialkylphosphine combined with tetrachloromethane, 1 ,2-dibromotetrafluoroethane, or bromine.
  • a dehydrating reagent such as e.g. anhydride, e.g. acetic anhydride, trifluoroacetic anhydride, or triflic anhydride, phosgene, thionyl chloride, oxalyl chloride, POCb, PCI 5 , P 4 Oio, triphenylphosphite, or triphenyl- or trialkylpho
  • the reactions are preferably carried out in dichloromethane, 1 ,2- dichloroethane, hexanes, ether, 1 ,4-dioxane, benzene, toluene, acetonitrile, mixtures thereof, or without a solvent at temperatures between 0 °C and 140 0 C.
  • Additives such as amines, e.g. pyridine or triethylamine, or dimethylformamide may be beneficial.
  • the subsequent reduction of a keto or an aldehydic group to obtain a secondary or primary alcohol may be carried out with a complex metal hydride such as sodium borohydride, lithium borohydride, lithium triethylborohydhde, diisobutylaluminum hydride, or lithium aluminum hydride.
  • a complex metal hydride such as sodium borohydride, lithium borohydride, lithium triethylborohydhde, diisobutylaluminum hydride, or lithium aluminum hydride.
  • the reductions may be conducted in e.g. dichloromethane, 1 ,2-dichloroethane, hexanes, ether, 1 ,4-dioxane, tetrahydrofuran, dimethylformamide, N-methylpyrrolidinone, benzene, toluene, alcohols, e.g.
  • reducing agents are compatible with all of these solvents.
  • Preferred temperatures are between -80 0 C and 140 0 C depending on the reducing power of the reagent.
  • hydrogen in the presence of a transition metal catalyst may be used for the reduction.
  • any reactive group present such as hydroxy, carboxy, amino, alkylamino, or imino group may be protected during the reaction by conventional protecting groups which are cleaved again after the reaction.
  • a protecting group for a hydroxy group may be a trimethylsilyl, terfbutyldimethylsilyl, triisopropylsilyl, acetyl, pivaloyl, benzoyl, methyl, terf-butyl, allyl, trityl, benzyl, 4-methoxybenzyl, tetrahydropyranyl, methoxymethyl, ethoxymethyl, or 2-trimethylsilylethoxymethyl group,
  • protecting groups for a carboxy group may be trimethylsilyl, methyl, ethyl, terfbutyl, allyl, benzyl, or tetrahydropyranyl,
  • protecting groups for a ketone or aldehyde may be a ketal or acetal, respectively, e.g. derived from methanol, glycol, or propane-1 ,3-diol,
  • protecting groups for an amino, alkylamino, or imino group may be methyl, formyl, acetyl, trifluoroacetyl, ethoxycarbonyl, terf-butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl, or 2,4-dimethoxybenzyl and for the amino group additionally phthalyl, and
  • protecting groups for a terminal alkyne may be trimethylsilyl, trisopropylsilyl, teributyldimethylsilyl, or 2-hydroxy-isopropyl.
  • Any acyl protecting group may be cleaved, for example, hydrolytically in an aqueous solvent, e.g. in water, isopropanol/water, acetic acid/water, tetrahydrofuran/water, or 1 ,4-dioxane/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid, or sulfuric acid or in the presence of an alkali metal base such as lithium hydroxide, sodium hydroxide, or potassium hydroxide or aprotically, e.g. in the presence of iodotrimethylsilane, at temperatures between 0 and 120 0 C, preferably between 10 and 100 0 C.
  • an aqueous solvent e.g. in water, isopropanol/water, acetic acid/water, tetrahydrofuran/water, or 1 ,4-dioxane/water
  • an acid such as trifluoroacetic acid, hydrochlor
  • a trifluoroacetyl group is preferably cleaved by treating with an acid such as hydrochloric acid, optionally in a solvent such as acetic acid, at temperatures between 50 and 120 0 C or by treating with sodium hydroxide solution, optionally in an additional solvent such as tetrahydrofuran or methanol, at temperatures between 0 and 80 0 C.
  • an acid such as hydrochloric acid
  • a solvent such as acetic acid
  • sodium hydroxide solution optionally in an additional solvent such as tetrahydrofuran or methanol
  • Any acetal or ketal protecting group used may be cleaved, for example, hydrolytically in an aqueous solvent, e.g. in water, isopropanol/water, acetic acid/water, tetrahydrofuran/water, or 1 ,4-dioxane/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid, or sulfuric acid or aprotically, e.g. in the presence of iodotrimethylsilane, at temperatures between 0 and 120 0 C, preferably between 10 and 100 0 C.
  • an acid such as trifluoroacetic acid, hydrochloric acid, or sulfuric acid or aprotically, e.g. in the presence of iodotrimethylsilane, at temperatures between 0 and 120 0 C, preferably between 10 and 100 0 C.
  • a trimethylsilyl group is cleaved, for example, in water, an aqueous solvent mixture or an alcohol, such as methanol or ethanol, in the presence of a base such as lithium hydroxide, sodium hydroxide, potassium carbonate, or sodium methoxide.
  • a base such as lithium hydroxide, sodium hydroxide, potassium carbonate, or sodium methoxide.
  • Acids such as e.g. hydrochloric acid, trifluoroacetic acid, or acetic acid may also be suitable.
  • the cleavage usually takes place at comparatively low temperatures, e.g. between -60 and 60 0 C.
  • SiIyI groups other than trimethylsilyl are preferentially cleaved in the presence of an acid, e.g.
  • a particularly suited cleaving method for silyl groups is based on the use of fluoride salts, e.g. tetrabutylammonium fluoride, hydrogen fluoride, or potassium fluoride, in organic solvents, such as for example diethyl ether, tetrahydrofuran, 1 ,4-dioxane, 1 ,2-dimethoxyethane, toluene, benzene, dichloroethane, or dichloromethane at temperatures between -20 and 100 0 C.
  • fluoride salts e.g. tetrabutylammonium fluoride, hydrogen fluoride, or potassium fluoride
  • organic solvents such as for example diethyl ether, tetrahydrofuran, 1 ,4-dioxane, 1 ,2-dimethoxyethane, toluene, benzene, dichloroethane, or dichloromethane at temperatures between
  • a benzyl, methoxybenzyl, or benzyloxycarbonyl group is advantageously cleaved hydrogenolytically, e.g. with hydrogen in the presence of a catalyst such as palladium on carbon, palladium hydroxide, or platinum oxide in a solvent such as methanol, ethanol, ethyl acetate, or glacial acetic acid, optionally in the presence of an acid, such as hydrochloric acid, at temperatures between 0 and 100 0 C, preferably between 20 and 60 0 C, and at hydrogen pressures of 1 to 7 bar, preferably 3 to 5 bar.
  • a catalyst such as palladium on carbon, palladium hydroxide, or platinum oxide
  • a solvent such as methanol, ethanol, ethyl acetate, or glacial acetic acid
  • an acid such as hydrochloric acid
  • Trimethylsilyl iodide, boron trichloride, or boron trifluoride in the presence of a scavenger such as anisol, thioanisol, or pentamethylbenzene may also be used with benzylether derivatives.
  • An electron-rich benzyl residue, such as methoxybenzyl may also be cleaved oxidatively with e.g. 2,3-dichloro-5,6-dicyano-1 ,4-benzoquinone (DDQ) or eerie ammonium nitrate (CAN) preferably in an alcoholic or aqueous solvent at temperatures between 10 and 120 0 C.
  • a 2,4-dimethoxybenzyl group is preferably cleaved in trifluoroacetic acid in the presence of a scavenger such as anisole.
  • a te/tbutyl or terfbutyloxycarbonyl group is preferably cleaved by treating with an acid such as trifluoroacetic acid, sulfuric acid, or hydrochloric acid or by treating with iodo- trimethylsilane optionally using a solvent such as methylene chloride, 1 ,4-dioxane, methanol, isopropanol, water, or diethylether.
  • an acid such as trifluoroacetic acid, sulfuric acid, or hydrochloric acid
  • iodo- trimethylsilane optionally using a solvent such as methylene chloride, 1 ,4-dioxane, methanol, isopropanol, water, or diethylether.
  • a methyl group at an tertiary amine may be cleaved by the treatment with 1-chloro- ethyl chloroformate.
  • Hydrobromic acid and borontribromide are particularly suited for the cleavage of methylethers.
  • the compounds of general formula I may be resolved into their enantiomers and/or diastereomers, as mentioned before.
  • cis/trans mixtures may be resolved into their cis and trans isomers, and racemic compounds may be separated into their enantiomers.
  • the cis/trans mixtures may be resolved, for example, by chromatography into the cis and trans isomers thereof.
  • the compounds of general formula I which occur as racemates may be separated by methods known per se (cf. Allinger N. L. and Eliel E. L. in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971) into their optical antipodes and diastereomeric mixtures of compounds of general formula I may be resolved into their diastereomers by taking advantage of their different physico- chemical properties using methods known per se, e.g. chromatography and/or fractional crystallization; if the compounds obtained thereafter are racemates, they may be resolved into the enantiomers as mentioned above.
  • racemates are preferably resolved by column chromatography on chiral phases or by crystallisation from an optically active solvent or by reacting with an optically active substance which forms salts or derivatives, such as e.g. esters or amides, with the racemic compound.
  • Salts may be formed with enantiopure acids for basic compounds and with enantiopure bases for acidic compounds.
  • Diastereomeric derivatives are formed with enantiopure auxiliary compounds such as e.g. acids, their activated derivatives, or alcohols. Separation of the diastereomeric mixture of salts or derivatives thus obtained may be achieved by taking advantage of their different physico-chemical properties, e.g.
  • Optically active acids in common use for such a purpose are e.g. the D- and L-forms of tartaric acid, dibenzoyltartaric acid, di-o-tolyltartaric acid, malic acid, mandelic acid, camphorsulfonic acid, glutamic acid, aspartic acid, or quinic acid.
  • Optically active alcohols applicable as auxiliary may be, for example, (+) or (-)-menthol and optically active acyl groups in amides may be, for example, (+)- or (-)-menthyloxycarbonyl.
  • the compounds of formula I may be converted into salts, particularly for pharmaceutical use into the physiologically acceptable salts with inorganic or organic acids provided that compound I bears a basic residue.
  • Acids which may be used for this purpose include for example hydrochloric acid, hydro- bromic acid, sulfuric acid, methanesulfonic acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid, or maleic acid.
  • the compounds of formula I may be converted into the salts thereof with inorganic or organic bases, particularly for pharmaceutical use into the physiologically acceptable salts thereof.
  • bases for this purpose include, for example, sodium hydroxide, potassium hydroxide, calcium hydroxide, calcium isopropoxide, magnesium hydroxide, magnesium ethoxide, ammonium hydroxide, cyclohexylamine, ethanolamine, diethanol- amine, triethanolamine, N-methyl-D-glucamine, L-lysine, L-arginine, and piperazine.
  • the compounds of general formula I according to the invention and the physiologically acceptable salts thereof have valuable pharmacological properties, particularly an inhibitory effect on the enzyme 11 ⁇ -hydroxysteroid dehydrogenase (HSD) 1.
  • HSD ⁇ -hydroxysteroid dehydrogenase
  • the biological properties of the new compounds may be investigated as follows:
  • HTRF Homogeneous Time-Resolved Fluorescence
  • the incubation period for detection reaction was typically 2 hours.
  • the amount of Cortisol is determined by reading the time-resolved fluorescence of the wells (Ex 320/75 nm; Em 615/8.5 nm and 665/7.5 nm). The ratio of the two emission signals is then calculated (Em665 * 10000/Em615).
  • Each assay contained incubations with vehicle controls instead of compound as controls for non-inhibited Cortisol generation (100% CTL; 'high values') and incubations with carbenoxolone as controls for fully inhibited enzyme and Cortisol background (0% CTL; 'low values').
  • Each assay also contained a calibration curve with Cortisol to transform the fluorescent data into Cortisol concentrations. Percent inhibition of each compound was determined relative to the carbenoxolone signal and IC 50 curves were generated.
  • the compounds of general formula I according to the invention for example have IC50 values below 10000 nM, particularly below 1000 nM, most preferably below 200 nM.
  • the %CTL values of some example compounds at a concentration of 1 ⁇ M are provided in the following Table 2 wherein 100% indicates no inhibition and a value of zero or below zero indicates complete inhibition. The measurement of %CTL is described hereinbefore.
  • retinopathy retinopathy, nephropathy or neuropathies, diabetic foot, ulcers, macroangiopathies, slow or poor wound healing
  • metabolic acidosis or ketosis reactive hypoglycaemia, hyperinsulinaemia, glucose metabolic disorder, insulin resistance, metabolic syndrome, dyslipidaemias of different origins, atherosclerosis and related diseases, obesity, high blood pressure, chronic heart failure, edema and hyperuricaemia.
  • beta-cell degeneration such as e.g. apoptosis or necrosis of pancreatic beta cells.
  • the substances are also suitable for improving or restoring the functionality of pancreatic cells, and also of increasing the number and size of pancreatic beta cells.
  • the compounds according to the invention may also be used as diuretics or antihypertensives and are suitable for the prevention and treatment of acute renal failure.
  • HSD 11 ⁇ -hydroxysteroid dehydrogenase
  • the compounds may have beneficial effects in treatment or prevention of osteoporosis.
  • HSD 11 ⁇ -hydroxysteroid dehydrogenase
  • the dynamic interaction between the immune system and the HPA (hypothalamo- pituitary-adrenal) axis is known, and glucocorticoids help balance between cell- mediated responses and humoral responses.
  • the immune reaction is typically biased towards a humoral response in certain disease states, such as tuberculosis, leprosy, and psoriasis. More appropriate would be a cell-based response.
  • An 11 ⁇ - hydroxysteroid dehydrogenase (HSD) 1 inhibitor would bolster a temporal immune response in association with immunization to ensure that a cell based response would be obtained, and as such could be useful in immunomodulation.
  • HSD 11 ⁇ - hydroxysteroid dehydrogenase
  • the compounds according to the invention are suitable for the prevention or treatment of diabetes, particularly type 1 diabetes mellitus, type 2 diabetes mellitus, and diabetic complications.
  • the dosage required to achieve the corresponding activity for treatment or prevention usually depends on the compound which is to be administered, the patient, the nature and gravity of the illness or condition and the method and frequency of administration and is for the patient's doctor to decide.
  • the dosage may be from 1 to 100 mg, preferably 1 to 30 mg, by intravenous route, and 1 to 1000 mg, preferably 1 to 100 mg, by oral route, in each case administered 1 to 4 times a day.
  • the compounds of formula I prepared according to the invention may be formulated, optionally together with other active substances, together with one or more inert conventional carriers and/or diluents, e.g.
  • active substances which are suitable for such combinations include for example those which potentiate the therapeutic effect of an 11 ⁇ -hydroxysteroid dehydrogenase (HSD) 1 antagonist according to the invention with respect to one of the indications mentioned and/or which allow the dosage of an 11 ⁇ -hydroxysteroid dehydrogenase (HSD) 1 antagonist according to the invention to be reduced.
  • Therapeutic agents which are suitable for such a combination include, for example, antidiabetic agents such as metformin, sulfonylureas (e.g. glibenclamide, tolbutamide, glimepiride), nateglinide, repaglinide, thiazolidinediones (e.g.
  • SGLT 2 inhibitors e.g. dapagliflozin, sergliflozin
  • PPAR-gamma-agonists e.g. Gl 262570
  • antagonists PPAR-gamma/alpha modulators
  • alpha-glucosidase inhibitors e.g. acarbose, voglibose
  • DPPIV inhibitors e.g.
  • Sitagliptin Vildagliptin, Saxagliptin, Alogliptin, Linagliptin), alpha2-antagonists, insulin and insulin analogues, GLP-1 and GLP-1 analogues (e.g. exendin-4) or amylin.
  • the list also includes inhibitors of protein tyrosinephosphatase 1 , substances that affect deregulated glucose production in the liver, such as e.g.
  • lipid lowering agents such as for example HMG-CoA-reductase inhibitors (e.g. simvastatin, atorvastatin), fibrates (e.g.
  • PPAR-alpha agonists e.g. avasimibe
  • cholesterol absorption inhibitors such as, for example, ezetimibe
  • bile acid-binding substances such as, for example, cholestyramine, inhibitors of ileac bile acid transport, HDL- raising compounds such as CETP inhibitors or ABC1 regulators or active substances for treating obesity, such as sibutramine or tetrahydrolipostatin, SDRIs, axokine, leptin, leptin mimetics, antagonists of the cannabinoidi receptor, MCH-1 receptor antagonists, MC4 receptor agonists, NPY5 or NPY2 antagonists or ⁇ 3-agonists such as SB-418790 or AD-9677 and agonists of the 5HT2c receptor.
  • ACAT inhibitors e.g. avasimibe
  • cholesterol absorption inhibitors such as, for example, ezetimibe
  • bile acid-binding substances such as, for example,
  • drugs for influencing high blood pressure, chronic heart failure or atherosclerosis such as e.g. A-Il antagonists or ACE inhibitors, ECE inhibitors, diuretics, ⁇ -blockers, Ca-antagonists, centrally acting antihypertensives, antagonists of the alpha-2-adrenergic receptor, inhibitors of neutral endopeptidase, thrombocyte aggregation inhibitors and others or combinations thereof are suitable.
  • drugs for influencing high blood pressure, chronic heart failure or atherosclerosis such as e.g. A-Il antagonists or ACE inhibitors, ECE inhibitors, diuretics, ⁇ -blockers, Ca-antagonists, centrally acting antihypertensives, antagonists of the alpha-2-adrenergic receptor, inhibitors of neutral endopeptidase, thrombocyte aggregation inhibitors and others or combinations thereof are suitable.
  • angiotensin Il receptor antagonists examples include candesartan cilexetil, potassium losartan, eprosartan mesylate, valsartan, telmisartan, irbesartan, EXP-3174, L- 158809, EXP-3312, olmesartan, medoxomil, tasosartan, KT-3-671 , GA-0113, RU- 64276, EMD-90423, BR-9701 , etc.
  • Angiotensin Il receptor antagonists are preferably used for the treatment or prevention of high blood pressure and complications of diabetes, often combined with a diuretic such as hydrochlorothiazide.
  • a combination with uric acid synthesis inhibitors or uricosurics is suitable for the treatment or prevention of gout.
  • a combination with GABA-receptor antagonists, Na-channel blockers, topiramat, protein-kinase C inhibitors, advanced glycation end product inhibitors or aldose reductase inhibitors may be used for the treatment or prevention of complications of diabetes.
  • the dosage for the combination partners mentioned above is usefully 1/5 of the lowest dose normally recommended up to 1/1 of the normally recommended dose.
  • this invention relates to the use of a compound according to the invention or a physiologically acceptable salt of such a compound combined with at least one of the active substances described above as a combi- nation partner, for preparing a pharmaceutical composition which is suitable for the treatment or prevention of diseases or conditions which can be affected by inhibiting the enzyme 11 ⁇ -hydroxysteroid dehydrogenase (HSD) 1.
  • HSD 11 ⁇ -hydroxysteroid dehydrogenase
  • the use of the compound according to the invention, or a physiologically acceptable salt thereof, in combination with another active substance may take place simultaneously or at staggered times, but particularly within a short space of time. If they are administered simultaneously, the two active substances are given to the patient together; while if they are used at staggered times the two active substances are given to the patient within a period of less than or equal to 12 hours, but particularly less than or equal to 6 hours.
  • this invention relates to a pharmaceutical composition which comprises a compound according to the invention or a physiologically acceptable salt of such a compound and at least one of the active substances described above as combination partners, optionally together with one or more inert carriers and/or diluents.
  • a pharmaceutical composition according to the invention comprises a combination of a compound of formula I according to the invention or a physiologically acceptable salt of such a compound and at least one angiotensin Il receptor antagonist optionally together with one or more inert carriers and/or diluents.
  • the compound according to the invention, or a physiologically acceptable salt thereof, and the additional active substance to be combined therewith may both be present together in one formulation, for example a tablet or capsule, or separately in two identical or different formulations, for example as a so-called kit-of-parts.
  • ambient temperature and “room temperature” are used interchangeably and designate a temperature of about 20 0 C.
  • Phenylacetylene (15.4 ml_) is added to a mixture of 2-bromo-4-methyl-pyridine (20.0 g), CuI (2.2 g), and Pd(PPh 3 ) 2 Cl 2 (4.1 g) in thethylamine (600 ml_) kept under argon atmosphere. The mixture is stirred at ambient temperature overnight. Then, water is added and the resulting mixture is extracted with diethylether. The combined organic extracts are washed with brine and dried (MgSO 4 ). The solvent is removed under reduced pressure and the residue is purified by chromatography on silica gel
  • the starting material, 3,11 ,11 -trimethyl-2, 3,4, 5-tetrahydro-1 H-2,6-methano- benzo[d]azocin-6-ol may be obtained in analogy to EP 28717 (1981 ) from 2-benzyl- 1 ,3,3-trimethyl-pipehdinone.
  • the starting material 8-hydroxy-3-methyl-2,3,4,5-tetrahydro-1 H-2,6-methano- benzo[d]azocine-6-carboxylic acid methyl ester, may be obtained in analogy to J. Med. Chem. 1962, 5, 357-361 and US 3687957 (1972) from 8-methoxy-3-methyl-1- oxo-2, 3,4, 5-tetrahydro-1 H-2,6-methano-benzo[d]azocine-6-carbonitrile.
  • the methoxy group on the aromatic ring may be cleaved by using boron tribromide in dichloromethane or hydrobromic acid in acetic acid (see e.g. J. Med. Chem. 1992, 35, 4135-4142; J. Med. Chem. 2004, 47, 165-174).
  • the starting material may also be obtained by reacting compound Example XXII(I ) with boron tribromide in dichloromethane.
  • the starting material 3,11 ,11-trimethyl-6-phenyl-1 ,2,3,4,5,6-hexahydro-2,6-methano- benzo[d]azocin-8-ol, may be obtained as described in DE 2027077 (1970).
  • 3-methyl-6-propyl-1 , 2,3,4, 5,6-hexahydro-2,6-methano- benzo[d]azocin-8-ol may be obtained as described in J. Med. Chem. 1963, 6, 322-5.
  • the starting material 3,6-Dimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano- benzo[d]azocin-8-ol, may be obtained as described in J. Org. Chem. 1960, 25, 1386- 8.
  • the compound is prepared from (2R,6S)-9-methoxy-6,11 ,11-trimethyl-1 , 2,3,4,5, 6- hexahydro-2,6-methano-benzo[d]azocine [tartaric acid salt, for preparation see WO 9959976] and isolated as the hydrogen bromide salt.
  • Di-terfbutyl dicarbonate (8.7 g) is added to a solution of 6,11 ,11-trimethyl-1 ,2,3,4,5,6- hexahydro-2,6-methano-benzo[d]azocin-9-ol (12.0 g) and triethylamine (8 ml) in 1 ,4- dioxane (100 ml_) and water (100 ml_). The solution is stirred at room temperature overnight. Then, ethyl acetate is added and the organic phase is separated. The aqueous phase is extracted with ethyl acetate and the organic extract and phase are combined.
  • the compound may be obtained by resolution of the racemic mixture by HPLC on chiral phase
  • the compound may be obtained by resolution of the racemic mixture by HPLC on chiral phase
  • the compound may be obtained by resolution of the racemic mixture by HPLC on chiral phase
  • the compound may be obtained by resolution of the racemic mixture by HPLC on chiral phase (7) 8-Hydroxy-6,11 ,11-trimethyl-1 ⁇ .S.e-tetrahydro ⁇ H ⁇ .e-methano-benzoIdlazocine- 3-carboxylic acid tert-butyl ester
  • the compound may be obtained by resolution of the racemic mixture by HPLC on chiral phase or by using the enantiomerically pure starting material that in turn may be obtained as described in Example XIII(I ) or by resolution of the racemic mixture by HPLC on chiral phase.
  • the synthesis of the racemic starting material is described in EP 521422 (1993).
  • Trifluoromethanesulfonic anhydride (9.7 ml_) is added to a solution of (2R,6S)-3- benzyl-6,11 ,11-tri methyl- 1 , 2,3,4,5, 6-hexahydro-2,6-methano-benzo[d]azocin-10-ol (13.7 g), triethylamine (43 mL), and 4-dimethylaminopyridine (50 mg) in dichloromethane (135 mL) chilled to -10 0 C under argon atmosphere. The solution is stirred at ca. -5 0 C for 30 min and then at room temperature overnight. The solution is added to ice-cold water and then aqueous ammonia solution is added.
  • the compound is prepared from end compound Example 35
  • Tetrakis(triphenylphosphine)palladium(0) (2.79 g) is added to a mixture of (2f?,6S)- trifluoro-methanesulfonic acid 3-benzyl-6,11 ,11-trimethyl-1 ⁇ .S ⁇ . ⁇ . ⁇ -hexahydro ⁇ . ⁇ - methano-benzo[d]azocin-10-yl ester (7.30 g) and zinc cyanide (2.85 g) in dimethyl- formamide (35 ml_) kept in argon atmosphere. The resulting mixture is stirred at 100 0 C for 6 h.
  • the compound is prepared from (2R,6f?,11 S)-6,11-dimethyl-1 , 2,3,4, 5,6-hexahydro-
  • the compound may be prepared from 1-hydroxy-8-methoxy-3-methyl-2, 3,4,5- tetrahydro-1 H-2,6-methano-benzo[d]azocine-6-carbonitrile [for synthesis see US 3687957 (1972)] as described above using methanol instead of ethanol.
  • the debenzylation is carried out in the presence of 1 equivalent of 1 M hydrochloric acid as described above.
  • Aqueous 2 M Na 2 CO 3 solution (5 mL) is added to a mixture of 6,11 ,11-trimethyl-9- trifluoromethanesulfonyloxy-1 ,2 ) 5,6-tetrahydro-4H-2,6-methano-benzo[d]azocine-3- carboxylic acid tert-butyl ester (1.00 g) and phenylboronic acid (0.34 g) in dimethyl- formamide (5 mL) in argon atmosphere. The resulting mixture is flushed with argon and then 1 ,1 '-bis(diphenylphosphino)ferrocene-palladium(ll) dichloride dichloro- methane complex (0.18 g) is added.
  • Trifluoroacetic acid (0.5 ml_) is added to a solution of 6,11 ,11 -trimethyl-9-phenyl- 1 ⁇ .S. ⁇ -tetrahydro ⁇ H ⁇ . ⁇ -methano-benzo[d]azocine-S-carboxylic acid tert-butyl ester (0.30 g) in dichloromethane (2.5 mL). The solution is stirred at ambient temperature for 1 h and is then concentrated under reduced pressure. The crude trifluoroacetic acid salt of the title compound is used without further purification. Yield: 0.31 g (100% of theory)
  • the transformation may also be carried out analogously using HCI in 1 ,4-dioxane or isopropanol instead of trifluoroacetic acid in dichloromethane.
  • the compound is obtained as its trifluoroacetic acid salt.
  • the compound is obtained as its double trifluoroacetic acid salt.
  • the compound may be obtained by resolution of the racemic mixture by HPLC on chiral phase or by using the enantiomerically pure (2S,6R)-8-methoxy-6,9,11 ,11- tetramethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocine-3-carboxylic acid tert-butyl ester.
  • the compound may be obtained by resolution of the racemic mixture by HPLC on chiral phase or by using the enantiomerically pure (2R,6S)-8-methoxy-6,9,11 ,11- tetramethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocine-3-carboxylic acid tert-butyl ester.
  • the compound may be obtained by resolution of the racemic mixture by HPLC on chiral phase or by using the enantiomerically pure (2S,6R)-9-methoxy-6,8,11 ,11- tetramethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocine-3-carboxylic acid tert-butyl ester.
  • the compound may be obtained by resolution of the racemic mixture by HPLC on chiral phase or by using the enantiomerically pure (2R,6S)-9-methoxy-6,8,11 ,11- tetramethyl-i ⁇ . ⁇ . ⁇ -tetrahydro ⁇ H ⁇ . ⁇ -methano-benzoIdJazocine-S-carboxylic acid tert-butyl ester.
  • the compound is obtained as its trifluoroacetic acid salt.
  • the compound may be obtained from the racemic mixture by HPLC on reversed phase.
  • the compound is obtained as the HCI salt from 7-oxo-2,8-diaza-spiro[5.5]undecane- 2-carboxylic acid tert-butyl ester using HCI in 1 ,4-dioxane.
  • the compound is isolated as its trifluoroacetic acid salt.
  • the compound may be obtained from 1-hydroxy-8-methoxy-3-methyl-2, 3,4,5- tetrahydro-I H ⁇ .e-methano-benzofdlazocine- ⁇ -carboxylic acid methyl ester employing the procedure described above.
  • the reduction may be conducted in analogy to J. Org. Chem. 1987, 52, 5233-5239.
  • Di-tert-butyl dicarbonate (0.34 g) is added to a solution of 6,11 ,11 -trimethyl- 1 ,2,3 AS.e-hexahydro ⁇ .e-methano-benzotdJazocine- ⁇ . ⁇ -diol (0.44 g) and triethylamine (0.43 ml_) in dichloromethane (5 ml_).
  • the solution is stirred at room temperature for 2 h. Then, the solution is washed twice with water and once with brine. After drying (MgSO 4 ), the solvent is removed under reduced pressure to yield the product. Yield: 0.43 g (80% of theory)
  • a mixture of 8,9-dihydroxy-6,11 ,11-trimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester (0.21 g), K 2 CO 3 (0.19 g) and diiodomethane (54 ⁇ l_) in dimethylformamide (5 ml_) is heated to 100 0 C and stirred at this temperature for 2 h. Then, another portion of diiodomethane (54 ⁇ L) and K 2 CO 3 (0.18 g) is added and the mixture is further stirred at 100 0 C for 5 h.
  • the racemic product mixture is resolved into its enantiomers by using HPLC on chiral phase.
  • the compound may also be obtained in analogy to the procedure described in J. Med. Chem. 1997, 40, 2922-2930.
  • Trifluoroacetic anhydride (5.0 mL) is added to a solution of the hydrobromic acid salt of (2R,6S)-6,11 ,11-trimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-10- ol (5.0 g) and thethylamine (5.5 mL) in dichloromethane (50 mL) chilled in an ice bath. The resulting solution is stirred at ambient temperature overnight. Then, water is added, the resulting mixture is stirred for an additional 15 min, and the organic phase is separated. The organic phase is washed with water and brine, dried (Na 2 SO 4 ), and the solvent is evaporated.
  • Nitric acid (0.4 ml_) is slowly added to a solution of 2,2,2-trifluoro-1-[(2R,6S)-10- hydroxy-6,11 ,11-trimethyl-1 ⁇ .S. ⁇ -tetrahydro ⁇ H ⁇ . ⁇ -methano-benzo[d]azocin-S-yl]- ethanone (2.9 g) in acetic acid (5 ml_) chilled in an ice bath. The ice bath is removed and the solution is stirred at ambient temperature overnight. The solution is poured into ice-cold water and the resulting mixture is extracted with ethyl acetate. The combined extracts are washed with brine and dried (Na 2 SO 4 ). After removal of the solvent under reduced pressure, the residue is purified by chromatography on silica gel (ethyl acetate/cyclohexane 1 :9->1 :3).
  • the compound is obtained in a mixture with compound Example XXXII(I ) that is separated by chromatography as described above.
  • the compound is obtained in a mixture with compound Example XXXII(4) that is separated by chromatography as described above.
  • Example XXXIH The compound is obtained in a mixture with compound Example XXXII(3) that is separated by chromatography as described above.
  • Example XXXIH The compound is obtained in a mixture with compound Example XXXII(3) that is separated by chromatography as described above.
  • Example XXXIH The compound is obtained in a mixture with compound Example XXXII(3) that is separated by chromatography as described above.
  • Example XXXIH Example XXXIH
  • Methyl iodide (80 ⁇ L) is added to a mixture of 2,2,2-trifluoro-1-[(2f?,6S)-10-hydroxy- 6,11 ,11-trimethyl-9-nitro-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocin-3-yl]- ethanone (0.40 g) and potassium carbonate (0.17 g) in dimethylformamide (5 ml_). The mixture is stirred at room temperature overnight, before another portion of methyl iodide (80 ⁇ L) and potassium carbonate (0.16 g) are added. The mixture is stirred for another 6 h at room temperature.
  • the compound may be obtained by resolution of the racemic mixture by HPLC on chiral phase or by using the enantiomerically pure (2S,6R)-8-hydroxy-6,9,11 ,11- tetramethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocine-3-carboxylic acid tert-butyl ester.
  • the compound may be obtained by resolution of the racemic mixture by HPLC on chiral phase or by using the enantiomerically pure (2/?,6S)-8-hydroxy-6,9, 11 ,11- tetramethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocine-3-carboxylic acid tert-butyl ester.
  • the compound may be obtained by resolution of the racemic mixture by HPLC on chiral phase or by using the enantiomerically pure (2S,6f?)-9-hydroxy-6,8,11 ,11- tetramethyl-i ⁇ . ⁇ . ⁇ -tetrahydro ⁇ H ⁇ . ⁇ -methano-benzoIdlazocine-S-carboxylic acid tert-butyl ester.
  • the compound may be obtained by resolution of the racemic mixture by HPLC on chiral phase or by using the enantiomerically pure (2R,6S)-9-hydroxy-6,8,11 ,11- tetramethyl-i ⁇ . ⁇ . ⁇ -tetrahydro ⁇ H ⁇ .e-methano-benzo[d]azocine-S-carboxylic acid tert-butyl ester. ( ⁇ J ⁇ . ⁇ -Dimethoxy-e.H .I I-trimethyl-I ⁇ .S.e-tetrahydro ⁇ H ⁇ .e-methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester
  • the compound is obtained in a mixture with 8-hydroxy-9-methoxy-6,11 ,11-trimethyl- 1 ⁇ . ⁇ . ⁇ -tetrahydro ⁇ H ⁇ . ⁇ -methano-benzo[d]azocine-S-carboxylic acid tert-butyl ester and 8,9-dimethoxy-6J 1 J I-trimethyl-I ⁇ .S.G-tetrahydro ⁇ H ⁇ -methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester from 8,9-dihydroxy-6,11 ,11- trimethyl-1 ⁇ . ⁇ .e-tetrahydro ⁇ H ⁇ . ⁇ -methano-benzotdjazocine-S-carboxylic acid tert- butyl ester that may be separated by HPLC on reversed phase (MeCN/H 2 O).
  • the compound is obtained in a mixture with 9-hydroxy-8-methoxy-6,11 ,11-trimethyl- 1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocine-3-carboxylic acid tert-butyl ester and S. ⁇ -dimethoxy-e.H .I I-trimethyl-I ⁇ .S.e-tetrahydro ⁇ H ⁇ . ⁇ -methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester from 8,9-dihydroxy-6,11 ,11- trimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocine-3-carboxylic acid tert- butyl ester that may be separated by HPLC on reversed phase (MeCN/H 2 O).
  • the compound may be obtained from the racemic mixture by HPLC on chiral phase.
  • the compound is obtained from S-carboxymethyl-S-phenyl-pyrrolidine-i-carboxylic acid tert-butyl ester employing the procedure described above.
  • the reaction mixture is stirred at 170 0 C for 5 h.
  • Chlorosulfonic acid (1.15 ml_) is slowly added to a solution of 2,2,2-trifluoro-1- [(2R,6S)-6,11 ,11-trimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocin-3-yl]- ethanone (0.90 g) in dichloromethane (10 ml_) at room temperature. Then, the solution is stirred at ambient temperature overnight. The solution is poured into ice- cold water and the resulting mixture is extracted with ethyl acetate. The combined organic extracts are washed with brine and dried (MgSO 4 ). The solvent is removed under reduced pressure to give the crude title compounds in a mixture that is used without further purification. Yield: 1.18 g
  • Acetyl chloride (0.25 ml_) is added to a suspension Of AICI 3 (1.3 g) in CH 2 CI 2 (5 ml_) chilled in an ice bath. After stirring the mixture for 5 min, 2,2,2-trifluoro-1-[(2R,6S)- 6,11 ,11-trimethyl-1 ⁇ . ⁇ .e-tetrahydro ⁇ H ⁇ . ⁇ -methano-benzofdJazocin-S-yll-ethanone (1.0 g) dissolved in dichloromethane (5 mL) is added dropwise. The mixture is stirred at ambient temperature overnight and then poured into ice-cold half-concentrated hydrochloric acid (20 mL).
  • the resulting mixture is extracted with CH 2 CI 2 and the combined organic extracts are washed with water, aqueous NaHCO 3 solution, and brine and dried (MgSO 4 ). The solvent is removed and the residue is purified by chromatography on silica gel (cyclohexane/ethyl acetate 3:1 ->1 :1) to give the two regioisomeric title compounds in a ca. 3:1 mixture.
  • N,N'-Carbonyldiimidazole (6.8 g) is added to (2R,6S)-6,11 ,11-trimethyl-1 , 2,3,4,5,6- hexahydro-2,6-methano-benzo[d]azocin-10-ol (9.66 g) dissolved in tetrahydrofuran (100 ml_). The resulting solution is stirred at reflux temperature for 3 h. Then, potassium carbonate (4.0 g) is added and the mixture is stirred at reflux temperature for another 4 h. After cooling to ambient temperature, aqueous NaHC ⁇ 3 solution is added and the resulting mixture is extracted with ethyl acetate.
  • AICI 3 (147 mg) is added to a solution of 2,2,2-trifluoro-1-[(2R,6S)-6, 11 ,11 -trimethyl- 1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocin-3-yl]-ethanone (275 mg) in 1 ,2- dichloroethane (10 mL). The resulting mixture is stirred at ambient temperature for 10 min before bromine (52 ⁇ L) is added. The mixture is heated to 50 °C. After stirring at 50 0 C for 1 h, the mixture is cooled to ambient temperature and diluted with dichloromethane (30 mL) and water (10 mL).
  • MeSO 2 Na (0.79 g) is added to a mixture of CuI (1.5 g) and 1-[(2R6S)-8-bromo- 6,11 ,11-trimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocin-3-yl]-2,2,2- trifluoro-ethanone/1 -[(2R6S)-10-bromo-6, 11 ,11 -trimethyl-1 ,2,5,6-tetrahydro-4H-2,6- methano-benzo[d]azocin-3-yl]-2,2,2-trifluoro-ethanone (300 mg, crude product from Example XLVIII) in dimethylsulfoxide (6 mL).
  • the resulting mixture is heated to 120 0 C and stirred at this temperature overnight. After cooling to ambient temperature, the mixture is poured into a solution of concentrated aqueous ammonia (20 mL) and water (80 mL). The resulting mixture is extracted with ethyl acetate and the combined organic extracts are washed with 2 M ammonia solution and brine. After drying (MgSO 4 ), the solvent is removed under reduced pressure and the residue is purified by HPLC on reversed phase (MeCN/water) to give the two title compounds separated.
  • Nitric acid (0.16 ml_) is added to a solution of trifluoroacetic acid (0.65 ml_) in dichloromethane (4 mL) chilled in an ice bath (ca. 0 0 C). After stirring for 10 min,
  • the compound is obtained by using diacetyl according to the procedure described above.
  • reaction is carried out with formic acid instead of acetic acid.
  • the two isomeric compounds (1 ) and (2) were obtained from the same starting compound and separated by HPLC on reversed phase.

Abstract

The present invention relates to compounds defined by formula (I) wherein the groups A, B, X, m, n and o are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity and dyslipidemia.

Description

Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
The present invention relates to compounds derived from the following chemical scaffold which is structurally defined by the formula I
Figure imgf000002_0001
wherein the groups A, B1 X, m, n and o are as defined hereinafter, including the tautomers, the stereoisomers, the mixtures thereof and the salts thereof. The invention further relates to pharmaceutical compositions containing a compound of formula I according to the invention as well as the use of a compound according to the invention for preparing a pharmaceutical composition for the treatment of metabolic disorders. In addition, the invention relates to processes for preparing a pharmaceutical composition as well as a compound according to the invention.
In the literature, compounds which have an inhibitory effect on the enzyme 11 β- hydroxysteroid dehydrogenase (HSD) 1 are proposed for the treatment of the metabolic syndrome, in particular diabetes type 2, obesity and dyslipidemia.
In the US 3,341 ,538 derivatives of benzomorphanes of the general formula
Figure imgf000002_0002
wherein R1, R2, R3, X and Y are as defined therein, are described as non-toxic analgesics having an activity of the same order of magnitude as codeine or morphine and as being free of addictive properties.
In the US 3,539,637 derivatives of 2,3,4, 5-tetrahydro-1 , 4-methano-1 H-3- benzazepines of the general formula
Figure imgf000003_0001
wherein R1, R2, R3, R4 and X are as defined therein, are described as non-toxic analgesics in the treatment of pain with little or no addiction liability. R1 and R2 are hydrogen or (lower)alkyl or R1 and R2 taken together with the nitrogen to which they are attached are morpholino, piperidino or pyrrolidino. Inter alia the following compounds are mentioned therein:
Figure imgf000003_0002
In the GB 1 ,077,711 derivatives of benzomorphanes of the general formula
Figure imgf000003_0003
wherein R-i, R2, R3, R4, R5 and X are as defined therein, are described as analgesics free of addictive properties and having antitussive action. R4 and R5 together with the adjacent nitrogen atom represent a saturated heterocycle, in which the nitrogen atom is the only hetero atom, having at most 7 carbon atoms, or a morpholino radical. Inter alia the following compound is mentioned therein:
Figure imgf000003_0004
The inventors are not aware that urea derivatives of benzomorphanes have been described as inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1. Aim of the invention
The aim of the present invention is to find new benzomorphanes or related compounds, particularly those which are active with regard to the enzyme 11 β- hydroxysteroid dehydrogenase (HSD) 1. A further aim of the present invention is to discover benzomorphanes or related compounds which have an inhibitory effect on the enzyme 11 β-hydroxysteroid dehydrogenase (HSD) 1 in vitro and/or in vivo and possess suitable pharmacological and pharmacokinetic properties to use them as medicaments.
A further aim of the present invention is to provide new pharmaceutical compositions which are suitable for the prevention and/or treatment of metabolic disorders, particularly diabetes and dyslipidemia.
Other aims of the present invention will become apparent to the skilled man directly from the foregoing and following remarks.
Object of the invention
In a first aspect the present invention relates to compounds derived from the following chemical scaffold which is structurally defined by the formula I
Figure imgf000004_0001
wherein
X denotes CH or N,
m, n, o independently of each other denote 0, 1 or 2,
wherein the Cs+m+n-azacycloalkene core structure of general formula I including the bridging group -(CH2)0- is optionally substituted with 1 , 2 or more substituents independently of each other selected from the group consisting of R11 and R12, A denotes a benzo, pyrido, pyrrolo, furo, thieno, pyridazino, pyrimido, or pyrazino ring wherein each of said rings is optionally substituted with one or more substituents independently of each other selected from R1, and wherein 2 adjacent C-atoms of each of said rings are optionally substituted with R2 and R3; or
a pyrazolo, imidazo, oxazolo, thiazolo, isoxazolo, or isothiazolo ring wherein each of said rings is optionally substituted with R1; or
a 1 ,2,3-triazolo ring optionally substituted with RN; and
B denotes a 3- to 8-membered monocylic, 7- to 12-membered spirocyclic, 6- to
12-membered bicyclic or 9- to 15-membered tricyclic azacycloalk-1-yl group, which is saturated or partially or fully unsaturated, wherein 1 or 2 -CH2- groups may be replaced by -NRN-, wherein 1 to 4 -CH2- groups may be replaced independently of each other by
O, S, carbonyl, or sulfonyl, wherein 1 or 2 -CH= groups may be replaced by -N=, and wherein said azacycloalkyl group may be substituted with one or more substituents independently of each other selected from L1, wherein said azacycloalkyl group may substituted with 1 or 2 substituents independently of each other selected from L2, wherein 2 adjacent C-atoms of said azacycloalkyl group may be substituted with L3 and L4, and wherein 2 adjacent C-atoms of said azacycloalkyl group may be substituted with L5 and L6;
RN independently of each other denotes hydrogen, d-6-alkyl, C3-6-alkenyl, C3-6- alkynyl, (het)aryl, Ci-4-alkylcarbonyl, C-M-alkylsulfonyl, (het)arylcarbonyl, (het)arylsulfonyl,
wherein each alkyl, alkenyl, and alkynyl group may be mono- or polysubstituted with fluorine, and may be monosubstitued with hydroxy, d-4-alkoxy, Ci-4-alkylsulfanyl, Ci-4-alkylsulfinyl, C1-4-alkylsulfonyl, amino, Ci-4-alkylamino, di-(Ci-4-alkyl)amino, Ci-4-alkylcarbonylamino, cyano, carboxy, Ci-4-alkoxycarbonyl, aminocarbonyl, C-M-alkylaminocarbonyl, di- (Ci-4-alkyl)aminocarbonyl, or (het)aryl,
independently of each other denotes fluorine, chlorine, bromine, iodine, cyano, nitro, C-i-4-alkyl, hydroxy, C^-alkyloxy, difluoromethyl, trifluoromethyl, difluoromethoxy, trifluoromethoxy, trifluoromethyl-hydroxy-Ci-2-alkyl, 2,2,2- trifluoro-1 -hydroxy-1 -(trifluoromethyl)ethyl, C3-6-cycloalkyl, Ca-θ-cycloalkyloxy, Ca-β-cycloalkyl-Ci-s-alkyl, Cs-β-cycloalkyl-C-i-s-alkyloxy, tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy, tetrahydrofuranyl-C-ι-3- alkyloxy, tetrahydropyranyl-Ci-3-alkyloxy, (het)aryl, (het)aryloxy, (het)aryl-Ci-3- alkyl, (het)aryl-Ci-3-alkyloxy, (het)aryloxy-Ci-3-alkyl, Ci-3-alkyl-carbonyl, (het)aryl-carbonyl,
amino, Ci-4-alkylamino, di-(Ci_4-alkyl)amino, pyrrolidin-1-yl, 2-oxo-pyrrolidin-1 - yl, piperidin-1-yl, 2-oxo-piperidin-i -yl, morpholin-4-yl, 3-oxo-morpholin-4-yl, piperazin-1 -yl, 2-oxo-piperazin-1-yl, 3-oxo-piperazin-1-yl, 4-(Ci-4-alkyl)-pi- perazin-1-yl, 4-(Ci-4-alkylcarbonyl)-piperazin-1-yl, 4-(C3-6-cycloalkylcarbonyl)- piperazin-1-yl, 4-(Ci-4-alkyloxycarbonyl)-piperazin-1 -yl, 4-(Ci-4-alkylsulfonyl)- piperazin-1 -yl, 2-oxo-4-(C1-4-alkyl)-piperazin-1-yl, 3-oxo-4-(Ci-4-alkyl)-pi- perazin-1 -yl,
Ci-4-alkyl-carbonylamino, (het)aryl-carbonylamino, (het)aryl-Ci-4-alkyl-carbo- nylamino, Ci-4-alkyloxy-carbonylamino, aminocarbonylamino, Ci-4-alkyl-amino- carbonylamino, di-(Ci-4-alkyl)aminocarbonylamino, pyrrolidin-1 -yl-carbonyl- amino, piperidin-1 -yl-carbonylamino, morpholin-4-yl-carbonylamino, piperazin- 1 -yl-carbonylamino, 4-(Ci-4-alkyl)-piperazin-1-yl-carbonylamino, Ci-4-alkyl-sul- fonylamino, aminosulfonylamino, Ci-4-alkylamino-sulfonylamino, di-(Ci-4-alkyl)- amino-sulfonylamino, pyrrolidin-1 -yl-sulfonylamino, piperidin-1 -yl-sulfonylami- no, morpholin-4-yl-sulfonylamino, piperazin-1 -yl-sulfonylamino, 4-(Ci-4-alkyl)- piperazin-1 -yl-sulfonylamino, (C1-4-alkyloxy-carbonylamino)carbonylamino, (het)arylsulfonylamino, (het)aryl-Ci-4-alkyl-sulfonylamino, N-(Ci-4-alkyl)-Ci-4-alkyl-carbonylamino, N-(Ci-4-alkyl)-(het)arylcarbonylamino, N-(Ci-4-alkyl)-(het)aryl-Ci-4-alkyl-carbonylamino, N-(Ci-4-alkyl)-Ci-4-alkyloxy- carbonylamino, N-(aminocarbonyl)-Ci-4-alkylamino, N-(Ci-4-alkyl-amino- carbonyl)-Ci-4-alkylamino, N-[di-(Ci-4-alkyl)aminocarbonyl]-Ci-4-alkylamino,
N-(Ci-4-alkyl)-Ci-4-alkyl-sulfonylamino, N-(Ci-4-alkyl)-(het)arylsulfonylamino, N-(Ci-4-alkyl)-(het)aryl-Ci-4-alkyl-sulfonylamino,
oxo-imidazolidin-1-yl, 2,4-dioxo-imidazolidin-1-yl, 2,5-dioxo-imidazolidin-i-yl, 2-oxo-hexahydropyrimidin-i-yl, wherein the nitrogen atom in position 3 of the aforementioned groups is optionally substituted with methyl or ethyl,
(hydroxyimino)aminomethyl, (Ci-3-alkyloxyimino)aminomethyl, carboxy, Ci-4- alkyloxy-carbonyl, aminocarbonyl, C-ι-4-alkyl-aminocarbonyl, di-(Ci-4-alkyl)- aminocarbonyl, pyrrolidin-1 -yl-carbonyl, piperidin-1 -yl-carbonyl, morpholin-4-yl- carbonyl, piperazin-1 -yl-carbonyl, 4-(Ci_4-alkyl)-piperazin-1-yl-carbonyl,
carboxy-Ci-4-alkyl, Ci^-alkyloxy-carbonyl-C-M-alkyl, cyano-Ci-4-alkyl, aminocarbonyl-Ci-4-alkyl, C-i^-alkyl-aminocarbonyl-C-M-alkyl, di-(Ci-4-alkyl)- aminocarbonyl-Ci-4-alkyl, pyrrolidin-i-yl-carbonyl-Ci-4-alkyl, piperidin-1-yl-
Figure imgf000007_0001
morpholin-4-yl-carbonyl-Ci-4-alkyl, piperazin-1-yl-carbonyl- Ci-4-alkyl, 4-(Ci.4-alkyl)-piperazin-1-yl-carbonyl-Ci.4-alkyl,
carboxy-Ci-4-alkyloxy, CWalkyloxy-carbonyl-Ci^-alkyloxy, cyano-Ci-4-alkyl- oxy, aminocarbonyl-Ci-4-alkyloxy, C1-4-alkyl-aminocarbonyl-Ci-4-alkyloxy, di-
(Ci-4-alkyl)-aminocarbonyl-Ci-4-alkyloxy, pyrrolidin-1
Figure imgf000007_0002
piperidin-i -yl-carbonyl-Ci-4-alkyloxy, morpholin-4-yl-carbonyl-Ci-4-alkyl-oxy, piperazin-i -yl-carbonyl-Ci-4-alkyloxy, 4-(Ci-4-alkyl)-piperazin-1-yl-carbonyl- Ci-4-alkyloxy,
hydroxy-Ci-4-alkyl, Ci-4-alkyloxy-C1-4-alkyl, amino-Ci-4-alkyl, Ci-4-alkylamino- Ci-4-alkyl, di-(C1-4-alkyl)-amino-Ci-4-alkyl, pyrrolidin-1-yl-Ci-4-alkyl, Ci-4-alkyl- carbonyl-amino-Ci-4-alkyl, N-(Ci-4-alkyl)-Ci-4-alkylcarbonyl-amino-Ci-4-alkylI 2-oxo-pyrrolidin-1-yl-Ci-4-alkyl,
Figure imgf000007_0003
2-oxo-piperidin-1-yl- Ci-4-alkyl, morpholin-4-yl-Ci-4-alkyl, 3-oxo-morpholin-4-yl-Ci.4-alkyl, piperazin- 1-yl-Ci-4-alkyl, 2-oxo-piperazin-1-yl-Ci-4-alkyl, 3-oxo-piperazin-1-yl-C-i.4-alkyl, 4-(Ci-4-alkyl)-piperazin-1-yl-Ci.4-alkyl, 2-oxo-4-(Ci-4-alkyl)-piperazin-1-yl-Ci-4- alkyl, 3-oxo-4-(d-4-alkyl)-piperazin-1 -yl-Ci-4-alkyl,
hyclroxy-Ci-4-alkyloxy,
Figure imgf000008_0001
oxy, Ci-4-alkylsulfinyl-Ci-4-alkyloxy, Ci-4-alkylsulfonyl-Ci.4-alkyloxy, amino-Ci-4- alkyloxy,
Figure imgf000008_0002
pyrrolidin-i-yl-Ci-4-alkyloxy, 2-oxo-pyrrolidin-1-yl-Ci-4-alkyloxy, piperidin-1-yl- C-ι-4-alkyloxy, 2-oxo-piperidin-1-yl-Ci-4-alkyloxy, morpholin-4-yl-Ci-4-alkyloxy, 3- oxo-morpholin-4-yl-Ci-4-alkyloxy, piperazin-1 -yl-Ci-4-alkyloxy, 2-oxo-piperazin- 1 -yl-Ci-4-alkyloxy, 3-oxo-piperazin-1 -yl-Ci-4-alkyloxy, 4-(Ci-4-alkyl)-piperazin-1 - yl-Ci-4-alkyloxy, 2-oxo-4-(Ci-4-alkyl)-piperazin-1-yl-Ci-4-alkyloxy, 3-oxo-4-(Ci-4- alkyl)-piperazin-1-yl-Ci-4-alkyloxy,
Ci-4-alkylsulfanyl, C-ι-4-alkysulfinyl, Ci-4-alkylsulfonyl, Ci-4-alkylsulfonyloxy, (het)arylsulfonyl, (het)arylsulfonyloxy, trifluoromethylsulfanyl, trifluoromethyl- sulfinyl, trifluoromethylsulfonyl, Cs-δ-cycloalkylsulfanyl, Cs-ε-cycloalkylsulfinyl, Cs-e-cycloalkylsulfonyl, Cs-e-cycloalkyl-Ci.s-alkylsulfanyl, C3.6-cycloalkyl-C1.3- alkylsulfinyl, Cs-e-cycloalkyl-d-s-alkylsulfonyl,
aminosulfonyl,
Figure imgf000008_0003
di-(Ci-4-alkyl)-aminosulfonyl, pyrroli- din-1 -yl-sulfonyl, piperidin-1 -yl-sulfonyl, morpholin-4-yl-sulfonyl, piperazin-1 -yl- sulfonyl, or 4-(Ci-4-alkyl)-piperazin-1 -yl-sulfonyl,
wherein the above-mentioned saturated heterocycles and cycloalkyl-rings are optionally substituted with one or two groups selected from fluorine, Ci-3-alkyl, C-ι-3-alkoxy, C-i-a-alkoxy-C-i-s-alkyl, or hydroxy,
R2, R3 are linked to each other to form a methylenedioxy, ethylenedioxy or 03.5- alkylene bridging group, which may be mono- or disubstituted with methyl, and which may be mono- or polyfluorinated; or
R2, R3 form combined with the carbon atoms to which they are attached a benzo, pyrido, pyrimido, pyrazino, pyridazino, pyrrolo, furano, thieno, pyrazolo, imidazo, triazolo, oxazolo, thiazolo, isoxazolo, or isothiazolo ring, wherein each of said rings may be substituted with one or more, preferably one to three, substituents independently selected from Rp;
Rp denotes halogen, d-β-alkyl, hydroxy-d-4-alkyl, Ci-3-alkyloxy-Ci-3-alkyl, C3-6- cycloalkyl, hydroxy-C4-6-cycloalkyl, d-s-alkyloxy-Cs-e-cycloalkyl, azetidinyl, 1- (Ci-3-alkyl)-azetidinyl, 1-(Ci-3-alkylcarbonyl)-azetidinyl, pyrrolidinyl, 1 -(Ci-3- alkyl)-pyrrolidinyl, 1-(Ci-3-alkylcarbonyl)-pyrrolidinyl, piperidinyl, 1-(Ci-3-alkyl)- piperidinyl, 1-(Ci-3-alkylcarbonyl)piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, difluoromethyl, trifluoromethyl, cyano, nitro, amino, Ci-3- alkylamino, di-(Ci-3-alkyl)amino, Ci-s-alkylcarbonylamino, methylsulfonylamino, carboxy, Ci-4-alkyloxycarbonyl, aminocarbonyl, Ci-s-alkylaminocarbonyl, di-(Ci-3-alkyl)-aminocarbonyl, aminosulfonyl, methylsulfanyl, methylsulfinyl, methylsulfonyl, hydroxy, d-3-alkyloxy, difluoromethoxy, trifluoromethoxy, phenyl, or
pyrrolyl, furanyl, thienyl, pyridyl, where in any of these groups 1 or 2 CH are optionally replaced by N atoms, or
1 ,2-dihydro-2-oxo-pyridinyl, 1 ,4-dihydro-4-oxo-pyridinyl, 2,3-dihydro-3-oxo- pyridazinyl, 1 ,2,3,6-tetrahydro-3,6-dioxo-pyridazinyl, 1 ,2-dihydro-2-oxo-pyrimi- dinyl, 3,4-dihydro-4-oxo-pyrimidinyl, 1 ^.S^-tetrahydro^^-dioxo-pyrimidinyl, 1 ,2-dihydro-2-oxo-pyrazinyl,
wherein each of the aromatic or heteroaromatic groups mentioned above is optionally substituted with one or two groups independently selected from fluorine, chlorine, Ci-3-alkyl, difluoromethyl, trifluoromethyl, cyano, amino, acetylamino, methylsulfonylamino, carboxy, Ci-4-alkyloxycarbonyl, aminocar- bonyl, Ci-3-alkylaminocarbonyl, di-(Ci-3-alkyl)-aminocarbonyl, hydroxy, Ci-3- alkyloxy, difluoromethoxy, and trifluoromethoxy,
R10 independently of each other enotes halogen, Ci-3-alkyl, difluoromethyl, trifluoromethyl, cyano, nitro, amino, Ci-3-alkylamino, di-(Ci-3-alkyl)amino, acetylamino, methylsulfonylamino, carboxy, C-M-alkyloxycarbonyl, aminocar- bonyl, Ci-3-alkylaminocarbonyl, di-(Ci.3-alkyl)-aminocarbonyl, aminosulfonyl, methylsulfanyl, methylsulfinyl, methylsulfonyl, hydroxy, Ci.3-alkyloxy, difluoromethoxy, trifluoromethoxy, or phenyl optionally substituted with 1 or 2 substituents independently of each other selected from fluorine, methyl, methoxy, cyano, or hydroxy,
R11 independently of each other denotes fluorine, Ci-4-alkyl, (het)aryl, hydroxy, Ci- 4-alkyloxy, cyano, carboxy, Ci-4-alkyloxycarbonyl, aminocarbonyl, Ci-4-alkylamino-carbonyl, di-(Ci-4-alkyl)-aminocarbonyl, hydroxy-Ci-4-alkyl or d-a-alkyloxy-C-M-alkyl,
R12 independently of each other denotes fluorine or Ci-4-alkyl, and
L1 independently of each other denotes halogen, Ci-4-alkyl, trifluoromethyl, hydroxy, Ci-4-alkyloxy, or cyano;
L2 independently of each other denotes fluorine, chlorine, bromine, iodine, nitro, cyano, hydroxy, C3-6-cycloalkyl, Cs-6-cycloalkyloxy, tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy, tetrahydrofuranyl-C-ι-3- alkyloxy, tetrahydropyranyl-C-ι-3-alkyloxy, (het)aryl, (het)aryloxy,
C-ι-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, Ci-4-alkyloxy, wherein in each group one CH2 group may be replaced by carbonyl or sulfonyl, and wherein each group may be mono or polyfluorinated, and wherein each group may additionally be substituted with
hydroxy, chlorine, Ci-3-alkyloxy, amino, Ci-3-alkylamino, di-(C-ι-3-alkyl)- amino, pyrrolidin-1 -yl, 2-oxo-pyrrolidin-1-yl, piperidin-1-yl, 2-oxo- piperidin-1 -yl, morpholin-4-yl, 3-oxo-morpholin-4-yl, piperazin-1-yl, 2- oxo-piperazin-1-yl, 3-oxo-piperazin-1 -yl, 4-(Ci-3-alkyl)-piperazin-1-yl, 2- oxo-4-(Ci-3-alkyl)-piperazin-1 -yl, 3-oxo-4-(Ci-3-alkyl)-piperazin-1 -yl, carboxy, C-ι-3-alkyloxy-carbonyl, cyano, aminocarbonyl, C-ι-3-alkyl- aminocarbonyl, di-(Ci-3-alkyl)-aminocarbonyl, pyrrolidin-1 -yl-carbonyl, piperidin-1 -yl-carbonyl, morpholin-4-yl-carbonyl, piperazin-1 -yl-carbonyl, 4-(Ci-3-alkyl)-piperazin-1-yl-carbonyl, Ci-3-alkylcarbonylamino, arylcarbonylamino, Ci-3-alkylsulfanyl, Ci-3-alkylsulfinyl, Ci-3- alkylsulfonyl, C3-6-cycloalkyl, (het)aryl, or (het)aryloxy;
amino, Ci-3-alkylamino, di-(Ci-3-alkyl)amino, pyrrolidin-1 -yl, 2-oxo-pyrrolidin-1 - yl, piperidin-1 -yl, 2-oxo-piperidin-1 -yl, morpholin-4-yl, 3-oxo-morpholin-4-yl, piperazin-1 -yl, 2-oxo-piperazin-1 -yl, 3-oxo-piperazin-1-yl, 4-(Ci-3-alkyl)- piperazin-1 -yl, 4-(Ci-4-alkylcarbonyl)-piperazin-1 -yl, 4-(C3-6-cycloalkylcarbonyl)- piperazin-1 -yl, 4-(Ci-4-alkyloxycarbonyl)-piperazin-1-yl, 4-(Ci-4-alkylsulfonyl)- piperazin-1-yl, 2-oxo-4-(Ci-3-alkyl)-piperazin-1-yl, 3-oxo-4-(Ci-3-alkyl)- piperazin-1-yl,
Ci-4-alkyl-carbonylamino, (het)aryl-carbonylamino, (het)aryl-Ci-3-alkyl-carbo- nylamino, Ci-3-alkyloxy-carbonylamino, aminocarbonylamino, Ci-3-alkyl-amino- carbonylamino, di-(Ci-3-alkyl)aminocarbonylainino, pyrrolidin-1 -yl-carbonyl- amino, piperidin-1 -yl-carbonylamino, morpholin-4-yl-carbonylamino, piperazin- 1-yl-carbonylamino, 4-(Ci-3-alkyl)-piperazin-1 -yl-carbonylamino, C-ι-3-alkyl- sulfonylamino, aminosulfonylamino, Ci-3-alkylamino-sulfonylamino, di-(C-i-3- alkyl)amino-sulfonylamino, pyrrolidin-1 -yl-sulfonylamino, piperidin-1 -yl- sulfonylamino, morpholin-4-yl-sulfonylamino, piperazin-1 -yl-sulfonylamino, 4- (Ci-3-alkyl)-piperazin-1 -yl-sulfonylamino, (Ci-3-alkyloxy-carbonylamino)car- bonylamino, (het)arylsulfonylamino, (het)aryl-Ci-3-alkyl-sulfonylamino,
N-(Ci-3-alkyl)-C1-3-alkyl-carbonylamino, N-(Ci-3-alkyl)-(het)arylcarbonylamino,
N-(Ci-3-alkyl)-(het)aryl-Ci-3-alkyl-carbonylamino, N-(C1-3-alkyl)-Ci-3-alkyloxy- carbonylamino, N-(aminocarbonyl)-Ci.3-alkylamino, N-(Ci-3-alkyl-amino- carbonyl)-Ci-3-alkylamino, N-ldi^Ci-s-alky^aminocarbonylJ-Ci-s-alkylamino,
N-(Ci-3-alkyl)-Ci-3-alkyl-sulfonylamino, N-(Ci-3-alkyl)-(het)arylsulfonylamino,
N-(Ci-3-alkyl)-(het)aryl-Ci-3-alkyl-sulfonylamino,
carboxy, Cvs-alkyloxy-carbonyl, aminocarbonyl, C-i-3-alkyl-aminocarbonyl, di- (Ci-3-alkyl)-aminocarbonyl, pyrrolidin-1 -yl-carbonyl, piperidin-1 -yl-carbonyl, morpholin-4-yl-carbonyl, piperazin-1-yl-carbonyl, 4-(Ci-3-alkyl)-piperazin-1-yl- carbonyl, (het)arylaminocarbonyl, N-(Ci-3-alkyl)-(het)arylaminocarbonyl, (het)aryl-Ci-3-alkylaminocarbonyl, N-(Ci-3-alkyl)-(het)aryl-Ci-3- alkylaminocarbonyl,
d-3-alkylsulfanyl, d-3-alkysulfinyl, (het)arylsulfonyl, trifluoromethylsulfanyl, trifluoromethylsulfinyl,
aminosulfonyl, Ci-3-alkyl-aminosulfonyl, di-(Ci-3-alkyl)-aminosulfonyl, pyrroli- din-1-yl-sulfonyl, piperidin-1 -yl-sulfonyl, morpholin-4-yl-sulfonyl, piperazin-1-yl- sulfonyl, 4-(C1-3-alkyl)-piperazin-1 -yl-sulfonyl,
wherein the above-mentioned saturated heterocycles and cycloalkyl-rings are optionally substituted with one or two groups selected from fluorine, d-3-alkyl, C-ι-3-alkoxy, Ci.3-alkoxy-Ci-3-alkyl, or hydroxy, and
L3 and L4 are linked to each other and
L5 and L6 are linked to each other, such that independently of each other and in each case together with the 2 adjacent C-atoms to which they are attached an aryl- or heteroaryl-group is formed which is fused to the cyclic group B, and which aryl- or heteroaryl-group is optionally substituted with 1 , 2 or 3 identical or different R10,
while by aryl is meant phenyl or naphthtyl and by heteroaryl is meant pyrrolyl, furanyl, thienyl, pyridyl, indolyl, benzofuranyl, benzothiophenyl, quinolinyl, isoquinolinyl, or pyrrolyl, furanyl, thienyl, pyridyl wherein in said pyrrolyl, furanyl, thienyl, pyridyl 1 or 2 CH groups are each replaced by N, or indolyl, benzofuranyl, benzothiophenyl, quinolinyl, isoquinolinyl wherein in said indolyl, benzofuranyl, benzothiophenyl, quinolinyl, isoquinolinyl 1 to 3 CH groups are each replaced by N, or tetrazolyl,
while the above-mentioned (het)aryl is an aryl group as defined hereinbefore, or a heteroaryl group as defined hereinbefore, or a ring selected from the group consisting of 1 ,2-dihydro-2-oxo-pyridinyl, 1 ,4-dihydro-4-oxo-pyridinyl, 2,3-dihydro-3- oxo-pyridazinyl, 1 ,2,3,6-tetrahydro-3,6-dioxo-pyridazinyl, 1 ,2-dihydro-2-oxo-pyrimi- dinyl, 3,4-dihydro-4-oxo-pyrimidinyl, 1 ,2,3,4-tetrahydro-2,4-dioxo-pyrimidinyl, 1 ,2- dihydro-2-oxo-pyrazinyl, 1 ,2,3,4-tetrahydro-2,3-dioxo-pyrazinyl, 2,3-dihydro-2-oxo- indolyl, 2,3-dihydrobenzofuranyl, 2,3-dihydro-2-oxo-1 /-/-benzimidazolyl, 2,3-dihydro- 2-oxo-benzoxazolyl, 1 ,2-dihydro-2-oxo-quinolinyl, 1 ,4-dihydro-4-oxo-quinolinyl, 1 ,2- dihydro-1-oxo-isoquinolinyl, 1 ,4-dihydro-4-oxo-cinnolinyl, 1 ,2-dihydro-2-oxo- quinazolinyl, 1 ,4-dihydro-4-oxo-quinazolinyl, 1 ,2,3,4-tetrahydro-2,4-dioxo- quinazolinyl, 1 ,2-dihydro-2-oxoquinoxalinyl, 1 ,2,3,4-tetrahydro-3-oxo-quinoxalinyl, 1 ,2,3,4-tetrahydro-2,3-dioxo-quinoxalinyl, 1 ,2-dihydro-1-oxo-phthalazinyl, 1 ,2,3,4- tetrahydro-1 ,4-dioxo-phthalazinyl, chromanyl, coumarinyl, 2,3-dihydro- benzo[1 ,4]dioxinyl and 3,4-dihydro-3-oxo-2/-/-benzo[1 ,4]oxazinyl, wherein each of said rings is optionally substituted with 1 , 2 or 3 substituents independently of each other selected from R10,
whilst each of the above-mentioned alkyl or alkylene moieties may be branched or unbranched,
the tautomers, the stereoisomers thereof, the mixtures thereof, and the salts thereof,
while the following compounds (M1 ) to (M4) are excluded,
Figure imgf000013_0001
The compounds of general formula I according to the invention and the physiologically acceptable salts thereof have valuable pharmacological properties, particularly an inhibitory effect on the enzyme 11 β-hydroxysteroid dehydrogenase (HSD) 1.
A further aspect of the invention also relates to the physiologically acceptable salts of the compounds of general formula I according to this invention with inorganic or organic acids.
In a further aspect this invention relates to pharmaceutical compositions, containing at least one compound of general formula I or a physiologically acceptable salt according to the invention, optionally together with one or more inert carriers and/or diluents.
In a further aspect this invention relates to the compounds according to general formula I, including the compounds (M1 ), (M2), (M3) and (M4), or the physiologically acceptable salts thereof, for treatment or prevention of diseases or conditions which can be influenced by inhibiting the enzyme 11 β-hydroxysteroid dehydrogenase (HSD) 1 , such as metabolic disorders.
In a further aspect this invention relates to the use of at least one compound according to general formula I, including the compounds (M1 ), (M2), (M3) and (M4), or one of the physiologically acceptable salts thereof for preparing a pharmaceutical composition which is suitable for the treatment or prevention of diseases or conditions which can be influenced by inhibiting the enzyme 11 β-hydroxysteroid dehydrogenase (HSD) 1 , such as metabolic disorders.
In a further aspect the present invention relates to a process for preparing the compounds of general formula I, characterized in that
in order to prepare compounds of general formula I which are defined as hereinbefore and hereinafter,
one of the amines of general formula Il
Figure imgf000015_0001
wherein
the groups A1 X, m, n and o are defined as hereinbefore and hereinafter,
or of general formula III
Figure imgf000015_0002
wherein B is definded as hereinbefore and hereinafter,
is reacted with a carbonic acid derivative Y-CO-Y yielding a compound either of general formula IV or V as intermediate
Figure imgf000015_0003
V IV which is optionally isolated and optionally purified, and the intermediate of the formula IV or V is reacted with the other amine of the formula III or Il to yield the compound of- the formula I, wherein Y is a leaving group and in particular denotes fluorine, chlorine, bromine, cyano, Ci-4-alkoxy, C2-4-alkenyloxy, C2-4-alkynyloxy, partially or fully fluorinated
C2-io-alkoxy, oxyarylotriazol, oxyheteroarylotriazol, heteroar-N-yl, 3-methyl- imidazol-1-yl, succinyl-N-oxy, di-(Ci-4-alkyl)aminocarbonyloxy, pyrrolylcarbonyloxy, piperidinylcarbonyloxy, morpholinylcarbonyloxy, aryloxy, or heteroaryloxy, while the alkyl, alkenyl, and alkynyl groups mentioned in the definition of the above groups, either alone or as part of another group, may be substituted with one or more substituents independently of each other selected from fluorine, chlorine, C-ι-3-alkyl, or C-ι-3-alkoxy,
while the aryl groups mentioned in the definition of the above groups, either alone or as part of another group, denote phenyl or naphthyl and the heteroaryl groups mentioned in the definition of the above groups, either alone or as part of another group, denote pyridinyl, pyrimidinyl, triazinyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, whilst both the aryl and heteroaryl groups optionally are substituted with one or more substituents independently of each other selected from fluorine, chlorine, bromine, d-3-alkyl, Ci-3-alkyloxy, nitro, cyano, or di-(C-ι-3-alkyl)amino groups,
while the two Y in Y-CO-Y may be identical or different,
while the second Y to be replaced may also be transformed to a more reactive Y after the first Y is replaced with one of the two amines,
optionally in the presence of an organic base such as an amine, e.g. ethyldiisopropylamine, triethylamine, imidazole or pyridine, or an inorganic base, e.g. potassium carbonate or calcium oxide, and/or an additive such as 4- dimethylaminopyridine or 1-hydroxybenzotriazol; wherein the reactions are preferably conducted between 0 and 120 0C; wherein preferred solvents are selected from tetrahydrofuran, 1 ,2-dimethoxyethane, ether, 1 ,4-dioxane, dimethylformamide, N1N- dimethylacetamide, N-methylpyrrolidinone, acetonitrile, dichloromethane, 1 ,2- dichloroethane, toluene, benzene, hexanes, ethyl acetate, but also aqueous and alcoholic solutions may be usable for some of the combinations listed above;
and, if necessary any protective group used in the reactions described above is cleaved concurrently or subsequently;
if desired a compound of general formula I thus obtained is resolved into its stereoisomers; if desired a compound of general formula I thus obtained is converted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts thereof.
Detailed Description of the invention
Unless otherwise stated, the groups, residues, and substituents, particularly A, B, RN, R1, R2, R3, R10, R11, R12, Rp, L1, L2, L3, L4, L5, L6, X1 m, n, and o are defined as above and hereinafter. If residues, substituents, or groups occur several times in a compound they may have the same or different meanings. Some preferred meanings of individual scaffolds, groups, and substituents of the compounds according to the invention will be given hereinafter.
The indexes m, n and o each denote independently of each other 0, 1 or 2. Preferably m, n and o are chosen such that the sum of m + n + o is 2, 3 or 4.
Preferred embodiments of this invention are described by each of the formulae 1.1 to 1.10
Figure imgf000017_0002
I.3
Figure imgf000017_0003
Figure imgf000018_0001
Figure imgf000018_0002
Figure imgf000018_0003
Figure imgf000018_0004
Figure imgf000018_0005
I.9
Figure imgf000018_0006
Figure imgf000019_0001
wherein the Cs+m+n-azacycloalkene core structure of general formulae 1.1 to 1.10 including the bridging group -(CH2)0- is optionally substituted with 1 , 2 or more substituents independently of each other selected from the group consisting of R11 and R12, and
wherein the rings A and B are defined as hereinbefore and hereinafter, their tautomers, their stereoisomers, mixtures thereof and the salts thereof, while the compounds (M1 ), (M2), (M3) and (M4) as defined hereinbefore, are excluded.
According to a preferred embodiment of the general formula 1.1 compounds of the invention are described by the formula 1.1 -RR
Figure imgf000019_0002
wherein the 2,6-methano-azocin core structure with the stereochemical configuration as depicted is optionally substituted with 1 , 2 or more substituents independently of each other selected from the group consisting of R11 and R12, and wherein the rings A, B and R11, R12 are defined as hereinbefore and hereinafter, their tautomers, their stereoisomers, mixtures thereof and the salts thereof.
According to another preferred embodiment of the general formula 1.1a compounds of the invention are described by the formula 1.1 -SS
Figure imgf000020_0001
wherein the 2,6-methano-azocin core structure with the stereochemical configuration as depicted is optionally substituted with 1 , 2 or more substituents independently of each other selected from the group consisting of R11 and R12, and wherein the rings A, B and R11, R12 are defined as hereinbefore and hereinafter, their tautomers, their stereoisomers, mixtures thereof and the salts thereof.
Even more preferred compounds are described by the formulae 1.1 to 1.10 and 1.1 -RR and 1.1 -SS wherein the C5+m+n-azacycloalkene core structure including the bridging group -(CH2)0- is optionally mono-substituted with R11 and optionally substituted with 1 , 2 or 3 substituents independently of each other selected from R12.
The nitrogen containing ring B preferably denotes azetidin-1-yl, pyrrolidin-1 -yl, piperidin-1-yl, azepan-1-yl, azocan-1-yl,
azetidin-1-yl, wherein one -CH2- group is replaced by O, S, NRN, carbonyl, or sulfonyl, or
pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, azocan-1-yl, which may be partially or fully unsaturated and wherein one or two -CH2- groups are independently of each other replaced by O, S, carbonyl, or sulfonyl, and wherein one -CH2- group may be replaced by -NRN-,
aza-bicyclohept-N-yl, aza-bicyclooct-N-yl, aza-bicyclonon-N-yl, aza-bicyclodec-N-yl, bicycloundec-N-yl, bicyclododec-N-yl, each of which may be partially unsaturated, and in each of which one or two -CH2- groups may be replaced independently of each other by O, S, -NRN-, carbonyl, or sulfonyl, and in each of which one -CH= group may be replaced by -N=, aza-tricyclonon-N-yl, aza-tricyclodec-N-yl, aza-tricycloundec-N-yl, aza-tricyclododec- N-yl, aza-tricyclotridec-N-yl, aza-tricyclotetradec-N-yl, in each of which one or two -CH2- groups may be replaced independently of each other by O1 S, NRN, carbonyl, or sulfonyl, and in each of which one -CH= group may be replaced by -N=,
wherein each of the above rings B may be substituted with one or more substituents independently of each other selected from L1, wherein each of the above rings B may be substituted with 1 or 2 substituents independently of each other selected from L2, wherein 2 adjacent C-atoms of each of the above rings B may be substituted with L3 and L4, and wherein 2 adjacent C-atoms of each of the above rings B may be substituted with L5 and L6.
More preferably, the ring B denotes pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, azocan-1-yl, which may be partially or fully unsaturated, and wherein one or two -CH2- groups may be independently of each other replaced by O, S, carbonyl, or sulfonyl, and wherein one -CH2- group may be replaced by -NRN-,
octahydro-cyclopentapyrrol-N-yl, octahydro-indol-N-yl, octahydro-isoindol-N-yl, octahydropyhndin-N-yl, decahydro-quinolin-N-yl, decahydro-isoquinolin-N-yl, decahydro-cyclopentaazepin-N-yl, each of which may be partially unsaturated, and in each of which one or two CH2 groups may be replaced independently of each other by O, S, -NRN-, carbonyl, or sulfonyl, and in each of which one -CH= group may be replaced by -N=,
aza-bicyclo[3.2.1]octan-N-yl, aza-bicyclo[3.3.1]nonan-N-yl, aza-bicyclo[4.2.1]nonan- N-yl, aza-bicyclo[3.2.2]nonan-N-yl, aza-bicyclo[5.2.1]decan-N-yl, aza-bicyclo- [4.2.2]decan-N-yl, aza-bicyclo[3.3.2]decan-N-yl, each of which may be partially unsaturated, and in each of which one or two -CH2- groups may be replaced independently of each other by O, S, -NRN-, carbonyl, or sulfonyl, and in each of which one -CH= group may be replaced by -N=, 2-aza-adamant-2-yl, in which one -CH2- group may be replaced by O, S, -NRN-, carbonyl, or sulfonyl, and in each of which one -CH= group may be replaced by -N=,
wherein each of the above rings B may be substituted with one or more substituents independently of each other selected from L1, wherein each of the above rings B may be substituted with 1 or 2 substituents independently of each other selected from L2, wherein 2 adjacent C-atoms of each of the above rings B may be substituted with L3 and L4, and wherein 2 adjacent C-atorhs of each of the above rings B may be substituted with L5 and L6.
Most preferably, the ring B denotes pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, azocan-1-yl, 2-oxo-pyrrolidin-1-yl, 2-oxo-imidazolidin-1-yl, 2-oxo-piperidin-1-yl, piperazin-1-yl, morpholin-4-yl, 2-oxo-piperazin-1-yl, 3-oxo-piperazin-1-yl, 2-oxo- morpholin-4-yl, 3-oxo-morpholin-4-yl, 2,3-dihydro-indol-1-yl, 5,6-dihydro-8H- [1 ,2,4]triazolo[4,3-a]pyrazin-7-yl, 1 ,2,3,4-tetrahydro-isoquinolin-2-yl, 2,3-dihydro- benzo[1 ,4]oxazin-4-yl, 8-aza-bicyclo[3.2.1]octan-8-yl, 3-aza-bicyclo[3.2.1]octan-3-yl, 3-oxo-8-aza-bicyclo[3.2.1]oct-8-yl, 9-aza-bicyclo[3.3.1]nonan-9-yl, 2-aza- bicyclo[3.3.1]nonan-2-yl, 3-aza-bicyclo[3.3.1]nonan-3-yl, 9-aza-bicyclo[4.2.1]nonan-9- yl, 3-aza-bicyclo[3.2.2]nonan-3-yl, 10-aza-bicyclo[5.2.1]decan-10-yl, 3-aza- bicyclo[4.2.2]decan-3-yl, 3-aza-bicyclo[3.3.2]decan-3-yl, 2-aza-adamant-2-yl, 1-oxo- 2,7-diaza-spiro[4.5]dec-7-yl, 7-oxo-2,8-diaza-spiro[5.5]undec-2-yl, particularly, azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, morpholin-4-yl, piperazin-1-yl, 2,3-dihydro-indol-1-yl, 5,6-dihydro-8H-[1 ,2,4]thazolo[4,3-a]pyrazin-7-yl, 1 ,2,3,4- tetrahydro-isoquinolin-2-yl, 2,3-dihydro-benzo[1 ,4]oxazin-4-yl, 8-aza- bicyclo[3.2.1]octan-8-yl, 9-aza-bicyclo[3.3.1]nonan-9-yl, 1-oxo-2,7-diaza- spiro[4.5]dec-7-yl, 7-oxo-2,8-diaza-spiro[5.5]undec-2-yl, 2-oxo-imidazolidin-1-yl,
wherein each of the above rings B may be substituted with one or more substituents independently of each other selected from L1, wherein each of the above rings B may be substituted with 1 or 2 substituents independently of each other selected from L2, wherein 2 adjacent C-atoms of each of the above rings B may be substituted with L3 and L4, and wherein 2 adjacent C-atoms of each of the above rings B may be substituted with L5 and L6.
Examples of preferred meanings of the ring B are shown in the following:
Figure imgf000023_0001
Figure imgf000024_0001
Figure imgf000025_0001
wherein these groups may additionally be monosubstitued with L1 and additionally monosubstitued with L2.
Preferably, the ring A denotes a benzo, pyrido, pyrrolo, furo, thieno, pyridazino, pyrimido, or pyrazino ring wherein each of said rings is optionally substituted with one or more substituents independently of each other selected from R1, and wherein 2 adjacent C-atoms of each of said rings are optionally substituted with R2 and R3; or a pyrazolo, oxazolo, thiazolo, or imidazo ring each of which is optionally substituted with R1.
More preferably, the ring A denotes a benzo or pyrido ring, most preferably a benzo ring, wherein each of said rings is optionally substituted with one or more substituents independently of each other selected from R1, and wherein 2 adjacent C-atoms of each of said rings are optionally substituted with R2 and R3.
Preferably, RN denotes hydrogen, d-β-alkyl, C3-6-alkenyl, phenyl, d-4-alkylcarbonyl, Ci-4-alkylsulfonyl, phenylcarbonyl, phenylsulfonyl, wherein each alkyl group may be mono- or polysubstituted with fluorine and may be monosubstituted with hydroxy, Ci. 4-alkoxy, Ci-4-alkylcarbonylamino, cyano, carboxy, C-i-4-alkoxycarbonyl, aminocarbonyl, Ci-4-alkylaminocarbonyl, di-(Ci-4-alkyl)aminocarbonyl or phenyl, and wherein each phenyl group may be monosubstitued with R10. More preferably, RN denotes hydrogen, d-6-alkyl, phenyl, Ci-4-alkylcarbonyl, d-4-alkylsulfonyl, wherein each alkyl group may be mono- or polysubstituted with fluorine and may be monosubstitued with hydroxy, Ci-4-alkoxy, or phenyl, and wherein each phenyl group may be monosubstitued with R10. Most preferably, RN denotes hydrogen, methyl, ethyl, isopropyl, phenyl, acetyl, methylsulfonyl.
Preferably, the one or more substituents L1, which may be identical or different, denote fluorine, chlorine, d-4-alkyl, trifluoromethyl, hydroxy, Ci-4-alkoxy, cyano, more preferably fluorine, methyl, ethyl, trifluoromethyl, hydroxy, methoxy, ethoxy, cyano, particularly fluorine, methyl, trifluoromethyl, hydroxy, and methoxy.
Preferably, the one or more substituents L2, which may be identical or different, denote fluorine, chlorine, bromine, cyano, hydroxy, d-6-alkyl, C2-6-alkenyl, C2-6- alkynyl, Ci-4-alkyloxy, difluoromethyl, trifluoromethyl, difluoromethoxy, thfluoromethoxy, C3-6-cycloalkyl, Cs-e-cycloalkyloxy, C3.6-cycloalkyl-Ci-3-alkyl, C3-6- cycloalkyl-d-3-alkyloxy, (het)aryl, (het)aryloxy, (het)aryl-d-3-alkyl, (het)aryl-d-3- alkyloxy, (het)aryloxy- d-3-alkyl,
amino, d-3-alkylamino, di-(Ci-3-alkyl)amino, pyrrolidin-1-yl, 2-oxo-pyrrolidin-1-yl, pipeήdin-1-yl, 2-oxo-piperidin-1-yl, morpholin-4-yl, 3-oxo-morpholin-4-yl, piperazin-1- yl, 2-oxo-piperazin-1-yl, 3-oxo-piperazin-1-yl, 4-(Ci-3-alkyl)-piperazin-1-yl, 4-(Ci-4- alkylcarbonyl)-piperazin-1-yl, 4-(C3-6-cycloalkylcarbonyl)-piperazin-1-yl, 4-(C1-4- alkyloxycarbonyl)-piperazin-1-yl, 4-(Ci-4-alkylsulfonyl)-piperazin-1-yl, 2-oxo-4-(d-3- alkyl)-piperazin-1-yl, 3-oxo-4-(Ci-3-alkyl)-piperazin-1-yl, Ci-3-alkyl-carbonylamino, (het)aryl-carbonylamino, (het)ai7l-Ci-3-alkyl-carbonylamino, Ci-a-alkyloxy-carbonylamino, aminocarbonylamino, Ci-s-alkyl-aminocarbonylamino, di^Ci-a-alky^aminocarbonylamino, pyrrolidin-1-yl-carbonylamino, piperidin-1-yl- carbonylamino, morpholin-4-yl-carbonylamino, piperazin-1-yl-carbonylamino, 4-(Ci-3- alkyl)-piperazin-1-yl-carbonylamino, Ci-3-alkyl-sulfonylamino, aminosulfonylamino, Ci-3-alkylamino-sulfonylamino, di-(Ci-3-alkyl)amino-sulfonylamino, pyrrolidin-1 -yl- sulfonylamino, piperidin-1-yl-sulfonylamino, morpholin-4-yl-sulfonylamino, piperazin- 1 -yl-sulfonylamino, 4-(C1-3-alkyl)-piperazin-1 -yl-sulfonylamino, (Ci_3-alkyloxy- carbonylamino)carbonylamino, (het)arylsulfonylamino, (het)aryl-Ci-3-alkyl- sulfonylamino,
N-(Ci-3-alkyl)-Ci.3-alkyl-carbonylannino, N-(Ci-3-alkyl)-(het)arylcarbonylamino, N-(Ci-3- alkyl)-(het)aryl-Ci-3-alkyl-carbonylamino, N-(Ci-3-alkyl)-Ci-3-alkyloxy-carbonylamino, N-(aminocarbonyl)-Ci-3-alkylamino, N^Ci-s-alkyl-aminocarbonyiJ-Ci-s-alkylamino, N- ^(-(Cva-alkyOaminocarbonylJ-Ci-s-alkylamino,
N-(Ci-3-alkyl)-Ci-3-alkyl-sulfonylamino, N-(Ci.3-alkyl)-(het)arylsulfonylamino, N-(Ci-3-alkyl)-(het)aryl-Ci-3-alkyl-sulfonylamino,
carboxy, d-3-alkyloxy-carbonyl, aminocarbonyl, Ci-3-alkyl-aminocarbonyl, di-(Ci-3- alkyl)-aminocarbonyl, pyrrolidin-1 -yl-carbonyl, piperidin-1-yl-carbonyl, morpholin-4-yl- carbonyl, piperazin-1 -yl-carbonyl, 4-(C-|.3-alkyl)-piperazin-1 -yl-carbonyl, (het)arylaminocarbonyl, N-(Ci-3-alkyl)-(het)arylaminocarbonyl, (het)aryl-Ci-3- alkylaminocarbonyl, N^Ci-s-alkylHhetJaryl-Ci-s-alkylaminocarbonyl,
Ci-3-alkyl-carbonyl, (het)aryl-carbonyl,
carboxy-Ci-3-alkyl, Ci.s-alkyloxy-carbonyl-Ci.s-alkyl, cyano-Ci-3-alkyl, aminocarbonyl- C-ι-3-alkyl, Ci.s-alkyl-aminocarbonyl-Ci-s-alkyl, di^Ci-s-alky^-aminocarbonyl-Ci-s-alkyl, pyrrolidin-1 -yl-carbonyl-Ci-3-alkyl, piperidin-i-yl-carbonyl-C-i-s-alkyl, morpholin-4-yl- carbonyl-Ci-3-alkyl, piperazin-i-yl-carbonyl-Cvs-alkyl, 4-(Ci-3-alkyl)-piperazin-1-yl- carbonyl-C-ι-3-alkyl, carboxy-d-3-alkyloxy, Ci-a-alkyloxy-carbonyl-C-i-s-alkyloxy, cyano-Ci-3-alkyloxy, aminocarbonyl-C1-3-alkyloxy, Ci.s-alkyl-aminocarbonyl-Ci.s-alkyloxy, di-(Ci-3-alkyl)- aminocarbonyl-Ci-3-alkyloxy, pyrrolidin-1 -yl-carbonyl-Ci-ralkyl-oxy, piperidin-1 -yl- carbonyl-C-i-3-alkyloxy, morpholin^-yl-carbonyl-C-i-s-alkyl-oxy, piperazin-1 -yl- carbonyl-Ci-3-alkyloxy, 4-(Ci.3-alkyl)-piperazin-1 -yl-carbonyl-C^s-alkyloxy,
hydroxy-Ci-3-alkyl, Ci-3-alkyloxy-Ci-3-alkyl, amino-Ci-3-alkyl, Ci-3-alkylamino-Ci-3- alkyl, di-(Ci-3-alkyl)-amino-Ci-3-alkyl, pyrrolidin-i-yl-Ci-3-alkyl, 2-oxo-pyrrolidin-1-yl-C i- 3-alkyl, piperidin-1 -yl-Ci-3-alkyl, 2-oxo-piperidin-i-yl-Ci-s-alkyl, morpholin-4-yl-C-i-3- alkyl, 3-oxo-morpholin-4-yl-Ci-3-alkyl, piperazin-1 -yl-Ci-3-alkyl, 2-oxo-piperazin-1-yl- Ci-3-alkyl, 3-oxo-piperazin-i-yl-Ci-s-alkyl, 4-(Ci-3-alkyl)-piperazin-1-yl-Ci-3-alkyl, 2- oxo-4-(Ci-3-alkyl)-piperazin-1-yl-Ci-3-alkyl, 3-oxo-4-(Ci-3-alkyl)-piperazin-1-yl-Ci-3- alkyl,
Ci-s-alkylcarbonylamino-Ci-a-alkyl, arylcarbonylamino-Ci-3-alkyl,
hydroxy-Ci-3-alkyloxy,
Figure imgf000028_0001
Ci-s-alkylsulfanyl-Ci-s-alkyloxy, Ci- 3-alkylsulfinyl-Ci-3-alkyloxy, Ci.s-alkylsulfonyl-Ci.s-alkyloxy, amino-Ci-3-alkyloxy, Ci-3- alkylamino-Ci-3-alkyloxy, di-(Ci-3-alkyl)-amino-Ci-3-alkyloxy, pyrrolidin-1 -yl-Ci-3- alkyloxy, 2-oxo-pyrrolidin-1-yl-Ci-3-alkyloxy, piperidin-1 -yl-Ci-3-alkyloxy, 2-oxo- piperidin-1 -yl-Ci-3-alkyloxy, morpholin-4-yl-Ci-3-alkyloxy, 3-oxo-morpholin-4-yl-Ci-3- alkyloxy, piperazin-1 -yl-Ci-3-alkyloxy, 2-oxo-piperazin-1-yl-Ci-3-alkyloxy, 3-oxo- piperazin-1-yl-Ci.3-alkyloxy, 4-(Ci-3-alkyl)-piperazin-1-yl-Ci-3-alkyloxy, 2-oxo-4-(Ci-3- alkyl)-piperazin-1 -yl-Ci-3-alkyloxy, 3-oxo-4-(Ci-3-alkyl)-piperazin-1 -yl-d-3-alkyloxy,
Ci-3-alkylsulfanyl, Ci_3-alkylsulfinyl, Ci-3-alkylsulfonyl, (het)arylsulfonyl, trifluoro- methylsulfanyl, trifluoromethylsulfinyl, trifluoromethylsulfonyl,
wherein the above-mentioned saturated heterocycles and cycloalkyl-rings are optionally substituted with one or two groups independently of each other selected from Ci.3-alkyl, Ci-3-alkoxy, Ci-3-alkoxy-Ci-3-alkyl, or hydroxy, and
wherein the above-mentioned (het)aryl is phenyl, naphthyl, pyrrolyl, furanyl, thienyl, pyridyl, indolyl, benzofuranyl, benzothiophenyl, quinolinyl, isoquinolinyl, or pyrrolyl, furanyl, thienyl, pyridyl in which 1 or 2 CH are each replaced by N, or indolyl, benzofuranyl, benzothiophenyl, quinolinyl, isoquinolinyl in which 1 to 3 CH are each replaced by N, or tetrazolyl, and
wherein the above-mentioned (het)aryl groups are optionally substituted with one or two R10 which may be identical or different.
More preferably, the one or more substituents L2, which may be identical or different, denote fluorine, chlorine, bromine, cyano, C-ι-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, hydroxy, C-ι-4-alkyloxy, trifluoromethyl, difluoromethoxy, trifluoromethoxy, C3-6- cycloalkyl, Cs-β-cycloalkyloxy, phenyl, phenoxy, tetrazolyl, benzimidazolyl,
amino, Ci-3-alkylamino, di-(Ci-3-alkyl)amino, Ci-3-alkyl-carbonylamino, phenyl- carbonylamino, Ci-3-alkyl-sulfonylamino, N^Ci-s-alkylJ-Ci-s-alkyl-carbonylamino, N- (C-i-s-alkylJ-phenylcarbonylamino, N-(Ci-3-alkyl)-Ci-3-alkyl-sulfonylamino,
carboxy, Ci-3-alkyloxy-carbonyl, aminocarbonyl, C-i-s-alkyl-aminocarbonyl, di-(Ci-3- alkyl)-aminocarbonyl, phenylaminocarbonyl, N-(Ci_3-alkyl)-phenylaminocarbonyl,
carboxy-Ci-3-alkyl, d-ralkyloxy-carbonyl-Ci-s-alkyl, cyano-Ci-3-alkyl, aminocarbonyl- Ci-3-alkyl, Ci-s-alkyl-aminocarbonyl-C-i-ralkyl, di^Ci.s-alkylJ-aminocarbonyl-Ci-s-alkyl,
carboxy-Ci-3-alkyloxy, d-s-alkyloxy-carbonyl-Ci-s-alkyloxy, cyano-Ci-3-alkyloxy, aminocarbonyl-Ci-3-alkyloxy, Ci.s-alkyl-aminocarbonyl-Ci-s-alkyloxy, di-(Ci-3-alkyl)- aminocarbonyl-Ci-3-alkyloxy,
hydroxy-Ci-3-alkyl, Ci.s-alkyloxy-Ci-s-alkyl, amino-Ci-3-alkyl, Ci-3-alkylamino-Ci-3- alkyl, di-(Ci-3-alkyl)-amino-Ci-3-alkyl,
Ci-s-alkylcarbonylamino-Ci-s-alkyl,
hydroxy-C-ι-3-alkyloxy, Ci-s-alkyloxy-Ci-3-alkyloxy, amino-Ci-3-alkyloxy, Ci-3- alkylamino-Ci-3-alkyloxy, di-(Ci-3-alkyl)-amino-Ci-3-alkyloxy, C-ι-3-alkylsulfanyl, d-3-alkylsulfinyl, Ci-3-alkylsulfonyl,
and wherein the above-mentioned phenyl groups are optionally substituted with one or two R10 which may be identical or different.
Most preferably, the one or more substituents L2, which may be identical or different, denote fluorine, C1-4-alkyl, hydroxy, d-3-alkoxy, hydroxy-C-ι-3-alkyl, C-i.3-alkyloxy-C-i.3- alkyl, d-3-alkyloxy-carbonyl, aminocarbonyl, phenylaminocarbonyl, tetrazolyl, benzimidazolyl, or phenyl which may be monosubstituted with R10, particularly methyl, tert-butyl, hydroxy, methoxy, hydroxymethyl, 2-hydroxy-prop-2-yl, methoxymethyl, ethoxycarbonyl, aminocarbonyl, phenylaminocarbonyl, phenyl, 4- fluorophenyl, tetrazol-5-yl, or benzimidazol-2-yl.
Preferably, L3 and L4, which are linked to each other, form with the atoms to which they are linked an aryl- or heteroaryl-group which is fused to the cyclic group B, and which is optionally substituted with 1 , 2 or 3 identical or different R10, while said aryl- or heteroaryl group is selected from the group consisting of phenyl, pyrrolyl, furanyl, thienyl, pyridyl, indolyl, benzofuranyl, benzothio- phenyl, quinolinyl, isoquinolinyl, and
pyrrolyl, furanyl, thienyl, pyridyl wherein in said pyrrolyl, furanyl, thienyl and pyridyl one -CH= group is replaced by -N=, and
indolyl, quinolinyl, isoquinolinyl wherein in said indolyl, quinolinyl and isoquinolinyl one or two -CH= groups are each replaced by -N=.
More preferably, L3 and L4, which are linked to each other, form with the atoms to which they are linked an aryl- or heteroaryl-group which is fused to the cyclic group B, wherein said fused aryl- or heteroaryl-group is selected from the group consisting of benzo, pyhdo, pyrimido, pyrazino, pyridazino, pyrrolo, furano, thieno, imidazo, pyrazolo, oxazolo, isoxazolo, thiazolo, isothiazolo, each of which is optionally substituted with one to three identical or different R10. Even more preferably L3 and L4, which are linked to each other, form with the atoms to which they are linked an aryl- or heteroaryl-group which is fused to the cyclic group B, wherein said fused aryl- or heteroaryl-group is selected from the group consisting of benzo, pyrido, pyrimido, pyrazino, pyridazino, pyrrolo, furano, thieno, imidazo, pyrazolo, oxazolo, isoxazolo, thiazolo and isothiazolo, each of which is optionally substituted with 1 , 2 or 3 identical or different R10.
Most preferably L3 and L4, which are linked to each other, form with the atoms to which they are linked an aryl- or heteroaryl-group which is fused to the cyclic group B, wherein said fused aryl- or heteroaryl-group is selected from the group consisting of benzo, pyrido, pyrimido, pyrrolo, furano, thieno, imidazo and oxazolo group, each of which is optionally substituted with 1 , 2 or 3 identical or different R10, particularly benzo, thieno, and imidazo, each of which is optionally substituted with 1 , 2 or 3 identical or different R10.
Preferably, L5 and L6, which are linked to each other, form with the atoms to which they are linked an aryl- or heteroaryl-group which is fused to the cyclic group B, wherein said fused aryl- or heteroaryl-group is selected from the group consisting of benzo, pyrido, pyrimido, pyrazino, pyridazino, pyrrolo, furano, thieno, imidazo, pyrazolo, oxazolo, isoxazolo, thiazolo, and isothiazolo, each of which is optionally substituted with 1 , 2 or 3 identical or different R10, more preferably selected from the group consisting of benzo, pyrido, pyrimido, pyrazino, and pyridazino, each of which is optionally substituted with one to three identical or different R10, most preferably benzo, which is optinally substituted with 1 , 2 or 3 identical or different R10.
Regarding the definitions of L3 and L4 and of L5 and L6 in cases where an N- containing heteroaryl-group fused to the cyclic group B is formed, and where said N- containing heteroaryl-group is substituted with hydroxy at the carbon atom adjacent to the nitrogen, then a tautomeric amide substructure may be formed and is part of the invention. Examples of substructures of the ring B wherein two adjacent C-atoms are substituted with L3 and L4, wherein a tautomeric amide is formed are depicted in the following table:
Figure imgf000032_0001
Figure imgf000032_0003
Figure imgf000032_0002
Figure imgf000032_0004
Preferably, the substituent R1 denotes fluorine, chlorine, cyano, C-M-alkyl, hydroxy, C-ι-4-alkyloxy, difluoromethyl, trifluoromethyl, trifluoromethyl-hydroxy-C-ι-2-alkyl, difluoromethoxy, trifluoromethoxy, C3-6-cycloalkyl, Ca-β-cycloalkyloxy, C3-6-cycloalkyl- Ci-3-alkyl, Ca-e-cycloalkyl-d-a-alkyloxy, tetrahydrofuran-3-yloxy, tetrahydropyran-3- yloxy, tetrahydropyran-4-yloxy, tetrahydrofuranyl-C-ι-3-alkyloxy, tetrahydropyranyl-Ci. 3-alkyloxy, (het)aryl, (het)aryloxy, (het)aryl-Ci-3-alkyl, (het)aryl-Ci-3-alkyloxy, (het)aryloxy- C-ι-3-alkyl, Ci-3-alkyl-carbonyl, (het)aryl-carbonyl, amino, Ci-3-alkylamino, di-(Ci-3-alkyl)amino, pyrrolidin-1-yl, 2-oxo-pyrrolidin-i-yl, piperidin-1-yl, 2-oxo-piperidin-1-yl, morpholin-4-yl, 3-oxo-morpholin-4-yl, 3-oxo- piperazin-1 -yl, 4-(Ci-4-alkylcarbonyl)-piperazin-1 -yl,
Ci-3-alkyl-carbonylamino, (het)aryl-carbonylamino, Ci-3-alkyloxy-carbonylamino, Ci-3- alkyl-aminocarbonylamino, di-(Ci-3-alkyl)aminocarbonylamino, pyrrolidin-1 -yl- carbonylamino, piperidin-1-yl-carbonylamino, morpholin-4-yl-carbonylamino, Ci-3- alkyl-sulfonylamino, Ci-3-alkylamino-sulfonylamino, di-(Ci-3-alkyl)amino- sulfonylamino, pyrrolidin-1 -yl-sulfonylamino, piperidin-1-yl-sulfonylamino, morpholin- 4-yl-sulfonylamino, (het)arylsulfonylamino,
N-CCi.s-alkyO-Ci.s-alkyl-carbonylamino, N-(Ci-3-alkyl)-(het)arylcarbonylamino, N-(Ci-3- alkyl)-Ci-3-alkyloxy-carbonylamino, N-(Ci-3-alkyl-aminocarbonyl)-Ci-3-alkylamino, N- ^(-(Ci-s-alkyOaminocarbonylJ-Ci-s-alkylamino,
N-(Ci-3-alkyl)-Ci-3-alkyl-sulfonylamino, N-(Ci-3-alkyl)-(het)arylsulfonylamino,
(hydroxyimino)aminomethyl, (Ci-3-alkyloxyimino)aminomethyl, carboxy, Ci-3-alkyloxy- carbonyl, aminocarbonyl, Ci-s-alkyl-aminocarbonyl, di-(Ci-3-alkyl)-aminocarbonyl, pyrrolidin-1 -yl-carbonyl, piperidin-1-yl-carbonyl, morpholin-4-yl-carbonyl,
carboxy-Ci-3-alkyl, Ci.s-alkyloxy-carbonyl-Ci.s-alkyl, cyano-d-3-alkyl, aminocarbonyl- Ci-3-alkyl, Ci.s-alkyl-aminocarbonyl-Ci-s-alkyl, di^Ci.s-alkyO-aminocarbonyl-Ci-s-alkyl, pyrrolidin-1 -yl-carbonyl-Ci-3-alkyl, piperidin-i-yl-carbonyl-Ci.s-alkyl, morpholin-4-yl- carbonyl-Ci-3-alkyl,
carboxy-Ci-3-alkyloxy, Ci.s-alkyloxy-carbonyl-Ci.s-alkyloxy, cyano-Ci-3-alkyloxy, aminocarbonyl-Ci-3-alkyloxy, Ci-s-alkyl-aminocarbonyl-Ci-s-alkyloxy, di-(Ci-3-alkyl)- aminocarbonyl-Ci-3-alkyloxy, pyrrolidin-1 -yl-carbonyl-Ci.s-alkyl-oxy, piperidin-1 -yl- carbonyl-Ci-3-alkyloxy, morpholin^-yl-carbonyl-Ci.s-alkyl-oxy,
hydroxy-Ci-3-alkyl, Ci.a-alkyloxy-Ci.s-alkyl, amino-Ci-3-alkyl, Ci-3-alkylamino-Ci-3- alkyl, di-(C1-3-alkyl)-amino-Ci-3-alkyl, pyrrolidin-1 -yl-Ci-3-alkyl, 2-oxo-pyrrolidin-i-yl-Ci. 3-alkyl, Ci^-alkylcarbonyl-amino-C-i-a-alkyl, N-(Ci-3-alkyl)-Ci-4-alkylcarbonyl-amino-Ci- 3-alkyl, 2-oxo-piperidin-1-yl-Ci-3-alkyl, S-oxo-morpholin^-yl-Ci-s-alkyl,
hydroxy-Ci-3-alkyloxy, Ci.a-alkyloxy-d.a-alkyloxy, Ci^-alkylsulfinyl-Ci-s-alkyloxy, Ci-3- alkylsulfonyl-C-ι-3-alkyloxy, di-(Ci-3-alkyl)-amino-Ci-3-alkyloxy, 2-oxo-pyrrolidin-1-yl-Ci. 3-alkyloxy, 2-oxo-piperidin-1-yl-Ci.3-alkyloxy, morpholin-4-yl-Ci-3-alkyloxy, 3-oxo- morpholin-4-yl-Ci-3-alkyloxy,
aminosulfonyl, Ci.3-alkyl-aminosulfonyl, di-(Ci-3-alkyl)-aminosulfonyl, pyrrolidin-1-yl- sulfonyl, piperidin-1 -yl-sulfonyl, morpholin-4-yl-sulfonyl,
wherein the above-mentioned (het)aryl is defined as described hereinbefore and hereinafter.
More preferably, R1 denotes fluorine, chlorine, cyano, C-M-alkyl, hydroxy, Ci-4- alkyloxy, trifluoromethyl, trifluoromethyl-hydroxy-Ci-2-alkyl, difluoromethoxy, trifluoromethoxy, Cs-6-cycloalkyloxy, tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy, tetrahydrofuranyl-Ci-3-alkyloxy, tetrahydropyranyl-Ci-3- alkyloxy, (het)aryl, (het)aryloxy, (het)aryl-Ci-3-alkyloxy, Ci-3-alkyl-carbonyl, or
amino, d-3-alkylamino, 2-oxo-pyrrolidin-1-yl, 2-oxo-piperidin-i-yl, morpholin-4-yl, 3- oxo-morpholin-4-yl, Ci-3-alkyl-carbonylamino, (het)aryl-carbonylamino, Ci_3-alkyl- sulfonylamino, N-(Ci.3-alkyl)-Ci-3-alkyl-carbonylamino, N-(Ci-3-alkyl)- (het)arylcarbonylamino,
N-(Ci-3-alkyl)-Ci-3-alkyl-sulfonylamino, N-(Ci-3-alkyl)-(het)arylsulfonylamino,
carboxy, d-3-alkyloxy-carbonyl, aminocarbonyl, Ci-3-alkyl-aminocarbonyl, di-(Ci-3- alkyl)-aminocarbonyl, pyrrolidin-1-yl-carbonyl, piperidin-1 -yl-carbonyl, morpholin-4-yl- carbonyl,
carboxy-d-3-alkyl, Ci.a-alkyloxy-carbonyl-Ci.s-alkyl, cyano-Ci-3-alkyl, aminocarbonyl- Ci-3-alkyl, Ci.s-alkyl-aminocarbonyl-Ci.s-alkyl, di^Ci-s-alkyO-aminocarbonyl-Ci.s-alkyl, pyrrol id in-1
Figure imgf000035_0002
piperidin-1
Figure imgf000035_0001
morpholin-4-yl- carbonyl-Ci-3-alkyl,
cyano-C-ι-3-alkyloxy, aminocarbonyl-Ci-3-alkyloxy, C1.3-alkyl-aminocarbonyl-C1.3- alkyloxy, di-(Ci-3-alkyl)-aminocarbonyl-Ci-3-alkyloxy, pyrrolidin-1-yl-carbonyl-Ci_3- alkyl-oxy, piperidin-1 -yl-carbonyl-Ci-s-alkyloxy, morpholin^-yl-carbonyl-d-s-alkyl-oxy,
hydroxy-Ci-3-alkyl, Ci-s-alkyloxy-Ci-s-alkyl, Ci^-alkylcarbonyl-amino-Ci-s-alkyl, N-(Ci- s-alkyO-Ci^-alkylcarbonyl-amino-Ci-s-alkyl, 2-oxo-pyrrolidin-1-yl-Ci-3-alkyl, 2-oxo- piperidin-1 -yl-Ci-3-alkyl, S-oxo-morpholin^-yl-Ci-s-alkyl,
hydroxy-Ci-3-alkyloxy,
Figure imgf000035_0003
aminosulfonyl, Ci-3-alkyl-aminosulfonyl, di-(Ci-3-alkyl)-aminosulfonyl,
wherein the above-mentioned (het)aryl groups are selected from the group consisting of phenyl, furanyl, thienyl, oxazolyl, thiazolyl, isoxazolyl, imidazolyl, pyrazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, 1 ,2- dihydro-1 -methyl-2-oxo-pyridinyl, 2,3-dihydro-2-methyl-3-oxo-pyridazinyl, and triazinyl, wherein each group is optionally mono- or disubstituted with identical or different R10.
Even more preferably, R1 denotes fluorine, chlorine, Ci-3-alkyl, hydroxy, Ci-3-alkyloxy, amino, Ci-3-alkyl-carbonylamino, Ci-3-alkyl-sulfonylamino, cyano, carboxy, C1-3- alkyloxy-carbonyl, aminocarbonyl, Ci-3-alkyl-aminocarbonyl, di-(Ci-3-alkyl)- aminocarbonyl, hydroxy-d-3-alkyl, trifluoromethyl-hydroxy-Ci-2-alkyl, Ci-3-alkyloxy-Ci- 3-alkyl, Ci-s-alkyl-carbonyl-amino-Ci-s-alkyl, cyano-Ci-3-alkyloxy, hydroxy-Ci-3- alkyloxy,
Figure imgf000035_0004
trifluoromethyl, difluoromethoxy, trifluoromethoxy, Ci-3-alkylcarbonyl, aminosulfonyl, d-3-alkyl-aminosulfonyl, di-(Ci-3- alkyl)-aminosulfonyl, cyano-Ci-3-alkyloxy, phenyl-Ci-3-alkyloxy, phenoxy, phenyl, pyridinyl, 1 ,2-dihydro-i -methyl-2-oxo-pyridinyl, pyrimidinyl, pyridazinyl, 2,3-dihydro-2- methyl-3-oxo-pyridazinyl, 4-methyl-4H-[1 ,2,4]thazol-3-yl, or oxadiazolyl, wherein each (het)aryl mentioned is optionally mono- or disubstituted with identical or different R10. Most preferably R1 denotes fluorine, chlorine, methyl, hydroxy, methoxy, amino, acetylamino, methylsulfonylamino, cyano, methoxycarbonyl, ethoxycarbonyl, acetyl, 1-hydroxyethyl, 1-hydroxy-1 -methyl-ethyl, 2,2,2-trifluoro-1-hydroxy-1 -methyl-ethyl, methylsulfonyl, aminosulfonyl, methylaminosulfonyl, dimethylaminosulfonyl, cyanomethoxy, benzyloxy, phenoxy, phenyl, pyridin-3-yl, pyridin-4-yl, 1 ,2-dihydro-1- methyl-2-oxo-pyridin-5-yl, 1 ,2-dihydro-1-methyl-2-oxo-pyhdin-4-yl, pyrimidin-4-yl, 2- methyl-pyhmidin-4-yl, 2-methyl-pyrimidin-5-yl, 6-methyl-pyridazin-3-yl, 2,3-dihydro-2- methyl-3-oxo-pyridazin-6-yl, 4,5-dimethyl-4H-[1 ,2,4]triazol-3-yl, oxadiazolyl, or methyloxadiazolyl.
If R2 and R3 are linked to each other to form a bridging group they are preferably selected from the group consisting of methylenedioxy, difluoromethylenedioxy, ethylenedioxy and C3-5-alkylene bridging group, even more preferably consisting of methylenedioxy, ethylenedioxy, propylene, and butylene, most preferably methylenedioxy or ethylenedioxy.
Additionally R2 and R3 may form combined with the carbon atoms to which they are attached a group preferably selected from the group consisting of a benzo, pyrazino, pyrazolo, imidazo, N-(Ci-3-alkyl)-pyrazolo, N-(Ci-3-alkyl)-imidazo, oxazolo, thiazolo, isoxazolo, and isothiazolo ring, wherein each of the five-membered rings is optionally monosubstituted with Rp and each of the six-membered rings is optionally substituted with one or two substituents independently of each other selected from Rp, or N-(Ci-3-alkyl)-thazolo or thazolo.
If R2 and R3 combined with the carbon atoms to which they are attached form a group as described hereinbefore said group is even more preferably selected from the group consisting of a benzo, pyrazino, pyrazolo, imidazo, N-(Ci-3-alkyl)-pyrazolo, N-(Ci-3-alkyl)-imidazo, oxazolo, thiazolo, isoxazolo, and isothiazolo ring, wherein each of the five-membered rings is optionally monosubstituted with Rp and each of the six-membered rings is optionally substituted with one or two substituents independently of each other selected from Rp, or N-(Ci-3-alkyl)-triazolo or triazolo.
If R2 and R3 combined with the carbon atoms to which they are attached form a group as described hereinbefore said group is most preferably selected from the group consisting of a benzo, pyrazino, imidazo, N-(Ci-3-alkyl)-imidazo, N-(Ci-3-alkyl)- triazolo, oxazolo, or thiazolo ring, wherein the benzo and pyrazino ring are optionally substituted with one or two substituents independently of each other selected from Rp and the imidazo, N-(Ci-3-alkyl)-imidazo, oxazolo, and thiazolo ring are optionally additionally monosubstituted with Rp.
Most preferably, R2 and R3 together denote methylenedioxy or together with the carbon atoms to which they are attached form an optionally additionally with methyl, tert-butyl, cyclopropyl, tetrahydrofuran-2-yl, 1 -acetyl-piperidin-4-yl, pyridin-3-yl, 1 ,2- dihydro-1-methyl-2-oxo-pyridin-5-yl, pyridazin-4-yl, pyrazinyl, or 5-methyl-pyrazin-2-yl substituted oxazolo, imidazo, or N-methyl-imidazo group, an optionally with methyl substituted triazolo group, or an optionally methyl or dimethyl substituted benzo or pyrazino ring.
Rp preferably is fluorine, Ci-4-alkyl, C3-6-cycloalkyl, pyrrolidinyl, 1-methyl-pyrrolidinyl, 1-acetyl-pyrrolidinyl, piperidinyl, 1-methyl-piperidinyl, 1-acetyl-piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, trifluoromethyl, cyano, amino, acetylamino, methylsulfonylamino, carboxy, d-3-alkyloxycarbonyl, aminocarbonyl, methylamino- carbonyl, dimethylaminocarbonyl, aminosulfonyl, hydroxy, C-ι-3-alkyloxy, or phenyl, pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, 1 ,2-dihydro-2-oxo-pyridinyl, which are optionally substituted with one or two groups independently selected from fluorine, chlorine, C-ι-3-alkyl, difluoromethyl, trifluoromethyl, cyano, amino, acetylamino, methylsulfonylamino, carboxy, C-ι-3-alkyloxycarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylamino-carbonyl, hydroxy, methoxy, difluoromethoxy, and trifluoromethoxy.
More preferably, Rp is fluorine, methyl, ethyl, tert-butyl, C3-6-cycloalkyl, pyrrolidinyl, 1- methyl-pyrrolidinyl, 1-acetyl-pyrrolidinyl, piperidinyl, 1-methyl-piperidinyl, 1-acetyl- piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, trifluoromethyl, cyano, amino, acetylamino, methylsulfonylamino, carboxy, methoxycarbonyl, ethoxycarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, aminosulfonyl, hydroxy, methoxy, or phenyl, pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, 1 ,2-dihydro-2-oxo-pyridinyl, which are optionally substituted with one or two groups independently selected from fluorine, methyl, trifluoromethyl, cyano, amino, acetylamino, methylsulfonylamino, carboxy, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, hydroxy, and methoxy.
Most preferably, Rp is fluorine, methyl, cyclopropyl, 1-acetyl-piperidinyl, tetrahydrofuranyl, acetylamino, methylsulfonylamino, carboxy, hydroxy, methoxy, or pyridyl, pyridazinyl, pyrazinyl, 1 ,2-dihydro-2-oxo-pyhdinyl, which are optionally substituted with one or two methyl groups; particularly, L is methyl, tert-butyl, cyclopropyl, tetrahydrofuran-2-yl, 1-acetyl-piperidin-4-yl, pyrid-3-yl, pyridazin-3-yl, pyrazinyl, 5-methylpyrazin-2-yl, 1 ,2-dihydro-2-oxo-pyridin-5-yl.
Preferably the one or more substituents R10 independently of each other denote fluorine, chlorine, bromine, d-3-alkyl, difluoromethyl, trifluoromethyl, cyano, nitro, amino, acetylamino, methylsulfonylamino, carboxy, C-M-alkyloxycarbonyl, aminocarbonyl, Ci-3-alkylaminocarbonyl, di-(Ci-3-alkyl)-aminocarbonyl, aminosulfonyl, methylsulfanyl, methylsulfinyl, methylsulfonyl, phenyl, hydroxy, Ci-3-alkyloxy, difluoromethoxy, or thfluoromethoxy.
More preferably, R10 denotes fluorine, chlorine, methyl, difluoromethyl, trifluoromethyl, cyano, hydroxy, methoxy, difluoromethoxy, or trifluoromethoxy. Most preferably, R10 denotes fluorine or methyl.
Preferably the one or more substituents R11 independently of each other denote fluorine, Ci-3-alkyl, phenyl, hydroxy, Ci-3-alkyloxy, cyano, carboxy, Ci-4-alkyloxy- carbonyl, aminocarbonyl, Ci-4-alkylamino-carbonyl, di-(Ci-4-alkyl)-aminocarbonyl, hydroxy-d-4-alkyl, or
Figure imgf000038_0001
More preferably R11 denotes fluorine, d-3-alkyl, hydroxy, or d-3-alkyloxy. Most preferably, R11 denotes methyl, ethyl, propyl, hydroxy, or methoxy, particularly methyl or hydroxy.
Preferably the one or more substituents R12 independently of each other denote fluorine, or Ci-3-alkyl, more preferably methyl or ethyl.
Particularly preferred embodiments of this invention are described by each of the formulae 1.1a to 1.10a
Figure imgf000039_0001
Figure imgf000039_0002
Figure imgf000039_0003
Figure imgf000039_0004
Figure imgf000039_0005
Figure imgf000040_0001
Figure imgf000040_0002
Figure imgf000040_0003
Figure imgf000040_0004
Figure imgf000040_0005
wherein the C5+m+n-azacycloalkene core structure of general formulae 1.1a to 1.10a including the bridging group -(CH2)0- is optionally substituted with 1 , 2 or more substituents independently of each other selected from the group consisting of R11 and R12, and wherein the ring B and R1, R2, R3, R11, R12 are defined as hereinbefore and hereinafter, their tautomers, their stereoisomers, mixtures thereof and the salts thereof, while the compounds (M1 ), (M2), (M3) and (M4) as defined hereinbefore, are excluded.
According to a preferred embodiment of the general formula 1.1a compounds of the invention are described by the formula Ma-RR
Figure imgf000041_0001
wherein the 2,6-methano-azocin core structure with the stereochemical configuration as depicted is optionally substituted with 1 , 2 or more substituents independently of each other selected from the group consisting of R11 and R12, and wherein the ring B and R1, R2, R3, R11, R12 are defined as hereinbefore and hereinafter, their tautomers, their stereoisomers, mixtures thereof and the salts thereof.
According to another preferred embodiment of the general formula M a compounds of the invention are described by the formula M a-SS
Figure imgf000041_0002
wherein the 2,6-methano-azocin core structure with the stereochemical configuration as depicted is optionally substituted with 1 , 2 or more substituents independently of each other selected from the group consisting of R11 and R12, and wherein the ring B and R1, R2, R3, R11, R12 are defined as hereinbefore and hereinafter, their tautomers, their stereoisomers, mixtures thereof and the salts thereof. Even more preferred compounds are described by the formulae 1.1a to 1.10a and Ma-RR and Ma-SS wherein the C5+m+n-azacycloalkene core structure including the bridging group -(CH2)0- is optionally mono-substituted with R11 and optionally substituted with 1 , 2 or 3 substituents independently of each other selected from R12, wherein the ring B and R1, R2, R3, R11, R12 are defined as hereinbefore and hereinafter, their tautomers, their stereoisomers, mixtures thereof and the salts thereof.
According to another embodiment the invention relates to compounds of the formula I1 in particular of the formulae M to MO, most preferably of the formulae M a to M Oa, in particular of the formula 1.5 and 1.5a, defined as hereinbefore wherein compounds of the formula l.5a-1
Figure imgf000042_0001
wherein R1 is hydrogen, hydroxy or Ci-4-alkyloxy, and R11 is C1-4-alkyl or phenyl, and the ring B is morpholin-4-yl, piperidin-1-yl or pyrrolidin-1-yl, and all remaining substituents are hydrogen, are excluded.
According to another embodiment the invention relates to compounds of the formula I, in particular of the formulae 1.1 to M O, most preferably of the formulae M a to MOa, in particular of the formula 1.1 and Ma, defined as hereinbefore wherein compounds of the formula Ma-1
Figure imgf000042_0002
wherein R1 is hydrogen, hydroxy or Ci-4-alkyloxy, and R11 is hydrogen, C1-4-alkyl, 2- methoxy-ethyl, or phenyl, wherein said phenyl is optionally substituted with halogen, hydroxy or C-ι-3-alkyloxy, and R12 is hydrogen, or Ci-4-alkyl, and the ring B is a 3- to 8- membered monocytic azacycloalk-1-yl group or morpholin-4-yl, and all remaining substituents are hydrogen, and their salts, are excluded. Some terms used above and hereinafter to describe the compounds according to the invention will now be defined more closely.
The term "substituted" as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valence is not exceeded, and that the substitution results in a stable compound.
The term "partially unsaturated" as used herein, means that in the designated group or moiety 1 , 2 or more, preferably 1 or 2, double bonds are present. Preferably as used herein, the term "partially unsaturated" does not cover fully unsaturated groups or moieties.
The term "fully unsaturated" as used herein, means that in the designated group or moiety conjugated double bonds are present such that an aromatic or heteroaromatic system is formed.
The term halogen denotes an atom selected from the group consisting of F, Cl, Br and I.
The term Ci-n-alkyl, wherein n may have a value of 1 to 18, denotes a saturated, branched or unbranched hydrocarbon group with 1 to n C atoms. Examples of such groups include methyl, ethyl, n-propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, neo-pentyl, tert-pentyl, n-hexyl, iso-hexyl, etc.
The term C2-n-alkenyl, wherein n has a value of 3 to 6, denotes a branched or unbranched hydrocarbon group with 2 to n C atoms and a C=C double bond. Examples of such groups include ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2- butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2- hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl etc.
The term C2-n-alkynyl, wherein n has a value of 3 to 6, denotes a branched or unbranched hydrocarbon group with 2 to n C atoms and a C≡C triple bond. Examples of such groups include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3- butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 3- hexynyl, 4-hexynyl, 5-hexynyl etc. Unless otherwise stated alkynyl groups are connected to the remainder of the molecule via the C atom in position 1. Therefore terms such as 1-propynyl, 2-propynyl, 1 -butynyl, etc. are equivalent to the terms 1- propyn-1-yl, 2-propyn-1-yl, 1-butyn-1-yl, etc.. This also applies analogously to C2-n- alkenyl groups.
The term Ci-n-alkoxy denotes a C-ι.n-alkyl-0 group, wherein Ci-n-alkyl is as hereinbefore defined. Examples of such groups include methoxy, ethoxy, n-propoxy, iso- propoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, iso-pentoxy, neo- pentoxy, tert-pentoxy, n-hexoxy, iso-hexoxy, etc.
The term Ci-n-alkylcarbonyl denotes a Ci-n-alkyl-C(=O) group, wherein Ci-n-alkyl is as hereinbefore defined. Examples of such groups include methylcarbonyl, ethylcarbo- nyl, n-propylcarbonyl, iso-propylcarbonyl, n-butylcarbonyl, iso-butylcarbonyl, sec-bu- tylcarbonyl, tert-butylcarbonyl, n-pentylcarbonyl, iso-pentylcarbonyl, neo-pentylcar- bonyl, tert-pentylcarbonyl, n-hexylcarbonyl, iso-hexylcarbonyl, etc.
The term C3-n-cycloalkyl denotes a saturated mono-, bi-, tri- or spirocarbocyclic group with 3 to n C atoms. Examples of such groups include cyclopropyl, cyclobutyl, cyclo- pentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclododecyl, bicyclo[3.2.1.]oc- tyl, spiro[4.5]decyl, norpinyl, norbonyl, norcaryl, adamantyl, etc. Preferably the term C3-7-cycloalkyl denotes saturated monocyclic groups.
The term Cs-n-cycloalkenyl denotes a Cs-n-cycloalkyl group which is as hereinbefore defined and additionally has at least one C=C double bond.
The term C3-n-cycloalkylcarbonyl denotes a C3-n-cycloalkyl-C(=O) group wherein C3-n-cycloalkyl is as hereinbefore defined.
The term tri-(Ci-4-alkyl)silyl comprises silyl groups which have identical or two or three different alkyl groups. The term di-(Ci-3-alkyl)amino comprises amino groups which have identical or two different alkyl groups.
If groups or residues are optionally substituted, this applies to any form of the group or residue. For instance, if an alkyl group is optionally mono- or polyfluorinated this comprises also alkyl residues which are part of larger groups, e.g. alkyloxy, alkylcarbonyl, alkoxyalkyl, etc., or if a (het)aryl group is optionally mono- or polysubstituted with a certain substituent or a set of substituents this also includes (het)aryl groups which are part of larger groups, e.g. (het)aryl-Ci-n-alkyl, (het)aryloxy, (het)aryloxy-Ci-n-alkyl, (het)aryl-Ci-π-alkyloxy, etc.. Accordingly, in cases where R1 or L2 have e.g. the meaning (het)aryloxy, while (het)aryl residues are optionally mono- or polyfluorinated and (het)aryl denotes inter alia phenyl, the meanings mono-, di-, tri- , tetra-, and pentafluorophenoxy are also comprised. The same applies to groups or residues in which a part of the group or residue is replaced as e.g. a CH2 group is optionally replaced with O, S, NR, CO, or SO2. For instance, a residue having inter alia the meaning hydroxy-Ci-3-alkyl, in which a CH2 group is optionally replaced by CO, this also comprises carboxy, carboxymethyl, hydroxymethylcarbonyl, carboxyethyl, hydroxyl-methylcarbonylmethyl, and hydroxyethylcarbonyl.
The compounds according to the invention may be obtained using methods of synthesis known in principle. Preferably, the compounds are obtained by the following methods according to the invention which are described in more detail hereinafter.
A general strategy to access compounds of the invention is delineated in Scheme 1 ; A, X, m, n, and 0 have the meanings as defined hereinbefore and hereinafter. The key reaction to assemble the bicyclic framework is an intramolecular reaction of an amino functionality with a carboxy group that results in the formation of an amide linkage. The fusion of the carboxylic acid function and the amino group may be carried out with or without an additive at elevated temperatures, preferably between 20 and 200 0C. Additives that remove the water forming during the reaction, such as molecular sieves or orthoesters, or other additives such as bases, e.g. hexamethyldisilazides, or boronic acids may facilitate the reaction. Though, more preferably the reaction is done with a more reactive entity of the carboxy function such as an acyl halide, ester, thioester, anhydride, mixed anhydride, or ketene which may be generated in a separate preceding reaction step or in situ. Preferred acyl halides or pseudohalides are acyl chloride, acyl fluoride, and acylcyanide. Preferred esters and thioesters are derived from e.g. methanol/methylthiol, ethanol/ethylthiol, 2,2,2-trifluoroethanol, phenol/thiophenol, substituted phenol/thiophenol such as 4- nitrophenol or pentafluorophenol, hydroxy heteroaryl such as hydroxybenzotriazol, hydroxypyridotriazol, or hydroxytriazines, or N-hydroxysuccinimid. Preferred mixed anhydrides are derived from alkylcarboxylic acids, e.g. pivalic acid, carbonates, e.g. methyl and ethyl carbonate, carbamates, e.g. N,N-dimethyl carbamate, phosphoric acids, e.g. dimethylphosphoric acid or (Me2N)2P(O)OH, or ureas, e.g. dicyclohexylurea, dimethylurea, or tetramethylurea. Additionally, N acylated derivatives derived from azaheteroaromatics such as imidazole, triazole, tetrazole, or pyridine such as e.g. 4-dimethylaminopyridine may be used as well. Some of the more popular reagents used for the activation of the carboxylic acid function are N,N'-carbonyldiimidazol, dicyclohexylcarbodiimide, (benzotriazol-1- yloxy)dipiperidinocarbenium hexafluorophosphate or tetrafluoroborate, (benzotriazol- 1-yloxy)dipyrrolidinocarbenium hexafluorophosphate or tetrafluoroborate, 1-(3- dimethylaminopropyl)-3-ethylcarbodiimide methiodide, POCI3, SOCI2, (COCI)2, COCI2, arylboronic acid, TiCI4, (MeO)2POCI, cyanuric chloride, 1 -hydroxybenzotriazol, 1-hydroxy-7-azabenzothazol, benzoltriazol-1-yloxytris(dimethylamino)phospho- nium hexafluorophosphate or tetrafluoroborate, benzoltriazol-1-yloxytripyrrolidino- phosphonium hexafluorophosphate or tetrafluoroborate, (7-aza-benzoltriazol-1- yloxy)tripyrrolidinophosphonium hexafluorophosphate or tetrafluoroborate, O-(benzo- triazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate or tetrafluoroborate, O-(7-aza-1 H-benzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium hexafluorophosphate or tetrafluoroborate. This compilation of reagents represents only a few possibilities to activate an carboxylic acid function. A host of additional reagents is known and may be used here as well. The reactive carboxylic acid derivatives may also serve as intermediates for other acylating reagents also sufficiently reactive for this transformation. The activation step and the ensuing amide forming step are often best carried out in the presence of additional additives such as bases, e.g. ethyldiisopro- pylamine, triethylamine, alkali metal carbonate, pyridine, 4-dimethylaminopyridine, imidazole, dimethylaluminum amides, lithium amides, alkali metal cyanide, or alkali metal hexamethyldisilazide. The reactions are preferably conducted in organic solvents but may also be carried out in aqueous solvents. Among the organic solvents ordinarily used are dimethylformamide, N.N-dimethylacetamide, N-methyl- pyrrolidinone, dimethylsulfoxide, tetrahydrofuran, hexane, ether, 1 ,4-dioxane, 1 ,2- dimethoxyethane, dichloromethane, dichloroethane, toluene, benzene, ethyl acetate, quinoline, pyridine, or mixtures thereof. The reactions may be carried out at -80 0C to 220 0C, preferably between -10 0C and 120 0C. Subsequently, the lactam group is reduced to give the secondary amine. This transformation is a well established reaction that may be carried out, for example, using LiAIH4, hydrogen in the presence of a catalyst, NaBH4 in the presence of e.g. iodine, LiBH4, borane, sodium in propanol, CI3SiH, silanes, e.g. Et3SiH, in the presence of a transition metal such as rhenium, 9-BBN, LiBH3NMe2, or Et3SiH combined with LiEt3BH. Solvents such as e.g. tetrahydrofuran, ether, 1 ,2-dimethoxyethane, 1 ,4-dioxane, hexane, benzene, toluene, dichloromethane, alcohols, water, or mixtures thereof may be employed at - 78 0C to 200 0C, preferably between -10 0C and 120 0C; though, in combination with some reducing reagents only a few of these solvents are usable. This strategy is well suited for the synthesis of the scaffolds 1.1 to 1.10.
Scheme 1. Strategy 1 to build the bicyclic skeleton
Figure imgf000047_0001
Y = see text
Another common synthetic route to acquire the compounds of the invention is summarized in Scheme 2; A, X, m, n, and o have the meanings as defined hereinbefore and hereinafter. The bicyclic framework is formed via an intramolecular reductive amination reaction of a primary amine with a ketone functionality. Reductive aminations have large precedence in organic chemistry and may be carried out e.g. using hydrogen in the presence of a transition metal catalyst such as one derived from Ni, Rh, Pd, or Pt, borohydride reagents, e.g. sodium borohydride, sodium cyanoborohydride, or sodium triacetoxyborohydhde, zinc in combination with hydrochloric acid, PhSiH3 with Bu2SnCb, Bi0Hi4, or formic acid or salts thereof. Some of these reagents are preferably used in combination with an additive such as acid, e.g. acetic acid or mineral acid. The reactions are preferably conducted in organic solvents or aqueous mixtures, e.g. dimethylformamide, N,N-dimethylacetamide, N- methylpyrrolidinone, dimethylsulfoxide, tetrahydrofuran, hexane, ether, 1 ,4-dioxane, 1 ,2-dimethoxyethane, dichloromethane, dichloroethane, toluene, benzene, alcohols, water, or mixtures thereof. The reactions may be carried out at -80 0C to 200 0C, preferably between -10 0C and 100 0C.
Scheme 2. Strategy 2 to build the bicyclic skeleton
Figure imgf000048_0001
The strategy shown in Scheme 3, wherein A, X, m, n, and o have the meanings as defined hereinbefore and hereinafter, is another valid approach based on the reductive amination reaction already delineated in Scheme 2. Reaction conditions described there may be employed analogously here.
Scheme 3. Strategy 3 to build the bicyclic skeleton
Figure imgf000048_0002
Scheme 4, wherein A, X, m, n, and o have the meanings as defined hereinbefore and hereinafter, shows another approach to assemble the bicyclic framework. This approach is an intramolecular alkylation of the nitrogen group with an appropriate electrophile of the side-chain. The nitrogen group may be an amino group, i.e. Ra denotes e.g. hydrogen, methyl, allyl, benzyl, or dimethoxybenzyl, or an amide group, i.e. Ra denotes e.g. methoxycarbonyl, benzyloxycarbonyl, allyloxycarbonyl, terfbut- oxycarbonyl, trifluormethylcarbonyl, acetyl, 2,2,2-trichloroethoxycarbonyl, tolylsulfo- nyl, phenylsulfonyl, methoxyphenylsulfonyl, nitrophenylsulfonyl, 2,2,2- trichloroethylsulfonyl, or 2-trimethylsilylethylsulfonyl. The nitrogen function is reacted with an electrophilic Csp3-center in the side-chain, i.e. LG in Scheme 4 denotes e.g. chlorine, bromine, iodine, mesyloxy, tosyloxy, or trifluoromethlysulfonyloxy, in the presence of a base such as e.g. triethylamine, ethyldiisopropylamine, diazabicycloundecene, alkali metal carbonate, alkali metal tertbutoxide, alkali metal diisopropylamide, butyllithium, or sodium hydride. The stronger bases among them are preferably used in combination with the amides in e.g. N-methylpyrrolidinone, dimethylsulfoxide, tetrahydrofuran, hexane, ether, 1 ,4-dioxane, 1 ,2-dimethoxyethane, toluene, benzene, terfoutanol, isopropanol, or mixtures thereof at temperatures between -70 and 100 0C, preferably between -30 and 60 0C. The milder bases listed are preferably used in combination with the amines in dichloromethane, dimethylformamide, N-methylpyrrolidinone, dimethylsulfoxide, tetrahydrofuran, hexane, ether, 1 ,4-dioxane, 1 ,2-dimethoxyethane, toluene, benzene, methanol, ethanol, tertbutanol, isopropanol, water, or mixtures thereof at temperatures between 0 and 140 0C, preferably between 20 and 120 0C. For the amides the conditions originally reported by Mitsunobu may be used as well. Accordingly, the side-chain leaving group LG is generated in situ from the hydroxy group (LG = OH) using a phosphine, e.g. triphenylphosphine or thbutylphosphine, in combination with an azodicarboxylate, e.g. diethyl azodicarboxylate, diisopropyl azodicarboxylate, or azodicarboxylic dipiperidide. Suited solvents may be selected from among dimethylformamide, N-methylpyrrolidinone, dichloromethane, tetrahydrofuran, hexane, ether, 1 ,4-dioxane, 1 ,2-dimethoxyethane, toluene, benzene, and mixtures thereof. The reaction is preferably conducted at temperatures between 0 and 100 °C. The opposite way around, i.e. LG denotes NHRa and NHRa denotes LG, may be applicable as well. Reaction conditions are equivalent to the original way around. Scheme 4. Strategy 4 to build the bicyclic skeleton
intramolecular
N-alkylation
Figure imgf000050_0002
Figure imgf000050_0001
A further generally applicable approach is based on an electrophilic aromatic substitution reaction (Scheme 5); A, X1 m, n, and o have the meanings as defined hereinbefore and hereinafter. Thereby the aromatic part of the molecule reacts with an activated carbon atom of the azacycle to form the bicyclic framework. The reactive intermediate bears a (partially) positively charged carbon atom in the azacycle that may be generated by the addition of an acid to an olefinic bond or by the activation of an appropriately positioned leaving group. A huge number of Bronstedt and Lewis acids have been described for this classical reaction that may also be used here. The following enumeration is supposed to give a few more widely used of them: hydrobromic acid, hydroiodic acid, hydrochloric acid, sulfuric acid, phosphoric acid, P4OiO, trifluoroacetic acid, methanesulfonic acid, toluenesulfonic acid, trifluorme- thanesulfonic acid, Sc(OSO2CFs)31 SnCI4, FeCI3, AIBr3, AICI3, SbCI5, BCI3, BF3, ZnCI2, montmorillonites, POCI3, and PCI5. Depending on the inclination of the leaving group to be substituted and the electronic nature of the aromatic a more or less powerful acid catalyst has to be used. Besides the acid catalysts mentioned silver salts, e.g. AgOSO2CF3, may be useful in the reactions using halides as leaving group. Preferred solvents are hydrocarbons such as hexanes or cyclohexane, chlorinated hydrocarbons such as dichloromethane or dichloroethane, perfluorinated hydrocarbons, nitrobenzene, chlorinated benzenes, heteroaromatics such as quinoline, 1 ,2-dimethoxyethane, 1 ,4-dioxane, ether, ionic liquids, or mixtures thereof. The reactions may be carried out between -10 0C and 220 0C, preferably between 20 0C and 180 °C. The reactions may also be conducted under microwave irradiation. This synthetic strategy is particularly suited for the scaffolds 1.1 and 1.3 to 1.10 bearing an electron rich aromatic. Scheme 5. Strategy 5 to build the bicyclic skeleton
Figure imgf000051_0001
LG = e.g. OH, OSO2Me, OSO2ToI, OSO2CF3, Cl, Br, I, OC^-alkyl, OCOC^-alkyl, ...
PG = protective group e.g. Me, Bn, C=O-ring B
Figure imgf000051_0002
Besides the strategies presented a host of additional approaches to construct the bicyclic systems of the present invention can be envisaged and are also reported in the literature (see e.g. J. Med. Chem. 1970, 13, 630-634; Chem. Rev. 1977, 77, 1-36; J. Med. Chem. 1979, 22, 537-553; J. Org. Chem. 1984, 49, 4033-4044; J. Med. Chem. 1996, 39, 1956-1966; Heterocycles 1996, 43, 15-22; J. Med. Chem. 2002, 45, 3755-3764; J. Org. Chem. 2006, 71, 2046-2055; and references quoted therein). Therefore, the preceding strategies are in no way meant to restrict the possible synthetic pathways to access the compounds of the invention but are only supposed to show a few routes by way of example.
The synthetic routes presented may rely on the use of protecting groups. Suitable protecting groups for the respective functionalities and their removal have been described hereinbefore and may be employed analogously (see also: Protecting Groups, Philip J. Kocienski, 3rd edition, Georg Thieme Verlag, Stuttgart, 2004 and references quoted therein). If in the process of manufacture according to the invention a compound of general formula I is obtained which contains an amino, alkylamino or imino group, this may be converted by acylation or sulfonylation into a corresponding acyl or sulfonyl compound of general formula I.
If a compound of general formula I is obtained which contains a hydroxy group, this may be converted by acylation or sulfonylation into a corresponding acyl or sulfonyl compound of general formula I.
If a compound of general formula I is obtained which contains a hydroxy group, this may be converted by alkylation into a corresponding ether of general formula I.
If a compound of general formula I is obtained which contains an amino, alkylamino or imino group, this may be converted by alkylation or reductive alkylation into a corresponding alkyl compound of general formula I.
If a compound of general formula I is obtained which contains a nitro group, this may be converted by reduction into a corresponding amino compound.
If a compound of general formula I is obtained which contains an imino group, this may be converted by nitrosation and subsequent reduction into a corresponding N- amino-imino compound.
If a compound of general formula I is obtained which contains a C-ι-3-alkyloxycarbonyl group, this may be converted by cleavage of the ester into the corresponding carboxy compound.
If a compound of general formula I is obtained which contains a carboxy group, this may be converted by esterification into a corresponding ester of general formula I.
If a compound of general formula I is obtained which contains a carboxy or ester group, this may be converted by reaction with an amine into a corresponding amide of general formula I. If a compound of general formula I is obtained which contains an aromatic substructure, this may be derivatized with a chlorine, bromine, or iodine atom or a nitro, sulfonic acid, chlorosulfonyl, or acyl group to a corresponding compound of general formula I by an electrophilic substitution reaction.
If a compound of general formula I is obtained which contains an aromatic amino group, this may be transformed into a corresponding cyano, fluoro, chloro, bromo, iodo, hydroxy, mercapto, or azido compound of general formula I by diazotization and subsequent replacement of the diazo group with cyanide, fluoride, chloride, bromide, iodide, hydroxide, alkyl or hydrogen sulfide, or azide, respectively.
If a compound of general formula I is obtained which contains an aromatic amino group, this may be converted into a corresponding aryl derivatized aromatic compound of general formula I by diazotization and subsequent replacement of the diazo group with an appropriate aryl nucleophile mediated by a suited transition metal species.
If a compound of general formula I is obtained which contains an aromatic chloro, bromo, iodo, trifluoromethylsulfonyloxy, mesyloxy, or tosyloxy group, this may be converted into a corresponding aryl, alkenyl, alkynyl, or alkyl derivatized compound of general formula I by replacement of the respective group by aryl, alkenyl, alkynyl, or alkyl using a transition metal species mediated process.
If a compound of general formula I is obtained which contains an aromatic chloro, bromo, iodo, trifluoromethylsulfonyloxy, mesyloxy, or tosyloxy group, this may be replaced for hydrogen to give a corresponding aromatic compound of general formula I.
If a compound of general formula I is obtained which contains two adjacent hetero- atoms that are amino and hydroxy, amino, or mercapto, these heteroatoms may be linked via a carboxy carbon atom to form a cyclic amidine, imino ester, or imino thioester substructure that may be part of an aromatic ring. If a compound of general formula I is obtained which contains a cyano group, this may be converted into an amino alkyl derivatized compound of general formula I by reduction.
If a compound of general formula I is obtained which contains a cyano group, this may be converted into a N-hydroxycarbamimidoyl group by the treatment with hydroxylamine.
If a compound of general formula I is obtained which contains an N-hydroxycarb- amimidoyl group, this may be converted to an oxadiazole derivatized compound of general formula I by the treatment with a carboxylic or related group.
If a compound of general formula I is obtained which contains an aminocarbonyl group, this may be converted by dehydration into a corresponding cyano compound of general formula I.
If a compound of general formula I is obtained which contains a keto or aldehydic group, this may be converted by reduction into a corresponding hydroxyl compound of general formula I.
The subsequent esterification is optionally carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chloro- benzene, tetrahydrofuran, benzene/tetrahydrofuran or 1 ,4-dioxane or particularly advantageously in the corresponding alcohol optionally in the presence of an acid such as hydrochloric acid or in the presence of a dehydrating agent, lsobutyl chloroformate, thionyl chloride, trimethylchlorosilane, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, phosphorus trichloride, phosphorus pentoxide, N,N'-di- cyclohexylcarbodiimide, N,N'-dicyclohexylcarbodiimide/N-hydroxysuccinimide, N,N'-carbonyldiimidazole, triphenylphosphine/carbon tetrachloride, or combinations thereof optionally in the presence of 4-dimethylamino-pyridine and/or
1-hydroxy-benzotriazole are among the routinely used reagents to accomplish this transformation. The reactions are conducted between 0 and 150 0C, preferably between 0 and 80 0C. The subsequent ester formation may also be carried out by reacting a compound which contains a carboxy group with a corresponding alkyl halide.
The subsequent acylation or sulfonylation is optionally carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran, or 1 ,4-dioxane with a corresponding acyl or sulfonyl derivative optionally in the presence of a tertiary organic base or in the presence of an inorganic base or in the presence of a dehydrating agent. Routinely used agents are e.g. isobutyl chloroformate, thionyl chloride, trimethylchlorosilane, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, phosphorus trichloride, phosphorus pentoxide, N,N'-dicyclohexylcarbodiimide, N.N'-dicyclohexylcarbodiimide/N-hydroxysuccinimide, N.N'-carbonyldiimidazole, triphenylphosphine/carbon tetrachloride, or combinations thereof that may be employed in the presence of 4-dimethylamino-pyridine and/or 1-hydroxy-benzotriazole at temperatures between 0 and 150 °C, preferably between 0 and 80 0C.
The subsequent alkylation is optionally carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran, or 1 ,4-dioxane with an alkylating agent such as a corresponding halide or sulfonic acid ester, e.g. methyl iodide, ethyl bromide, dimethylsulfate, or benzyl chloride, optionally in the presence of a tertiary organic base or in the presence of an inorganic base at temperatures between 0 and 150 0C, preferably between 0 and 100 0C.
The subsequent reductive alkylation is carried out with a corresponding carbonyl compound such as e.g. formaldehyde, acetaldehyde, propionaldehyde, acetone, or butyraldehyde in the presence of a complex metal hydride such as sodium borohy- dride, lithium borohydride, sodium triacetoxyborohydhde, or sodium cyanoborohydhde conveniently at a pH of 6-7 and at ambient temperature or using hydrogen in the presence of a transition metal catalyst, e.g. palladium/charcoal at a hydrogen pressure of 1 to 5 bar. Methylation may also be carried out in the presence of formic acid as reducing agent at elevated temperature, e.g. between 60 and 120 0C. The subsequent reduction of a nitro group is carried out, for example, with hydrogen and a catalyst such as palladium on carbon, platinum dioxide, or Raney nickel, or using other reducing agents such as iron or zinc in the presence of an acid such as acetic acid.
The subsequent nitrosation of an imino group followed by reduction to obtain the N- amino-imino compound is carried out, for example, with an alkyl nitrite such as isoamyl nitrite to form the N-nitroso-imino compound that is then reduced to the N- amino-imino compound using, for example, zinc in the presence of an acid such as acetic acid.
The subsequent cleaving of a Ci-3-alkyloxycarbony! group to obtain the carboxy group is carried out, for example, by hydrolysis with an acid such as hydrochloric acid or sulfuric acid or an alkali metal hydroxide such as lithium hydroxide, sodium hydroxide, or potassium hydroxide.
The subsequent amide formation is carried out by reacting a corresponding reactive carboxylic acid derivative with a corresponding amine optionally in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or 1 ,4-dioxane, while the amine used may also serve as solvent, optionally in the presence of a tertiary organic base or in the presence of an inorganic base or with a corresponding carboxylic acid in the presence of a dehydrating agent, lsobutyl chloroformate, thionyl chloride, trimethylchlorosilane, phosphorus trichloride, phosphorus pentoxide,
N.N'-dicyclohexylcarbodiimide, N.N'-dicyclohexylcarbodiimide/N-hydroxysuccinimide, 1-hydroxy-benzotriazole, N,N'-carbonyldiimidazole or triphenylphosphine/carbon tetrachloride, or combinations thereof optionally in the presence of 4-dimethylamino- pyridine at temperatures between 0 and 150 0C, preferably between 0 and 80 0C, may be applied to achieve the coupling.
The subsequent introduction of a chlorine, bromine, or iodine atom onto an aromatic substructure may be carried out by reacting the aromatic compound with an appropriate electrophile of the halogen atom. Suited chlorine and bromine electrophiles may be e.g. N-halosuccinimide, HOCI1 HOBr, ferfBuOCI, terfBuOBr, chlorine, bromine, dibromoisocyanuric acid, pyridinium dichlorobromate, pyridinium tribromide, or sulfu- ryl chloride that may be used alone or in combination with an acid, e.g. hydrochloric acid, hydrobromic acid, tetrafluoroboric acid, triflic acid, sulfuric acid, or acetic acid, or a Lewis acid, e.g. iron(lll) halide, borontrifluoride hydrate, borontrifluoride etherate, or aluminum halide. Further useful combinations may be LiBr and eerie ammonium nitrate, KCI or KBr with Oxone®, or KBr and sodium perborate. Suited iodine electro- philes may be generated from iodine combined with an oxidizing agent such as nitric acid, sulfur trioxide, manganese dioxide, HIO3, hydrogen peroxide, sodium periodate, peroxydisulfates, and Oxone®. Further suited iodine electrophiles may be e.g. iodine chloride, dichloroiodates, and N-iodosuccinimide. These iodine electrophiles may be used without an additive or in the presence of an acid such as e.g. acetic acid, trifluoroacetic acid, or sulfuric acid, or a Lewis acid such as borontrifluoride hydrate, or copper salts. If a nitro group is to be introduced appropriate nitro electrophiles may be generated from, for example, nitric acid, acetyl nitrate, eerie ammonium nitrate, sodium nitrate, N2Os, alkyl nitrate, and nitronium tetrafluoroborate. Some of these reagents may be used without an additive, though, several of them are better used in combination with an acid, e.g. sulfuric acid or triflic acid, acetic anhydride, trifluoroacetic anhydride, Lewis acid, e.g. ytterbium triflate or iron acetate, P2O5, or a base. The SO3H group may be introduced by reacting the aromatic compound with, for example, concentrated sulfuric acid, SO3, CISO3H, or CISO2NMe2 combined with indium triflate. Reacting the aromatic compound with CISO3H gives the corresponding chlorosulfonylated derivative that may be hydrolyzed to the sulfonic acid. Acylating the aromatic part is conducted using an acyl electrophile that may be generated from the respective acyl halide, e.g. chloride, or acyl anhydride and a Lewis acid such as e.g. aluminum halide, diethylaluminum halide, indium halide, iron(lll) halide, tin(IV) halide, borontrifluoride, titanium(IV) halide, or a Brønsted acid, e.g. sulfuric acid or triflic acid. The formyl group is best introduced using the so-called Vilsmeier or Vilsmeier-Haack conditions: dialkylformamide combined with phosgene, thionyl chloride, POCI3, or oxalyl chloride. Preferred solvents for the electrophilic substitutions described may differ depending on the electrophile employed; in the following some more generally applicable are mentioned: methylene chloride, dichloroethane, chlorobenzene, dichlorobenzene, ether, fluorinated hydrocarbons, hexanes, quinoline, or acetonitrile. The temperatures preferably applied range from 0 to 180 0C.
The subsequent replacement of an aromatic amino group is initiated by diazotization of the amino group using a nitrous acid or nitrosonium source or equivalent such as a nitrite salt combined with an acid, e.g. sodium nitrite and hydrochloric acid, nitrosonium tetrafluoroborate, or an alkylnitrite, e.g. terfbutylnitrite or /soamyl nitrite. The diazotization is optionally carried out in methylene chloride, dichloroethane, dimethyl- formamide, N-methylpyrrolidinone, benzene, toluene, chlorobenzene, tetrahydro- furan, water, ethyl acetate, alcohol, ether, 1 ,2-dimethoxyethane, 1 ,4-dioxane, or mixtures thereof at temperatures between -10 0C and 100 0C (diazotization of amino groups is detailed in, for example, Angew. Chem. Int. Ed. 1976, 15, 251 ). The subsequent displacement of the diazo group for a cyano group, chlorine, or bromine using cuprous cyanide, chloride, or bromide, respectively, is known as the Sandmeyer reaction (see e.g. March's Advanced Organic Chemistry, Michael B. Smith and Jerry March, John Wiley & Sons Inc., 6. Ed., New Jersey, 2007 and references quoted therein); the reaction is optionally conducted between -10 °C and 120 0C in one of the solvents or mixtures mentioned above. The replacement of the diazo group for a fluorine atom may be achieved with a tetrafluoroborate salt or tetrafluoroboric acid and heating to 20 to 160 0C; the reaction is known as the
Schiemann reaction. Iodine may be introduced by treatment of the diazo compound with an iodide salt, e.g. sodium iodide, preferably using water or an aqueous solvent mixture at temperatures between 0 and 120 0C. The diazo group is replaced for hydroxy using water or an aqueous solvent mixture at temperatures between 0 and 180 0C. The reaction usually works without further additives but the addition of cuprous oxide or strong acid may be advantageous. Mercapto or alkylmercapto may be introduced via their corresponding disulfide salts or dialkyldisulfides at temperatures between 0 and 120 0C; depending on the sulfur species used an inert solvent or aqueous solvent system may be preferred (see e.g. Synth. Commun. 2001 , 31, 1857 and references quoted therein).
The subsequent replacement of an aromatic amino group by an aryl group may be carried out via the corresponding diazo compound obtainable as described above. The reaction with an aryl nucleophile, preferably an aryl boronic acid, boronic ester, trifluoroborate, zinc halide, or stannane, is conducted in the presence of a transition metal species derived from palladium, nickel, rhodium, copper, or iron, preferably palladium. The active catalyst may be a complex of the transition metal with ligands such as e.g. phosphines, phosphites, imdiazole carbenes, imidazolidine carbenes, dibenzylideneacetone, ally!, or nitriles, an elemental form of the transition metal such as palladium on carbon or nanoparticles, or salts such as chloride, bromide, acetate, or trifluoroacetate. In these reactions the diazo compound is preferably employed as its tetrafluoroborate salt optionally in methylene chloride, dimethylformamide, N-me- thylpyrrolidinone, benzene, toluene, tetrahydrofuran, water, ethyl acetate, alcohol, ether, 1 ,2-dimethoxyethane, 1 ,4-dioxane, or mixtures thereof at temperatures between 10 0C and 180 0C, preferably between 20 0C and 140 0C.
The subsequent replacement of an aromatic chloro, bromo, iodo atom or an aromatic trifluoromethylsulfonyloxy, mesyloxy, or tosyloxy group for an aryl, alkenyl, alkynyl, or alkyl residue is preferably mediated by a transition metal species derived from palladium, nickel, rhodium, copper, or iron. The active catalyst may be a complex of the transition metal with ligands such as e.g. phosphines (e.g. triterfbutylphosphine, tricyclohexylphosphine, substituted biphenyldicyclohexylphosphines, substituted biphenylditerfbutylphosphines, triphenylphosphine, tritolylphosphine, trifurylphos- phine, 1 ,1 '-bis(diphenylphosphino)ferrocene), phosphites, imdiazole carbenes, imidazolidine carbenes, dibenzylideneacetone, allyl, or nitriles, an elemental form of the transition metal such as palladium on carbon or nanoparticles of iron or palladium, or a salt such as fluoride, chloride, bromide, acetate, thflate, or trifluoroacetate. The replacement is preferably conducted with a trifluoroborate, boronic acid, or boronic ester (Suzuki or Suzuki-type reaction), zinc halide (Negishi or Negishi-type reaction), stannane (Stille reaction), silane (Hiyama or Hiyama-type reaction), magnesium halide (Kumada or Kumada-type reaction) of the aryl, alkenyl, or alkyl residue to be introduced. The terminal alkyne is preferably used as it is or as the zinc acetylide derivative. Depending on the electrophilic and nucleophilic reaction partners additives such as halide salts, e.g. lithium chloride, potassium fluoride, tetrabutyl- ammonium fluoride, hydroxide sources such as potassium hydroxide or potassium carbonate, silver salts such as silver oxide or triflate, copper salts such as copper chloride or copper thiophenecarboxylate may be advantageous or even essential. Copper iodide is a preferred additive in the coupling with a terminal alkyne group (Sonogashira reaction). The coupling reactions are optionally conducted in methylene chloride, dimethylformamide, N-methylpyrrolidinone, benzene, toluene, tetrahydrofuran, water, ethyl acetate, alcohol, ether, dimethylsulfoxide, 1 ,2- dimethoxyethane, 1 ,4-dioxane, or mixtures thereof, though, depending on the nucleophile some of them are less or not suited at all. Preferred temperatures are in the range from -10 0C to 180 0C.
The subsequent replacement of an aromatic chlorine, bromine, or iodine atom or an aromatic trifluoromethylsulfonyloxy, mesyloxy, or tosyloxy group for a hydrogen atom is preferably mediated by a transition metal species derived from palladium, nickel, platinum, or rhodium. The active catalyst may be a complex of the transition metal with ligands, an elemental form, or a salt of the transition metal as mentioned above. Raney nickel or palladium on carbon are among the preferred catalyst species. Suited hydrogen sources may be hydrogen, preferably at pressures of 1 to 5 bar, silanes, e.g. trialkoxysilane, boranes, hydrides, e.g. alkali metal borohydride, formic acid, or formates, e.g. ammonium formate. The reactions are preferably carried out in methylene chloride, dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, benzene, toluene, tetrahydrofuran, water, ethyl acetate, alcohol, ether, 1 ,2-dimethoxyethane, 1 ,4-dioxane, or mixtures thereof at -10 0C to 180 0C, more preferably at 20 0C to 140 0C.
The subsequent cyclization of two adjacent heteroatoms is optionally conducted with a carboxy equivalent such as nitrile, carboxylic chloride or fluoride, carboxylic acid, ketene, carboxylic ester, or carboxylic thioester. The overall transformation consists of two reaction steps: attachment of the carboxy equivalent to one of the two heteroatoms followed by cyclization with the other heteroatom. The first step is an amide formation with the amino functionality that may be carried out as described hereinbefore. The ensuing reaction step, cyclization with the second heteroatom, may be accomplished by heating in the presence of an acid, e.g. acetic acid, trifluoroacetic acid, sulfuric acid, or hydrochloric acid, or a base, e.g. sodium hydroxide, sodium ethoxide, or sodium terfbutoxide. The use of dehydrating reagents such as anhydrides, e.g. acetic anhydride, orthoesters, e.g. trimethylorthoformate, thionylchloride, phosgene, diphosgene, triphosgene, phosphorous oxychloride, phosphorous penta- chloride, dialkylcarbodiimides, combinations of phosphines, e.g. triphenylphosphine or trialkylphosphine with dialkyl azodicarboxylates, bromine, iodine, or 1 ,2-dihalo- ethanes, e.g. 1 ,2-dibromotetrafluoroethane, may be advantageous. The reactions are preferably carried out in inert solvents or mixtures such as methylene chloride, dichlo- roethane, benzene, toluene, tetrahydrofuran, ether, or combinations thereof, though, cyclization in the presence of an acid or a base may also be conducted in water or an alcohol, e.g. methanol, ethanol, /sopropanol, or terfoutanol, or combinations with these solvents. The reactions are carried out at temperatures between 0 0C and 200 0C, preferably between 20 0C and 140 0C.
The subsequent reduction of a cyano group to obtain an aminomethyl group is optionally conducted with hydrogen in the presence of a transition metal species or with a hydride. Suited transition metals may be derived from palladium, nickel, platinum, rhodium, or ruthenium such as, for example, palladium on charcoal, palladium hydroxide, platinum oxide, or Raney nickel that may be used in solvents such as ethyl acetate, alcohols, e.g. methanol or ethanol, dichloromethane, tetrahydrofuran, ether, benzene, toluene, dimethylformamide, or N-methylpyrrolidinone at hydrogen pressures between 1 and 10 bar, preferably between 1 and 5 bar, and at temperatures between 0 and 180 0C1 preferably between 20 and 120 0C. Additives such as acids, e.g. hydrochloric acid, methanesulfonic acid, sulfuric acid, or acetic acid, may be beneficial for the hydrogenation. Appropriate hydride sources may be selected from e.g. borohydrides, e.g. sodium borohydride, potassium trisecbutylboro- hydride, borane, or lithium triethylborohydride, or alanates, e.g. lithium aluminum hydride or diisobutylaluminum hydride. Some of these reagents are best used in combination with nickel chloride or cobalt chloride as sodium borohydride. These reagents may be used in e.g. tetrahydrofuran, ether, 1 ,4-dioxane, 1 ,2- dimethoxyethane, dichloromethane, 1 ,2-dichloroethane, benzene, or toluene; some are also compatible with alcoholic solutions. Preferred reaction temperatures range from -80 0C to 160 0C, more preferred from -40 0C to 80 0C.
The subsequent formation of a N-hydroxycarbamimidoyl group from a cyano group may be carried out by the treatment of the cyano compound with hydroxylamine. The reaction is preferably conducted in aqueous or alcoholic solvents at temperatures between 0 0C and 140 0C. The subsequent formation of an oxadiazole from an N-hydroxycarbamimidoyl is optionally conducted with a carboxy equivalent such as nitrile, carboxylic chloride or fluoride, carboxylic acid, ketene, carboxylic ester, or carboxylic thioester. The transformation is related to the formation of a ring starting from two adjacent heteroatoms described above and may be carried out analogously.
The subsequent formation of a cyano group from an amino carbonyl group is optionally conducted by using a dehydrating reagent such as e.g. anhydride, e.g. acetic anhydride, trifluoroacetic anhydride, or triflic anhydride, phosgene, thionyl chloride, oxalyl chloride, POCb, PCI5, P4Oio, triphenylphosphite, or triphenyl- or trialkylphosphine combined with tetrachloromethane, 1 ,2-dibromotetrafluoroethane, or bromine. The reactions are preferably carried out in dichloromethane, 1 ,2- dichloroethane, hexanes, ether, 1 ,4-dioxane, benzene, toluene, acetonitrile, mixtures thereof, or without a solvent at temperatures between 0 °C and 140 0C. Additives such as amines, e.g. pyridine or triethylamine, or dimethylformamide may be beneficial.
The subsequent reduction of a keto or an aldehydic group to obtain a secondary or primary alcohol may be carried out with a complex metal hydride such as sodium borohydride, lithium borohydride, lithium triethylborohydhde, diisobutylaluminum hydride, or lithium aluminum hydride. The reductions may be conducted in e.g. dichloromethane, 1 ,2-dichloroethane, hexanes, ether, 1 ,4-dioxane, tetrahydrofuran, dimethylformamide, N-methylpyrrolidinone, benzene, toluene, alcohols, e.g. methanol, water, or mixtures thereof, though, not all reducing agents are compatible with all of these solvents. Preferred temperatures are between -80 0C and 140 0C depending on the reducing power of the reagent. Alternatively, hydrogen in the presence of a transition metal catalyst may be used for the reduction.
In the reactions described hereinbefore, any reactive group present such as hydroxy, carboxy, amino, alkylamino, or imino group may be protected during the reaction by conventional protecting groups which are cleaved again after the reaction.
For example, a protecting group for a hydroxy group may be a trimethylsilyl, terfbutyldimethylsilyl, triisopropylsilyl, acetyl, pivaloyl, benzoyl, methyl, terf-butyl, allyl, trityl, benzyl, 4-methoxybenzyl, tetrahydropyranyl, methoxymethyl, ethoxymethyl, or 2-trimethylsilylethoxymethyl group,
protecting groups for a carboxy group may be trimethylsilyl, methyl, ethyl, terfbutyl, allyl, benzyl, or tetrahydropyranyl,
protecting groups for a ketone or aldehyde may be a ketal or acetal, respectively, e.g. derived from methanol, glycol, or propane-1 ,3-diol,
protecting groups for an amino, alkylamino, or imino group may be methyl, formyl, acetyl, trifluoroacetyl, ethoxycarbonyl, terf-butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl, or 2,4-dimethoxybenzyl and for the amino group additionally phthalyl, and
protecting groups for a terminal alkyne may be trimethylsilyl, trisopropylsilyl, teributyldimethylsilyl, or 2-hydroxy-isopropyl.
Any acyl protecting group may be cleaved, for example, hydrolytically in an aqueous solvent, e.g. in water, isopropanol/water, acetic acid/water, tetrahydrofuran/water, or 1 ,4-dioxane/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid, or sulfuric acid or in the presence of an alkali metal base such as lithium hydroxide, sodium hydroxide, or potassium hydroxide or aprotically, e.g. in the presence of iodotrimethylsilane, at temperatures between 0 and 120 0C, preferably between 10 and 100 0C. A trifluoroacetyl group is preferably cleaved by treating with an acid such as hydrochloric acid, optionally in a solvent such as acetic acid, at temperatures between 50 and 120 0C or by treating with sodium hydroxide solution, optionally in an additional solvent such as tetrahydrofuran or methanol, at temperatures between 0 and 80 0C.
Any acetal or ketal protecting group used may be cleaved, for example, hydrolytically in an aqueous solvent, e.g. in water, isopropanol/water, acetic acid/water, tetrahydrofuran/water, or 1 ,4-dioxane/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid, or sulfuric acid or aprotically, e.g. in the presence of iodotrimethylsilane, at temperatures between 0 and 120 0C, preferably between 10 and 100 0C.
A trimethylsilyl group is cleaved, for example, in water, an aqueous solvent mixture or an alcohol, such as methanol or ethanol, in the presence of a base such as lithium hydroxide, sodium hydroxide, potassium carbonate, or sodium methoxide. Acids such as e.g. hydrochloric acid, trifluoroacetic acid, or acetic acid may also be suitable. The cleavage usually takes place at comparatively low temperatures, e.g. between -60 and 60 0C. SiIyI groups other than trimethylsilyl are preferentially cleaved in the presence of an acid, e.g. trifluoroacetic acid, hydrochloric acid, or sulfuric acid, at temperatures between 0 0C and 100 0C. A particularly suited cleaving method for silyl groups is based on the use of fluoride salts, e.g. tetrabutylammonium fluoride, hydrogen fluoride, or potassium fluoride, in organic solvents, such as for example diethyl ether, tetrahydrofuran, 1 ,4-dioxane, 1 ,2-dimethoxyethane, toluene, benzene, dichloroethane, or dichloromethane at temperatures between -20 and 100 0C.
A benzyl, methoxybenzyl, or benzyloxycarbonyl group is advantageously cleaved hydrogenolytically, e.g. with hydrogen in the presence of a catalyst such as palladium on carbon, palladium hydroxide, or platinum oxide in a solvent such as methanol, ethanol, ethyl acetate, or glacial acetic acid, optionally in the presence of an acid, such as hydrochloric acid, at temperatures between 0 and 100 0C, preferably between 20 and 60 0C, and at hydrogen pressures of 1 to 7 bar, preferably 3 to 5 bar. Trimethylsilyl iodide, boron trichloride, or boron trifluoride in the presence of a scavenger such as anisol, thioanisol, or pentamethylbenzene may also be used with benzylether derivatives. An electron-rich benzyl residue, such as methoxybenzyl, may also be cleaved oxidatively with e.g. 2,3-dichloro-5,6-dicyano-1 ,4-benzoquinone (DDQ) or eerie ammonium nitrate (CAN) preferably in an alcoholic or aqueous solvent at temperatures between 10 and 120 0C. A 2,4-dimethoxybenzyl group is preferably cleaved in trifluoroacetic acid in the presence of a scavenger such as anisole.
A te/tbutyl or terfbutyloxycarbonyl group is preferably cleaved by treating with an acid such as trifluoroacetic acid, sulfuric acid, or hydrochloric acid or by treating with iodo- trimethylsilane optionally using a solvent such as methylene chloride, 1 ,4-dioxane, methanol, isopropanol, water, or diethylether.
A methyl group at an tertiary amine may be cleaved by the treatment with 1-chloro- ethyl chloroformate. Hydrobromic acid and borontribromide are particularly suited for the cleavage of methylethers.
The compounds of general formula I may be resolved into their enantiomers and/or diastereomers, as mentioned before. Thus, for example, cis/trans mixtures may be resolved into their cis and trans isomers, and racemic compounds may be separated into their enantiomers.
The cis/trans mixtures may be resolved, for example, by chromatography into the cis and trans isomers thereof. The compounds of general formula I which occur as racemates may be separated by methods known per se (cf. Allinger N. L. and Eliel E. L. in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971) into their optical antipodes and diastereomeric mixtures of compounds of general formula I may be resolved into their diastereomers by taking advantage of their different physico- chemical properties using methods known per se, e.g. chromatography and/or fractional crystallization; if the compounds obtained thereafter are racemates, they may be resolved into the enantiomers as mentioned above.
The racemates are preferably resolved by column chromatography on chiral phases or by crystallisation from an optically active solvent or by reacting with an optically active substance which forms salts or derivatives, such as e.g. esters or amides, with the racemic compound. Salts may be formed with enantiopure acids for basic compounds and with enantiopure bases for acidic compounds. Diastereomeric derivatives are formed with enantiopure auxiliary compounds such as e.g. acids, their activated derivatives, or alcohols. Separation of the diastereomeric mixture of salts or derivatives thus obtained may be achieved by taking advantage of their different physico-chemical properties, e.g. differences in solubility; the free antipodes may be released from the pure diastereomeric salts or derivatives by the action of suitable agents. Optically active acids in common use for such a purpose are e.g. the D- and L-forms of tartaric acid, dibenzoyltartaric acid, di-o-tolyltartaric acid, malic acid, mandelic acid, camphorsulfonic acid, glutamic acid, aspartic acid, or quinic acid. Optically active alcohols applicable as auxiliary may be, for example, (+) or (-)-menthol and optically active acyl groups in amides may be, for example, (+)- or (-)-menthyloxycarbonyl.
As mentioned above, the compounds of formula I may be converted into salts, particularly for pharmaceutical use into the physiologically acceptable salts with inorganic or organic acids provided that compound I bears a basic residue. Acids which may be used for this purpose include for example hydrochloric acid, hydro- bromic acid, sulfuric acid, methanesulfonic acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid, or maleic acid.
If the compounds of formula I contain an acidic residue like, for example, a carboxy group, they may be converted into the salts thereof with inorganic or organic bases, particularly for pharmaceutical use into the physiologically acceptable salts thereof. Suitable bases for this purpose include, for example, sodium hydroxide, potassium hydroxide, calcium hydroxide, calcium isopropoxide, magnesium hydroxide, magnesium ethoxide, ammonium hydroxide, cyclohexylamine, ethanolamine, diethanol- amine, triethanolamine, N-methyl-D-glucamine, L-lysine, L-arginine, and piperazine.
The compounds according to the invention are advantageously also obtainable using the methods described in the examples that follow, which may also be combined for this purpose with methods known to the skilled man from the literature.
As already mentioned, the compounds of general formula I according to the invention and the physiologically acceptable salts thereof have valuable pharmacological properties, particularly an inhibitory effect on the enzyme 11 β-hydroxysteroid dehydrogenase (HSD) 1.
The biological properties of the new compounds may be investigated as follows:
In vitro inhibition of 11 β-HSD1 by test compounds was determined with HTRF (Homogeneous Time-Resolved Fluorescence) technology (cisbio international, France) detecting Cortisol generated from cortisterone by human liver microsomes. Briefly, compounds were incubated for 1 hour at 37°C in Tris buffer (20 mM tris, 5 mM EDTA1 pH 6.0) containing NADPH (200μM) and cortisone (8OnM). Cortisol generated in the reaction is then detected with a competitive immunoassay, involving two HTRF conjugates: Cortisol linked to XL665 and anti-cortisol antibody labeled with Europium cryptate. The incubation period for detection reaction was typically 2 hours. The amount of Cortisol is determined by reading the time-resolved fluorescence of the wells (Ex 320/75 nm; Em 615/8.5 nm and 665/7.5 nm). The ratio of the two emission signals is then calculated (Em665*10000/Em615). Each assay contained incubations with vehicle controls instead of compound as controls for non-inhibited Cortisol generation (100% CTL; 'high values') and incubations with carbenoxolone as controls for fully inhibited enzyme and Cortisol background (0% CTL; 'low values'). Each assay also contained a calibration curve with Cortisol to transform the fluorescent data into Cortisol concentrations. Percent inhibition of each compound was determined relative to the carbenoxolone signal and IC50 curves were generated.
The compounds of general formula I according to the invention for example have IC50 values below 10000 nM, particularly below 1000 nM, most preferably below 200 nM. The %CTL values of some example compounds at a concentration of 1 μM are provided in the following Table 2 wherein 100% indicates no inhibition and a value of zero or below zero indicates complete inhibition. The measurement of %CTL is described hereinbefore.
Table 2. Inhibition of 11 β-HSD 1 mediated by the compounds described in the experimental section
Figure imgf000068_0001
In view of their ability to inhibit the enzyme 11 β-hydroxysteroid dehydrogenase (HSD) 1 , the compounds of general formula I according to the invention and the corresponding pharmaceutically acceptable salts thereof are theoretically suitable for the treatment and/or preventative treatment of all those conditions or diseases which may be affected by the inhibition of the 11 β-hydroxysteroid dehydrogenase (HSD) 1 activity. Therefore, compounds according to the invention are particularly suitable for the prevention or treatment of diseases, particularly metabolic disorders, or conditions such as type 1 diabetes mellitus, type 2 diabetes mellitus, complications of diabetes (such as e.g. retinopathy, nephropathy or neuropathies, diabetic foot, ulcers, macroangiopathies, slow or poor wound healing), metabolic acidosis or ketosis, reactive hypoglycaemia, hyperinsulinaemia, glucose metabolic disorder, insulin resistance, metabolic syndrome, dyslipidaemias of different origins, atherosclerosis and related diseases, obesity, high blood pressure, chronic heart failure, edema and hyperuricaemia. These substances are also suitable for preventing beta-cell degeneration such as e.g. apoptosis or necrosis of pancreatic beta cells. The substances are also suitable for improving or restoring the functionality of pancreatic cells, and also of increasing the number and size of pancreatic beta cells. The compounds according to the invention may also be used as diuretics or antihypertensives and are suitable for the prevention and treatment of acute renal failure.
Additionally, inhibition of 11 β-hydroxysteroid dehydrogenase (HSD) 1 has been shown to lower intraocular pressure in subjects with ocular hypertension, therefore the compounds could be used to treat glaucoma.
In view of the role of 11 β-hydroxysteroid dehydrogenase (HSD) 1 in modulating Cortisol levels for interaction with the glucocorticoid receptor, and the known role of excess glucocorticoids in bone loss, the compounds may have beneficial effects in treatment or prevention of osteoporosis.
Stress and/or glucocorticoids have been shown to influence cognitive function, and excess Cortisol has been associated with brain neuronal loss or dysfunction. Treatment with an 11 β-hydroxysteroid dehydrogenase (HSD) 1 inhibitor may result in amelioration or prevention of cognitive impairment. Such compounds may also be useful in treating anxiety or depression.
The dynamic interaction between the immune system and the HPA (hypothalamo- pituitary-adrenal) axis is known, and glucocorticoids help balance between cell- mediated responses and humoral responses. The immune reaction is typically biased towards a humoral response in certain disease states, such as tuberculosis, leprosy, and psoriasis. More appropriate would be a cell-based response. An 11 β- hydroxysteroid dehydrogenase (HSD) 1 inhibitor would bolster a temporal immune response in association with immunization to ensure that a cell based response would be obtained, and as such could be useful in immunomodulation.
In particular, the compounds according to the invention, including the physiologically acceptable salts thereof, are suitable for the prevention or treatment of diabetes, particularly type 1 diabetes mellitus, type 2 diabetes mellitus, and diabetic complications.
The dosage required to achieve the corresponding activity for treatment or prevention usually depends on the compound which is to be administered, the patient, the nature and gravity of the illness or condition and the method and frequency of administration and is for the patient's doctor to decide. Expediently, the dosage may be from 1 to 100 mg, preferably 1 to 30 mg, by intravenous route, and 1 to 1000 mg, preferably 1 to 100 mg, by oral route, in each case administered 1 to 4 times a day. For this purpose, the compounds of formula I prepared according to the invention may be formulated, optionally together with other active substances, together with one or more inert conventional carriers and/or diluents, e.g. with corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethylene glycol, propylene glycol, cetylstearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof, to produce conventional galenic preparations such as plain or coated tablets, capsules, powders, suspensions or suppositories. The compounds according to the invention may also be used in conjunction with other active substances, particularly for the treatment and/or prevention of the diseases and conditions mentioned above. Other active substances which are suitable for such combinations include for example those which potentiate the therapeutic effect of an 11 β-hydroxysteroid dehydrogenase (HSD) 1 antagonist according to the invention with respect to one of the indications mentioned and/or which allow the dosage of an 11 β-hydroxysteroid dehydrogenase (HSD) 1 antagonist according to the invention to be reduced. Therapeutic agents which are suitable for such a combination include, for example, antidiabetic agents such as metformin, sulfonylureas (e.g. glibenclamide, tolbutamide, glimepiride), nateglinide, repaglinide, thiazolidinediones (e.g. rosiglitazone, pioglitazone), SGLT 2 inhibitors (e.g. dapagliflozin, sergliflozin), PPAR-gamma-agonists (e.g. Gl 262570) and antagonists, PPAR-gamma/alpha modulators (e.g. KRP 297), alpha-glucosidase inhibitors (e.g. acarbose, voglibose), DPPIV inhibitors (e.g. Sitagliptin, Vildagliptin, Saxagliptin, Alogliptin, Linagliptin), alpha2-antagonists, insulin and insulin analogues, GLP-1 and GLP-1 analogues (e.g. exendin-4) or amylin. The list also includes inhibitors of protein tyrosinephosphatase 1 , substances that affect deregulated glucose production in the liver, such as e.g. inhibitors of glucose-6-phosphatase, or fructose- 1 ,6-bisphosphatase, glycogen phosphorylase, glucagon receptor antagonists and inhibitors of phosphoenol pyruvate carboxykinase, glycogen synthase kinase or pyruvate dehydrokinase and glucokinase activators, lipid lowering agents such as for example HMG-CoA-reductase inhibitors (e.g. simvastatin, atorvastatin), fibrates (e.g. bezafibrate, fenofibrate), nicotinic acid and the derivatives thereof, PPAR-alpha agonists, PPAR-delta agonists, ACAT inhibitors (e.g. avasimibe) or cholesterol absorption inhibitors such as, for example, ezetimibe, bile acid-binding substances such as, for example, cholestyramine, inhibitors of ileac bile acid transport, HDL- raising compounds such as CETP inhibitors or ABC1 regulators or active substances for treating obesity, such as sibutramine or tetrahydrolipostatin, SDRIs, axokine, leptin, leptin mimetics, antagonists of the cannabinoidi receptor, MCH-1 receptor antagonists, MC4 receptor agonists, NPY5 or NPY2 antagonists or β3-agonists such as SB-418790 or AD-9677 and agonists of the 5HT2c receptor.
Moreover, combinations with drugs for influencing high blood pressure, chronic heart failure or atherosclerosis such as e.g. A-Il antagonists or ACE inhibitors, ECE inhibitors, diuretics, β-blockers, Ca-antagonists, centrally acting antihypertensives, antagonists of the alpha-2-adrenergic receptor, inhibitors of neutral endopeptidase, thrombocyte aggregation inhibitors and others or combinations thereof are suitable. Examples of angiotensin Il receptor antagonists are candesartan cilexetil, potassium losartan, eprosartan mesylate, valsartan, telmisartan, irbesartan, EXP-3174, L- 158809, EXP-3312, olmesartan, medoxomil, tasosartan, KT-3-671 , GA-0113, RU- 64276, EMD-90423, BR-9701 , etc.. Angiotensin Il receptor antagonists are preferably used for the treatment or prevention of high blood pressure and complications of diabetes, often combined with a diuretic such as hydrochlorothiazide.
A combination with uric acid synthesis inhibitors or uricosurics is suitable for the treatment or prevention of gout.
A combination with GABA-receptor antagonists, Na-channel blockers, topiramat, protein-kinase C inhibitors, advanced glycation end product inhibitors or aldose reductase inhibitors may be used for the treatment or prevention of complications of diabetes.
The dosage for the combination partners mentioned above is usefully 1/5 of the lowest dose normally recommended up to 1/1 of the normally recommended dose.
Therefore, in another aspect, this invention relates to the use of a compound according to the invention or a physiologically acceptable salt of such a compound combined with at least one of the active substances described above as a combi- nation partner, for preparing a pharmaceutical composition which is suitable for the treatment or prevention of diseases or conditions which can be affected by inhibiting the enzyme 11 β-hydroxysteroid dehydrogenase (HSD) 1. These are preferably metabolic diseases, particularly one of the diseases or conditions listed above, most particularly diabetes or diabetic complications.
The use of the compound according to the invention, or a physiologically acceptable salt thereof, in combination with another active substance may take place simultaneously or at staggered times, but particularly within a short space of time. If they are administered simultaneously, the two active substances are given to the patient together; while if they are used at staggered times the two active substances are given to the patient within a period of less than or equal to 12 hours, but particularly less than or equal to 6 hours.
Consequently, in another aspect, this invention relates to a pharmaceutical composition which comprises a compound according to the invention or a physiologically acceptable salt of such a compound and at least one of the active substances described above as combination partners, optionally together with one or more inert carriers and/or diluents.
Thus, for example, a pharmaceutical composition according to the invention comprises a combination of a compound of formula I according to the invention or a physiologically acceptable salt of such a compound and at least one angiotensin Il receptor antagonist optionally together with one or more inert carriers and/or diluents.
The compound according to the invention, or a physiologically acceptable salt thereof, and the additional active substance to be combined therewith may both be present together in one formulation, for example a tablet or capsule, or separately in two identical or different formulations, for example as a so-called kit-of-parts.
The Examples that follow are intended to illustrate the present invention without restricting it. The terms "ambient temperature" and "room temperature" are used interchangeably and designate a temperature of about 200C.
Preparation of the starting compounds:
Example I
Figure imgf000073_0001
4-Methyl-2-phenylethvnyl-pyridine
Phenylacetylene (15.4 ml_) is added to a mixture of 2-bromo-4-methyl-pyridine (20.0 g), CuI (2.2 g), and Pd(PPh3)2Cl2 (4.1 g) in thethylamine (600 ml_) kept under argon atmosphere. The mixture is stirred at ambient temperature overnight. Then, water is added and the resulting mixture is extracted with diethylether. The combined organic extracts are washed with brine and dried (MgSO4). The solvent is removed under reduced pressure and the residue is purified by chromatography on silica gel
(cyclohexane/ethyl acetate 9:1->4:1 ) to give the product as an oil.
Yield: 18.6 g (83% of theory)
Mass spectrum (ESI+): m/z = 194 [M+H]+
Example Il
Figure imgf000074_0001
4-Methyl-2-phenethyl-pyridine A mixture of 4-methyl-2-phenylethynyl-pyridine (18.2 g) and 10% palladium on carbon (2.0 g) in methanol (300 ml_) is stirred under hydrogen atmosphere (50 psi) at ambient temperature until the triple bond is completely reduced (20 h). The mixture is filtrered and the solvent is removed under reduced pressure.
Yield: 17.6 g (95% of theory) Mass spectrum (ESI+): m/z = 198 [M+H]+
Example
Figure imgf000074_0002
1 ,4-Dimethvl-2-phenethvl-pvhdinium iodide lodomethane (8.3 ml_) is added to a solution of 4-methyl-2-phenethyl-pyridine (17.5 g) in acetonitrile (70 ml_). The resulting solution is stirred at room temperature overnight before another portion of iodomethane (2.8 mL) is added and the solution is further stirred at ca. 35 °C for another 14 h. After cooling to room temperature, the precipitate is separated by filtration, washed with acetonitrile, and dried at 50 °C. Yield: 20.9 g (69% of theory) Mass spectrum (ESI+): m/z = 212 [1 ,4-dimethyl-2-phenethyl-pyridinium]+
Example IV
Figure imgf000075_0001
1 ,4-Dimethyl-6-phenethyl-1 ,2,3,6-tetrahvdro-pyridine and 1.4-dimethyl-2-phenethyl-
1 ,2,3,6-tetrahvdro-pyridine
Sodium borohydride (2.9 g) is added in one portion to a mixture of 1 ,4-dimethyl-2- phenethyl-pyridinium iodide (20.9 g) and sodium hydroxide (23.9 g) in water (60 mL) and methanol (75 mL). The mixture is stirred at 60 °C for 1 h and then cooled to room temperature. The reaction mixture is extracted with diethylether and the organic extracts are dried (MgSO4). After removing the solvent, the residue is purified by chromatography on silica gel (dichloromethane/methanol 30:1->9:1 ) to give a mixture of the two title compounds (ca. 3:1 ).
Yield: 16.4 g (61 % of theory)
Mass spectrum (ESI+): m/z = 216 [M+H]+
Example V
Figure imgf000075_0002
1.11-Dimethyl-11-aza-tricvclof8.3.1.0*2.7*1tetradeca-2.4.6-triene
A mixture of 1 ,4-dimethyl-6-phenethyl-1 ,2,3,6-tetrahydro-pyridine and 1 ,4-dimethyl-2- phenethyl-1 ,2,3,6-tetrahydro-pyridine (ca. 3:1 , 1.0 g) dissolved in polyphosphoric acid (5 mL) is stirred at 150 0C for 2 d. After cooling to ca. 80 0C, water (30 ml_) is added and the mixture is stirred vigorously for another 5 min. Then, the mixture is cooled in an ice bath, more water is added, and the mixture is basified using 40% NaOH in water. The resulting mixture is extracted with ethyl acetate, the combined organic extracts are washed with brine and dried (MgSO4). The solvent is removed under reduced pressure to yield the title compound. Yield: 0.76 g (76% of theory) Mass spectrum (ESI+): m/z = 216 [M+H]+
The following compound may be obtained analogously to Example V:
(1 ) 1-Methyl-10-aza-tricyclo[7.2.1.0*2,7*]dodeca-2,4,6-triene
Figure imgf000076_0001
Mass spectrum (ESI+): m/z = 174 [M+H]+ 2-Benzyl-4-methyl-2,5-dihydro-pyrrole-1-carboxylic acid tert-butyl ester is used as the starting material.
Example Vl
Figure imgf000076_0002
1-Methyl-11-aza-tricvclor.8.3.1.0*2,7*ltetradeca-2.4.6-triene
1-Chloroethyl chloroformate (3.8 mL) is added dropwise to a mixture of 1 ,11- dimethyl-11-aza-tricyclo[8.3.1.0*2,7*]tetradeca-2,4,6-tπene (0.75 g) and NaHCO3 (2.9 g) in 1 ,2-dichloroethane (3.5 mL) chilled in an ice bath. The reaction mixture is warmed to room temperature in the cooling bath and stirred overnight. Then, dichloromethane (20 mL) is added and the precipitate is removed by filtration. The filtrate is concentrated under reduced pressure and the residue is dissolved in methanol (20 mL). The resulting solution is stirred at reflux temperature for 2 h. After cooling to ambient temperature, the solution is concentrated and the residue is purified by HPLC (water/MeCN/NH3) to give the title compound. Yield: 0.11 g (16% of theory)
The following compounds may be obtained analogously to Example Vl:
(1 ) I I .H-Dimethyl-Σ.S^.δ-tetrahydro-I H^.e-methano-benzo^azocin-e-ol
Figure imgf000077_0001
The starting material, 3,11 ,11 -trimethyl-2, 3,4, 5-tetrahydro-1 H-2,6-methano- benzo[d]azocin-6-ol, may be obtained in analogy to EP 28717 (1981 ) from 2-benzyl- 1 ,3,3-trimethyl-pipehdinone.
(2) 8-Hydroxy-2,3,4,5-tetrahydro-1 H-2,6-methano-benzo[d]azocine-6-carboxylic acid methyl ester
Figure imgf000077_0002
The starting material, 8-hydroxy-3-methyl-2,3,4,5-tetrahydro-1 H-2,6-methano- benzo[d]azocine-6-carboxylic acid methyl ester, may be obtained in analogy to J. Med. Chem. 1962, 5, 357-361 and US 3687957 (1972) from 8-methoxy-3-methyl-1- oxo-2, 3,4, 5-tetrahydro-1 H-2,6-methano-benzo[d]azocine-6-carbonitrile. The methoxy group on the aromatic ring may be cleaved by using boron tribromide in dichloromethane or hydrobromic acid in acetic acid (see e.g. J. Med. Chem. 1992, 35, 4135-4142; J. Med. Chem. 2004, 47, 165-174).
The starting material may also be obtained by reacting compound Example XXII(I ) with boron tribromide in dichloromethane.
(3) 11 ,11-Dimethyl-6-phenyl-1 ,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol
Figure imgf000078_0001
The starting material, 3,11 ,11-trimethyl-6-phenyl-1 ,2,3,4,5,6-hexahydro-2,6-methano- benzo[d]azocin-8-ol, may be obtained as described in DE 2027077 (1970).
(4) 6-Propyl-1 ,2,3,4,5, 6-hexahydro-2,6-methano-benzo[d]azocin-8-ol
Figure imgf000078_0002
The starting material, 3-methyl-6-propyl-1 , 2,3,4, 5,6-hexahydro-2,6-methano- benzo[d]azocin-8-ol, may be obtained as described in J. Med. Chem. 1963, 6, 322-5.
(5) 6-Methyl-1 ,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol
Figure imgf000078_0003
The starting material, 3,6-Dimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano- benzo[d]azocin-8-ol, may be obtained as described in J. Org. Chem. 1960, 25, 1386- 8.
Example VII
Figure imgf000078_0004
(G-Methoxy-S-oxo-indan-i-vO-acetic acid methyl ester
Concentrated sulfuric acid (3.0 ml_) is added to δ-methoxy-i-indanone-S-acetic acid (13.0 g) dissolved in methanol (100 ml_). The solution is stirred at reflux temperature for 4 h and then cooled to room temperature. About two third of the methanol is removed under reduced pressure and water (100 mL) and ethyl acetate (200 ml_) are added to the remainder. The organic phase is separated and washed with water, 1 M NaOH solution, and brine. The organic phase is dried (MgSO4) and the solvent is evaporated to give the product as a yellow oil. Yield: 13.2 g (95% of theory) Mass spectrum (ESI+): m/z = 235 [M+H]+
Example VIII
Figure imgf000079_0001
O-Hvdroxyimino-δ-methoxy-indan-i-vD-acetic acid methyl ester (β-Methoxy-S-oxo-indan-i-ylJ-acetic acid methyl ester (12.0 g), hydroxylamine hydrochloride (4.6 g), and sodium acetate (5.5 g) dissolved in water (40 mL) and methanol (50 mL) are stirred at reflux temperature for 3 h. After cooling to room temperature, water (100 mL) is added and the solution is extracted with ethyl acetate.
The combined organic extracts are washed with water and brine and dried (MgSO4). The solvent is evaporated to give the product as a brown oil.
Yield: 12.5 g (98% of theory)
Mass spectrum (ESI+): m/z = 250 [M+H]+
Example IX
Figure imgf000080_0001
δ-Methoxy-S-methoxycarbonylmethyl-indan-i -yl-ammonium chloride
A mixture of 10% palladium on carbon (3.0 g), (3-hydroxyimino-6-methoxy-indan-1- yl)-acetic acid methyl ester (12.5 g), and concentrated hydrochloric acid (4.7 ml.) in methanol (150 ml_) is stirred under hydrogen atmosphere at room temperature overnight. The mixture is filtered and the filtrate is concentrated under reduced pressure. The residue is azeotropically dried using toluene and triturated with diisopropylether to give the product as a white solid after drying at 50 0C.
Yield: 13.0 g (100% of theory)
Mass spectrum (ESI+): m/z = 236 [M+H]+ ([M+H]+ of (3-amino-6-methoxy-indan-1-yl)- acetic acid methyl ester)
Example X
Figure imgf000080_0002
S-Carboxymethyl-δ-methoxy-indan-i -yl-ammonium chloride
5-Methoxy-3-methoxycarbonylmethyl-indan-1-yl-ammonium chloride (12.5 g) dissolved in 2 M hydrochloric acid (120 ml_) is stirred at reflux temperature for 3 h. Then, the solvent is removed and the residue is azeotropically dried using toluene and further purified by washing with diisopropylether. The product is dried at 50 0C. Yield: 11.8 g (100% of theory)
Mass spectrum (ESI+): m/z = 222 [M+H]+ ([M+H]+ of (3-amino-6-methoxy-indan-1-yl)- acetic acid) Example Xl
Figure imgf000081_0001
4-Methoxy-9-aza-tricvclor6.3.1.0*2.7*1dodeca-2.4,6-trien-10-one S-Carboxymethyl-S-methoxy-indan-i-yl-ammonium chloride (13.2 g) and 1- cyclohexyl-3-(2-morpholinoethyl)carbodiimide methyl-p-toluenesulfonate (21.7 g) dissolved in pyridine (500 ml_) are stirred at room temperature for 7 d. Then, the pyridine is removed under reduced pressure and the residue is taken up in water (200 ml_) and dichloromethane (200 ml_). The organic phase is separated and the aqueous phase is extracted twice with dichloromethane. The combined organic phases are washed with 1 M hydrochloric acid, 1 M NaOH solution, and water. After drying (MgSO4), the solvent is evaporated under reduced pressure to yield the product as a beige solid. Yield: 3.O g (29% of theory) Mass spectrum (ESI+): m/z = 204 [M+H]+
Example XII
Figure imgf000081_0002
4-Methoxy-9-aza-thcvclor6.3.1.0*2,7*ldodeca-2.4.6-triene
1 M Borane tetrahydrofuran complex (70 ml_) is added dropwise to a solution of 4- methoxy-9-aza-tricyclo[6.3.1.0*2,7*]dodeca-2,4,6-trien-10-one (3.0 g) in THF (20 ml_) chilled in an ice bath. The resulting solution is stirred at reflux temperature for 5 h and then at room temperature overnight. The solution is cooled to ca. -10 CC and half- concentrated hydrochloric acid (50 ml_) is added carefully. The mixture is stirred at room temperature for 1 h and an additional hour at reflux temperature. The solvent is removed and 2 M NaOH solution (50 ml_) is added to the residue. The resulting mixture is extracted with dichloromethane and the combined organic extracts are dried (MgSO4). After removal of the solvent, the residue is taken up in ethanol (20 ml_) and the resulting solution is treated with oxalic acid (3 ml_) to obtain the oxalate salt of the title compound. Yield: 0.8 g (19% of theory)
Mass spectrum (ESI+): m/z = 190 [M+H]H
Example XIII
Figure imgf000082_0001
4-Hvdroxy-9-azonia-tricvclo[6.3.1.0*2.7*ldodeca-2.4,6-triene bromide A solution of 4-methoxy-9-aza-tricyclo[6.3.1.0*2,7*]dodeca-2,4)6-triene (0.50 g of oxalate salt) in hydrobromic acid (48% in water, 10 ml_) is stirred at reflux temperature for 3 h. Then, the solution is concentrated under reduced pressure and the residue is azetropically dried using toluene and ethanol. The residue is washed with acetone and dried to give the product as a solid. Yield: 0.23 g (49% of theory) Mass spectrum (ESI+): m/z = 176 [M+H]+ (of free amine)
The following compound may be obtained analogously to Example XIII:
(1 ) (2R,6S)-6,11 ,11-Trimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-9- ol
Figure imgf000082_0002
Mass spectrum (ESI+): m/z = 232 [M+H]+
The compound is prepared from (2R,6S)-9-methoxy-6,11 ,11-trimethyl-1 , 2,3,4,5, 6- hexahydro-2,6-methano-benzo[d]azocine [tartaric acid salt, for preparation see WO 9959976] and isolated as the hydrogen bromide salt.
Example XIV
Figure imgf000082_0003
9-Hvdroxy-6,11 ,11-trimethyl-1 ^.δ.G-tetrahvdro^H^.B-methano-benzordlazocine-β- carboxylic acid tert-butyl ester
Di-terfbutyl dicarbonate (8.7 g) is added to a solution of 6,11 ,11-trimethyl-1 ,2,3,4,5,6- hexahydro-2,6-methano-benzo[d]azocin-9-ol (12.0 g) and triethylamine (8 ml) in 1 ,4- dioxane (100 ml_) and water (100 ml_). The solution is stirred at room temperature overnight. Then, ethyl acetate is added and the organic phase is separated. The aqueous phase is extracted with ethyl acetate and the organic extract and phase are combined. The organic phase is washed with 1 M hydrochloric acid, water, and brine, and then dried (MgSO4). After removal of the solvent under reduced pressure, the residue is crystallized from diisopropylether to give the title compound. Yield: 6.5 g (51 % of theory) Mass spectrum (ESI+): m/z = 332 [M+H]+
The following compounds may be obtained analogously to Example XIV:
(1 ) (2R,6S)-10-Hydroxy-6,11 ,11-trimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester
Figure imgf000083_0001
Mass spectrum (ESI+): m/z = 332 [M+H]+
(2) (2R,6R,11 S)-8-Hydroxy-6,11-dimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester
Figure imgf000083_0002
(3) (2S,6/?)-8-Hydroxy-6,9,11 ,11-tetramethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester
Figure imgf000084_0001
The compound may be obtained by resolution of the racemic mixture by HPLC on chiral phase
(4) (2R>6S)-8-Hydroxy-6,9,11 ,11-tetramethyM ,2,5,6-tetrahydro-4H-2,6-methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester
Figure imgf000084_0002
The compound may be obtained by resolution of the racemic mixture by HPLC on chiral phase
(5) (2S,6R)-9-Hydroxy-6,8,11 ,11-tetramethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester
Figure imgf000084_0003
The compound may be obtained by resolution of the racemic mixture by HPLC on chiral phase
(6) (2f?,6S)-9-Hydroxy-6,8,11 ,11-tetramethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester
Figure imgf000084_0004
The compound may be obtained by resolution of the racemic mixture by HPLC on chiral phase (7) 8-Hydroxy-6,11 ,11-trimethyl-1 ^.S.e-tetrahydro^H^.e-methano-benzoIdlazocine- 3-carboxylic acid tert-butyl ester
Figure imgf000085_0001
8) (2R,6S)-9-Hydroxy-6,11 ,11-trimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester
Figure imgf000085_0002
Mass spectrum (ESI+): m/z = 332 [M+H]+
The compound may be obtained by resolution of the racemic mixture by HPLC on chiral phase or by using the enantiomerically pure starting material that in turn may be obtained as described in Example XIII(I ) or by resolution of the racemic mixture by HPLC on chiral phase. The synthesis of the racemic starting material is described in EP 521422 (1993).
(9) 7-Hydroxy-6, 11 ,11 -trimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocine- 3-carboxylic acid tert-butyl ester
Figure imgf000085_0003
Mass spectrum (ESI+): m/z = 332 [M+H]+
(10) (2f?,6S)-8-Acetyl-6,11 I11-trimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester
Figure imgf000085_0004
Mass spectrum (ESI+): m/z = 358 [M+H]+
Example XV
Figure imgf000086_0001
(2R6S)-Thfluoro-methanesulfonic acid 3-benzyl-6.11.11-trimethyl-i .2.3.4,5.6- hexahvdro-2.6-methano-benzordlazocin-10-yl ester
Trifluoromethanesulfonic anhydride (9.7 ml_) is added to a solution of (2R,6S)-3- benzyl-6,11 ,11-tri methyl- 1 , 2,3,4,5, 6-hexahydro-2,6-methano-benzo[d]azocin-10-ol (13.7 g), triethylamine (43 mL), and 4-dimethylaminopyridine (50 mg) in dichloromethane (135 mL) chilled to -10 0C under argon atmosphere. The solution is stirred at ca. -5 0C for 30 min and then at room temperature overnight. The solution is added to ice-cold water and then aqueous ammonia solution is added. The resulting mixture is extracted with dichloromethane and then the combined organic extracts are washed with water and dried (MgSO4). The solvent is removed under reduced pressure to give the crude product that is used without further purification. Yield: 18.0 g (93% of theory) Mass spectrum (ESI+): m/z = 454 [M+H]+
The following compounds may be obtained analogously to Example XV:
(1 ) 6,11 ,11-Trimethyl-9-trifluoromethanesulfonyloxy-1 ,2,5,6-tetrahydro-4H-2,6- methano-benzo[d]azocine-3-carboxylic acid tert-butyl ester
Figure imgf000086_0002
Mass spectrum (ESI+): m/z = 464 [M+H]+ (2) (2R,6S)-6,11 ,1 i-Trimethyl-10-trifluoromethanesulfonyloxy-i ,2,5,6-tetrahydro-4H- 2,6-methano-benzo[d]azocine-3-carboxylic acid tert-butyl ester
Figure imgf000087_0001
Mass spectrum (ESI+): m/z = 481 [M+NH4]+
(3) (2R6R.11 S)-6,11-Dimethyl-8-trifluoromethanesulfonyloxy-1 ,2,5,6-tetrahydrc-4H- 2,6-methano-benzo[d]azocine-3-carboxylic acid tert-butyl ester
Figure imgf000087_0002
Mass spectrum (ESI+): m/z = 450 [M+H]+
(4) 6,11 ,11-Trimethyl-8-trifluoromethanesulfonyloxy-1 ,2,5,6-tetrahydro-4H-2,6- methano-benzo[d]azocine-3-carboxylic acid tert-butyl ester
Figure imgf000087_0003
(5) (2R,6S)-6,11 ,11-Trimethyl-9-trifluoromethanesulfonyloxy-1 ,2,5,6-tetrahydro-4H- 2,6-methano-benzo[d]azocine-3-carboxylic acid tert-butyl ester
Figure imgf000087_0004
Mass spectrum (ESI+): m/z = 464 [M+H]+ (6) (2R,6S)-Trifluoro-methanesulfonic acid 9-cyano-6l11 ,11-trimethyl-3-(piperidine-1- carbonyl)-1 ,2,3 Aδ.e-hexahydro^.β-methano-benzotdjazocin-i 0-yl ester
Figure imgf000088_0001
Mass spectrum (ESI+): m/z = 500 [M+H]+
The compound is prepared from end compound Example 35
(7) (2R,6R)11 R)-Trifluoro-methanesulfonic acid 9-cyano-6,11-dimethyl-3-(2,2,2- trifluoro-acetylJ-I ^.S^.δ.δ-hexahydro^.δ-methano-benzofdlazocin-δ-yl ester
Figure imgf000088_0002
Mass spectrum (ESI+): m/z = 488 [M+NH4]+
(8) 6,11 ,11-Trimethyl-7-trifluoromethanesulfonyloxy-1 ,2,5,6-tetrahydro-4H-2,6- methano-benzo[d]azocine-3-carboxylic acid tert-butyl ester
Figure imgf000088_0003
Mass spectrum (ESI+): m/z = 464 [M+H]+
(9) Trifluoro-methanesulfonic acid (2f?,6f?,11 S)-6,11-dimethyl-3-(2,2,2-trifluoro- acetyO-I ^.SAδ.θ-hexahydro^.e-methano-benzotdJazocin-δ-yl ester
Figure imgf000089_0001
Mass spectrum (ESI+): m/z = 446 [M+H]+
Example XVI
Figure imgf000089_0002
(2R.6S)-3-Benzyl-6.11.11-trimethyl-1 ,2.3.4,5,6-hexahvdro-2.6-methano-benzo[dla zocine-10-carbonitrile
Tetrakis(triphenylphosphine)palladium(0) (2.79 g) is added to a mixture of (2f?,6S)- trifluoro-methanesulfonic acid 3-benzyl-6,11 ,11-trimethyl-1 ^.SΛ.δ.θ-hexahydro^.θ- methano-benzo[d]azocin-10-yl ester (7.30 g) and zinc cyanide (2.85 g) in dimethyl- formamide (35 ml_) kept in argon atmosphere. The resulting mixture is stirred at 100 0C for 6 h. After cooling to room temperature, water (300 mL), concentrated ammonia solution (10 mL), and ethyl acetate (150 mL) are added and the forming precipitate is separated by filtration. The organic layer of the filtrate is separated and the aqueous layer is extracted twice with ethyl acetate. The combined organic phases are washed with brine and dried (MgSO4). The solvent is removed under reduced pressure and the residue is purified by chromatography on silica gel (cyclohexane/ethyl acetate 19:1 ) to give the product. Yield: 4.43 g (62% of theory) Mass spectrum (ESI+): m/z = 331 [M+H]+
The following compounds may be obtained analogously to Example XVI:
(1 ) {2R,6R,^ 1 S)-8-Cyano-6,11-dimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester
Figure imgf000090_0001
Mass spectrum (ESI+): m/z = 327 [M+NH4]+
(2) 9-Cyano-6,11 ,1 i-trimethyl-I ^.S.e-tetrahydro^H^.β-methano-benzo[d]azocine-S- carboxylic acid tert-butyl ester
Figure imgf000090_0002
Mass spectrum (ESI+): m/z = 341 [M+H]+
(3) (2RI6S)-9-Cyano-6,11 ,11-trimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester
Figure imgf000090_0003
Mass spectrum (ESI+): m/z = 341 [M+H]+
(4) 7-Cyano-6,11 ,11-trimethyl-1 ,2,5l6-tetrahydro-4H-2,6-methano-benzo[d]azocine-3- carboxylic acid tert-butyl ester
Figure imgf000090_0004
Mass spectrum (ESI+): m/z = 341 [M+H]+
Example XVII
Figure imgf000091_0001
(2R6S)-3-Benzyl-6.11 ,11-trimethyl-1.2.3.4.5,6-hexahvdro-2,6-methano- benzofdlazocine-IO-carboxylic acid ethyl ester
A solution of (2f?,6S)-3-benzyl-6, 11 ,11 -trimethyl-1 , 2,3,4, 5,6-hexahydro-2,6-methano- benzo[d]azocine-10-carbonitrile (1.14 g) in 80% sulfuric acid (4 ml_) is stirred at 150 0C for 1 h. After cooling to room temperature, ethanol (30 ml_) is added and the solution is stirred at 100 0C for 2 d. Then, the cooled solution is added to water (100 ml_) and the mixture is basified using 40% aqueous NaOH solution. The resulting mixture is extracted twice with ethyl acetate and the combined extracts are dried (MgSO4). The solvent is removed under reduced pressure to give the crude product. Yield: 1.14 g (87% of theory) Mass spectrum (ESI+): m/z = 378 [M+H]+
The following compounds may be obtained analogously to Example XVII:
(1 ) 6,11 ,11-Thmethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine-9- carboxylic acid ethyl ester
Figure imgf000091_0002
Mass spectrum (ESI+): m/z = 288 [M+H]+ The compound is prepared from 6,11 ,11-trimethyl-1 ,2,3,4,5,6-hexahydro-2,6- methano-benzo[d]azocine-9-carbonitrile applying the procedure described above.
(2) (2R,6f?,11 S)-6,11-Dimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine- 8-carboxylic acid ethyl ester
Figure imgf000092_0001
Mass spectrum (ESI+): m/z = 274 [M+H]+
The compound is prepared from (2R,6f?,11 S)-6,11-dimethyl-1 , 2,3,4, 5,6-hexahydro-
2,6-methano-benzo[d]azocine-8-carbonitrile applying the procedure described above.
(3) 1 -Hydroxy-8-methoxy-3-methyl-2,3,4,5-tetrahydro-1 H-2,6-methano- benzo[d]azocine-6-carboxylic acid methyl ester
Figure imgf000092_0002
The compound may be prepared from 1-hydroxy-8-methoxy-3-methyl-2, 3,4,5- tetrahydro-1 H-2,6-methano-benzo[d]azocine-6-carbonitrile [for synthesis see US 3687957 (1972)] as described above using methanol instead of ethanol.
Example XVIII
Figure imgf000092_0003
(2R6SV6.11.11-Thmethyl-1 ^.SAδ.B-hexahvdro^.e-methano-benzordiazocine-i 0- carboxylic acid ethyl ester
Pd(OH)2 (0.20 g) is added to a solution of (2R,6S)-3-benzyl-6,11 ,11-trimethyl- I ^.SAS.Θ-hexahydro^.θ-methano-benzo[d]azocine-IO-carboxylic acid ethyl ester (1.13 g) in ethanol (20 ml_). The resulting mixture is stirred under hydrogen atmosphere (50 psi) at room temperature overnight. Then, the catalyst is separated by filtration and the filtrate is concentrated under reduced pressure to give the product.
Yield: 0.61 g (71 % of theory)
Mass spectrum (ESI+): m/z = 288 [M+H]+
The following compounds may be obtained analogously to Example XVIII:
(1 ) (2f?,6S)-6,11 ,11-Trimethyl-1 ,2,3,4, 5,6-hexahydro-2,6-methano-benzo[d]azocine- 10-carbonitrile
Figure imgf000093_0001
(2) 2, 3,4,5,6, 7-Hexahydro-2,6-methano-1 H-azocino[5,4-b]indole (racemic mixture of the diastereomer shown)
Figure imgf000093_0002
(3) 5,6,7,8,9, 10-Hexahydro-6,10-methano-pyrido[3,2-d]azocine (racemic mixture of the diastereomer shown)
Figure imgf000093_0003
Mass spectrum (ESI+): m/z = 175 [M+H]+
The debenzylation is carried out in the presence of 1 equivalent of 1 M hydrochloric acid as described above.
(4) 4-Methyl-3,5,9-triaza-tricyclo[6.3.1.0*2,6*]dodeca-2(6),4-diene (racemic mixture of the diastereomer shown)
Figure imgf000094_0001
Mass spectrum (ESI+): m/z = 178 [M+H]+
Example XIX
Figure imgf000094_0002
6,11.11-Trimethyl-9-phenyl-1 ^.S.Θ-tetrahvdrcHlH^.e-methano-benzordiazocine^- carboxylic acid tert-butyl ester
Aqueous 2 M Na2CO3 solution (5 mL) is added to a mixture of 6,11 ,11-trimethyl-9- trifluoromethanesulfonyloxy-1 ,2)5,6-tetrahydro-4H-2,6-methano-benzo[d]azocine-3- carboxylic acid tert-butyl ester (1.00 g) and phenylboronic acid (0.34 g) in dimethyl- formamide (5 mL) in argon atmosphere. The resulting mixture is flushed with argon and then 1 ,1 '-bis(diphenylphosphino)ferrocene-palladium(ll) dichloride dichloro- methane complex (0.18 g) is added. The mixture is heated to 100 0C and stirred at this temperature for 4 h. After cooling to room temperature, water is added and the resulting mixture is extracted with ethyl acetate. The combined organic extracts are dried (MgSO4) and the solvent is removed under reduced pressure. The residue is purified by chromatography on silica gel (cyclohexane/ethyl acetate 9:1->1 :1 ) to give the product as a colorless oil. Yield: 0.35 g (41 % of theory) Mass spectrum (ESI+): m/z = 392 [M+H]+
The following compounds may be obtained in analogy to Example XIX:
(1 ) (2R,6R,11 S)-6,11-Dimethyl-8-phenyl-1 ,2,5,6-tetrahydro-4H-2,6-methano- benzotdJazocine-S-carboxylic acid tert-butyl ester
Figure imgf000095_0001
Mass spectrum (ESI+): m/z = 378 [M+H]+
(2) (2R1GR^ -I S)-6,11-Dimethyl-8-pyridin-3-yl-1 ^.S.Θ-tetrahydro^H^.e-methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester
Figure imgf000095_0002
Mass spectrum (ESI+): m/z = 379 [M+H]+
(3) (2R,6R,11 S)-6,11-Dimethyl-8-pyridin-4-yl-1 ,2,5,6-tetrahydro-4H-2,6-methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester
Figure imgf000095_0003
Mass spectrum (ESI+): m/z = 379 [M+H]+
(4) (2R,6f?,11 S)-6,11-Dimethyl-8-pyrimidin-5-yl-1 ,2,5,6-tetrahydro-4H-2,6-methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester
Figure imgf000095_0004
Mass spectrum (ESI+): m/z = 380 [M+H]+ (5) 6,11 ,11-Trimethyl-7-pyridin-3-yl-1 ,2,5,6-tetrahydro-4H-2,6-methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester
Figure imgf000096_0001
Mass spectrum (ESI+): m/z = 393 [M+H]+
Example XX
Figure imgf000096_0002
6, 11.11-Trimethyl-9-phenyl-1 ,2.3,4.5.6-hexahvdro-2,6-methano-benzord1azocine Trifluoroacetic acid (0.5 ml_) is added to a solution of 6,11 ,11 -trimethyl-9-phenyl- 1 ^.S.Θ-tetrahydro^H^.Θ-methano-benzo[d]azocine-S-carboxylic acid tert-butyl ester (0.30 g) in dichloromethane (2.5 mL). The solution is stirred at ambient temperature for 1 h and is then concentrated under reduced pressure. The crude trifluoroacetic acid salt of the title compound is used without further purification. Yield: 0.31 g (100% of theory)
The transformation may also be carried out analogously using HCI in 1 ,4-dioxane or isopropanol instead of trifluoroacetic acid in dichloromethane.
The following compounds may be obtained analogously to Example XX:
(Alternatively, in cases in which the purity of the product after applying the procedure described above is insufficient, the compounds are purified by HPLC on reversed phase (MeCN/water) to obtain the pure compounds.) (1 ) (2R6R,11 S)-6I11-Dimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine- 8-carbonitrile
Figure imgf000097_0001
Mass spectrum (ESI+): m/z = 227 [M+H]+ The compound is obtained as its trifluoroacetic acid salt.
(2) 6,11 ,11-TMmethyl-1 ,2,3 ,4,5,6-hexahydiO-2,6-methano-benzo[d]azocine-9- carbonitrile
Figure imgf000097_0002
Mass spectrum (ESI+): m/z = 241 [M+H]+
The compound is obtained as its trifluoroacetic acid salt.
(3) (2R,6S)-6,11 ,11-Trimethyl-1 ^.SAS^-hexahydro^.e-methano-benzo^azocin- 10-ylamine
Figure imgf000097_0003
Mass spectrum (ESI+): m/z = 231 [M+NH4]+
The compound is obtained as its double trifluoroacetic acid salt.
(4) 6,11 ,11-Trimethyl-1 ,2,3 AS.e-hexahydro^.θ-methano-benzofdlazocin-θ-ylamine
Figure imgf000097_0004
Mass spectrum (ESI+): m/z = 231 [M+H]+
The compound is obtained as its double trifluoroacetic acid salt. (5) (2S,6R)-8-Methoxy-6,9,11 ,11-tetramethyl-1 ^.S^.δ.e-hexahydro^.θ-methano- benzo[d]azocine
Figure imgf000098_0001
The compound may be obtained by resolution of the racemic mixture by HPLC on chiral phase or by using the enantiomerically pure (2S,6R)-8-methoxy-6,9,11 ,11- tetramethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocine-3-carboxylic acid tert-butyl ester.
(6) (2f?,6S)-8-Methoxy-6,9,11 ,11 -tetramethyl-1 ,2,3,4, 5,6-hexahydro-2,6-methano- benzo[d]azocine
Figure imgf000098_0002
The compound may be obtained by resolution of the racemic mixture by HPLC on chiral phase or by using the enantiomerically pure (2R,6S)-8-methoxy-6,9,11 ,11- tetramethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocine-3-carboxylic acid tert-butyl ester.
(7) (2S,6R)-9-Methoxy-6,8,11 ,11-tetramethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano- benzo[d]azocine
Figure imgf000098_0003
The compound may be obtained by resolution of the racemic mixture by HPLC on chiral phase or by using the enantiomerically pure (2S,6R)-9-methoxy-6,8,11 ,11- tetramethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocine-3-carboxylic acid tert-butyl ester.
(8) (2R,6S)-9-Methoxy-6,8, 11 ,11-tetramethyl-1 , 2,3,4,5, 6-hexahydro-2,6-methano- benzo[d]azocine
Figure imgf000099_0001
The compound may be obtained by resolution of the racemic mixture by HPLC on chiral phase or by using the enantiomerically pure (2R,6S)-9-methoxy-6,8,11 ,11- tetramethyl-i ^.δ.θ-tetrahydro^H^.Θ-methano-benzoIdJazocine-S-carboxylic acid tert-butyl ester.
(9) 8,9-Dimethoxy-6,11 ,11-trimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano- benzo[d]azocine
Figure imgf000099_0002
(10) 8-Methoxy-6,11 ,11-trimethyl-ϊ,2,3,4,5,6-hexahydro-2,6-methano- benzo[d]azocin-9-ol
Figure imgf000099_0003
(11) 9-Methoxy-6, 11 ,11 -trimethyl-1 , 2,3,4, 5,6-hexahydro-2,6-methano- benzo[d]azocin-8-ol
Figure imgf000099_0004
(12) (2f?,6S)-6, 11 ,11 -Trimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine- 9-carbonitrile
Figure imgf000099_0005
Mass spectrum (ESI+): m/z = 241 [M+H]+
The compound is obtained as its trifluoroacetic acid salt.
(13) (2S,6R)-9-Methoxy-6,11 ,11-trimethyl-1 ^.S^^.β-hexahydro^.β-methano- benzo[d]azocine
Figure imgf000100_0001
The compound may be obtained from the racemic mixture by HPLC on reversed phase.
(14) (2f?,6R,11 S)-6,11-Dimethyl-8-phenyl-1 ^.SAS.Θ-hexahydro^.θ-methano- benzo[d]azocine
Figure imgf000100_0002
Mass spectrum (ESI+): m/z = 278 [M+H]+
(15) (2R,6R, 11 S)-6, 11 -Dimethyl-8-pyridin-3-yl-1 ,2,3,4,5,6-hexahydro-2,6-methano- benzo[d]azocine
Figure imgf000100_0003
Mass spectrum (ESI+): m/z = 279 [M+H]+
(16) (2RI6R,11 S)-6,11-Dimethyl-8-pyridin-4-yl-1 ,2,3,4,5I6-hexahydro-2,6-methano- benzo[d]azocine
Figure imgf000101_0001
Mass spectrum (ESI+): m/z = 279 [M+H]+
(17) (2R,6R,11 S)-6,11-Dimethyl-8-pyrimidin-5-yl-1- ,2,3,4,5,6-hexahydro-2,6-methano- benzo[d]azocine
Figure imgf000101_0002
Mass spectrum (ESI+): m/z = 280 [M+H]+
(18)6,11 ,11-Trimethyl-7-pyridin-3-yl-1 ,2,3,4,5,6-hexahydro-2,6- methano- benzo[d]azocine
Figure imgf000101_0003
Mass spectrum (ESI+): m/z = 293 [M+H]+
(19)6,11 ,11-Trimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine-7- carbonitrile
Figure imgf000101_0004
Mass spectrum (ESI+): m/z = 241 [M+H]+ (20) 2,8-Diaza-spiro[5.5]undecan-1 -one
Figure imgf000102_0001
The compound is obtained as the HCI salt from 7-oxo-2,8-diaza-spiro[5.5]undecane- 2-carboxylic acid tert-butyl ester using HCI in 1 ,4-dioxane.
(21 ) (2R.6R, 11 S)-6,11-Dimethyl-8-(5-methyl-[1 ,3,4]oxadiazol-2-yl)-1 ,2,3,4,5,6- hexahydro-2,6-methano-benzo[d]azocine
Figure imgf000102_0002
Mass spectrum (ESI+): m/z = 284 [M+H]+
The compound is isolated as its trifluoroacetic acid salt.
(22) {2R,6R, 11 S)-6, 11 -Dimethyl-8-[1 ,3,4]oxadiazol-2-yl-1 ,2,3,4,5,6-hexahydro-2,6- methano-benzo[d]azocine
Figure imgf000102_0003
Mass spectrum (ESI+): m/z = 270 [M+H]+
(23) 1 ,1 ,1-Trifluoro-2-[(2R,6S)-6,11 ,11-trimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano- benzo[d]azocin-8-yl]-propan-2-ol
Figure imgf000102_0004
Mass spectrum (ESI+): m/z = 328 [M+H]+ (24) (2f?,6S)-9-Methanesulfonyl-6,11 ,11-trimethyl-1 l21314,5,6-hexahydro-2I6-ethano- benzo[d]azocine
Figure imgf000103_0001
Mass spectrum (ESI+): m/z = 294 [M+H]+
(25) (3-Phenyl-pyrrolidin-3-yl)-acetic acid methyl ester
Figure imgf000103_0002
Mass spectrum (ESI+): m/z = 220 [M+H]+ The compound is obtained from S-methoxycarbonylmethyl-S-phenyl-pyrrolidine-i- carboxylic acid tert-butyl ester employing the procedure described above.
Example XXI
Figure imgf000103_0003
f(2R6SV3-Benzyl-6.11.11-trimethyl-1.2.3.4.5.6-hexahvdro-2.6-methano- benzordlazocin-10-yll-methanol
A solution of (2R,6S)-3-benzyl-6,11 ,11-trimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano- benzo[d)azocine-10-carboxylic acid ethyl ester (0.96 g) in tetrahydrofuran (2 mL) is added dropwise to LiAIH4 (1.6 mL, 2.4 mol/L in THF) in tetrahydrofuran (1.5 mL). The reaction mixture is stirred at ambient temperature for 90 min. Then, water (4 mL) is added carefully and the resulting mixture is extracted with ethyl acetate. The combined organic extracts are washed with water and brine and dried (MgSO4). The solvent is removed under reduced pressure to give the product. Yield: 0.62 g (72% of theory)
Mass spectrum (ESI+): m/z = 336 [M+H]+
Example XXII
Figure imgf000104_0001
(2R6SV6,10.11.11-Tetramethyl-1 ,2.3.4,5,6-hexahvdro-2.6-methano-benzordlazocine 10% Palladium on carbon (0.10 g) is added to a solution of [(2f?,6S)-3-benzyl- 6,11 ,11-trimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-10-yl]-methanol (0.60 g) in methanol (10 mL). The mixture is stirred under hydrogen atmosphere (50 psi) at room temperature overnight. Then, another portion of 10% palladium on carbon (0.2 g) and 4 M hydrochloric acid (1 mL) are added and the mixture is further stirred in hydrogen atmosphere for 4 h. After the catalyst is separated by filtration, the filtrate is concentrated under reduced pressure to give the hydrochloric acid salt of the title compound. Yield: 0.5O g (100% of theory)
The following compound may be obtained analogously to Example XXII:
(1 ) 8-Methoxy-3-methyl-2,3,4,5-tetrahydro-1 H-2,6-methano-benzo[d]azocine-6- carboxylic acid methyl ester
Figure imgf000104_0002
The compound may be obtained from 1-hydroxy-8-methoxy-3-methyl-2, 3,4,5- tetrahydro-I H^.e-methano-benzofdlazocine-δ-carboxylic acid methyl ester employing the procedure described above. Alternatively, the reduction may be conducted in analogy to J. Org. Chem. 1987, 52, 5233-5239.
Example XXIII
Figure imgf000105_0001
(2R6S)-10-Amino-6,11.11 -trimethyl-1.2.5,6-tetrahvdro-4H-2,6-methano- benzofdlazocine-3-carboxylic acid tert-butyl ester
A flask charged with a stir bar, (2R,6S)-6,11 ,11-trimethyl-10-trifluoromethanesul- fonyloxy-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocine-3-carboxylic acid tert- butyl ester (4.0 g), benzhydrylideneamine (3.2 mL), CS2CO3 (5.6 g), and toluene (80 mL) is flushed with argon for 10 min. Then, 2,2'-bis-diphenylphosphanyl- [1 ,1 ']binaphthalenyl (0.35 g) and ths(dibenzylideneacetone)dipalladium (0.18 g) are added and the resulting mixture is stirred at reflux temperature overnight. After cooling to room temperature, the reaction mixture is washed with water and concentrated. The residue is taken up in tetrahydrofuran and 2 M hydrochloric acid is added. The mixture is stirred at ambient temperature for 4 h. The precipitate is separated by filtration and the filtrate is concentrated under reduced pressure. The residue is purified by chromatography on silica gel (cyclohexane/ethyl acetate 1 :7) to give the product as a brown oil. Yield: 0.83 g (29% of theory) Mass spectrum (ESI+): m/z = 331 [M+H]+
The following compounds may be obtained analogously to Example XXIII:
(1 ) 9-Amino-6,11 ,11-trimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocine-3- carboxylic acid tert-butyl ester
Figure imgf000105_0002
Mass spectrum (ESI+): m/z = 331 [M+H]+
(2) 8-Amino-6,11 ,11-trimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocine-3- carboxylic acid tert-butyl ester
Figure imgf000106_0001
Mass spectrum (ESI+): m/z = 331 [M+H]+
Example XXIV
Figure imgf000106_0002
(2R6S)-10-Fluoro-6.11.11-trimethyl-1.2.3.4Λ6-hexahvdro-2.6-methano- benzofdiazocine
A solution of nitrosonium tetrafluoroborate (0.25 g) in 1 ,4-dioxane (2 mL) is added to a solution of (2R,6S)-10-amino-6,11 ,11 -trimethyl-1 , 2I5,6-tetrahydro-4H-2,6-methano- benzo^Jazocine-S-carboxylic acid tert-butyl ester (0.10 g) in 1 ,4-dioxane (2 mL). The solution is heated to 50 0C and stirred at this temperature overnight. After cooling to ambient temperature, the reaction solution is diluted with methanol and then concentrated under reduced pressure. The residue is purified by HPLC on reversed phase (MeCNZH2OZF3CCO2H) to yield the title product. Yield: 25 mg (36% of theory)
Mass spectrum (ESI+): mZz = 234 [M+H]+
The following compounds may be obtained analogously to Example XXIV:
(1 ) 8-Fluoro-6,11 ,11 -trimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine
Figure imgf000106_0003
(2) 9-Fluoro-6,11 ,11 -trimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine
Figure imgf000106_0004
In cases in which the terfbutyloxycarbonyl group is not completely cleaved off after the reaction the crude product is treated with trifluoroacetic acid in dichloromethane.
Example XXV
Figure imgf000107_0001
8,9-Dihvdroxy-6,11 ,11-trimethyl-1 ^.δ.δ-tetrahvdro^H^.Θ-methano-benzordiazocine-
3-carboxylic acid tert-butyl ester
Di-tert-butyl dicarbonate (0.34 g) is added to a solution of 6,11 ,11 -trimethyl- 1 ,2,3 AS.e-hexahydro^.e-methano-benzotdJazocine-δ.θ-diol (0.44 g) and triethylamine (0.43 ml_) in dichloromethane (5 ml_). The solution is stirred at room temperature for 2 h. Then, the solution is washed twice with water and once with brine. After drying (MgSO4), the solvent is removed under reduced pressure to yield the product. Yield: 0.43 g (80% of theory)
Mass spectrum (ESI"): m/z = 346 [M-H]"
Example XXVI
Figure imgf000107_0002
8,9-Methylenedioxy-6J 1 J 1-trimethyM .2Λ6-tetrahvdro-4H-2.6-methano- benzofdlazocine-3-carboxylic acid tert-butyl ester
A mixture of 8,9-dihydroxy-6,11 ,11-trimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester (0.21 g), K2CO3 (0.19 g) and diiodomethane (54 μl_) in dimethylformamide (5 ml_) is heated to 100 0C and stirred at this temperature for 2 h. Then, another portion of diiodomethane (54 μL) and K2CO3 (0.18 g) is added and the mixture is further stirred at 100 0C for 5 h. After cooling to room temperature, water is added and the resulting mixture is extracted with ethyl acetate. The combined organic extracts are washed with brine and dried (MgSO4). After removal of the solvent, the residue is purified by chromatography on silica gel (cyclohexane/ethyl acetate 1 :1 ).
Yield: 0.20 g (93% of theory)
Mass spectrum (ESI+): m/z = 360 [M+H]+
Example XXVII
Figure imgf000108_0001
8.9-Methylenedioxy- 6.11.11-trimethyl-1.2.3.4.5,6-hexahvdro-2.6-methano- benzordiazocine lsopropanolic hydrochloric acid (5 mol/L, 0.55 ml_) is added to 8,9-methylenedioxy- 6,11 ,11-trimethyl-1 ^.S^-tetrahydro^H^.β-methano-benzo[d]azocine-S-carboxylic acid tert-butyl ester (0.19 g) dissolved in dichloromethane (2 ml_). The resulting solution is stirred for 2 h at room temperature. Then, the solution is concentrated under reduced pressure to give the title product as its hydrochloric acid salt. Yield: 0.15 g (97% of theory)
Mass spectrum (ESI+): m/z = 260 [M+H]+
Example XXVIII
Figure imgf000108_0002
2-(2-Methoxy-benzvD-3.3-dimethyl-piperidin-4-ol
Sodium borohydride (0.31 g) is added to 2-(2-methoxy-benzyl)-3,3-dimethyl-piperidin- 4-one (2.00 g, prepared according to J. Med. Chem. 2002, 45, 3755-3765 from racemic starting material) dissolved in methanol (20 ml_). The solution is stirred for 3 h at room temperature and then 1 M sodium hydroxide solution (40 ml_) is added. After stirring for 10 min, the mixture is extracted with dichloromethane. The combined organic extracts are washed with water and dried (MgSO4). The solvent is evaporated to give the title product. Yield: 2.0O g (99% of theory)
Mass spectrum (ESI+): m/z = 250 [M+H]+
Figure imgf000109_0001
10-Methoxy-11.11 -dimethyl-1 ,2.3 ,4.5,6-hexahvdro-2,6-methano-benzordlazocine A solution of 2-(2-methoxy-benzyl)-3,3-dimethyl-piperidin-4-ol (0.80 g) in polyphosphoric acid (10 ml_) is stirred at 120 0C overnight. After cooling the solution to ca. 80 0C, water (300 ml_) is added and the mixture is stirred vigorously for another 10 min. Then, the mixture is cooled in an ice bath, more water is added, and the mixture is basified using 10 M aqueous NaOH. The resulting mixture is extracted with ethyl acetate and the combined organic extracts are washed with brine and dried (MgSO4). The solvent is removed under reduced pressure to yield the title product that is used without further purification. Yield: 0.36 g (49% of theory)
The following compound may be obtained analogously to Example XXIX:
(1 ) (2S,6R)-9-Methoxy-6,11 ,11-trimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano- benzo[d]azocine
Figure imgf000109_0002
The racemic product mixture is resolved into its enantiomers by using HPLC on chiral phase.
The compound may also be obtained in analogy to the procedure described in J. Med. Chem. 1997, 40, 2922-2930.
Example XXX
Figure imgf000110_0001
(2R6S)-6.11.11-Trimethyl-1.2.3 ,4.5.6-hexahvdro-2.6-methano-benzord1azocine 10% Pd/C (0.20 g) is added to a solution of (2R,6S)-trifluoro-methanesulfonic acid 3- benzyl-6J 1 J I-trimethyl-I ^.SAS.Θ-hexahydro^.δ-methano-benzo^azocin-IO-yl ester (0.50 g) in ethanol (10 mL). The resulting mixture is shaken under hydrogen atmosphere (50 psi) at room temperature overnight. Then, the catalyst is separated by filtration and Pd(OH)2 (0.2 g) is added to the filtrate (the benzyl group was not completely removed after the treatment in the presence of Pd/C). The mixture is shaken for another 16 h in hydrogen atmosphere (50 psi) at room temperature. The catalyst is separated and the filtrate is concentrated under reduced pressure to give the crude product that is used without further purification. Yield: 0.23 g (98% of theory)
The following compound may be obtained analogously to Example XXX:
(1) 3,5,9-Triaza-tricyclo[6.3.1.0*2,6*]dodeca-2(6),4-diene (racemic mixture of the diastereomer shown)
Figure imgf000110_0002
Example XXXI
Figure imgf000110_0003
2.2.2-Trifluoro-1-f(2R6S)-10-hvdroxy-6.11.11-trimethyl-1.2.5.6-tetrahvdro-4H-2.6- methano-benzordlazocin-3-yll-ethanone
Trifluoroacetic anhydride (5.0 mL) is added to a solution of the hydrobromic acid salt of (2R,6S)-6,11 ,11-trimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-10- ol (5.0 g) and thethylamine (5.5 mL) in dichloromethane (50 mL) chilled in an ice bath. The resulting solution is stirred at ambient temperature overnight. Then, water is added, the resulting mixture is stirred for an additional 15 min, and the organic phase is separated. The organic phase is washed with water and brine, dried (Na2SO4), and the solvent is evaporated. The residue is purified by chromatography on silica gel (ethyl acetate/cyclohexane 1 :4) to give the product as a foam-like solid. Yield: 3.34 g (64% of theory) Mass spectrum (ESI+): m/z = 328 [M+H]+
The following compounds may be obtained analogously to Example XXXI:
(1) 2,2,2-Trifluoro-1-[(2f?,6S)-6,11 ,11-trimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano- benzo[d]azocin-3-yl]-ethanone
Figure imgf000111_0001
Mass spectrum (ESI+): m/z = 312 [M+H]+
(2) 2,2,2-Trifluoro-1-[(2R,6R,11 S)-8-hydroxy-6)11-dimethyl-1 ,2,5,6-tetrahydro-4H-2,6- methano-benzo[d]azocin-3-yl]-ethanone
Figure imgf000111_0002
Mass spectrum (ESI+): m/z = 314 [M+H]+
(3) 2,2I2-Trifluoro-1-[(2/?,6R,11 R)-8-hydroxy-6,11-dimethyl-1 I2,5)6-tetrahydro-4H-2,6- methano-benzo[d]azocin-3-yl]-ethanone
Figure imgf000111_0003
Mass spectrum (ESI+): m/z = 314 [M+H]+ (4) 2>2,2-Trifluoro-1-[(2Rl6S)-9-hydroxy-6l11 l11-trimethyl-1 ,2,5,6-tetrahydro-4H-2l6- methano-benzo[d]azocin-3-yl]-ethanone
Figure imgf000112_0001
Example XXXII
Figure imgf000112_0002
2,2,2-Trifluoro-1-[(2R6SV10-hvdroxy-6.11 ,11-trimethyl-9-nitro-1 ,2,5,6-tetrahvdro-4H-
2,6-methano-benzofd1azocin-3-yll-ethanone
Nitric acid (0.4 ml_) is slowly added to a solution of 2,2,2-trifluoro-1-[(2R,6S)-10- hydroxy-6,11 ,11-trimethyl-1 ^.S.Θ-tetrahydro^H^.δ-methano-benzo[d]azocin-S-yl]- ethanone (2.9 g) in acetic acid (5 ml_) chilled in an ice bath. The ice bath is removed and the solution is stirred at ambient temperature overnight. The solution is poured into ice-cold water and the resulting mixture is extracted with ethyl acetate. The combined extracts are washed with brine and dried (Na2SO4). After removal of the solvent under reduced pressure, the residue is purified by chromatography on silica gel (ethyl acetate/cyclohexane 1 :9->1 :3).
Yield: 1.3 g (39% of theory)
Mass spectrum (ESI'): m/z = 371 [M-H]"
The following compounds may be obtained analogously to Example XXXII:
(1 ) 2,2,2-Trifluoro-i -[{2R.6R, 11 S)-8-hydroxy-6, 11 -dimethyl-9-nitro-1 ,2,5,6-tetrahydro- 4H-2,6-methano-benzo[d]azocin-3-yl]-ethanone
Figure imgf000112_0003
Mass spectrum (ESI+): m/z = 359 [M+H]+
(2) 2I2I2-Tιϊfluoro-1-[(2F?,6/?,11 S)-8-hydroxy-6,11-dimethyl-7-nitro-1 ,2,5,6-tetrahydro- 4H-2,6-methano-benzo[d]azocin-3-yl]-ethanone
Figure imgf000113_0001
Mass spectrum (ESI+): m/z = 359 [M+H]+
The compound is obtained in a mixture with compound Example XXXII(I ) that is separated by chromatography as described above.
(3) 2I2,2-Trifluoro-1-[(2Rl6S)-9-hydroxy-6,11 I11-trimethyl-8-nitro-1 ,2>5,6-tetrahydro- 4H-2,6-methano-benzo[d]azocin-3-yl]-ethanone
Figure imgf000113_0002
Mass spectrum (ESI+): m/z = 373 [M+H]+
The compound is obtained in a mixture with compound Example XXXII(4) that is separated by chromatography as described above.
(4) 2,2,2-Trifluoro-i -[(2R,6S)-9-hydroxy-6, 11 ,11 -trimethyl-10-nitro-1 ,2,5,6-tetrahydro- 4H-2,6-methano-benzo[d]azocin-3-yl]-ethanone
Figure imgf000113_0003
Mass spectrum (ESI+): m/z = 373 [M+H]+
The compound is obtained in a mixture with compound Example XXXII(3) that is separated by chromatography as described above. Example XXXIH
Figure imgf000114_0001
2.2.2-Thfluoro-1-r(2R,6S)-10-methoxy-6.11.11-thmethyl-9-nitro-1.2.5.6-tetrahvdro- 4H-2,6-methano-benzofdlazocin-3-yll-ethanone
Methyl iodide (80 μL) is added to a mixture of 2,2,2-trifluoro-1-[(2f?,6S)-10-hydroxy- 6,11 ,11-trimethyl-9-nitro-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocin-3-yl]- ethanone (0.40 g) and potassium carbonate (0.17 g) in dimethylformamide (5 ml_). The mixture is stirred at room temperature overnight, before another portion of methyl iodide (80 μL) and potassium carbonate (0.16 g) are added. The mixture is stirred for another 6 h at room temperature. Then, water and ethyl acetate are added, the organic phase is separated, and the aqueous phase is extracted with ethyl acetate. The combined organic phases are washed with brine and dried (Na2SO4). The solvent is evaporated to give the crude product that is used without further purification.
Yield: 0.41 g (100% of theory)
Mass spectrum (ESI+): m/z = 387 [M+H]+
The following compounds may be obtained analogously to Example XXXIII:
(1 ) (2S,6R)-8-Methoxy-6,9, 11 ,11 -tetramethyl-1 , 2,5,6-tetrahydro-4H-2,6-methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester
Figure imgf000114_0002
The compound may be obtained by resolution of the racemic mixture by HPLC on chiral phase or by using the enantiomerically pure (2S,6R)-8-hydroxy-6,9,11 ,11- tetramethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocine-3-carboxylic acid tert-butyl ester. (2) (2/?,6S)-8-Methoxy-6,9,11 ,11-tetramethyl-1 ^.δ.e-tetrahydro^H-Σ.β-methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester
Figure imgf000115_0001
The compound may be obtained by resolution of the racemic mixture by HPLC on chiral phase or by using the enantiomerically pure (2/?,6S)-8-hydroxy-6,9, 11 ,11- tetramethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocine-3-carboxylic acid tert-butyl ester.
(3) (2S,6f?)-9-Methoxy-6,8,11 ,11-tetramethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester
Figure imgf000115_0002
The compound may be obtained by resolution of the racemic mixture by HPLC on chiral phase or by using the enantiomerically pure (2S,6f?)-9-hydroxy-6,8,11 ,11- tetramethyl-i ^.δ.δ-tetrahydro^H^.β-methano-benzoIdlazocine-S-carboxylic acid tert-butyl ester.
(4) (2R,6S)-9-Methoxy-6,8,11 ,11-tetramethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester
Figure imgf000115_0003
The compound may be obtained by resolution of the racemic mixture by HPLC on chiral phase or by using the enantiomerically pure (2R,6S)-9-hydroxy-6,8,11 ,11- tetramethyl-i ^.δ.θ-tetrahydro^H^.e-methano-benzo[d]azocine-S-carboxylic acid tert-butyl ester. (δJ δ.θ-Dimethoxy-e.H .I I-trimethyl-I ^.S.e-tetrahydro^H^.e-methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester
Figure imgf000116_0001
Twice the amount of methyl iodide and potassium carbonate as described in the procedure above are employed to prepare the compound from 8,9-dihydroxy- 6,11 ,11-trimethyl-1 ^.δ.θ-tetrahydro^H^.Θ-methano-benzo[d]azocine-3-carboxylic acid tert-butyl ester.
(6) 9-Hydroxy-8-methoxy-6,11 ,11-trimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester
Figure imgf000116_0002
The compound is obtained in a mixture with 8-hydroxy-9-methoxy-6,11 ,11-trimethyl- 1 ^.δ.θ-tetrahydro^H^.Θ-methano-benzo[d]azocine-S-carboxylic acid tert-butyl ester and 8,9-dimethoxy-6J 1 J I-trimethyl-I ^.S.G-tetrahydro^H^Θ-methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester from 8,9-dihydroxy-6,11 ,11- trimethyl-1 ^.δ.e-tetrahydro^H^.Θ-methano-benzotdjazocine-S-carboxylic acid tert- butyl ester that may be separated by HPLC on reversed phase (MeCN/H2O).
(7) 8-Hydroxy-9-methoxy-6,11 ,11-trimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester
Figure imgf000116_0003
The compound is obtained in a mixture with 9-hydroxy-8-methoxy-6,11 ,11-trimethyl- 1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocine-3-carboxylic acid tert-butyl ester and S.Θ-dimethoxy-e.H .I I-trimethyl-I ^.S.e-tetrahydro^H^.Θ-methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester from 8,9-dihydroxy-6,11 ,11- trimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocine-3-carboxylic acid tert- butyl ester that may be separated by HPLC on reversed phase (MeCN/H2O).
(8) 9-Methoxy-6,11 ,11-trimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine
Figure imgf000117_0001
(9) (2S,6ft)-9-Methoxy-6,11 ,11-trimethyl-1 ,2,3,4, 5,6-hexahydro-2,6-methano- benzo[d]azocine
Figure imgf000117_0002
The compound may be obtained from the racemic mixture by HPLC on chiral phase.
(10) 2,2,2-Trifluoro-1-[(2R,6f?,11 S)-8-methoxy-6,11-dimethyl-9-nitro-1 , 2,5,6- tetrahydro-4H-2,6-methano-benzo[d]azocin-3-yl]-ethanone
Figure imgf000117_0003
Mass spectrum (ESI+): m/z = 373 [M+H]+
(11 ) 2,2,2-Trifluoro-i -[(2R,6R, 11 S)-8-methoxy-6,11 -dimethyl-7-nitro-1 ,2,5,6- tetrahydro-4H-2,6-methano-benzo[d]azocin-3-yl]-ethanone
Figure imgf000118_0001
Mass spectrum (ESI+): m/z = 373 [M+H]+
(12) S-Methoxycarbonylmethyl-S-phenyl-pyrrolidine-i-carboxylic acid tert-butyl ester
Figure imgf000118_0002
Mass spectrum (ESI+): m/z = 320 [M+H]+
The compound is obtained from S-carboxymethyl-S-phenyl-pyrrolidine-i-carboxylic acid tert-butyl ester employing the procedure described above.
Example XXXIV
Figure imgf000118_0003
1-r(2R6S)-10-Benzylamino-6,11.11-trimethyl-9-nitro-1.2.5,6-tetrahvdro-4H-2.6- methano-benzo[dlazocin-3-yll-2.2.2-trifluoro-ethanone
2I2>2-Trifluoro-1-[(2R,6S)-10-methoxy-6,11 ,11-trimethyl-9-nitro-1 ,2,5I6-tetrahydro- 4H-2,6-methano-benzo[d]azocin-3-yl]-ethanone (0.41 g) is combined with benzylamine (0.7 ml_) and the resulting mixture is stirred at 70 0C overnight. After cooling to room temperature, the mixture is purified by HPLC on reversed phase (MeCN/H2θ/F3CCO2H) to give the product as an oil. Yield: 0.19 g (38% of theory) Mass spectrum (ESI+): m/z = 462 [M+H]+
The following compound may be obtained analogously to Example XXXIV:
(1 ) 1-[(2R,6f?,11 S)-8-Benzylamino-6,11-dimethyl-9-nitro-1 ^.δ.θ-tetrahydro^H^.δ- methano-benzo[d]azocin-3-yl]-2,2,2-thfluoro-ethanone
Figure imgf000119_0001
The reaction mixture is stirred at 170 0C for 5 h.
Example XXXV
Figure imgf000119_0002
(5R.9S)-4.5.6,7,8,9-hexahvdro-9.12.12-trimethyl-5.9-methano-1 H-imidazor5,4- ilf31benzazocine
A mixture of Raney-Ni (0.1 g), [(2fi,6S)-1-10-benzylamino-6,11 ,11-trimethyl-9-nitro- 1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocin-3-yl]-2,2I2-trifluoro-ethanone (0.19 g), and formic acid (10 ml_) is stirred in hydrogen atmosphere at 50 0C overnight. Then, the catalyst is separated by filtration and the filtrate is concentrated. The remainder is taken up in methanol (10 mL) and treated with 4 M NaOH solution (2 mL) at 50 0C overnight. After cooling to room temperature, the solution is neutralized with 2 M hydrochloric acid and the solvent is removed. The residue is purified by HPLC on reversed phase (MeCN/H2O). Yield: 35 mg (33% of theory) The following compound may be obtained analogously to Example XXXV:
(1 ) (6R, 10f?,125^5,6,7,8,9,I O-Hexahydro-10,12-dimethyl-6,10-methano-1 H- imidazo[5,4-i][3]benzazocine
Figure imgf000120_0001
Mass spectrum (ESI+): m/z = 242 [M+H]+
Example XXXVI
Figure imgf000120_0002
(2R6S)-6,11 ,11-Trimethyl-3-(2,2,2-trifluoro-acetvn-1.2,3 ,4,5,6-hexahvdro-2,6- methano-benzordlazocine-8-sulfonyl chloride and (2R6S)-6.11.11-trimethyl-3-(2.2.2- trifluoro-acetvD-I ^.SΛ.S.Θ-hexahvdro^.β-methano-benzofdlazocine-Q-sulfonyl chloride
Chlorosulfonic acid (1.15 ml_) is slowly added to a solution of 2,2,2-trifluoro-1- [(2R,6S)-6,11 ,11-trimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocin-3-yl]- ethanone (0.90 g) in dichloromethane (10 ml_) at room temperature. Then, the solution is stirred at ambient temperature overnight. The solution is poured into ice- cold water and the resulting mixture is extracted with ethyl acetate. The combined organic extracts are washed with brine and dried (MgSO4). The solvent is removed under reduced pressure to give the crude title compounds in a mixture that is used without further purification. Yield: 1.18 g
Example XXXVII
Figure imgf000121_0001
(2R6SV6.11.11-Trimethyl-i ,2.3,4,5,6-hexahvdro-2.6-methano-benzo[dlazocine-8- sulfonic acid dimethylamide and (2R6S)-6,11.11-trimethyl-1.2,3.4.5.6-hexahvdro- 2,6-methano-benzordlazocine-9-sulfonic acid diethylamide Dimethylamine (3.3 mL, 2 M in THF) is added to a mixture of (2R,6S)-6, 11 ,11- trimethyl-3-(2,2)2-trifluoro-acetyl)-1 ,2,3,4I5,6-hexahydro-2,6-methano- benzo[d]azocine-8-sulfonyl chloride and (2R6S)-6,11 ,11-trimethyl-3-(2,2,2-trifluoro- acetyl)-1 ,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine-9-sulfonyl chloride (0.90 g, crude product from Example XXXVII) dissolved in ethanol (5 mL) and chilled in an ice bath. The cooling bath is removed and the solution is stirred at room temperature for 2 h. Then, 4 M NaOH solution (2.2 mL) is added to cleave off the trifluoroacetyl group. After stirring at room temperature for 1 h, the solution is diluted with water and the resulting mixture is extracted with ethyl acetate. The combined extracts are washed with brine and dried (MgSO4). The solvent is removed and the residue is purified by HPLC on reversed phase (MeCN/H2O/NH3) to give the two title compounds separated.
(2R6S)-6,11 ,11-Trimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine-8- sulfonic acid dimethylamide: Yield: 500 mg (71 % of theory) Mass spectrum (ESI+): m/z = 323 [M+H]+ (2R6S)-6,11 ,11-Trimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine-9- sulfonic acid dimethylamide: Yield: 50 mg (7% of theory) Mass spectrum (ESI+): m/z = 323 [M+H]+
The following compounds may be obtained analogously to Example XXXVII:
(1 ) (2R6S)-6,11 ,11-Trimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine- 8-sulfonic acid methylamide
Figure imgf000122_0001
Mass spectrum (ESI+): m/z = 309 [M+H]+ Methylamine is used as coupling partner.
(2) (2R,6S)-6,11 ,11-Trimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine- 8-sulfonic acid amide
Figure imgf000122_0002
Mass spectrum (ESI+): m/z = 295 [M+H]+ Ammonia is used as coupling partner.
Example XXXVIII
Figure imgf000122_0003
1-r(2R6S)-8-Acetyl-6.11.11-trimethyl-1.2.5.6-tetrahvdro-4H-2,6-methano- benzordlazocin-3-yll-2.2.2-trifluoro-ethanone and 1-r(2R6SV-9-acetyl-6.11.11- trimethyl-i ^.δ.θ-tetrahvdro^H^.e-methano-benzordlazocin-S-yll^^^-trifluoro- ethanone
Acetyl chloride (0.25 ml_) is added to a suspension Of AICI3 (1.3 g) in CH2CI2 (5 ml_) chilled in an ice bath. After stirring the mixture for 5 min, 2,2,2-trifluoro-1-[(2R,6S)- 6,11 ,11-trimethyl-1 ^.δ.e-tetrahydro^H^.Θ-methano-benzofdJazocin-S-yll-ethanone (1.0 g) dissolved in dichloromethane (5 mL) is added dropwise. The mixture is stirred at ambient temperature overnight and then poured into ice-cold half-concentrated hydrochloric acid (20 mL). The resulting mixture is extracted with CH2CI2 and the combined organic extracts are washed with water, aqueous NaHCO3 solution, and brine and dried (MgSO4). The solvent is removed and the residue is purified by chromatography on silica gel (cyclohexane/ethyl acetate 3:1 ->1 :1) to give the two regioisomeric title compounds in a ca. 3:1 mixture.
Yield: 0.83 g (73% of theory)
Mass spectrum (ESI+): m/z = 354 [M+H]+
Example XXXIX
Figure imgf000123_0001
1-f(2R6S)-6.11.11-Trimethyl-1.2.3,4.5.6-hexahvdro-2.6-methano-benzo[dlazocin-8- yli-ethanone and 1-f(2R6SV6.11.11-trimethyl-1 ,2.3.4.5.6-hexahvdro-2.6-methano- benzordlazocin-9-yll-ethanone
4 M NaOH solution (2.5 mL) is added to a ca. 3:1 mixture of 1-[(2R6S)-8-acetyl- 6,11 ,11 -trimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocin-3-yl]-2,2,2- trifluoro-ethanone and 1-[(2R6S)-9-acetyl-6,11 ,11-trimethyl-1 ,2,5,6-tetrahydro-4H- 2,6-methano-benzo[d]azocin-3-yl]-2,2,2-trifluoro-ethanone (0.83 g, from Example XXXVIII) in methanol (10 mL). The resulting solution is stirred at room temperature overnight. Then, the solution is neutralized with 1 M hydrochloric acid and concentrated. The residue is purified by HPLC on reversed phase (MeCN/water/NH3) to give the two title compounds separated. Yield: 0.35 g of 1-[(2R,6S)-6,11 ,11 -trimethyl-1 ,2I3,4,5,6-hexahydro-2l6-methano- benzo[d]azocin-8-yl]-ethanone and 0.07 g of 1-[(2R6S)-6,11 ,11 -trimethyl-1 , 2,3,4,5,6- hexahydro-2,6-methano-benzo[d]azocin-9-yl]-ethanone (combined 71 % of theory) Mass spectrum (ESI+): m/z = 258 [M+H]+
The following compounds may be obtained analogously to Example XXXIX:
(1 ) (2R6R,11 S)-8-Hydroxy-6,11-dimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano- benzo[d]azocine-9-carbonitrile
Figure imgf000124_0001
Mass spectrum (ESI+): m/z = 243 [M+H]+
(2) (2R,6S)-8-Methanesulfonyl-6,11 ,11-trimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methanc- benzo[d]azocine
Figure imgf000124_0002
Mass spectrum (ESI+): m/z = 294 [M+H]+
(3) (2R,6S)-10-Methanesulfonyl-6l11 l11-trimethyl-1 I2,3l4,5l6-hexahydro-2,6- methano-benzo[d]azocine
Figure imgf000124_0003
Mass spectrum (ESI+): m/z = 294 [M+H]+
(4) (6f?,10S)-5,6)7)8,9,10-Hexahydro-2,10)12,12-tetramethyl-6,10-methano-1 H- imidazo[5,4-i][3]benzazocine
Figure imgf000124_0004
(5) (6RI10S)-5,6,7,8,9,10-Hexahydro-10,12,12-trimethyl-6,10-methano-1 H- imidazo[5,4-i][3]benzazocine
Figure imgf000124_0005
(6) (2R.6R.11 S)-6,11-Dimethyl-7-nitro-1 ,2,3,4, 5,6-hexahydrc-2,6-methanc- benzo[d]azocin-8-ol
Figure imgf000125_0001
Mass spectrum (ESI+): m/z = 227 [M+H]+
(7) (6R)10S)-5,6,7,8,9,10-Hexahydro-10,12,12-trimethyl-6,10-methano-1 H- triazolo[5,4-i][3]benzazocine
Figure imgf000125_0002
Mass spectrum (ESI+): m/z = 257 [M+H]+
(8) (6R, 10S)-5,6,7,8,9, 10-Hexahydro-10,12,12-trimethyl-2-pyrazin-2-yl-6, 10- methano-1 H-imidazo[5,4-i][3]benzazocine
Figure imgf000125_0003
Mass spectrum (ESI+): m/z = 334 [M+H]+
(9) (6R,10S)-2-(1-Acetyl-piperidin-4-yl)-5,6,7,8,9,10-hexahydro-10,12,12-trimethyl- 6,10-methano-1 H-imidazo[5,4-i][3]benzazocine
Figure imgf000125_0004
(10) (6R, 10S^-Cyclopropyl-δ.θJ.δ.g, 10-hexahydro-10,12,12-trimethyl-6, 10- methano-1 H-imidazo[5,4-i][3]benzazocine
Figure imgf000125_0005
(l η tβR.IOSJ-S.βJ.β.g.i O-Hexahydro-IO.^.^-trimethyl^i-methyl-β-oxo-i .e- dihydro-pyridin-3-yl)-6,10-methano-1 H-imidazo[5,4-i][3]benzazocine
Figure imgf000126_0001
(^XβR.IOS^-teAf-Butyl-δ.β.Z.β.S.IO-hexahydro-IO.^.IΣ-trimethyl-β.iO-methano- 1 H-imidazo[5,4-i][3]benzazocine
Figure imgf000126_0002
(13) (6R)10S)-5,6I7I8,9,10-Hexahydro-10,12I12-trimethyl-2-pyridin-3-yl-6,10- methano-1 H-imidazo[5,4-i][3]benzazocine
Figure imgf000126_0003
(14) (6R,10S)-5,6,7,8,9,10-Hexahydro-10,12,12-trimethyl-2-[(S)-tetrahydrofuran-2-yl]- 6,10-methano-1 H-imidazo[5,4-i][3]benzazocine
Figure imgf000126_0004
Mass spectrum (ESI+): m/z = 326 [M+H]+
(15) (6R.10S)-5,6, 7,8,9,10-Hexahydro-10,12,12-trimethyl-2-pyridazin-4-yl-6, 10- methano-1 H-imidazo[5,4-i][3]benzazocine
Figure imgf000126_0005
(16) (6RI10S)-5,6,7,8,9,10-Hexahydro-10,12,12-trimethyl-2-(5-methyl-pyrazin-2-yl)- 6, 10-methano-1 H-imidazo[5,4-i][3]benzazocine
Figure imgf000126_0006
Mass spectrum (ESI+): m/z = 348 [M+H]+
(lyxeR.I OSJ-S.β./.β.θ.iO-Hexahydro-IO.^.^-trimethyl^-KRHetrahydrofuran-Z-yl]- 6,10-methano-1 H-imidazo[5,4-i][3]benzazocine
Figure imgf000127_0001
Mass spectrum (ESI+): m/z = 326 [M+H]+
(18) (7/?,11/?I12S)-6,7l8l9,10,11-Hexahydro-2I11 ,12-trimethyl-7,11-methano- oxazolo[4,5-h][3]benzazocine
Figure imgf000127_0002
Mass spectrum (ESI+): m/z = 257 [M+H]+
(19) (6R)10S)-5,6,7)8,9,10-Hexahydro-2,10I12)12-tetramethyl-6,10-methano- oxazolo[4,5-i][3]benzazocine
Figure imgf000127_0003
(20) (6f?,10S)-2-Cyclopropyl-5)6,7,8,9,10-hexahydro-10,12)12-trimethyl-6,10- methano-oxazolo[4,5-i][3]benzazocine
Figure imgf000127_0004
(21 ) (6RI10R,12S)-5,6l7)8I9,10-Hexahydro-2I10,12-trimethyl-6)10-methano- oxazolo[5,4-i][3]benzazocine
Figure imgf000127_0005
Mass spectrum (ESI+): m/z = 257 [M+H]+
(22) (6RI10R>12S)-2-Cyclopropyl-5,6,7)8,9,10-hexahydro-10,12-dimethyl-6I10- methano-oxazolo[5,4-i][3]benzazocine
Figure imgf000128_0001
(23) (6R110S)-2-terf-Butyl-5,6,7,8,9, 10-hexahydro-10,12,12-trimethyl-6, 10-methano- oxazolo[4,5-i][3]benzazocine
Figure imgf000128_0002
(24) (6R110S)-5,6,7,8,9, 10-hexahydro-10,12,12-trimethyl-2-(5-methyl-pyrazin-2-yl)- 6,10-methano-oxazolo[4,5-i][3]benzazocine
Figure imgf000128_0003
(25) (6R)10R,12S)-5,6,7,8,9,10-hexahydro-10,12-dimethyl-2-(5-methyl-pyrazin-2-yl)- 6,10-methano-oxazolo[5,4-i][3]benzazocine
Figure imgf000128_0004
Mass spectrum (ESI+): m/z = 335 [M+H]+
(26) (6R, 10S)-5,6,7,8,9, 10-hexahydro-10,12,12-trimethyl-2-[(R)-tetrahydrofuran-2-yl]- 6,10-methano-oxazolo[4,5-i][3]benzazocine
Figure imgf000128_0005
(27) (6/?,10S)-5,6)7,8>9I10-hexahydro-10,12,12-trimethyl-2-[(S)-tetrahydrofuran-2-yl]- 6,10-methano-oxazolo[4,5-i][3]benzazocine
Figure imgf000129_0001
Example XL
Figure imgf000129_0002
r(2R,6SV10-Hvdroxy-6.11 ,11-trimethyl-1.2.5,6-tetrahvdro-4H-2,6-methano- benzordlazocin-3-yll-imidazol-1-yl-methanone
N,N'-Carbonyldiimidazole (6.8 g) is added to (2R,6S)-6,11 ,11-trimethyl-1 , 2,3,4,5,6- hexahydro-2,6-methano-benzo[d]azocin-10-ol (9.66 g) dissolved in tetrahydrofuran (100 ml_). The resulting solution is stirred at reflux temperature for 3 h. Then, potassium carbonate (4.0 g) is added and the mixture is stirred at reflux temperature for another 4 h. After cooling to ambient temperature, aqueous NaHCθ3 solution is added and the resulting mixture is extracted with ethyl acetate. The combined extracts are dried (MgSO4) and the solvent is evaporated. The residue is purified by chromatography on silica gel (dichloromethane/MeOH 1 :0->18:1 ). Yield: 3.40 g (25% of theory)
Mass spectrum (ESI+): m/z = 323 [M+H]+
Example XLI
Figure imgf000129_0003
I 3-r(2R6S)-10-Hvdroxy-6.11.11 -trimethyl-I ^.S.e-tetrahvdro^H^.e-methano- benzordlazocine-S-carbonyll-i-methyl-SH-imidazol-i-ium iodide lodomethane (0.8 mL) is added to a solution of [(2f?,6S)-10-hydroxy-6,11 ,11- trimethyl-I ^.S.e-tetrahydro^H^.β-methano-benzotdJazocin-S-yll-imidazol-i-yl- methanone (3.4 g) in acetonitrile (30 ml_). After stirring overnight, another portion of iodomethane (1 ml_) is added. The solution is stirred for additional 16 h at room temperature and then concentrated under reduced pressure to give the crude title compound that is used without further purification. Yield: 4.9 g (100% of theory)
Mass spectrum (ESI+): m/z = 340 [M]+ [= 3-(10-hydroxy-6,11 ,11-trimethyl-1 ,2,5,6- tetrahydro^H^.β-methano-benzoIdjazocine-S-carbonylJ-i-methyl-SH-imidazol-i- ium]
Example XLII
Figure imgf000130_0001
δ-Benzyl-S-^-fluoro-phenvD-δ-aza-bicvclorS^.πoctan-S-ol
1-Bromo-4-fluoro-benzene (22.7 g) dissolved in diethylether (100 ml_) is added to a solution of n-butyllithium (1.7 mol/L in pentane, 86.8 ml_) in diethylether (200 ml_) cooled to -35 °C. The combined solutions are stirred at -35 - -40 0C for 1 h, before 8- benzyl-8-aza-bicyclo[3.2.1]octan-3-one (22.5 g) dissolved in diethylether (150 ml_) is added quickly. The solution is warmed to -10 0C within 1 h and then quenched by the addition of aqueous NH4CI solution. The resulting mixture is extracted with ethyl acetate, the combined extracts are washed with brine and 4 M hydrochloric acid is added. The organic phase is separated from the aqueous phase and an oily precipitation formed after the addition. The oily and aqueous phase are basified with 4 M NaOH solution and the resulting mixture is extracted with ethyl acetate. The organic phase and extracts are dried (Na2SO4) and the solvent is evaporated to give the title compound. Yield: 21.0 g (75% of theory)
Mass spectrum (ESI+): m/z = 312 [M+H]+
Example XLIII
Figure imgf000131_0001
8-Benzyl-3-(4-fluoro-phenyl)-8-aza-bicvclor3.2.1 loct-2-ene A solution of 8-benzyl-3-(4-fluoro-phenyl)-8-aza-bicyclo[3.2.1]octan-3-ol (21.0 g) in concentrated aqueous hydrochloric acid (80 ml_) is stirred at reflux temperature for 1 h. After cooling to ambient temperature, the solution is basified by the addition of 4 M aqueous NaOH solution. The resulting mixture is extracted with ethyl acetate and the combined extracts are dried (Na2SO4). The solvent is evaporated and the residue is dissolved in ether. Methanesulfonic acid (4.3 ml_) is added and the solvent is removed under reduced pressure to give the methanesulfonic acid salt of the title compound.
Yield: 19.1 g (73% of theory)
Example XLIV
Figure imgf000131_0002
eπdo-3-(4-Fluoro-phenyl)-8-aza-bicvclor3.2.1 loctane
A mixture of the methanesulfonic acid salt of 8-benzyl-3-(4-fluoro-phenyl)-8-aza- bicyclo[3.2.1]oct-2-ene (19.1 g) and 5% palladium on carbon (2 g) in methanol (170 ml_) is shaken under hydrogen atmosphere (5 bar) at 55 0C overnight. Then, the catalyst is separated by filtration and the filtrate is concentrated. The residue is taken up in ethyl acetate and washed with saturated aqueous K2CO3 solution. The organic phase is concentrated again and the residue is purified by chromatography on silica gel (dichloromethane/methanol 99:1->9:1 ). Yield: 3.5 g (35% of theory) Mass spectrum (ESI+): m/z = 206 [M+H]+
Example XLV
Figure imgf000132_0001
1-r(2R.6R11 SV9-Bromo-8-hvdroxy-6.11-dimethyl-1.2.5,6-tetrahvdro-4H-2.6- methano-benzordlazocin-3-vn-2,2.2-trifluoro-ethanone
A solution of 2,2,2-trifluoro-1 -[(2f?,6R,11 S)-8-hydroxy-6,11 -dimethyl-1 ,2,5,6- tetrahydro-4H-2,6-methano-benzo[d]azocin-3-yl]-ethanone (3.0 g) and pyridinium tribromide (3.3 g) in acetic acid (2 mL) is stirred at 80 0C for 2 h. After cooling to room temperature, water is added and the resulting mixture is extracted with ethyl acetate.
The combined organic extracts are washed with water, aqueous NaHCO3 solution, and brine. After drying (Na2SO4), the solvent is removed and the residue is purified by chromatography on silica gel (cyclohexane/ethyl acetate 4:1->1 :1 ).
Yield: 2.5 g (67% of theory)
Mass spectrum (ESI+): m/z = 392/394 (Br) [M+H]+
The following compound may be obtained analogously to Example XLV:
(1 ) 1-[(2R,6R,11 R)-9-Bromo-8-hydroxy-6,11 -dimethyl-1 ,2,5,6-tetrahydro-4H-2,6- methano-benzo[d]azocin-3-yl]-2,2,2-trifluoro-ethanone
Figure imgf000132_0002
Mass spectrum (ESI+): m/z = 392/394 (Br) [M+H]+
Example XLVI
Figure imgf000132_0003
(2R6R11 $)-8-Hvdroxy-6.11-dimethyl-3-(2.2,2-trifluoro-acetvn-1.2, 3,4.5.6- hexahvdro-2,6-methano-benzordlazocine-9-carbonithle A mixture of i-^R.eR.I I SJ-θ-bromo-δ-hydroxy-e.i i-dimethyl-I ^.S.Θ-tetrahydro^H- 2,6-methano-benzo[d]azocin-3-yl]-2,2,2-trifluoro-ethanone (0.50 g) and copper cyanide (0.23 g) in N-methyl-pyrrolidone (2 ml_) is stirred in a microwave oven at 180 0C for 1 h. After cooling to room temperature, water is added and the resulting mixture is extracted with ethyl acetate. The combined organic extracts are washed with brine and dried (Na2SO4). After removing the solvent, the residue is purified by chromatography on silica gel (cyclohexane/ethyl acetate 2:1->1 :2). Yield: 0.2O g (46% of theory) Mass spectrum (ESI+): m/z = 339 [M+H]+
The following compound may be obtained analogously to Example XLVI:
(1 ) (2R6R.11 R)-8-Hydroxy-6, 11 -dimethyl-3-(2,2,2-trifluoro-acetyl)-1 ,2,3,4,5,6- hexahydro-2,6-methano-benzo[d]azocine-9-carbonitrile
Figure imgf000133_0001
Mass spectrum (ESI+): m/z = 339 [M+H]+
Example XLVII
Figure imgf000133_0002
(2R6R11 S)-6.11-Dimethyl-1 ,2,3.4,5.6-hexahvdro-2,6-methano-benzord1azocine-9- carbonitrile
A solution of KF (76 mg) in water (1 mL) followed by polymethylhydrosiloxane (1.0 g) is added to a mixture of (2R,6f?,11 S)-trifluoro-methanesulfonic acid 9-cyano-6,11- dimethyl-3-(2,2,2-trifluoro-acetyl)-1 ,2,3,4,5,6-hexahydro-2,6-methano- benzo[d]azocin-8-yl ester (0.30 g) and Pd(OAc)2 (7 mg) in tetrahydrofuran (3 mL). The resulting mixture is stirred at room temperature overnight before 1 M NaOH (20 mL) is added. After stirring vigorously for 1 h, the organic phase is separated and the aqueous phase is extracted with ethyl acetate. The combined organic phases are washed with water and brine and dried (MgSO4). The solvent is removed and the residue is taken up in 4 M NaOH (1 ml_) and methanol (3 ml_) and stirred at room temperature overnight. Then, the solution is neutralized with 1 M hydrochloric acid, filtered, concentrated and the residue is purified by HPLC on reversed phase
(MeCN/water).
Yield: 0.07 g (48% of theory)
Mass spectrum (ESI+): m/z = 227 [M+H]+
The following compound may be obtained analogously to Example XLVII:
(1 ) (2R6R,11 R)-6,11-Dimethyl-1 ,2)3,4)5,6-hexahydro-2,6-methano-benzo[d]azocine-
9-carbonitrile
Figure imgf000134_0001
Example XLVIII
Figure imgf000134_0002
1-r(2R6S)-8-Bromo-6,11.11-trimethyl-1 ,2.5.6-tetrahvdro-4H-2,6-methano- benzord1azocin-3-yll-2.2.2-trifluoro-ethanone and 1 -r(2R6S)-10-bromo-6, 11.11 - trimethyl-i ^.δ.G-tetrahvdro^H^.e-methano-benzordlazocin-S-yll^^^-trifluoro- ethanone
AICI3 (147 mg) is added to a solution of 2,2,2-trifluoro-1-[(2R,6S)-6, 11 ,11 -trimethyl- 1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocin-3-yl]-ethanone (275 mg) in 1 ,2- dichloroethane (10 mL). The resulting mixture is stirred at ambient temperature for 10 min before bromine (52 μL) is added. The mixture is heated to 50 °C. After stirring at 50 0C for 1 h, the mixture is cooled to ambient temperature and diluted with dichloromethane (30 mL) and water (10 mL). The resulting mixture is stirred vigorously for 5 min and then 4 M hydrochloric acid (10 mL) is added. The organic phase is separated and washed with 4 M hydrochloric acid and water and dried (MgSO4). The solvent is removed under reduced pressure to give the two title compounds in a mixture with a further regioisomerically brominated educt. Yield: 328 mg (95% of theory) Mass spectrum (ESI+): m/z = 390/392 (Br) [M+H]+
Example IL
Figure imgf000135_0001
2,2,2-Thfluoro-1-r(2R6SV8-methanesulfonyl-6,11 ,11-trimethyl-1.2,5.6-tetrahvdro-4H- 2.6-methano-benzofdlazocin-3-vn-ethanone and 2,2,2-trifluoro-1-r(2R6S)-10- methanesulfonyl-6,11 ,11-thmethyl-1.2.5.6-tetrahvdro-4H-2.6-methano- benzordlazocin-3-vπ-ethanone
MeSO2Na (0.79 g) is added to a mixture of CuI (1.5 g) and 1-[(2R6S)-8-bromo- 6,11 ,11-trimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocin-3-yl]-2,2,2- trifluoro-ethanone/1 -[(2R6S)-10-bromo-6, 11 ,11 -trimethyl-1 ,2,5,6-tetrahydro-4H-2,6- methano-benzo[d]azocin-3-yl]-2,2,2-trifluoro-ethanone (300 mg, crude product from Example XLVIII) in dimethylsulfoxide (6 mL). The resulting mixture is heated to 120 0C and stirred at this temperature overnight. After cooling to ambient temperature, the mixture is poured into a solution of concentrated aqueous ammonia (20 mL) and water (80 mL). The resulting mixture is extracted with ethyl acetate and the combined organic extracts are washed with 2 M ammonia solution and brine. After drying (MgSO4), the solvent is removed under reduced pressure and the residue is purified by HPLC on reversed phase (MeCN/water) to give the two title compounds separated.
2,2,2-Trifluoro-1-[(2R6S)-8-methanesulfonyl-6,11 ,11-trimethyl-1 ,2,5,6-tetrahydro-4H- 2,6-methano-benzo[d]azocin-3-yl]-ethanone: Yield: 150 mg (50% of theory) Mass spectrum (ESI+): m/z = 390 [M+H]+
2,2,2-Thfluoro-1 -[(2R6S)-10-methanesulfonyl-6, 11 ,11 -trimethyl-1 ,2,5,6-tetrahydro- 4H-2,6-methano-benzo[d]azocin-3-yl]-ethanone: Yield: 100 mg (33% of theory) Mass spectrum (ESI+): m/z = 390 [M+H]+ Example L
Figure imgf000136_0001
2.2,2-Trifluoro-1-r(2R6SV6.11 ,11-trimethyl-8,9-dinitro-1 ,2,5.6-tetrahvdro-4H-2.6- methano-benzo[dlazocin-3-vn-ethanone
Nitric acid (0.16 ml_) is added to a solution of trifluoroacetic acid (0.65 ml_) in dichloromethane (4 mL) chilled in an ice bath (ca. 0 0C). After stirring for 10 min,
2)2,2-trifluoro-1-[(2R,6S)-6)11 >11-trimethyl-1 ,2,5,6-tetrahydro-4H-2)6-methano- benzo[d]azocin-3-yl]-ethanone (0.50 g) in dichloromethane (5 mL) is added. The resulting solution is stirred in the cooling bath for 2 h and then at ambient temperature overnight. The solution is poured into ice-cold water and the resulting mixture is extracted with dichloromethane. The combined organic extracts are washed with aqueous NaHCθ3 solution and dried (MgSO4). The solvent is removed under reduced pressure and the residue is purified by chromatography on silica gel
(cyclohexane/ethyl acetate 1 :0->9:1 ).
Yield: 330 mg (51% of theory)
Mass spectrum (ESI+): m/z = 402 [M+H]+
Example LI
Figure imgf000136_0002
1-f(2R6SV8.9-Diamino-6.11.11-trimethyl-1.2.5.6-tetrahvdro-4H-2.6-methano- benzordlazocin-3-yll-2.2,2-thfluoro-ethanone
A mixture of 10% palladium on carbon (300 mg) and 2,2,2-trifluoro-1-[(2R6S)- 6,11 ,11-trimethyl-8,9-dinitro-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocin-3-yl]- ethanone (330 mg) in methanol (5 mL) is shaken under hydrogen atmosphere at room temperature for 2 h. Then, the catalyst is separated by filtration and the solvent is removed under reduced pressure to give the crude title compound that is used without further purification. Yield: 260 mg (93% of theory)
Mass spectrum (ESI+): m/z = 342 [M+H]+
The following compounds may be obtained analogously to Example Ll:
(1 ) 1-[(2R,6R,11 S)-7-Amino-8-hydroxy-6I11-dimethyl-1 I2l5,6-tetrahydro-4H-2I6- methano-benzo[d]azocin-3-yl]-2,2,2-thfluoro-ethanone
Figure imgf000137_0001
Mass spectrum (ESI+): m/z = 329 [M+H]+
(2) 1-[(2/?l6S)-8-Amino-9-hydroxy-6I11 ,11-trimethyl-1 l2,5,6-tetrahydro-4H-2>6- methano-benzo[d]azocin-3-yl]-2,2,2-trifluoro-ethanone
Figure imgf000137_0002
Mass spectrum (ESI+): m/z = 343 [M+H]+
(3) 1-[(2R6R11S)-9-Amino-8-hydroxy-6,11-dimethyl-1 ,2,5,6-tetrahydro-4H-2>6- methano-benzo[d]azocin-3-yl]-2,2,2-trifluoro-ethanone
Figure imgf000137_0003
Mass spectrum (ESI+): m/z = 329 [M+H]+
Example LII
Figure imgf000137_0004
(7R11 S)-6.7.8.9, 10.11-Hexahvdro-11.13.13-trimethyl-7.11-methano-Dyrazinof2.3- il[31benzazocine
Glyoxal (40% in water, 95 μl_) is added to 1-[(2f?,6S)-8,9-diamino-6, 11 ,11 -trimethyl-
1 )2l5,6-tetrahydro-4H-2,6-methano-benzo[d]azocin-3-yl]-2l2,2-trifluoro-ethanone (260 mg) dissolved in ethanol (3 ml_) and chilled in an ice bath. The cooling bath is removed and the solution is stirred at ambient temperature overnight. Then, the solution is concentrated and the residue is taken up in methanol (1 ml_) and treated with 4 M aqueous NaOH solution (0.38 ml_). After stirring at ambient temperature overnight, brine is added and the resulting mixture is extracted with ethyl acetate.
The combined organic extracts are washed with brine, dried (MgSO4), and the solvent is removed under reduced pressure to give the crude title compound that is used without further purification.
Yield: 204 mg
Mass spectrum (ESI+): m/z = 268 [M+H]+
The following compounds may be obtained analogously to Example LII:
(1 ) (7R,11 S)-6, 7,8,9, 10,11-Hexahydro-2,3,11 ,13,13-pentamethyl-7,11-methano- pyrazino[2,3-i][3]benzazocine
Figure imgf000138_0001
Mass spectrum (ESI+): m/z = 296 [M+H]+
The compound is obtained by using diacetyl according to the procedure described above.
(2) (7R11 SJ-β./.β.θ.iO.H-Hexahydro-S.11 ,13,13-tetramethyl-7,11-methano- pyrazino[2,3-i][3]benzazocine and (7R,11 S)-6,7,8,9,10,11-hexahydro-2,11 ,13,13- tetramethyl-7,11-methano-pyrazino[2,3-i][3]benzazocine
Figure imgf000138_0002
Mass spectrum (ESI+): m/z = 296 [M+H]+ The compounds are obtained as a mixture of each other by using methylglyoxal.
Example LIII
Figure imgf000139_0001
2,2,2-Trifluoro-1-f(6R10S)-5.6,7,8.9.10-hexahvdro-2.10.12, 12-tetramethyl-6.10- methano-1 H-imidazor5,4-ilf3lbenzazocin-7-yll-ethanone 1 -[(2R,6S)-8,9-Diamino-6, 11 ,11 -trimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano- benzo[d]-azocin-3-yl]-2,2,2-trifluoro-ethanone (600 mg) dissolved in glacial acetic acid is stirred at 130 0C for 3 h. After cooling to ambient temperature, the solution is concentrated under reduced pressure and the residue is taken up in ethyl acetate. The organic solution is washed with aqueous K2CO3 solution and brine and dried (MgSO4). The solvent is removed under reduced pressure to give the crude title compound as a foam-like solid. Yield: 642 mg Mass spectrum (ESI+): m/z = 366 [M+H]+
The following compound may be obtained analogously to Example LIII:
(1 ) 2,2,2-Trifluoro-1-[(6R,10S)-5,6,7,8,9,10-hexahydro-10,12,12-trimethyl-6,10- methano-1 H-imidazo[5,4-i][3]benzazocin-7-yl]-ethanone
Figure imgf000139_0002
Mass spectrum (ESI+): m/z = 352 [M+H]+
The reaction is carried out with formic acid instead of acetic acid.
Example LIV
Figure imgf000140_0001
(6R 10S)-5.6.7.8.9.10-Hexahvdro-3.10.12.12-tetramethyl-6, 10-methano-imidazor4.5- iir31benzazocine and (6R10S)-5.6.7.8.9.10-hexahvdro-1.10.12.12-tetramethyl-6.10- methano-imidazo[5.4-iir31benzazocine Methyl iodide (69 μL) is added to a mixture of 2,2,2-trifluoro-1-[(6R,10S)-5,6,7,8,9,10- hexahydro-10 ,12 ,12-trimethyl-6,10-methano-1 H-imidazo[5,4-i][3]benzazocin-7-yl]- ethanone (300 mg) and K2CO3 (118 mg) in dimethylformamide (2 ml_). The resulting mixture is stirred at room temperature overnight. Then, water is added and the mixture is extracted with ethyl acetate. The combined extracts are washed with brine and dried (MgSO4). The solvent is removed and the residue is taken up in methanol (3 ml_) and treated with 4 M aqueous NaOH solution (0.5 ml_). The solution is stirred at room temperature overnight and then diluted with ethyl acetate. The resulting solution is washed with water and brine and dried (MgSO4). The solvent is removed under reduced pressure to give the crude title compounds as a mixture. Yield: 90 mg (39% of theory)
The following compounds may be obtained analogously to Example LIV:
(1 ) (6R,10S)-5,6, 7,8,9, 10-hexahydro-1 , 2,10, 12,12-pentamethyl-6,10-methano- imidazo[5,4-i][3]benzazocine
Figure imgf000140_0002
Mass spectrum (ESI+): m/z = 284 [M+H]+
(2) (6R110S)-5,6, 7,8,9, 10-hexahydro-2,3,10, 12,12-pentamethyl-6, 10-methano- imidazo[4,5-i][3]benzazocine
Figure imgf000141_0001
Mass spectrum (ESI+): m/z = 284 [M+H]+
The two isomeric compounds (1 ) and (2) were obtained from the same starting compound and separated by HPLC on reversed phase.
(3) Mixture of (6R.1 OSJ-δ.βJ.β.θ.i O-hexahydro-1 ,10,12,12-tetramethyl-6,10- methano-triazolo[5,4-i][3]benzazocine and (6f?,10S)-5,6,7,8,9,10-hexahydro- 3,10,12,12-tetramethyl-6,10-methano-triazolo[4,5-i][3]benzazocine
Figure imgf000141_0002
The compounds are obtained from compound Example LXIII after carrying out the reactions described above.
Example LV
Figure imgf000141_0003
2-Benzyl-2-aza-bicvclof3.3.πnonan-6-ol
Diisobutylaluminumhydride (1.5 mol/L in toluene, 21 mL) is added to a solution of acetic acid 2-benzyl-3-oxo-2-aza-bicyclo[3.3.1]non-6-yl ester (1.50 g, for synthesis see J. Chem. Soc, Perkin Trans. 1 1999, 1157-1162) in toluene (30 mL) cooled to - 70 0C. The cooling bath is removed and the solution is stirred at ambient temperature overnight. Then, another portion of diisobutylaluminumhydride (1.5 mol/L in toluene, 20 mL) is added and the solution is stirred for additional 4 h at room temperature. Then, the solution is poured into ice-cold water and the resulting mixture is extracted with ethyl acetate. The aqueous phase is acidified using 4 M hydrochloric acid and extracted one more time with ethyl acetate. The combined organic extracts are dried (Na2SO4) and the solvent is removed. The residue is purified by chromatography on silica gel (dichloromethane/methanol 1 :0->2:1 ).
Yield: 440 mg (36% of theory)
Mass spectrum (ESI+): m/z = 232 [M+H]+
Example LVI
Figure imgf000142_0001
2-Benzyl-2-aza-bicyclo[3.3.1 lnonan-6-one
Dess-Martin periodinane (1.30 g) is added to a solution of 2-benzyl-2-aza- bicyclo[3.3.1]-nonan-6-ol (0.60 g) in dichloromethane (15 ml_) chilled in an ice bath. The cooling bath is removed and the solution is stirred at ambient temperature for 1 h. Then, the solution is diluted with dichloromethane and washed with a mixture of aqueous Na2S2θ3 solution and aqueous NaHCθ3 solution. The solution is dried (Na2SO4) and the solvent is removed. The residue is purified by chromatography on silica gel (dichloromethane/methanol 1 :0->2:1 ). Yield: 250 mg (42% of theory) Mass spectrum (ESI+): m/z = 230 [M+H]+
Example LVII
Figure imgf000142_0002
S-Benzyl^.SAS.ej-hexahvdro^.e-methano-I H-azocinorδΛ-blindole A solution of 2-benzyl-2-aza-bicyclo[3.3.1]nonan-6-one in acetic acid (0.24 g) is added to a solution of PhNHNH2 *HCI (173 mg) in acetic acid (4 mL) heated at reflux temperature. After stirring at this temperature for 2 h, the solution is cooled to room temperature and aqueous K2CO3 solution is added. The resulting mixture is extracted with ethyl acetate, the combined organic extracts are dried (Na2SO4), and the solvent is removed. The residue is purified by HPLC on reversed phase (MeCN/water). Yield: 160 mg (49% of theory) Example LVIII
Figure imgf000143_0001
2-Benzyl-1 ,4.6-trimethyl-1.2-dihvdro-pyridine
PhCH2MgCI (1 M in Et2O, 180 mL) is added dropwise to a solution of 1 ,2,4-trimethyl- pyridinium iodide (24.3 g) in Et2O (90 mL) chilled in an ice bath. After stirring in the ice bath for 2 h, the solution is poured into a mixture of 72% aqueous HCIO4 (40 mL) and crushed ice (ca. 900 mL). The resulting mixture is stirred for 1 h and the precipitate formed is separated by filtration. The precipitate is washed with methanol and dried to afford the HCIO4 salt of the title compound.
Yield: 22.6 g (74% of theory)
Mass spectrum (ESI+): m/z = 214 [M+H]+
Example LIX
Figure imgf000143_0002
6-Benzyl-1.2,4-trimethyl-1 ,2,3,6-tetrahvdro-pyhdine and 2-benzyl-1 ,4,6-thmethyl-
1 ,2.3.6-tetrahvdro-pyridine
NaBH4 (3.8 g) is added portionwise to a solution of 2-benzyl-1 ,4,6-trimethyl-1 ,2- dihydro-pyridine (22.6 g) in MeOH (65 mL) and NaOH (1 M in water, 200 mL). The resulting mixture is stirred at room temperature for 20 min and then at 60 CC for 30 min. After cooling to ambient temperature, the mixture is diluted with water (150 mL) and extracted with Et2O (3x 150 mL). The combined organic extracts are dried
(Na2SO4) and the solvent is removed to give a mixture of the two title compounds that is used without further purification for the next reaction step.
Yield: 11.7 g (76% of theory)
Mass spectrum (ESI+): m/z = 216 [M+H]+ Example LX
Figure imgf000144_0001
3,4,6-Trimethyl-1 ,2.3,4,5,6-hexahvdro-2,6-methano-benzordlazocine A mixture of 6-benzyl-1 ,2,4-trimethyl-i ,2,3,6-tetrahydro-pyridine and 2-benzyl-1 ,4,6- trimethyl-1 ,2,3,6-tetrahydropyridine (from Example LIX, 11.7 g) is combined with 48% HBr in water (30 mL) and 33% HBr in acetic acid (20 mL). The mixture is heated to reflux temperature and stirred at this temperature for 4 d. After cooling to ambient temperature, aqueous ammonia (32%, 45 mL) is carefully added and the resulting mixture is extracted with Et2O (3x 50 mL). The combined organic extracts are extracted with 2 M hydrochloric acid (3x 50 mL), the combined aqueous extracts are basified using 32% aqueous ammonia (20 mL), and the basic aqueous phase is extracted with Et2O (3x 50 mL). The combined organic extracts are dried (MgSO4), the solvent is removed, and the residue is purified by chromatography on silica gel (EtOAc/MeOH/NH3 95:5:0.5->75:25:2.5). The title compound obtained thereafter is dissolved in /PrOH and treated with HCI in /PrOH to precipitate the HCI salt of the title compound from the /PrOH solution. Yield: 1.7 g (15% of theory) Mass spectrum (ESI+): m/z = 216 [M+H]+
Example LXI
Figure imgf000144_0002
4,6-Dimethyl-1 ,2.5.6-tetrahvdro-4H-2,6-methano-benzordlazocine-3-carbonitrile (one diastereomer, relative configurations of the substituents given in the structure drawn above are confirmed by NMR experiments)
3,4,6-Trimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine (from Example LX, 1.7 g) dissolved in CH2CI2 (40 mL) is added to a solution of BrCN (1.17 g) in CH2CI2 (10 mL) chilled in an ice bath. The cooling bath is removed and the mixture is stirred at ambient temperature for 1 h and at 45 0C for 2 h. After cooling to ambient temperature, the solution is washed with water, 2 M hydrochloric acid, and 10% aqueous K2CO3 solution. The solution is dried (MgSO4), the solvent is removed, and the residue is triturated with little acetone to give the title compound. Yield: 0.98 g (54% of theory) Mass spectrum (ESI+): m/z = 227 [M+H]+
The following compound may be obtained in analogy to Example LXI:
(1 ) 5,6-Dimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocine-3-carbonitrile (racemic mixture of diastereomer shown)
Figure imgf000145_0001
Mass spectrum (ESI+): m/z = 227 [M+H]+
The starting compound, 3,5,6-trimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano- benzo[d]azocine, may be obtained as described in J. Med. Chem. 1971 , 14, 565-68.
Example LXII
Figure imgf000145_0002
3.4,6-Trimethyl-1.2.3.4.5.6-hexahvdro-2.6-methano-benzord1azocine (racemic mixture of diastereomer shown) A mixture of 4,6-dimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocine-3- carbonitrile (one diastereomer, 925 mg), water (30 mL), and 4 M hydrochloric acid (30 mL) is stirred at reflux temperature for 9 h. After cooling to ambient temperature, the solution is basified using concentrated aqueous ammonia solution and the resulting mixture is extracted with EtOAc (2x 50 mL). The combined organic extracts are washed with brine and dried (MgSO4). Removal of the solvent under reduced pressure affords the title compound. Yield: 439 mg (53% of theory) Mass spectrum (ESI+): m/z = 202 [M+H]+ The following compound may be obtained in analogy to Example LXII:
(1 ) 5,6-Dimethyl-1 ,2,3,4,5, 6-hexahydro-2,6-methano-benzo[d]azocine (racemic mixture of diastereomer shown)
Figure imgf000146_0001
Mass spectrum (ESI+): m/z = 202 [M+H]+
Example LXIII
Figure imgf000146_0002
2,2.2-Thfluoro-1-r(6R10S)-5.6.7.8,9,10-hexahvdro-10,12,12-thmethyl-6.10-methano-
1 H-triazolor5,4-iir3lbenzazocin-7-vn-ethanone
A solution of NaNO2 (330 mg) in water (2 mL) is slowly added to a flask charged with a stir bar, 1 -[(2/?,6S)-8,9-diamino-6, 11 ,11 -trimethyl-1 ,2,5,6-tetrahydro-4H-2,6- methano-benzo[d]azocin-3-yl]-2,2,2-trifluoro-ethanone (650 mg), and acetic acid (15 mL) and chilled in an ice bath. The resulting mixture is stirred in the cooling bath for 2 h and at ambient temperature for 1 h. Then, the solution is poured into ice-cold water and the precipitate formed is separated by filtration and dried to afford the title compound that is used without further purification. Yield: 610 mg (91 % of theory)
Mass spectrum (ESI+): m/z = 353 [M+H]+
Example LXIV
Figure imgf000147_0001
(2R6R11 SV6.11-Dimethyl-8-(4 ,4.5.5-tetramethyl-M .3.2ldioxaborolaπ-2-vn-1.2.5.6- tetrahvdro-4H-2.6-methano-benzordlazocine-3-carboxylic acid tert-butyl ester A flask charged with a stir bar, (2R,6R,11 S)-6,11-dimethyl-8-trifluoromethanesulfonyl- oxy-1 ,2,5,6-tetrahydro-4H-2)6-methano-benzo[d]azocine-3-carboxylic acid tert-butyl ester (9.90 g), bis(pinacolato)diboron (6.15 g), 1 ,1 '-bis(diphenylphosphino)ferrocene (0.73 g), and 1 ,4-dioxane (50 mL) is flushed with argon for 15 min. Then, 1 ,1'- bis(diphenylphosphino)-ferrocene-palladium dichloride dichloromethane complex (1.08 g) is added and the mixture is heated to 80 0C. After stirring at 80 0C for 2 d and cooling to ambient temperature, the mixture is diluted with fBuOMe (150 mL) and washed with water (3x 100 mL) and brine (1x 100 mL). The organic phase is dried (MgSO4) and the solvent is removed under reduced pressure. The residue is purified by chromatography on silica gel (cyclohexane/ethyl acetate 9:1->2:3) to give the title compound as a colorless oil. Yield: 6.90 g (73% of theory)
Mass spectrum (ESI+): m/z = 428 [M+H]+
Example LXV
Figure imgf000147_0002
(2R.6R11 SV6.11-Dimethyl-8-borono-1.2.5,6-tetrahvdro-4H-2.6-methano- benzo[dlazocine-3-carboxylic acid tert-butyl ester
A solution of {2R,6R,ϊ 1 S)-6,11-dimethyl-8-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2- yl)-1 ^^.β-tetrahydro^H^.e-methano-benzofdlazocine-S-carboxylic acid tert-butyl ester (2.50 g) and NaIO4 (5.00 g) in 1 M aqueous NH4OAc solution (34 mL) and acetone (60 mL) is stirred at room temperature overnight. Then, the solution is concentrated, water is added to the residue, and the resulting mixture is extracted with ethyl acetate. The combined organic extracts are washed with water and brine and dried (Na2SO4). The solvent is removed under reduced pressure to give the title compound as a colorless, foam-like solid. Yield: 1.83 g (91% of theory) Mass spectrum (ESI'): m/z = 390 [M+HCOO]"
Example LXVI
Figure imgf000148_0001
(2R.6RA 1 S)-6.11-Dimethyl-8-(2-methyl-pyrimidin-4-vπ-1 ,2,3 ,4.5.6-hexahvdro-2.6- methano-benzordlazocine
Pd(OAc)2 (3.3 mg) is added to a mixture of (2R,6R,11 S)-6,11-dimethyl-8-borono- 1 ,2,5I6-tetrahydro-4H-2,6-methano-benzo[d]azocine-3-carboxylic acid tert-butyl ester (0.30 g), 4-chloro-2-methyl-pyrimidine (93 mg), K3PO4 (0.31 g), and 2-dicyclohexyl- phosphino-2',6'-dimethoxy-1 ,1 '-biphenyl (11.5 mg) in n-butanol (2 ml_) under argon atmosphere. The resulting mixture is heated to 100 °C and stirred at this temperature overnight. After cooling to room temperature, ethyl acetate is added, the resulting mixture is filtered, and the filtrate is concentrated under reduced pressure. The residue is taken up in CH2CI2 (3 ml_) and treated with F3CCO2H (0.5 ml_) for 1 h. Then, the solution is concentrated and the residue is purified by HPLC on reversed phase (MeCN/H2O/NH3) to afford the title compound. Yield: 0.1O g (48% of theory) Mass spectrum (ESI+): m/z = 294 [M+H]+
The following compound may be obtained in analogy to Example LXVI:
(1 ) {2R.6R, 11 S)-6, 11 -Dimethyl-8-pyrimidin-4-yl-1 ,2,3,4,5,6-hexahydro-2,6-methano- benzo[d]azocine
Figure imgf000149_0001
Mass spectrum (ESI+): m/z = 280 [M+H]+
ExampleLXVII
Figure imgf000149_0002
(2R6R.11 SV-6.11-Dimethyl-8-(6-methyl-pyridazin-3-yl)-1.2,3,4,5,6-hexahvdro-2,6- methano-benzofdlazocine
2 M Aqueous Na2CO3 solution (1.13 ml_) is added to a mixture of (2R,6R,11 S)-6,11- dimethyl-8-(4>4I5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-1 ,2,5,6-tetrahydro-4H-2,6- methano-benzoIdlazocine-S-carboxylic acid tert-butyl ester (483 mg) and 3-chloro-6- methyl-pyridazine (218 mg) in dimethylformamide (2 imL). The resulting mixture is flushed with argon and then 1 ,1'-bis(diphenylphosphino)ferrocene-palladium dichloride dichloromethane complex (73 mg) is added. The mixture is heated to 100 0C and stirred at this temperature overnight. After cooling to room temperature, water is added and the resulting mixture is extracted with ethyl acetate. The combined organic extracts are washed with water and brine and dried (MgSO4). The solvent is removed under reduced pressure and the residue is taken up in CH2CI2 (3 ml_) and treated with F3CCO2H (0.5 ml_) for 1 h. Then, the solution is concentrated and the residue is purified by HPLC on reversed phase (MeCN/H2O/NH3) to afford the title compound.
Yield: 225 mg (68% of theory)
Mass spectrum (ESI+): m/z = 294 [M+H]+
The following compounds may be obtained in analogy to Example LXVII:
(1 ) (2R,6f?,11 S)-6,11-Dimethyl-8-(1-methyl-2-oxo-1 ,2-dihydro-pyridin-4-yl)- 1 ,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine
Figure imgf000150_0001
Mass spectrum (ESI+): m/z = 309 [M+H]+
Trifluoro-methanesulfonic acid 1-methyl-2-oxo-1 ,2-dihydro-pyridin-4-yl ester or 4- bromo-1-methyl-1 H-pyridin-2-one are used as the coupling partner
(2) 5-[(2/?,6Rl11 S)-6,11-Dimethyl-1 )2,3I4,5,6-hexahydro-2I6-methano- benzo[d]azocin-8-yl]-1-methyl-1 H-pyridin-2-one
Figure imgf000150_0002
(3) 6-[(2R,6R,11 S)-6,11-Dimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano- benzo[d]azocin-8-yl]-2-methyl-2H-pyridazin-3-one
Figure imgf000150_0003
6-Chloro-2-methyl-2H-pyridazin-3-one is used as the coupling partner.
(4) (2R,6R,11 S)-6,11-Dimethyl-8-(2-methyl-pyrimidin-5-yl)-1 , 2,3,4, 5,6-hexahydro-2,6- methano-benzo[d]azocine
Figure imgf000150_0004
Mass spectrum (ESI+): m/z = 294 [M+H]+ 5-Bromo-2-methyl-pyrimidine is used as the coupling partner.
Example LXVIII
Figure imgf000151_0001
2,2,2-Trifluoro-1-r(6R10S)-5.6.7.8.9.10-hexahvdro-10.12,12-trimethyl-2-pyrazin-2-yl- 6,10-methano-1 H-imidazor5,4-iir3lbenzazocin-7-yll-ethanone A solution of pyrazine-2-carboxylic acid (152 mg), 2-(1 H-benzotriazol-1-yl)-1 , 1 ,3,3- tetramethyluronium tetrafluoroborate (397 mg), and triethylamine (0.5 mL) in dimethylformamide (5 mL) is stirred at room temperature for 30 min, before 1- [(2f?,6S)-8,9-diamino-6,11 ,11-trimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano- benzo[d]azocin-3-yl]-2,2,2-trifluoro-ethanone (300 mg) is added. The solution is stirred at room temperature overnight. Then, the solution is diluted with EtOAc and washed with water and 2 M aqueous K2CO3 solution and dried (MgSO4). The solvent is removed under reduced pressure and the residue is taken up in acetic acid (5 mL). The resulting solution is heated at 80 0C overnight. Then, the solvent is removed under reduced pressure and the residue is evaporated twice with toluene to give the crude title compound that is used without further purification. Yield: 380 mg (quantitative) Mass spectrum (ESI+): m/z = 430 [M+H]+
The following compounds may be obtained in analogy to Example LXVIII:
(1 ) 1 -[(6R.10S)-2-(1 -Acetyl-piperidin-4-yl)-5,6,7,8,9, 10-hexahydro-10,12,12-trimethyl- 6,10-methano-1 H-imidazo[5,4-i][3]benzazocin-7-yl]-2,2,2-trifluoro-ethanone
Figure imgf000151_0002
Mass spectrum (ESI+): m/z = 477 [M+H]+ (2) 1-[(6/?,10S)-2-Cyclopropyl-5,6,7,8,9,10-hexahydro-10I12)12-trimethyl-6I10- methano-1 H-imidazo[5,4-i][3]benzazocin-7-yl]-2,2,2-trifluoro-ethanone
Figure imgf000152_0001
(3) 2,2>2-Trifluoro-1-[(6R,10S)-5)6I7,8,9,10-hexahydro-10,12>12-trimethyl-2-(1- methyl-6-oxo-1 ,6-dihydro-pyridin-3-yl)- 6,10-methano-1 H-imidazo[5,4- i][3]benzazocin-7-yl]-ethanone
Figure imgf000152_0002
(4) 1 -[(6R, 10S)-2-terf-Butyl-5,6,7,8,9, 10-hexahydro-10,12,12-trimethyl-6, 10-methano- 1 H-imidazo[5,4-i][3]benzazocin-7-yl]-2,2,2-trifluoro-ethanone
Figure imgf000152_0003
(5) 2,2,2-Trifluoro-1 -[(6R, 10S)-5,6,7,8,9, 10-hexahydro-10,12,12-trimethyl-2-pyridin-3- yl-6, 10-methano-1 H-imidazo[5,4-i][3]benzazocin-7-yl]-ethanone
Figure imgf000152_0004
(6) 2,2,2-Trifluoro-1-{(6/?,10S)-5,6,7,8,9,10-hexahydro-10,12,12-trimethyl-2-[(S)- tetrahydrofuran-2-yl]-6,10-methano-1 H-imidazo[5,4-i][3]benzazocin-7-yl}-ethanone
Figure imgf000152_0005
(7) 2,2,2-Trifluoro-1 -[{6R, 10S)-5,6,7,8,9, 10-hexahydro-10,12,12-trimethyl-2-pyridazin- 4-yl-6,10-methano-1 H-imidazo[5,4-i][3]benzazocin-7-yl]-ethanone
Figure imgf000153_0001
(8) 2,2I2-Trifluoro-1-[(6R,10S)-5,6I7,8I9l10-hexahydro-10>12)12-trimethyl-2-(5- methyl-pyrazin-2-yl)-6, 10-methano-1 H-imidazo[5,4-i][3]benzazocin-7-yl]-ethanone
Figure imgf000153_0002
(9) 2,2,2-Trifluoro-1-{(6RI10S)-5,6,7)8,9l10-hexahydro-10,12,12-trimethyl-2-[(R)- tetrahydrofuran-2-yl]-6,10-methano-1 H-imidazo[5,4-i][3]benzazocin-7-yl}-ethanone
Figure imgf000153_0003
Mass spectrum (ESI+): m/z = 422 [M+H]+
Example LXIX
Figure imgf000153_0004
2.2,2-Trifluoro-1-r(7R.11R,12S)-6,7.8.9.10,11-hexahvdro-2.11 ,12-trimethyl-7.11- methano-1 H-oxazolor4.5-hir3lbenzazocin-8-yll-ethanone i-PRΘR.I I S^-Amino-δ-hydroxy-e.i i-dimethyl-I ^.S.Θ-tetrahydro^H^.Θ- methano-benzo[d]azocin-3-yl]-2,2,2-trifluoro-ethanone (200 mg) taken up in trimethyl orthoacetate (1 mL) is heated at 100 0C for 3 h. After cooling to ambient temperature, the mixture is concentrated and the residue is triturated with little methanol and dried to give the title compound.
Yield: 100 mg (47% of theory)
Mass spectrum (ESI+): m/z = 353 [M+H]+ The following compounds may be obtained in analogy to Example LXIX:
(1 ) 2I2,2-Trifluoro-1-[(6R,10S)-5l6,7,8,9,10-hexahydro-2,10I12,12-tetramethyl-6,10- methano-oxazolo[4,5-i][3]benzazocin-7-yl]-ethanone
Figure imgf000154_0001
Mass spectrum (ESI+): m/z = 367 [M+H]+
(2) 2,2,2-Trifluoro-1 -[(6R, 10R, 12S)-516I7,8,9, 1 O-hexahydro-2, 10,12-trimethyl-6, 10- methano-oxazolo[5,4-i][3]benzazocin-7-yl]-ethanone
Figure imgf000154_0002
Mass spectrum (ESI+): m/z = 353 [M+H]+
Figure imgf000154_0003
Cvclopropanecarboxylic acid f(2R6SV9-hvdroxy-6.11.11-trimethyl-3-(2.2.2-trifluoro- acetyl)-1 ,2,3,4.5.6-hexahvdro-2,6-methano-benzofd1azocin-8-vn-amide Cyclopropylcarbonyl chloride (0.13 ml_) is added to a solution of 1-[(2R,6S)-8-amino- 9-hydroxy-6,11 ,11-trimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocin-3-yl]- 2,2,2-trifluoro-ethanone (0.50 g) and triethylamine (0.25 ml_) in dichloromethane (3 mL). After stirring the solution at room temperature overnight, concentrated aqueous ammonia solution (1 mL) and methanol (2 mL) are added and the resulting mixture is stirred for additional 2 h. Then, the solution is concentrated and water is added to the residue. The resulting mixture is extracted with ethyl acetate and the combined organic extracts are washed with brine and dried (MgSO4). The solvent is removed under reduced pressure to give the crude title compound that is used without further purification.
Yield: 0.62 g (quantitative)
The following compounds may be obtained in analogy to Example LXX:
(1 ) Cyclopropanecarboxylic acid [(2R,6R,11 S)-9-hydroxy-6,11-dimethyl-3-(2,2,2- trifluoro-acetyO-I ^.S^.δ.θ-hexahydro^.e-methano-benzotdJazocin-δ-yll-amide
Figure imgf000155_0001
(2) Cyclopropanecarboxylic acid [(2R,6f?,11 S)-8-hydroxy-6,11-dimethyl-3-(2,2,2- trifluoro-acetylJ-I ^.S^.δ.θ-hexahydro^.θ-methano-benzo[d]azocin-θ-yll-amide
Figure imgf000155_0002
Mass spectrum (ESI+): m/z = 397 [M+H]+
(3) N-[(2fl,6S)-9-Hydroxy-6,11 ,11-trimethyl-3-(2,2,2-trifluoro-acetyl)-1 ,2,3,4,5,6- hexahydro-2,6-methano-benzo[d]azocin-8-yl]-2,2-dimethyl-propionamide
Figure imgf000155_0003
(4) 5-Methyl-pyrazine-2-carboxylic acid [(2R,6S)-9-hydroxy-6,11 ,11-trimethyl-3- (2,2,2-trifluoro-acetyl)-1 ,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-yl]- amide
Figure imgf000156_0001
Mass spectrum (ESI+): m/z = 463 [M+H]+
Alternatively, the compound may be obtained from δ-methyl-pyrazine^-carboxylic acid using 2-(1 H-benzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium tetrafluoroborate and ethyldiisopropylamine in dimethylformamide as described in Example LXXXII.
(5) S-Methyl-pyrazine-2-carboxylic acid [(2R.6R11 S)-8-hydroxy-6,11-dimethyl-3- (2,2,2-trifluoro-acetyl)-1 ,2,3)4,5,6-hexahydro-2)6-methano-benzo[d]azocin-9-yl]- amide
Figure imgf000156_0002
Mass spectrum (ESI+): m/z = 449 [M+H]+
Alternatively, the compound is obtained from δ-methyl-pyrazine^-carboxylic acid using 2-(1 H-benzotriazol-1-yl)-1 ,1 ,3)3-tetramethyluronium tetrafluoroborate and ethyldiisopropylamine in dimethylformamide as described in Example LXXXII.
(6) (R)-Tetrahydro-furan-2-carboxylic acid [(2R,6S)-9-hydroxy-6,11 ,11-trimethyl-3- (2,2,2-trifluoro-acetyl)-1 ,2,3,4, 5,6-hexahydro-2,6-methano-benzo[d]azocin-8-yl]- amide
Figure imgf000156_0003
Preferably, the compound is obtained from (f?)-tetrahydro-furan-2-carboxylic acid using 2-(1 H-benzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium tetrafluoroborate and ethyldiisopropylamine in dimethylformamide as described in Example LXXXII. (7) (S)-Tetrahydro-furan-2-carboxylic acid [(2R)6S)-9-hydroxy-6l11 ,11-trimethyl-3-
(2,2l2-trifluoro-acetyl)-1 ,2,3,4I5)6-hexahydro-2,6-methano-benzo[d]azocin-8-yl]- amide
Figure imgf000157_0001
Preferably, the compound is obtained from (S)-tetrahydro-furan-2-carboxylic acid using 2-(1 H-benzotriazol-1-yl)-1 ,1 ,3)3-tetramethyluronium tetrafluoroborate and ethyldiisopropylamine in dimethylformamide as described in Example LXXXII.
Example LXXI
Figure imgf000157_0002
i-rfGRIOS^-Cvclopropyl-δ.ej.S.Q.I O-hexahvdro-i 0.12.12-trimethyl-6.10-methano- oxazolor4.5-iir31benzazocin-7-yll-2,2.2-trifluoro-ethanone
A solution of cyclopropanecarboxylic acid [(2R,6S)-9-hydroxy-6,11 ,11-trimethyl-3-
(2,2,2-trifluoro-acetyl)-1 ,2,3,4l5I6-hexahydro-2,6-methano-benzo[d]azocin-8-yl]- amide (0.62 g) and pyridinium p-toluenesulfonate (76 mg) in xylene (6 mL) is stirred at reflux temperature for 5 h. After cooling to room temperature, the solution is concentrated, ethyl acetate is added to the residue, and the resulting mixture is washed with water and brine. The organic solution is dried (MgSO4) and the solvent is evaporated to afford the title compound. Yield: 0.52 g (89% of theory)
The following compounds may be obtained in analogy to Example LXXI:
(I J I-KeRIOR.IZS^-Cyclopropyl-S.βJ.β.θ.i O-hexahydro-I O.^-dimethyl-β.iO- methano-oxazolo[4,5-i][3]benzazocin-7-yl]-2,2,2-trifluoro-ethanone
Figure imgf000158_0001
(2) 1-[(6R1IOR112S)-2-Cyclopropyl-5,6,7, 8,9,10-hexahydro-10,12-dimethyl-6, 10- methano-oxazolo[5,4-i][3]benzazocin-7-yl]-2,2,2-trifluoro-ethanone
Figure imgf000158_0002
Mass spectrum (ESI+): m/z = 379 [M+H]+
(3) ^[(6RJ0S)-2-tert-Buty\-5,6Jβ,9J0-hexahyόro-W2J2Anme\hy\-6J0-meVnano- oxazolo[4,5-i][3]benzazocin-7-yl]-2,2,2-trifluoro-ethanone
Figure imgf000158_0003
(4) 2,2I2-Trifluoro-1-[(6R>10S)-5)6,7,8,9,10-hexahydro-10,12>12-trimethyl-2-(5- methyl-pyrazin-2-yl)-6,10-methano-oxazolo[4,5-i][3]benzazocin-7-yl]-ethanone
Figure imgf000158_0004
(5) 2,2,2-Trifluoro-1 -[(6R,1 OR, 12S)-5,6)7,8,9, 10-hexahydro-10,12-dimethyl-2-(5- methyl-pyrazin-2-yl)-6,10-methano-oxazolo[5,4-i][3]benzazocin-7-yl]-ethanone
Figure imgf000158_0005
(6) 2,2,2-Trifluoro-1-[(6R,10S)-5,6,7,8,9,10-hexahydro-10,12,12-trimethyl-2-[(R)- tetrahydrofuran-2-yl]-6,10-methano-oxazolo[4,5-i][3]benzazocin-7-yl]-ethanone
Figure imgf000159_0001
(7) 2)2,2-Trifluoro-1-[(6RI10S)-5,6I7I8,9,10-hexahyclro-10)12,12-trimethyl-2-[(S)- tetrahydrofuran-2-yl]-6,10-methano-oxazolo[4,5-i][3]benzazocin-7-yl]-ethanone
Figure imgf000159_0002
Example LXXII
Figure imgf000159_0003
6,11.11-Thmethyl-i ^.SΛ.δ.θ-hexahvdro^.G-methano-benzofdlazocin-Z-ol and 6,11.11-trimethyl-1.2.3.4,5,6-hexahvdro-2.6-methano-benzo[d1azocin-9-ol 2-(3-Methoxy-benzyl)-3,3-dimethyl-4-methylene-piperidine-1-carbaldehyde (for preparation see J. Med. Chem. 1997, 40, 2928-2939; 47.5 g) is combined with 48% HBr in water (300 ml_). The mixture is heated to reflux temperature and stirred at this temperrature for 24 h. After cooling to ambient temperature, the precipitate is separated by filtration, washed with water, and triturated with acetone. Then, the precipitate is taken up in a mixture of 1 N aqueous NaOH solution and CH2CI2. The CH2Cb phase is separated, dried (Na2SO4), and concentrated. The residue is recrystallized from EtOAc to afford 6,11 ,11-trimethyl-1 , 2,3,4,5, 6-hexahydro-2,6- methano-benzo[d]azocin-7-ol. The filtrate of the reaction mixture is combined with the water and acetone phases (from washing and triturating the precipitate) and basified using concentrated aqueous ammonia solution. The resulting mixture is extracted with CH2CI2, the combined organic extracts are dried (MgSO4), and the solvent is evaporated. The residue is purified by chromatography on silica gel (EtOAc/MeOH/ NH4OH 90:10:1->70:30:3) to afford 6,11 ,11-trimethyl-1 , 2, 3,4,5, 6-hexahydro-2,6- methano-benzo[d]azocin-9-ol. 6,11 ,11-Trimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-7-ol: Yield: 5.2 g (13% of theory) Mass spectrum (ESI+): m/z = 232 [M+H]+
6,11 ,11-Trimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-9-ol: Yield: 9.3 g (23% of theory) Mass spectrum (ESI+): m/z = 232 [M+H]+
Example LXXIII
Figure imgf000160_0001
(1-Benzyl-allylM2-methyl-allvD-carbamic acid tert-butyl ester NaH (60% in mineral oil, 0.15 g) is added to a solution of (i-benzyl-allyl)-carbamic acid tert-butyl ester (for preparation see e.g. Eur. J. Org. Chem. 2002, 1, 139-144;
0.86 g) in N-methylpyrrolidinone (5 ml_). The resulting mixture is stirred at room temperature for 30 min, before 3-bromo-2-methyl-propene (0.38 ml_) is added. After stirring for 5 h, brine is added and the resulting mixture is extracted with EtOAc. The combined organic extracts are dried (Na2SO4), the solvent is evaporated, and the residue is purified by chromatography on silica gel (cyclohexane/EtOAc 1 :0→1 :1 ).
Yield: 0.79 g (75% of theory)
Mass spectrum (ESI+): m/z = 302 [M+H]+
The following compound may be obtained in analogy to Example LXXIII:
(1 ) (1-Benzyl-allyl)-(4-methyl-pent-4-enyl)-carbamic acid tert-butyl ester
Figure imgf000160_0002
Mass spectrum (ESI+): m/z = 330 [M+H]+ Methanesulfonic acid 4-methyl-pent-4-enyl ester, prepared from 4-methyl-pent-4-en- 1-ol and mesyl chloride in the presence of NEt3 in dichloromethane, is used as the electrophile.
Example LXXIV
Figure imgf000161_0001
2-Benzyl-4-methyl-2,5-dihvdro-pyrrole-1-carboxylic acid tert-butyl ester [(1 ,3-Bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene]-dichloro-(phenylmethylene)- (tricyclohexylphosphine)-ruthenium (28 mg) is added to a solution of (1-benzyl-allyl)- (2-methyl-allyl)-carbamic acid tert-butyl ester (0.79 g) in toluene (50 ml_) under argon atmosphere at room temperature. The resulting mixture is heated to 60 0C and stirred at this temperature for 3 h. After cooling to room temperature, the solvent is removed and the residue is purified by chromatography on silica gel (cyclohexane/ethyl acetate 1 :0->1 :1 ). Yield: 0.40 g (56% of theory)
Mass spectrum (ESI+): m/z = 274 [IvHH]+
The following compound may be obtained in analogy to Example LXXIV:
(1 ) 7-Benzyl-5-methyl-2,3,4,7-tetrahydro-azepine-1-carboxylic acid tert-butyl ester
Figure imgf000161_0002
Mass spectrum (ESI+): m/z = 302 [M+H]+ Example LXXV
Figure imgf000162_0001
1 -Methyl-10-aza-tricvclor7.4.1.0*2.7*ltetradeca-2.4,6-triene Trifluoromethanesulfonic acid (2.5 mL) is added to a solution of 7-benzyl-5-methyl- 2,3,4, 7-tetrahydro-azepine-i-carboxylic acid tert-butyl ester (0.30 g) in CH2Cb (5 mL) chilled in an ice bath. The ice bath is removed and the solution is stirred at room temperature for 5 h. Then, ice-cold water and aqueous K2CO3 solution are added and the resulting mixture is extracted with ethyl acetate. The combined extracts are dried (Na2SO4), the solvent is evaporated, and the residue is purified by chromatography on silica gel (dichloromethane/methanol 99:1 ->9:1 ). Yield: 0.1O g (50% of theory)
Example LXXVI
Figure imgf000162_0002
7-Benzyl-6,7,9.10-tetrahvdro-5H-6.10-methano-pyridof3,2-d1azocin-8-one (racemic mixture of diastereomer shown)
A flask charged with a stir bar, 2-benzyl-2-aza-bicyclo[3.3.1]nonane-3,6-dione (for preparation see J. Chem. Soc, Perkin Trans. 1, 1999, 1157-1162; 0.80 g), NaAuCI4 * 2 H2O (30 mg), propargylamine (0.45 mL), and ethanol (5 mL) is heated at 100 0C with microwave irradiation for 10 min. After cooling to room temperature, the mixture is filtered and the filtrate is concentrated. The residue is purified by chromatography on silica gel (cyclohexane/ethyl acetate/methanol 6:4:1 ).
Yield: 0.52 g (56% of theory)
Example LXXVII
Figure imgf000163_0001
7-Benzyl-5.6,7,8,9.10-hexahvdro-6,10-methano-pyrido[3,2-dlazocine (racemic mixture of diastereomer shown)
LiAIH4 (1 M in THF, 4.5 ml_) is added dropwise to a solution of 7-benzyl-6,7,9,10- tetrahydro-5H-6,10-methano-pyrido[3,2-d]azocin-8-one (0.55 g) in tetrahydrofuran (3 ml_) chilled in an ice bath. The cooling bath is removed and the mixture is stirred at room temperature for 2 h. Ice-cold water and 4 M hydrochloric acid (4 ml_) are added and the mixture is stirred for another 15 min. Then, the mixture is basified using 4 M aqueous NaOH solution and the mixture is extracted with ethyl acetate. The combined organic extracts are dried (Na2SO4), the solvent is evaporated, and the residue is purified by chromatography on silica gel (cyclohexane/EtOAc/methanol 4:1 :0->1 :1 :1 ). Yield: 0.16 g (32% of theory)
The following compounds may be obtained in analogy to Example LXXVII:
(1 ) 9-Benzyl-3,5)9-triaza-tricyclo[6.3.1.0*2,6*]dodeca-2(6),4-diene (racemic mixture of diastereomer shown)
Figure imgf000163_0002
Mass spectrum (ESI+): m/z = 254 [M+H]+
(2) θ-BenzyM-methyl-S.δ.θ-triaza-tricyclote.S.1.0*2,6*]dodeca-2(6),4-diene (racemic mixture of diastereomer shown)
Figure imgf000163_0003
Mass spectrum (ESI+): m/z = 268 [M+H]+ (3) 2, 3,4,48,9, 9a-Hexahydro-1 H-indeno[2,1-b]pyridine (racemic mixture of diastereomer shown)
Figure imgf000164_0001
Mass spectrum (ESI+): m/z = 174 [M+H]+
The reaction mixture is stirred at reflux temperature for 1 h after stirring with LiAIH4 at ambient temperature for 2 h.
Example LXXVIII
Figure imgf000164_0002
2-Benzyl-7,7-dibromo-2-aza-bicvclor3.3.1lnonane-3,6-dione (racemic mixture of diastereomer shown)
A solution of bromine (1.2 mL) in acetic acid (5 mL) is added to a solution of 2- benzyl-2-aza-bicyclo[3.3.1]nonane-3,6-dione (for preparation see J. Chem. Soc, Perkin Trans. 1, 1999, 1157-1162; 3.05 g) in acetic acid (40 mL). The resulting solution is stirred at room temperature for 2 h. Then, the solution is poured into ice- cold water and the resulting mixture is extracted with ethyl acetate. The combined organic extracts are dried (Na2SO4) and the solvent is evaporated to afford the title compound as a solid. Yield: 4.69 g (88% of theory) Mass spectrum (ESI+): m/z = 400/402/404 (2 Br) [M+H]+
Example LXXIX
Figure imgf000164_0003
9-Benzyl-3.5.9-triaza-tricvclor6.3.1.0*2.6*ldodeca-2(6).4-dien-10-one (racemic mixture of diastereomer shown) A mixture of 2-benzyl-7,7-dibromo-2-aza-bicyclo[3.3.1]nonane-3,6-dione (one diastereomer, 2.50 g), paraforamaldehyde (0.19 g), and ca. 7 M ammonia in methanol (25 ml_) is stirred at room temperature overnight. Then, the solution is concentrated and the residue is purified by chromatography on silica gel (CH2CI2/Me0H 99:1->9:1 ).
Yield: 0.85 g (ca. 85% pure, 44% of theory) Mass spectrum (ESI+): m/z = 268 [M+H]+
The following compound may be obtained in analogy to Example LXXIX:
(1 ) 9-Benzyl-4-methyl-3,5)9-triaza-tricyclo[6.3.1.0*2,6*]dodeca-2(6),4-dien-10-one (racemic mixture of diastereomer shown)
Figure imgf000165_0001
Acetaldehyde is used instead of paraformaldehyde.
Example LXXX
Figure imgf000165_0002
(2ff.6fl.11 SV6.11-Dimethyl-3-(2,2,2-trifluoro-acetvn-1 ,2.3.4.5.6-hexahvdro-2.6- methano-benzo[dlazocine-8-carboxylic acid methyl ester 2,2,6,6-Tetramethylpiperidine (5.4 mL), 1 ,3-bis(diphenylphosphino)propane (1.30 g), and Pd(OAc)2 (0.78 g) are added in turn to a flask charged with trifluoromethane- sulfonic acid (2ft,6R,11 S)-6,11-dimethyl-3-(2,2,2-trifluoro-acetyl)-1 ,2,3,4,5,6- hexahydro-2,6-methano-benzo[d]azocin-8-yl ester (7.0 g), dimethylformamide (30 mL), and methanol (30 mL) in argon atmosphere. The reaction flask is put under CO pressure (7 bar) and shaken at 70 0C for 17 h. After cooling to ambient temperature, water is added and the resulting mixture is extracted with Et2O. The combined organic extracts are washed with water and brine and dried (MgSO4). The solvent is evaporated to give the title compound as an oil that crystallizes while standing. Yield: 5.2 g (93% of theory)
Mass spectrum (ESI+): m/z = 356 [M+H]+
Example LXXXI
Figure imgf000166_0001
(2R6R11 S)-6.11-Dimethyl-1 ,2,5.6-tetrahvdro-4H-2.6-methano-benzordlazocine-3.8- dicarboxylic acid 3-tert-butyl ester
4 M aqueous NaOH solution (18.5 mL) is added to a solution of (2ReR1H S)-B1H - dimethyl-3-(2,2,2-trifluoro-acetyl)-1 , 2,3,4, 5,6-hexahydro-2,6-methano- benzo[d]azocine-8-carboxylic acid methyl ester (5.2 g) in methanol (40 mL). The solution is stirred at room temperature overnight. After neutralization of the solution with MeCOOH, NEt3 (10 mL) and THF (20 mL) are added and the solution is cooled in an ice bath. Then, di-terfbutyl dicarbonate (4.0 g) is added, the cooling bath is removed, and the solution is stirred at ambient temperature overnight. 1 M aqueous HCI solution (30 mL) is added and the resulting mixture is extracted with ethyl acetate. The combined organic extracts are washed with brine and dried (MgSO4). The solvent is evaporated to give the title compound. Yield: 5.3 g (quantitative)
Mass spectrum (ESI+): m/z = 346 [M+H]+
Example LXXXII
Figure imgf000166_0002
(2R6R11 S)-8-Hvdrazinocarbonyl-6.11-dimethyl-1.2.5.6-tetrahvdro-4H-2.6-methano- benzofdlazocine-3-carboxylic acid tert-butyl ester
NEt3 (1.7 mL) and 2-(1 H-benzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium tetrafluoro- borate (3.9 g) are added in turn to a solution of (2R6R11 S)-6,11-dimethyl-1 ,2,5,6- tetrahydrcHΦH^.δ-methano-benzotdJazocine-S.δ-dicarboxylic acid 3-terfbutyl ester (4.2 g) in dimethylformamide (10 mL). The resulting solution is stirred at ambient temperature for 30 min, before hydrazine hydrate (3 ml_) is added. The solution is stirred further at room temperature for 1 h and then water (30 mL) is added. The resulting mixture is extracted with ethyl acetate and the combined organic extracts are washed with 1 M aqueous NaOH solution, water, and brine. After drying (MgSO4), the solvent is evaporated and the residue is purified by chromatography on silica gel (cyclohexane/EtOAc 1 :4->0:1 ) to give the title compound. Yield: 2.8 g (64% of theory) Mass spectrum (ESI'): m/z = 358 [M-H]"
Example LXXXIII
Figure imgf000167_0001
(2R.6R11 S)-6,11-Dimethyl-8-(5-methyl-f1 ,3.4loxadiazol-2-vn-1.2.5.6-tetrahvdro-4H- 2,6-methano-benzofdlazocine-3-carboxylic acid tert-butyl ester (2f?I6R,11 S)-8-Hydrazinocarbonyl-6,11-dimethyl-1 ,2,5>6-tetrahydro-4H-2,6-methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester (0.50 g) in (EtO^CMe (2 mL) is heated in a microwave oven at 120 0C for 30 min. After cooling to room temperature, the mixture is concentrated under reduced pressure and the residue is purified by HPLC on reversed phase (MeCN/H2O/NH4OH) to give the title compound. Yield: 93 mg (17% of theory) Mass spectrum (ESI+): m/z = 384 [M+H]+
The following compound is obtained in analogy to Example LXXXIII:
(1 ) (2R6R11 S)-6,11-Dimethyl-8-[1 ,3,4]oxadiazol-2-yl-1 ,2,5,6-tetrahydro-4H-2,6- methano-benzotdJazocine-S-carboxylic acid tert-butyl ester
Figure imgf000167_0002
Mass spectrum (ESI+): m/z = 370 [M+H]+ The reaction is conducted at 145 0C with (EtO)3CH.
Example LXXXIV
Figure imgf000168_0001
(2R.6R, 11 S)-8-(4.5-Dimethyl-4H-ri ,2.41triazol-3-vn-6.11 -dimethyl-1.2.3.4,5,6- hexahvdro-2.6-methano-benzo[d1azocine
Oxalylic chloride (0.12 ml_) is added to a solution N-methylacetamide (102 mg) and 2,6-lutidine (0.33 ml.) in dichloromethane (5 ml_) chilled in an ice bath. After stirring the solution for 15 min, (2f?I6f?,11 S)-8-hydrazinocarbonyl-6I11-dimethyl-1 ,2,5,6- tetrahydro-4H-2,6-methano-benzo[d]azocine-3-carboxylic acid tert-butyl ester (0.50 g) is added and the cooling bath is removed. The resulting solution is stirred at ambient temperature for 1 h and then neutralized with aqueous NaHCO3 solution. The resulting mixture is extracted with dichloromethane, the combined organic extracts are dried (MgSO4), and the solvent is evaporated. The residue is taken up in acetic acid (3 ml_) and stirred at 120 °C for 2.5 h. After cooling to room temperature, the mixture is concentrated under reduced pressure and the residue is taken up in trifluoroacetic acid (1 ml_) and dichloromethane (5 ml_) to cleave off the tert-butoxy- carbonyl group. The solution is stirred at room temperature overnight and then concentrated. The residue is dissolved in little methanol/acetonithle, neutralized with aqueous ammonia, and purified by HPLC on reversed phase (MeCN/H2O/NH4OH) to give the title compound. Yield: 50 mg (12% of theory) Mass spectrum (ESI+): m/z = 297 [M+H]+
Example LXXXV
Figure imgf000168_0002
2-r(2R.6R.11 S)-6.11-Dimethyl-1 ,2.3.4.5.6-hexahvdro-2.6-methano-benzordlazocin-8- yll-propan-2-ol and (2R6R.11 S)-6.11-dimethyl-1.2.3,4.5.6-hexahvdro-2.6-methano- benzofdlazocine-8-carboxylic acid methyl ester
MeMgBr (1.4 mol/L in tetrahydrofuran/toluene, 2.0 ml.) is added to a solution of (2R.6R.11 S)-6,11-dimethyl-3-(2)2,2-trifluoro-acetyl)-1 ,2,3,4,5,6-hexahydro-2,6- methano-benzo[d]azocine-8-carboxylic acid methyl ester (0.20 g) in tetrahydrofuran (5 ml_) chilled in an ice bath. The solution is stirred with cooling for 2 h, before aqueous NH4CI solution is added carefully. The resulting mixture is extracted with ethyl acetate and the combined organic extracts are washed with brine and dried (MgSO4). The solvent is evaporated to yield a mixture of the title compounds (ca. 4:1 in favor of 2-[(2fi,6R,11 S)-6,11-dimethyl-1 ,2,3,4, 5,6-hexahydro-2,6-methano- benzo[d]azocin-8-yl]-propan-2-ol). Yield: 0.15 g Mass spectrum (ESi+): m/z = 260 [M+H]+ for both compounds determined with analytical HPLC-MS
Example LXXXVI
Figure imgf000169_0001
(2R6SV6.11.11-Trimethyl-8-(2.2,2-trifluoro-1-hvdroxy-1-methyl-ethvn-1.2.5.6- tetrahydro^H^.e-methano-benzordiazocine-S-carboxylic acid tert-butyl ester Mβ3SiCF3 (2 M in tetrahydrofuran, 0.42 mL) is added dropwise to a mixture of (2R,6S)-8-acetyl-6,11 ,11-trimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano- benzo[d]azocine-3-carboxylic acid tert-butyl ester (0.30 g) and CsF (13 mg) in tetrahydrofuran (3 mL) cooled to ca. -5 0C. The mixture is stirred at -5 0C for 1.5 h. Then, 1 M aqueous HCI solution (70 mL) is added and the mixture is stirred for 1 h. The mixture is basified using aqueous K2CO3 solution and then extracted with ethyl acetate. The combined organic extracts are washed with brine and dried (MgSO4). The solvent is evaporated to give the crude title compound that is submitted for cleaving the protective group without further purification. Yield: 0.36 g (crude) Example LXXXVII
Figure imgf000170_0001
i-O-Bromo-propyD^-oxo-indan-i-carboxylic acid methyl ester A solution of 2-oxo-indan-1-carboxylic acid methyl ester (3.8 g) and NaOH (1 M in water, 20 ml_) in ethanol (30 ml_) is added dropwise to a solution of 1 ,3-dibromo- propane (10 mL) in ethanol (20 mL) at room temperature. The solution is warmed to 40 CC and stirred at this temperature for 2 d. Then, the solution is concentrated under reduced pressure and ethyl acetate is added to the residue. The resulting mixture is washed with water and brine and dried (MgSO4). After removing the solvent, the residue is purified by chromatography on silica gel (cyclohexane/EtOAc 20:1->9:1 ) to give the title compound as an oil.
Yield: 2.1 g (33% of theory)
Mass spectrum (ESI+): m/z = 311/313 (Br) [M+H]+
Example LXXXVIII
Figure imgf000170_0002
1 ,2,3,4,9.9a-Hexahvdro-indeno[2.1-blpyridine-4a-carboxylic acid methyl ester NaN3 (0.44 g) is added to a solution of 1-(3-bromo-propyl)-2-oxo-indan-1-carboxylic acid methyl ester (2.06 g) in dimethylformamide (10 mL) at room temperature. The solution is stirred at room temperature for 4 h and then 'BuOMe and ethyl acetate are added. The resulting mixture is washed with water and brine and dried (MgSO4). Most of the organic solvent is evaporated and tetrahydrofuran (10 mL), acetic acid (0.5 mL), and finally 10% Pd/C (150 mg) are added to the residue. The resulting mixture is shaken in hydrogen atmosphere (1 bar) at room temperature for 14 h.
Then, the mixture is filtered, the filtrate is concentrated, and the residue is taken up in 'BuOMe. The organic phase is washed with aqueous Na2CO3 solution and brine and dried (MgSO4). Then, the solvent is evaporated and the residue is dissolved in methanol (10 ml_). To the solution is added acetic acid (0.5 ml_) and 10% Pd/C (50 mg) and the resulting mixture is shaken under hydrogen atmosphere (1 bar) at room temperature for 6 h. Then, the mixture is filtered and the filtrate is concentrated under reduced pressure to give the crude title compound that is used without further purification. Yield: 0.44 g (crude)
Example LXXXIX
Figure imgf000171_0001
1 ,3.4,9-Tetrahvdro-indeno[2.1 -blpyridin-2-one
A mixture of acrylamide (6.15 g) and 1-(1 H-lnden-2-yl)-pyrrolidine (for preparation see e.g. J. Org. Chem. 1961 , 26, 3761-9; 5.34 g) is stirred under argon atmosphere at 100 0C for 30 min. Then, the mixture is heated to 130 0C and stirred at this temperature for another 15 min. After cooling to ambient temperature, water (50 ml_) and acetic acid (5 drops) are added and the resulting mixture is stirred at room temperature for 30 min. Then, ethyl acetate (300 ml_) is added and the solution is separated from the precipitate formed thereafter. The organic part of the solution is separated and washed with brine and dried (MgSO4). The solvent is evaporated and the residue is purified by chromatography on silica gel (cyclohexane/EtOAc 1 :1->0:1 ) to give the title compound as a solid that is triturated with ethyl acetate and dried. Yield: 1.12 g (21 % of theory) Mass spectrum (ESI+): m/z = 186 [M+H]+
Example XC
Figure imgf000171_0002
1 ,3.4.4a, 9, 9a-Hexahvdro-indeno[2.1-blpyridin-2-one (racemic mixture of diastereomer shown)
10% Palladium on carbon (0.15 g) is added to a solution of 1 ,3,4,9-tetrahydro- indeno[2,1-b]pyridin-2-one (1.10 g) and acetic acid (0.75 ml_) in methanol (20 ml). The resulting mixture is shaken in hydrogen atmosphere (1 bar) at room temperature for 6 h. Then, the mixture is filtered and the filtrate is concentrated. The residue is triturated with 'BuOMe and dried to yield the title compound as a colorless solid. Yield: 0.97 g (87% of theory) Mass spectrum (ESI+): m/z = 188 [M+H]+
Example XCI
Figure imgf000172_0001
(2R6SV6.11.11-Trimethyl-9-triisopropylsilanylsulfanyl-1 ,2,5,6-tetrahvdro-4H-2.6- methano-benzordlazocine-3-carboxylic acid tert-butyl ester A flask charged with a stir bar, (2f?,6S)-6,11 ,11-trimethyl-9-trifluoromethanesulfonyl- oxy-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocine-3-carboxylic acid tert-butyl ester (1.00 g), Cs2CO3 (0.92 g), and toluene (20 mL) is sparged with argon for 10 min. Then, triisopropylsilylthiol (0.61 mL) and 1 ,1 '-bis(diphenylphosphino)ferrocene- palladium dichloride dichloromethane complex (135 mg) are added and the mixture is heated to reflux temperature. The mixture is stirred at this temperature for 4 h and then cooled to ambient temperature. Water is added and the resulting mixture is extracted with ethyl acetate. The combined organic extracts are dried (MgSO4) and the solvent is evaporated. The residue is purified by chromatography on silica gel (cyclohexane/ethyl acetate 20:1 ->4:1 ) to give the title compound. Yield: 0.77 g (70% of theory)
Mass spectrum (ESI+): m/z = 504 [M+H]+
Example XCII
Figure imgf000173_0001
(2R6SV6.11.11-Trimethyl-9-methylsulfanyl-1 ,2.5.6-tetrahvdro-4H-2.6-methano- benzofdlazocine-3-carboxylic acid tert-butyl ester
MeI (0.38 mL) and CsF (0.11 g) are added to a solution of (2R6S)-6,11 ,11-trimethyl- 9-triisopropylsilanyl-sulfanyl-1,2,5,6-tetrahydro-4H-2l6-methano-benzo[d]azocine-3- carboxylic acid tert-butyl ester (0.30 g) in dimethylformamide (2 ml). The resulting mixture is strirred at room temperature overnight. Then, the mixture is concentrated, water is added, and the resulting mixture is extracted with ethyl acetate. The combined extracts are washed with water and brine and dried (MgSO4). The solvent is evaporated to afford the title compound as a yellow oil. Yield: 0.21 g (97% of theory) Mass spectrum (ESI+): m/z = 362 [M+H]+
Example XCIII
Figure imgf000173_0002
(2R6S)-9-Methanesulfonyl-6,11.11-trimethyl-1 ,2,5.6-tetrahvdro-4H-2.6-methano- benzordlazocine-3-carboxylic acid tert-butyl ester
3-Chloroperoxybenzoic acid (70%, 0.32 g) is added to a solution of (2R,6S)-6,11 ,11- trimethyl-9-methylsulfanyl-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocine-3- carboxylic acid tert-butyl ester (0.19 g) in dichloromethane (4 ml) chilled in an ice bath. After stirring at room temperature overnight, 10% aqueous K2CO3 solution (20 mL) is added to the reaction solution and the resulting mixture is extracted with ethyl acetate. The combined extracts are washed with brine and dried (MgSO4). The solvent is evaporated to afford the crude title compound as a resin-like solid that is used without further purification. Yield: 0.21 g (quantitative) Mass spectrum (ESI+): m/z = 394 [M+H]+ Preparation of the end compounds:
Procedure A (described for Example 1. Table 3)
Figure imgf000174_0001
r(2/?,6S)-10-Hvdroxy-6.11 ,11-trimethyl-1.2.5.6-tetrahvdro-4H-2.6-methano- benzord1azocin-3-yll-piperidin-1-yl-methanone
Piperidine-1-carbonyl chloride (92 μl_) is added to a solution of (2R,6S)-6, 11 ,11 - trimethyl-1 ,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-10-ol (0.15 g) and triethylamine (0.15 ml_) in dimethylformamide (2 ml_). The resulting solution is stirred at room temperature for 3 h. Then, water is added and the mixture is extracted with ethyl acetate. The combined organic extracts are dried (Na2SO4) and the solvent is evaporated. The residue is purified by HPLC on reversed phase (H2θ/MeCN). Yield: 85 mg (38% of theory) Mass spectrum (ESI+): m/z = 343 [M+H]+
Procedure B (described for Example 7, Table 3)
Figure imgf000174_0002
(4,7-Dihvdro-5H-thienof2.3-clpyhdin-6-vn-f(2R6S)-10-hvdroxy-6,11.11-trimethyl- 1 ,2,5.6-tetrahvdro-4H-2.6-methano-benzo[dlazocin-3-yll-methanone 4,5,6,7-Tetrahydro-thieno[2,3-c]pyridine (91 mg) is added to a solution of triphosgene (68 mg) and triethylamine (0.23 ml_) in dichloromethane (4 ml_) chilled in an ice bath. The resulting solution is stirred for 0.5 h before (2R,6S)-6,11 ,11-trimethyl-1 , 2,3,4,5,6- hexahydro-2,6-methano-benzo[d]azocin-10-ol (0.15 g) in dichloromethane (2 mL) is added. The cooling bath is removed and the solution is stirred at room temperature overnight. Then, water is added and the mixture is extracted with ethyl acetate. The combined organic extracts are dried (Na2SO4) and the solvent is evaporated. The residue is purified by HPLC on reversed phase (H2O/MeCN). Yield: 25 mg (10% of theory) Mass spectrum (ESI+): m/z = 397 [M+H]+
Remark: The order of addition of the two amino compounds to phosgene may be reversed.
Procedure C (described for Example 9, Table 3)
Figure imgf000175_0001
K2R6SM O-Hvdroxy-6, 11.11 -trimethyl-1.2.5.6-tetrahvdro-4H-2.6-methano- benzord1azocin-3-vπ-(4-methyl-piperidin-1-yl)-methanone A mixture of 3-[(2R,6S)-10-hydroxy-6,11 ,11-trimethyl-1 ,2,5,6-tetrahydro-4H-2,6- methano-benzo[d]azocine-3-carbonyl]-1-methyl-3H-imidazol-1-ium iodide (116 mg) and 4-methylpiperidine (0.06 mL) is stirred at 90 0C for 3 h. After cooling to ambient temperature, the mixture is purified by HPLC on reversed phase (water/acetonitrile).
Yield: 62 mg (70% of theory) Mass spectrum (ESI+): m/z = 357 [M+H]+
Remark: If the amine is a solid the reaction is conducted in tetrahydrofuran (1 mL) as described above.
Procedure D (described for Example 31 , Table 3)
Figure imgf000175_0002
K2R6S)-10-Methoxy-6.11.11 -trimethyl-1 , 2.5.6-tetrahvdro-4H-2.6-methano- benzordlazocin-3-yll-piperidin-1-yl-methanone
Methyl iodide (41 μl_) is added to a mixture of [(2R,6S)-10-hydroxy-6,11 ,11-trimethyl-
1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocin-3-yl]-pipehdin-1-yl-methanone (200 mg) and potassium carbonate (0.11 g) in dimethylformamide (3 mL). The resulting mixture is stirred at ambient temperature overnight. Then, water is added and the resulting mixture is extracted with ethyl acetate. The combined extracts are dried (Na2SO4) and the solvent is evaporated. The residue is purified by HPLC on reversed phase (water/acetonitrile). Yield: 100 mg (48% of theory) Mass spectrum (ESI+): m/z = 357 [M+H]+
Procedure E (described for Example 34, Table 3)
Figure imgf000176_0001
Piperidin-1 -yl-r(2R.6S)-6, 11.11 -trimethyl-10-phenoxy-1.2.5,6-tetrahydro-4H-2,6- methano-benzofdlazocin-3-yll-methanone Cu(OAc)2 (0.11 g) is added to a mixture of [(2R,6S)-10-hydroxy-6, 11 ,11 -trimethyl- 1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocin-3-yl]-piperidin-1-yl-methanone (0.20 g), phenylboronic acid (0.14 g), molecular sieves 4A (0.4 g), and pyridine (0.25 ml_) in dichloromethane (2 ml_). The resulting mixture is stirred in air at ambient temperature overnight. Then, the mixture is filtered through Celite and the filtrate is concentrated under reduced pressure. The residue is triturated with methanol to give after drying the pure title compound. Yield: 45 mg (18% of theory) Mass spectrum (ESI+): m/z = 419 [M+H]+
Procedure F (described for Example 35. Table 3)
Figure imgf000176_0002
(2R6S)-10-Hvdroxy-6.11.11 -trimethyl-3-(piperidine-1 -carbonyl)-1 ,2,3,4.5.6- hexahydro-2,6-methano-benzord1azocine-9-carbonitrile Boron trichloride (1 M in heptane, 3.5 ml_), thiocyanatomethane (0.24 ml_), and aluminum chloride (0.39 g) are added in succession to a solution of [(2R6S)-10- hydroxy-6,11 ,11-trimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocin-3-yl]- piperidin-1-yl-methanone (1.0 g) in dichloroethane (12 ml_) chilled in an ice bath. The resulting mixture is stirred at ambient temperature until a homogenous solution is formed and then heated to 80 0C. After stirring for 3 h, another portion of boron trichloride (1 M in heptane, 3.5 ml_), thiocyanatomethane (0.24 ml_), and aluminum chloride (0.39 g) are added and the mixture is further stirred at 80 0C for another 3 h. After cooling to room temperature, 4 M aqueous NaOH solution (9.5 mL) is added and the solution is stirred at 80 °C for 30 min. Then, the solution is cooled to room temperature and extracted with dichloromethane. The aqueous phase is acidified using 4 M hydrochloric acid mixture and extracted with ether. The combined organic extracts are dried (Na2SO4) and concentrated. The residue is purified by chromatography on silica gel (cyclohexane/ethyl acetate 1 :0->1 :1 ). Yield: 0.25 g (23% of theory) Mass spectrum (ESI+): m/z = 368 [M+H]+
Procedure G (described for Example 36. Table 3)
Figure imgf000177_0001
(2R6SV6.11.11-Trimethyl-3-(piperidine-1-carbonyl)-1.2.3,4.5,6-hexahvdro-2.6- methano-benzordlazocine-9-carbonitrile Polymethylhydrosiloxane (0.94 g) is added to a mixture of (2R,6S)-trifluoro-methane- sulfonic acid 9-cyano-6, 11 ,11-trimethyl-3-(piperidine-1-carbonyl)-1 , 2, 3,4,5,6- hexahydro-2,6-methano-benzo[d]azocin-10-yl ester (0.30 g), KF solution (71 mg in 1 mL water), and palladium(ll)acetate (7 mg) in tetrahydrofuran (3 mL) under argon atmosphere. The resulting mixture is stirred at room temperature overnight. Then, 4 M aqueous NaOH solution (5 mL) is added and the mixture is stirred for 4 h. The mixture is extracted with ethyl acetate, the combined extracts are dried (Na2SO4) and the solvent is evaporated. The residue is purified by HPLC on reversed phase
(water/acetonitrile).
Yield: 30 mg (14% of theory) Mass spectrum (ESI+): m/z = 352 [M+H]+ Procedure H (described for Example 46, Table 3)
Figure imgf000178_0001
(8-Hvdroxy-3.4-dihvdro-1 H-isoαuinolin-2-vn-r(2R6S)-10-hvdroxy-6,11.11-trimethyl- 1 ,2,5.6-tetrahvdro-4H-2,6-methano-benzo[d1azocin-3-yll-methanone Boron tribromide (1 M in CH2CI2, 0.22 mL) is added to a solution of [(2R,6S)-10- hydroxy-6,11 ,11-trimethyl-1 ,2,5,6-tetrahydro-4H-2,6-methano-benzo[d]azocin-3-yl)- (8-methoxy-3,4-dihydro-1 H-isoquinolin-2-yl]-methanone (42 mg) in CH2CI2 (4 mL) chilled in an ice bath. The cooling bath is removed and the resulting solution is stirred at ambient temperature overnight. Then, the solution is diluted with ice-cold water and the resulting mixture is extracted with CH2CI2. The combined organic extracts are dried (Na2SO4) and the solvent is evaporated. The residue is purified by HPLC on reversed phase (water/MeCN) to give the title compound as a solid. Yield: 40 mg (99% of theory) Mass spectrum (ESI+): m/z = 407 [IvHH]+
Procedure I (described for Example 66, Table 3)
Figure imgf000178_0002
[(ffl-3-(1 -Hvdroxy-1 -methyl-ethyl)-piperidin-1 -ylH(2R6S)-6.11.11 -trimethyl-1.2,5,6- tetrahvdro-4H-2,6-methano-benzo[dlazocin-3-yll-methanone 1.4 M MeMgBr solution in tetrahydrofuran and toluene (0.65 mL) is added dropwise to a solution of (R)-1-[(2R,6S)-6,11 ,11-trimethyl-1 ,2,5,6-tetrahydro-4H-2>6-methano- benzo[d]azocine-3-carbonyl]-piperidine-3-carboxylic acid ethyl ester (120 mg) in tetrahydrofuran (2 mL) chilled in an ice bath. The resulting solution is stirred in the cooling bath for 2 h before the reaction is quenched by the addition of aqueous NH4CI solution. The resulting mixture is extracted with tert-BuOMe and the combined organic extracts are dried (Na2SO4). The solvent is evaporated to give the title compound.
Yield: 115 mg (quantitative) Mass spectrum (ESI+): m/z = 385 [M+H]+
Procedure J (described for Example 71. Table 3)
Figure imgf000179_0001
[(R)-3-Hvdroxymethyl-piperidin-1-yll-f(2R6S)-6.11.11-trimethyl-1.2.5.6-tetrahvdro-
4H-2,6-methano-benzofdlazocin-3-yl)-methanone LiAIH4 (1 M in Et2O, 0.25 ml_) is added to a solution of (R)-1-[(2R,6S)-6,11 ,11- trimethyl-I ^.S.Θ-tetrahydro^H^.Θ-methano-benzoIdlazocine-S-carbonylj-piperidine-
3-carboxylic acid ethyl ester (90 mg) in tetrahydrofuran (3 ml_) chilled in an ice bath.
The cooling bath is removed and the resulting mixture is stirred at ambient temperature overnight. Then, water is added and the mixture is extracted with tert- BuOMe. The combined organic extracts are washed with brine and dried (Na2SO4).
The solvent is evaporated to give the title compound as an oil.
Yield: 80 mg (ca. 90% pure)
Mass spectrum (ESI+): m/z = 357 [M+H]+
Procedure K (described for Example 79. Table 3)
Figure imgf000179_0002
(exo-S-Hvdroxy-δ-aza-bicvclorS^.iloct-δ-vn-^ReSVe.11.11 -trimethyl-1.2,5.6- tetrahvdro-4H-2,6-methano-benzofdlazocin-3-yll-methanone
NaBH4 (35 mg) dissolved in methanol (1 ml_) is added to a solution of 8-[(2R,6S)- 6,11 ,11-trimethyl-1 ^.δ.θ-tetrahydro^H^.Θ-methano-benzotdJazocine-S-carbonylJ-δ- aza-bicyclo[3.2.1]octan-3-one (90 mg) in tetrahydrofuran (3 ml_) and methanol (1 ml_). The resulting mixture is stirred at ambient temperature for 2 h and then concentrated under reduced pressure. The residue is purified by HPLC on reversed phase (water/MeCN) to give the title compound and the corresponding diastereomer,
(enofo-3-hydroxy-8-aza-bicyclo[3.2.1]oct-8-yl)-[(2RI6S)-6>11 ,11-trimethyl-1 ,2,5,6- tetrahydro-4H-2,6-methano-benzo[d]azocin-3-yl]-methanone (86 mg, 29% of theory), in separate fractions.
Yield: 128 mg (42% of theory)
Mass spectrum (ESI+): m/z = 369 [M+H]+
Table 3. End compounds
Figure imgf000180_0001
Figure imgf000181_0001
Figure imgf000182_0001
Figure imgf000183_0001
Figure imgf000184_0001
Figure imgf000185_0001
Figure imgf000186_0001
Figure imgf000187_0001
Figure imgf000188_0001
Figure imgf000189_0001
Figure imgf000190_0001
Figure imgf000191_0001
Figure imgf000192_0001
Figure imgf000193_0001
Figure imgf000194_0001
Figure imgf000195_0001
Figure imgf000196_0001
Figure imgf000197_0001
Figure imgf000198_0001
Figure imgf000199_0001
The following compounds are also prepared analogously to the above-mentioned Examples from the respective polycyclic scaffold, preparation of each is described in the section "Preparation of the starting compounds", and piperidine-1-carbonyl chloride or a derivative thereof:
Figure imgf000199_0002
Figure imgf000200_0001
Figure imgf000201_0001
Figure imgf000202_0001
Figure imgf000203_0001
Figure imgf000204_0001
Figure imgf000204_0002
Figure imgf000205_0001
Figure imgf000206_0001
Figure imgf000207_0001
Figure imgf000208_0001
Figure imgf000209_0001
Figure imgf000210_0001
Figure imgf000211_0001
Figure imgf000212_0001
Figure imgf000213_0001
Figure imgf000214_0001
Figure imgf000215_0001
Figure imgf000216_0001
Figure imgf000217_0001
Figure imgf000218_0001
Figure imgf000219_0001
Figure imgf000220_0001
Some examples of formulations will now be described in which the term "active substance" denotes one or more compounds according to the invention, including the salts thereof. In the case of one of the combinations with one or additional active substances as described previously, the term "active substance" also includes the additional active substances.
Example A
Tablets containing 100 mq of active substance
Composition:
1 tablet contains: active substance 100.0 mg lactose 80.0 mg corn starch 34.0 mg polyvinylpyrrolidone 4.0 mg magnesium stearate 2.0 mg
220.0 mg Method of Preparation:
The active substance, lactose and starch are mixed together and uniformly moistened with an aqueous solution of the polyvinylpyrrolidone. After the moist composition has been screened (2.0 mm mesh size) and dried in a rack-type drier at 500C it is screened again (1.5 mm mesh size) and the lubricant is added. The finished mixture is compressed to form tablets.
Weight of tablet: 220 mg
Diameter: 10 mm, biplanar, facetted on both sides and notched on one side.
Example B
Tablets containing 150 mq of active substance Composition: 1 tablet contains: active substance 150.0 mg powdered lactose 89.0 mg corn starch 40.0 mg colloidal silica 10.0 mg polyvinylpyrrolidone 10.0 mg magnesium stearate 1.0 mg
300.0 mg
Preparation:
The active substance mixed with lactose, corn starch and silica is moistened with a 20% aqueous polyvinylpyrrolidone solution and passed through a screen with a mesh size of 1.5 mm. The granules, dried at 45°C, are passed through the same screen again and mixed with the specified amount of magnesium stearate. Tablets are pressed from the mixture.
Weight of tablet: 300 mg die: 10 mm, flat
Example C
Hard gelatine capsules containing 150 mq of active substance
Composition: 1 capsule contains: active substance 150.0 mg corn starch (dried) approx. 180.0 mg lactose (powdered) approx. 87.0 mg magnesium stearate 3.0 mg approx. 420.0 mg
Preparation:
The active substance is mixed with the excipients, passed through a screen with a mesh size of 0.75 mm and homogeneously mixed using a suitable apparatus. The finished mixture is packed into size 1 hard gelatine capsules.
Capsule filling: approx. 320 mg
Capsule shell: size 1 hard gelatine capsule.
Example D
Suppositories containing 150 mg of active substance Composition: 1 suppository contains: active substance 150.0 mg polyethyleneglycol 1500 550.0 mg polyethyleneglycol 6000 460.0 mg polyoxyethylene sorbitan monostearate 840.0 mg
2,000.0 mg
Preparation:
After the suppository mass has been melted the active substance is homogeneously distributed therein and the melt is poured into chilled moulds.
Example E Ampoules containing 10 mg active substance Composition: active substance 10.0 mg
0.01 N hydrochloric acid q.s. double-distilled water ad 2.0 mL Preparation:
The active substance is dissolved in the necessary amount of 0.01 N HCI, made isotonic with common salt, filtered sterile and transferred into 2 mL ampoules.
Example F
Ampoules containing 50 mq of active substance
Composition: active substance 50.0 mg 0.01 N hydrochloric acid q.s. double-distilled water ad 10.O mL
Preparation:
The active substance is dissolved in the necessary amount of 0.01 N HCI, made isotonic with common salt, filtered sterile and transferred into 10 mL ampoules.

Claims

Claims
1. Compounds of formula I
Figure imgf000224_0001
wherein
X denotes CH or N,
m, n, o independently of each other denote 0, 1 or 2,
wherein the C5+m+n-azacycloalkene core structure of the general formula I including the bridging group -(CH2)0- is optionally substituted with 1 , 2 or more substituents independently of each other selected from the group consisting of R11 and R12,
A denotes a benzo, pyrido, pyrrolo, furo, thieno, pyridazino, pyrimido, or pyrazino ring wherein each of said rings is optionally substituted with one or more substituents independently of each other selected from R1, and wherein 2 adjacent C-atoms of each of said rings are optionally substituted with R2 and R3; or
a pyrazolo, imidazo, oxazolo, thiazolo, isoxazolo, or isothiazolo ring wherein each of said rings is optionally substituted with R1; or
a 1 ,2,3-triazolo ring optionally substituted with R N. ; and
B denotes a 3- to 8-membered monocylic, 7- to 12-membered spirocyclic, 6- to 12-membered bicyclic or 9- to 15-membered tricyclic azacycloalk-1-yl group, which is saturated or partially or fully unsaturated, wherein 1 or 2 -CH2- groups may be replaced by -NRN-, wherein 1 to 4 -CH2- groups may be replaced independently of each other by
O1 S, carbonyl, or sulfonyl, wherein 1 or 2 -CH= groups may be replaced by -N=, and wherein said azacycloalkyl group may be substituted with one or more substituents independently of each other selected from L1, wherein said azacycloalkyl group may be substituted with 1 or 2 substituents independently of each other selected from L2, wherein 2 adjacent C-atoms of said azacycloalkyl group may be substituted with L3 and L4, and wherein 2 adjacent C-atoms of said azacycloalkyl group may be substituted with L5 and L6;
RN independently of each other denotes hydrogen, d-6-alkyl, C3_6-alkenyl, C3-6- alkynyl, (het)aryl, Ci-4-alkylcarbonyl, Ci-4-alkylsulfonyl, (het)arylcarbonyl, (het)arylsulfonyl,
wherein each alkyl, alkenyl, and alkynyl group may be mono- or polysubstituted with fluorine, and may be monosubstitued with hydroxy, Ci-4-alkoxy, C-ι-4-alkylsulfanyl, Ci-4-alkylsulfinyl, C-ι-4-alkylsulfonyl, amino, Ci-4-alkylamino, di-(Ci-4-alkyl)amino, d-4-alkylcarbonylamino, cyano, carboxy, C-ι-4-alkoxycarbonyl, aminocarbonyl, Ci-4-alkylaminocarbonyl, di- (Ci-4-alkyl)aminocarbonyl, or (het)aryl,
R1 independently of each other denotes fluorine, chlorine, bromine, iodine, cyano, nitro, C-M-alkyl, hydroxy, Ci-4-alkyloxy, difluoromethyl, trifluoromethyl, difluoromethoxy, trifluoromethoxy, trifluoromethyl-hydroxy-Ci-2-alkyl, 2,2,2- trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl, C3-6-cycloalkyl, C3-6-cycloalkyloxy, C3-6-cycloalkyl-Ci-3-alkyl, Cs-β-cycloalkyl-C-i-s-alkyloxy, tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy, tetrahydrofuranyl-C-ι-3- alkyloxy, tetrahydropyranyl-d-3-alkyloxy, (het)aryl, (het)aryloxy, (het)aryl-Ci-3- alkyl, (het)aryl-Ci-3-alkyloxy, (het)aryloxy-Ci-3-alkyl, Ci-3-alkyl-carbonyl, (het)aryl-carbonyl, amino, C-M-alkylamino, di-(Ci-4-alkyl)amino, pyrrolidin-1 -yl, 2-oxo-pyrrolidin-1 - yl, piperidin-1 -yl, 2-oxo-piperidin-i -yl, morpholin-4-yl, 3-oxo-morpholin-4-yl, piperazin-1 -yl, 2-oxo-piperazin-1 -yl, 3-oxo-piperazin-i-yl, 4-(Ci-4-alkyl)-pi- perazin-1 -yl, 4-(Ci-4-alkylcarbonyl)-piperazin-1-yl, 4-(C3-6-cycloalkylcarbonyl)- piperazin-1 -yl, 4-(Ci-4-alkyloxycarbonyl)-piperazin-1 -yl, 4-(Ci-4-alkylsulfonyl)- piperazin-1-yl, 2-oxo-4-(Ci_4-alkyl)-piperazin-1-yl, 3-oxo-4-(Ci-4-alkyl)-pi- perazin-1 -yl,
Ci-4-alkyl-carbonylamino, (het)aryl-carbonylamino, (het)aryl-Ci-4-alkyl-carbo- nylamino, Ci-4-alkyloxy-carbonylamino, aminocarbonylamino, Ci-4-alkyl-amino- carbonylamino, di-(Ci-4-alkyl)aminocarbonylamino, pyrrolidin-1 -yl-carbonyl- amino, pipehdin-1 -yl-carbonylamino, morpholin-4-yl-carbonylamino, piperazin- 1 -yl-carbonylamino, 4-(Ci-4-alkyl)-piperazin-1-yl-carbonylamino, Ci-4-alkyl-sul- fonylamino, aminosulfonylamino, Ci-4-alkylamino-sulfonylamino, di-(Ci-4-alkyl)- amino-sulfonylamino, pyrrolidin-1-yl-sulfonylamino, piperidin-1-yl-sulfonylami- no, morpholin-4-yl-sulfonylamino, piperazin-1-yl-sulfonylamino, 4-(Ci-4-alkyl)- piperazin-1 -yl-sulfonylamino, (Ci^-alkyloxy-carbonylaminojcarbonylamino, (het)arylsulfonylamino, (het)aryl-Ci-4-alkyl-sulfonylamino,
N-CCi^-alkyO-Ci^-alkyl-carbonylamino, N-(Ci-4-alkyl)-(het)arylcarbonylamino,
N-(Ci-4-alkyl)-(het)aryl-Ci-4-alkyl-carbonylamino, N-(Ci-4-alkyl)-Ci-4-alkyloxy- carbonylamino, N-(aminocarbonyl)-Ci-4-alkylamino, N-(Ci-4-alkyl-amino- carbonyl)-Ci-4-alkylamino, N-[di-(Ci-4-alkyl)aminocarbonyl]-Ci-4-alkylamino,
N-(Ci-4-alkyl)-Ci-4-alkyl-sulfonylamino, N-(Ci-4-alkyl)-(het)arylsulfonylamino,
N-(Ci-4-alkyl)-(het)aryl-Ci-4-alkyl-sulfonylamino,
oxo-imidazolidin-1 -yl, 2,4-dioxo-imidazolidin-1-yl, 2,5-dioxo-imidazolidin-1 -yl, 2-oxo-hexahydropyrimidin-i-yl, wherein the nitrogen atom in position 3 of the aforementioned groups is optionally substituted with methyl or ethyl,
(hydroxyimino)aminomethyl, (Ci-3-alkyloxyimino)aminomethyl, carboxy, Ci-4- alkyloxy-carbonyl, aminocarbonyl, Ci-4-alkyl-aminocarbonyl, di-(Ci-4-alkyl)- aminocarbonyl, pyrrolidin-1 -yl-carbonyl, piperidin-1-yl-carbonyl, morpholin-4-yl- carbonyl, piperazin-1 -yl-carbonyl, 4-(Ci-4-alkyl)-piperazin-1-yl-carbonyl,
carboxy-Ci-4-alkyl, C-M-alkyloxy-carbonyl-C-M-alkyl, cyano-Ci-4-alkyl, aminocarbonyl-C-M-alkyl, Ci^-alkyl-aminocarbonyl-Ci^-alkyl, di-(Ci-4-alkyl)- aminocarbonyl-Ci-4-alkyl, pyrrolidin-i-yl-carbonyl-Ci-4-alkyl, piperidin-1-yl- carbonyl-C1-4-alkyl, morpholin-4-yl-carbonyl-Ci-4-alkyl, piperazin-1 -yl-carbonyl- C-ι-4-alkyl, 4-(Ci-4-alkyl)-piperazin-1-yl-carbonyl-Ci-4-alkyl,
carboxy-Ci-4-alkyloxy, C-M-alkyloxy-carbonyl-C-M-alkyloxy, cyano-C-M-alkyl- oxy, aminocarbonyl-Ci-4-alkyloxy, C-M-alkyl-aminocarbonyl-d^-alkyloxy, di- (Ci^-alkyO-aminocarbonyl-C-i^-alkyloxy, pyrrolidin-i-yl-carbonyl-C-i^-alkyl-oxy, piperidin-1 -yl-carbonyl-Ci-4-alkyloxy, morpholin^-yl-carbonyl-C-M-alkyl-oxy, piperazin-1 -yl-carbonyl-Ci-4-alkyloxy, 4-(Ci-4-alkyl)-piperazin-1-yl-carbonyl- Ci-4-alkyloxy,
hydroxy-C1-4-alkyl, Ci-4-alkyloxy-Ci-4-alkyl, amino-Ci-4-alkyl, Ci-4-alkylamino- Ci-4-alkyl, di-(Ci-4-alkyl)-amino-Ci-4-alkyl, pyrrolidin-1-yl-Ci-4-alkyl, Ci-4-alkyl- carbonyl-amino-Ci-4-alkyl, N-(Ci-4-alkyl)-Ci-4-alkylcarbonyl-amino-Ci-4-alkyl, 2-oxo-pyrrolidin-1-yl-Ci-4-alkyl, piperidin-1-yl-Ci-4-alkyl, 2-oxo-piperidin-1-yl-
Ci-4-alkyl, morpholin-4-yl-Ci-4-alkyl, 3-oxo-morpholin-4-yl-Ci-4-alkyl, piperazin- 1 -yl-Ci-4-alkyl, 2-oxo-piperazin-1 -yl-Ci-4-alkyl, 3-oxo-piperazin-1 -yl-Ci-4-alkyl, 4-(Ci-4-alkyl)-piperazin-1-yl-Ci-4-alkyl, 2-oxo-4-(C1-4-alkyl)-piperazin-1-yl-Ci-4- alkyl, 3-oxo-4-(Ci-4-alkyl)-piperazin-1 -yl-Ci-4-alkyl,
hydroxy-C1-4-alkyloxy, Ci^-alkyloxy-Ci^-alkyloxy, Ci-4-alkylsulfanyl-Ci-4-alkyl- oxy, Ci^-alkylsulfinyl-Ci^-alkyloxy, Ci^-alkylsulfonyl-Ci^-alkyloxy, amino-Ci-4- alkyloxy,
Figure imgf000227_0001
di-(Ci-4-alkyl)-amino-C1-4-alkyloxy, pyrrolidin-1 -yl-Ci-4-alkyloxy, 2-oxo-pyrrolidin-1 -yl-Ci-4-alkyloxy, piperidin-1 -yl- C-ι-4-alkyloxy, 2-oxo-piperidin-1-yl-Ci-4-alkyloxy, morpholin-4-yl-Ci-4-alkyloxy, 3- oxo-morpholin-4-yl-Ci-4-alkyloxy, piperazin-1 -yl-Ci-4-alkyloxy, 2-oxo-piperazin- 1 -yl-Ci-4-alkyloxy, 3-oxo-piperazin-1 -yl-Ci-4-alkyloxy, 4-(Ci-4-alkyl)-piperazin-1 - yl-d-4-alkyloxy, 2-oxo-4-(Ci-4-alkyl)-piperazin-1 -yl-Ci-4-alkyloxy, 3-oxo-4-(C1-4- alkyl)-piperazin-1-yl-Ci-4-alkyloxy, Ci-4-alkylsu!fanyl, C-M-alkysulfinyl, C-M-alkylsulfonyl, Ci-4-alkylsulfonyloxy, (het)arylsulfonyl, (het)arylsulfonyloxy, trifluoromethylsulfanyl, trifluoromethyl- sulfinyl, trifluoromethylsulfonyl, Ca-θ-cycloalkylsulfanyl, Cs-β-cycloalkylsulfinyt, Cs-e-cycloalkylsulfonyl, Ca-β-cycloalkyl-Ci-a-alkylsulfanyl, C3.6-cycloalkyl-C1.3- alkylsulfinyl, Cs-e-cycloalkyl-d-s-alkylsulfonyl,
aminosulfonyl, d-4-alkyl-aminosulfonyl, di-(Ci_4-alkyl)-aminosulfonyl, pyrroli- din-1 -yl-sulfonyl, piperidin-1 -yl-sulfonyl, morpholin-4-yl-sulfonyl, piperazin-1-yl- sulfonyl, or 4-(Ci-4-alkyl)-piperazin-1 -yl-sulfonyl,
wherein the above-mentioned saturated heterocycles and cycloalkyl-rings are optionally substituted with one or two groups independently of each other selected from fluorine, Ci-3-alkyl, C-ι-3-alkoxy, C-i-s-alkoxy-C-i-s-alkyl, or hydroxy,
R2, R3 are linked to each other to form a methylenedioxy, ethylenedioxy or C3-5- alkylene bridging group, which may be mono- or disubstituted with methyl, and which may be mono- or polyfluorinated; or
R2, R3 form combined with the carbon atoms to which they are attached a benzo, pyrido, pyrimido, pyrazino, pyridazino, pyrrolo, furano, thieno, pyrazolo, imidazo, triazolo, oxazolo, thiazolo, isoxazolo, or isothiazolo ring, wherein each of said rings may be substituted with one or more substituents independently of each other selected from Rp;
Rp denotes halogen, d-6-alkyl, hydroxy-Ci-4-alkyl, d-3-alkyloxy-d-3-alkyl, C3-6- cycloalkyl, hydroxy-d-6-cycloalkyl, d-s-alkyloxy-Cs-e-cycloalkyl, azetidinyl, 1 - (Ci-3-alkyl)-azetidinyl, 1 -(C-i-3-alkylcarbonyl)-azetidinyl, pyrrolidinyl, 1 -(Ci-3- alkyl)-pyrrolidinyl, 1-(Ci-3-alkylcarbonyl)-pyrrolidinyl, piperidinyl, 1 -(Ci-3-alkyl)- piperidinyl, 1-(Ci-3-alkylcarbonyl)piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, difluoromethyl, trifluoromethyl, cyano, nitro, amino, Ci-3- alkylamino, di-(Ci-3-alkyl)amino, d-3-alkylcarbonylamino, methylsulfonylamino, carboxy, Ci-4-alkyloxycarbonyl, aminocarbonyl, Ci-3-alkylaminocarbonyl, di-(d-3-alkyl)-aminocarbonyl, aminosulfonyl, methylsulfanyl, methylsulfinyl, methylsulfonyl, hydroxy, Ci-3-alkyloxy, difluoromethoxy, trifluoromethoxy, phenyl, or
pyrrolyl, furanyl, thienyl, pyridyl, where in any of these groups 1 or 2 CH are optionally replaced by N atoms, or
1 ,2-dihydro-2-oxo-pyridinyl, 1 ,4-dihydro-4-oxo-pyridinyl, 2,3-dihydro-3-oxo- pyridazinyl, 1 ,2,3,6-tetrahydro-3,6-dioxo-pyridazinyl, 1 ,2-dihydro-2-oxo-pyrimi- dinyl, 3,4-dihydro-4-oxo-pyrimidinyl, 1 ,2,3,4-tetrahydro-2,4-dioxo-pyrimidinyl, 1 ,2-dihydro-2-oxo-pyrazinyl,
wherein each of the aromatic or heteroaromatic groups mentioned above is optionally substituted with one or two groups independently selected from fluorine, chlorine, d-3-alkyl, difluoromethyl, trifluoromethyl, cyano, amino, acetylamino, methylsulfonylamino, carboxy, d-4-alkyloxycarbonyl, aminocar- bonyl,
Figure imgf000229_0001
di-(Ci-3-alkyl)-aminocarbonyl, hydroxy, d-3- alkyloxy, difluoromethoxy, and trifluoromethoxy,
R10 independently of each other denotes halogen, d-3-alkyl, difluoromethyl, trifluoromethyl, cyano, nitro, amino, Ci-3-alkylamino, di-(Ci-3-alkyl)amino, acetylamino, methylsulfonylamino, carboxy, d-4-alkyloxycarbonyl, aminocar- bonyl, Ci-3-alkylaminocarbonyl, di-(Ci-3-alkyl)-aminocarbonyl, aminosulfonyl, methylsulfanyl, methylsulfinyl, methylsulfonyl, hydroxy, C-ι-3-alkyloxy, difluoromethoxy, trifluoromethoxy, or phenyl optionally substituted with 1 or 2 substituents independently of each other selected from fluorine, methyl, methoxy, cyano, or hydroxy,
R11 independently of each other denotes fluorine, d-4-alkyl, (het)aryl, hydroxy, Ci- 4-alkyloxy, cyano, carboxy, Ci-4-alkyloxycarbonyl, aminocarbonyl, d-4-alkylamino-carbonyl, di-(Ci-4-alkyl)-aminocarbonyl, hydroxy-Ci-4-alkyl, or
Ci.3-alkyloxy-d-4-alkyl,
R12 independently of each other denotes fluorine or d-4-alkyl, and L1 independently of each other denotes halogen, d-4-alkyl, trifluoromethyl, hydroxy, C-^-alkyloxy, or cyano;
L2 independently of each other denotes fluorine, chlorine, bromine, iodine, nitro, cyano, hydroxy, C3-6-cycloalkyl, Cs-β-cycloalkyloxy, tetrahydrofuran-3-yl-oxy, tetrahydropyran-3-yl-oxy, tetrahydropyran-4-yl-oxy, tetrahydrofuranyl-Ci-3- alkyloxy, tetrahydropyranyl-d-3-alkyloxy, (het)aryl, (het)aryloxy, or
C-ι-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C-ι-4-alkyloxy, wherein in each group one CH2 group may be replaced by carbonyl or sulfonyl, and wherein each group may be mono or polyfluorinated, and wherein each group may additionally be substituted with
hydroxy, chlorine, d-3-alkyloxy, amino, Ci-3-alkylamino, di-(Ci-3-alkyl)- amino, pyrrolidin-1-yl, 2-oxo-pyrrolidin-1-yl, piperidin-1-yl, 2-oxo- piperidin-1-yl, morpholin-4-yl, 3-oxo-morpholin-4-yl, piperazin-1-yl, 2- oxo-piperazin-1-yl, 3-oxo-piperazin-1-yl, 4-(Ci-3-alkyl)-piperazin-1-yl, 2- oxo-4-(Ci-3-alkyl)-piperazin-1-yl, 3-oxo-4-(Ci-3-alkyl)-piperazin-1-yl, carboxy, d-3-alkyloxy-carbonyl, cyano, aminocarbonyl, Ci-3-alkyl- aminocarbonyl, di-(Ci-3-alkyl)-aminocarbonyl, pyrrolidin-1-yl-carbonyl, pipehdin-1 -yl-carbonyl, morpholin-4-yl-carbonyl, piperazin-1 -yl-carbonyl, 4-(Ci-3-alkyl)-piperazin-1-yl-carbonyl, Ci-3-alkylcarbonylamino, arylcarbonylamino, Ci-3-alkylsulfanyl, d-3-alkylsulfinyl, Ci-3- alkylsulfonyl, C3-6-cycloalkyl, (het)aryl, or (het)aryloxy;
amino, d-3-alkylamino, di-(d-3-alkyl)amino, pyrrolidin-1-yl, 2-oxo-pyrrolidin-1- yl, piperidin-1-yl, 2-oxo-piperidin-1-yl, morpholin-4-yl, 3-oxo-morpholin-4-yl, piperazin-1-yl, 2-oxo-piperazin-1-yl, 3-oxo-piperazin-1-yl, 4-(Ci-3-alkyl)- piperazin-1 -yl, 4-(Ci-4-alkylcarbonyl)-piperazin-1 -yl, 4-(C3-6-cycloalkylcarbonyl)- piperazin-1-yl, 4-(Ci-4-alkyloxycarbonyl)-piperazin-1-yl, 4-(Ci-4-alkylsulfonyl)- piperazin-1-yl, 2-oxo-4-(Ci-3-alkyl)-piperazin-1-yl, 3-oxo-4-(Ci-3-alkyl)- piperazin-1-yl, Ci-4-alkyl-carbonylamino, (het)aryl-carbonylamino, (het)aryl-Ci-3-alkyl-carbo- nylamino,
Figure imgf000231_0001
aminocarbonylamino, Ci-3-alkyl-amino- carbonylamino, di-(Ci-3-alkyl)aminocarbonylamino, pyrrolidin-1 -yl-carbonyl- amino, piperidin-1 -yl-carbonylamino, morpholin-4-yl-carbonylamino, piperazin- 1-yl-carbonylamino, 4-(Ci-3-alkyl)-piperazin-1-yl-carbonylamino, d-3-alkyl- sulfonylamino, aminosulfonylamino, Ci-3-alkylamino-sulfonylamino, di-(Ci-3- alkyl)amino-sulfonylamino, pyrrolidin-1 -yl-sulfonylamino, piperidin-1 -yl- sulfonylamino, morpholin-4-yl-sulfonylamino, piperazin-1 -yl-sulfonylamino, 4- (Ci-3-alkyl)-piperazin-1 -yl-sulfonylamino, (Ci-3-alkyloxy-carbonylamino)car- bonylamino, (het)arylsulfonylamino, (het)aryl-Ci-3-alkyl-sulfonylamino,
N-(Ci-3-alkyl)-Ci.3-alkyl-carbonylamino, N-(Ci-3-alkyl)-(het)arylcarbonylamino, N-(Ci-3-alkyl)-(het)aryl-Ci-3-alkyl-carbonylamino, N-(C1-3-alkyl)-Ci-3-alkyloxy- carbonylamino, N-(aminocarbonyl)-Ci-3-alkylamino, N-(Ci_3-alkyl-amino- carbonyl)-Ci-3-alkylamino, N-[di-(Ci-3-alkyl)aminocarbonyl]-Ci-3-alkylamino,
N-(Ci-3-alkyl)-Ci.3-alkyl-sulfonylamino, N-(Ci-3-alkyl)-(het)arylsulfonylamino, N-(Ci-3-alkyl)-(het)aryl-Ci.3-alkyl-sulfonylamino,
carboxy, Ci-3-alkyloxy-carbonyl, aminocarbonyl, Ci-3-alkyl-aminocarbonyl, di-
(Ci-3-alkyl)-aminocarbonyl, pyrrolidin-1 -yl-carbonyl, piperidin-1 -yl-carbonyl, morpholin-4-yl-carbonyl, piperazin-1 -yl-carbonyl, 4-(Ci.3-alkyl)-piperazin-1-yl- carbonyl, (het)arylaminocarbonyl, N-(Ci-3-alkyl)-(het)arylaminocarbonyl, (hetJaryl-Ci-s-alkylaminocarbonyl, N-(Ci-3-alkyl)-(het)aryl-Ci-3- alkylaminocarbonyl,
Ci-3-alkylsulfanyl, Ci-3-alkysulfinyl, (het)arylsulfonyl, trifluoromethylsulfanyl, trifluoromethylsulfinyl,
aminosulfonyl, Ci-3-alkyl-aminosulfonyl, di-(Ci-3-alkyl)-aminosulfonyl, pyrrolidin-1 -yl-sulfonyl, piperidin-1 -yl-sulfonyl, morpholin-4-yl-sulfonyl, piperazin-1 -yl- sulfonyl, 4-(Ci-3-alkyl)-piperazin-1 -yl-sulfonyl, wherein the above-mentioned saturated heterocyclic- and cycloalkyl-rings are optionally substituted with one or two groups selected from fluorine, Ci-3-alkyl, Cva-alkoxy, C-i-a-alkoxy-Ci-s-alkyl, or hydroxy, and
L3 and L4 are linked to each other, and
L5 and L6 are linked to each other, such that independently of each other and in each case together with the 2 adjacent C-atoms to which they are attached an aryl- or heteroaryl-group is formed which is fused to the cyclic group B, and which aryl- or heteroaryl-group is optionally substituted with 1 , 2 or 3 identical or different R10,
while by aryl is meant phenyl or naphthtyl and by heteroaryl is meant pyrrolyl, furanyl, thienyl, pyridyl, indolyl, benzofuranyl, benzothiophenyl, quinolinyl, isoquinolinyl, or pyrrolyl, furanyl, thienyl, pyridyl wherein in said pyrrolyl, furanyl, thienyl, pyridyl 1 or 2 CH groups are each replaced by N, or indolyl, benzofuranyl, benzothiophenyl, quinolinyl, isoquinolinyl wherein in said indolyl, benzofuranyl, benzothiophenyl, quinolinyl, isoquinolinyl 1 to 3 CH groups are each replaced by N, or tetrazolyl,
while the above-mentioned (het)aryl is an aryl group as defined hereinbefore, or a heteroaryl group as defined hereinbefore, or a ring selected from the group consisting of 1 ,2-dihydro-2-oxo-pyridinyl, 1 ,4-dihydro-4-oxo-pyridinyl, 2,3-dihydro-3- oxo-pyridazinyl, 1 ,2,3,6-tetrahydro-3,6-dioxo-pyridazinyl, 1 ,2-dihydro-2-oxo-pyrimi- dinyl, 3,4-dihydro-4-oxo-pyrimidinyl, 1 ,2,3,4-tetrahydro-2,4-dioxo-pyrimidinyl, 1 ,2- dihydro-2-oxo-pyrazinyl, 1 ,2,3,4-tetrahydro-2,3-dioxo-pyrazinyl, 2,3-dihydro-2-oxo- indolyl, 2,3-dihydrobenzofuranyl, 2,3-dihydro-2-oxo-1 /-/-benzimidazolyl, 2,3-dihydro- 2-oxo-benzoxazolyl, 1 ,2-dihydro-2-oxo-quinolinyl, 1 ,4-dihydro-4-oxo-quinolinyl, 1 ,2- dihydro-1-oxo-isoquinolinyl, 1 ,4-dihydro-4-oxo-cinnolinyl, 1 ,2-dihydro-2-oxo- quinazolinyl, 1 ,4-dihydro-4-oxo-quinazolinyl, 1 ,2,3,4-tetrahydro-2,4-dioxo- quinazolinyl, 1 ,2-dihydro-2-oxoquinoxalinyl, 1 ,2,3,4-tetrahydro-3-oxo-quinoxalinyl, 1 ,2,3,4-tetrahydro-2,3-dioxo-quinoxalinyl, 1 ,2-dihydro-1 -oxo-phthalazinyl, 1 ,2,3,4- tetrahydro-1 ,4-dioxo-phthalazinyl, chromanyl, coumarinyl, 2,3-dihydro- benzo[1 ,4]dioxinyl and 3,4-dihydro-3-oxo-2H-benzo[1 ,4]oxazinyl, wherein each of said rings is optionally substituted with 1 , 2 or 3 substituents independently of each other selected from R10, whilst each of the above-mentioned alkyl or alkylene moieties may be branched or unbranched,
the tautomers, the stereoisomers thereof, the mixtures thereof, and the salts thereof,
while the following compounds (M1 ) to (M4) are excluded,
Figure imgf000233_0001
2. Compounds according to claim 1 , characterized by a general formula selected from one or more of the formulae 1.1 to 1.10
Figure imgf000233_0002
I.2
Figure imgf000233_0003
Figure imgf000234_0001
Figure imgf000234_0002
Figure imgf000234_0003
Figure imgf000234_0004
Figure imgf000234_0005
1.8
Figure imgf000234_0006
Figure imgf000235_0001
Figure imgf000235_0002
wherein the Cs+m+n-azacycloalkene core structure of general formulae 1.1 to 1.10 including the bridging group -(CH2)0- is optionally substituted with 1 , 2 or more substituents independently of each other selected from the group consisting of R11 and R12, and
wherein the rings A and B and m, n, o, R11, R12 are defined as in claim 1 , their tautomers, their stereoisomers, mixtures thereof and the salts thereof, while the compounds (M1 ), (M2), (M3) and (M4) as defined in claim 1 , are excluded.
3. Compounds according to claim 1 or 2, wherein the nitrogen containing ring B denotes azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, azocan-1-yl,
azetidin-1-yl, wherein one -CH2- group is replaced by O, S, NRN, carbonyl, or sulfonyl, or
pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, azocan-1-yl, which may be partially or fully unsaturated and wherein one or two -CH2- groups are independently of each other replaced by O, S, carbonyl, or sulfonyl, and wherein one -CH2- group may be replaced by -NRN-,
aza-bicyclohept-N-yl, aza-bicyclooct-N-yl, aza-bicyclonon-N-yl, aza-bicyclodec-N-yl, bicycloundec-N-yl, bicyclododec-N-yl, each of which may be partially unsaturated, and in each of which one or two -CH2- groups may be replaced independently of each other by O, S, -NRN-, carbonyl, or sulfonyl, and in each of which one -CH= group may be replaced by -N=,
aza-tricyclonon-N-yl, aza-tricyclodec-N-yl, aza-tricycloundec-N-yl, aza-tricyclododec- N-yl, aza-tricyclotridec-N-yl, aza-tricyclotetradec-N-yl, in each of which one or two -CH2- groups may be replaced independently of each other by O, S1 NRN, carbonyl, or sulfonyl, and in each of which one -CH= group may be replaced by -N=,
wherein each of the above rings B may be substituted with one or more substituents independently of each other selected from L1, wherein each of the above rings B may be substituted with 1 or 2 substituents independently of each other selected from L2, wherein 2 adjacent C-atoms of each of the above rings B may be substituted with L3 and L4, and wherein 2 adjacent C-atoms of each of the above rings B may be substituted with L5 and L6; wherein RN, L1, L2, L3, L4, L5, L6 are defined as in claim 1.
4. Compounds according to claim 1 , 2 or 3, wherein the ring A denotes a benzo, pyrido, pyrrolo, furo, thieno, pyridazino, pyrimido, or pyrazino ring wherein each of said rings is optionally substituted with one or more substituents independently of each other selected from R1, and wherein 2 adjacent C-atoms of each of said rings are optionally substituted with R2 and R3; or a pyrazolo, oxazolo, thiazolo, or imidazo ring each of which is optionally substituted with R1; wherein R1, R2 and R3 are defined as in claim 1.
5. Physiologically acceptable salts of the compounds according to at least one of claims 1 to 4 with inorganic or organic acids or bases.
6. Pharmaceutical compositions containing a compound according to at least one of claims 1 to 4 or a physiologically acceptable salt according to claim 5 optionally together with one or more inert carriers and/or diluents.
7. Compounds according to at least one of claims 1 to 4 or a physiologically acceptable salt according to claim 5, including the compounds disclaimed in claim 1 , for treatment or prevention of diseases or conditions which can be influenced by inhibiting the enzyme 11 β-hydroxysteroid dehydrogenase (HSD) 1 , such as metabolic disorders.
8. Use of at least one compound according to at least one of claims 1 to 4 or a physiologically acceptable salt according to claim 5, including the compounds disclaimed in claim 1 , for preparing a pharmaceutical composition which is suitable for the treatment or prevention or diseases or conditions which can be influenced by inhibiting the enzyme 11 β-hydroxysteroid dehydrogenase (HSD) 1 , such as metabolic disorders.
9. Process for preparing a compound of the general formula I according to any of claims 1 to 4 or a physiologically acceptable salt according to claim 5, characterized in that
one of the amines of general formula Il
Figure imgf000237_0001
wherein the groups A, X, m, n and o are defined as in claim 1 ,
or of general formula III
Figure imgf000238_0001
wherein B is definded as in claim 1 ,
is reacted with ε \ carbonic acid derivative Y-CO-Y yielding a compound either of general formula IV or V as intermediate
Figure imgf000238_0002
V
IV which is optionally isolated and optionally purified, and the intermediate of the formula IV or V is reacted with the other amine of the formula III or Il to yield the compound of the formula I,
wherein Y is a leaving group and in particular denotes fluorine, chlorine, bromine, cyano, Ci-4-alkoxy, C2-4-alkenyloxy, C2-4-alkynyloxy, partially or fully fluorinated C2-io-alkoxy, oxyarylotriazol, oxyheteroarylotriazol, heteroar-N-yl, 3-methyl- imidazol-1-yl, succinyl-N-oxy, di-(Ci-4-alkyl)aminocarbonyloxy, pyrrolylcarbonyloxy, pipehdinylcarbonyloxy, morpholinylcarbonyloxy, aryloxy, or heteroaryloxy,
while the alkyl, alkenyl, and alkynyl groups mentioned in the definition of the above groups, either alone or as part of another group, may be substituted with one or more substituents independently of each other selected from fluorine, chlorine, Ci-3-alkyl, and C-ι-3-alkoxy,
while the aryl groups mentioned in the definition of the above groups, either alone or as part of another group, denote phenyl or naphthyl and the heteroaryl groups mentioned in the definition of the above groups, either alone or as part of another group, denote pyridinyl, pyrimidinyl, triazinyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, whilst both the aryl and heteroaryl groups option- ally are substituted with one or more substituents independently of each other selected from fluorine, chlorine, bromine, Ci-3-alkyl, Ci-3-alkyloxy, nitro, cyano, and di-(Ci-3-alkyl)amino groups,
while the two Y in Y-CO-Y may be identical or different,
while the second Y to be replaced may also be transformed to a more reactive Y after the first Y is replaced with one of the two amines,
optionally in the presence of an organic base or another additive;
and, if necessary any protective group used in the reactions described above is cleaved concurrently or subsequently;
if desired a compound of general formula I thus obtained is resolved into its stereoisomers;
if desired a compound of general formula I thus obtained is converted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts thereof.
PCT/EP2009/000905 2008-02-12 2009-02-10 Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use WO2009100872A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AT09709660T ATE531696T1 (en) 2008-02-12 2009-02-10 UREA DERIVATIVES OF BENZOMORPHANES, CORRESPONDING SCAFFOLDS, MEDICATIONS CONTAINING SUCH COMPOUNDS AND THEIR USE
CA2711757A CA2711757C (en) 2008-02-12 2009-02-10 Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
US12/866,125 US20110028445A1 (en) 2008-02-12 2009-02-10 Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
EP09709660A EP2245014B1 (en) 2008-02-12 2009-02-10 Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
JP2010546254A JP5538239B2 (en) 2008-02-12 2009-02-10 Benzomorphane and related skeleton urea derivatives, medicaments containing such compounds and their use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08151295 2008-02-12
EP08151295.6 2008-02-12

Publications (2)

Publication Number Publication Date
WO2009100872A1 true WO2009100872A1 (en) 2009-08-20
WO2009100872A8 WO2009100872A8 (en) 2010-08-05

Family

ID=40613098

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/000905 WO2009100872A1 (en) 2008-02-12 2009-02-10 Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use

Country Status (9)

Country Link
US (1) US20110028445A1 (en)
EP (1) EP2245014B1 (en)
JP (1) JP5538239B2 (en)
AR (1) AR070526A1 (en)
AT (1) ATE531696T1 (en)
CA (1) CA2711757C (en)
CL (1) CL2009000316A1 (en)
TW (1) TW200938198A (en)
WO (1) WO2009100872A1 (en)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010046445A2 (en) * 2008-10-23 2010-04-29 Boehringer Ingelheim International Gmbh Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use
WO2011057054A1 (en) * 2009-11-06 2011-05-12 Vitae Pharmaceuticals, Inc. Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
WO2011161030A1 (en) 2010-06-21 2011-12-29 Sanofi Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators
WO2012004270A1 (en) 2010-07-05 2012-01-12 Sanofi Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament
WO2012004269A1 (en) 2010-07-05 2012-01-12 Sanofi (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals
WO2012010413A1 (en) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8637505B2 (en) 2009-02-04 2014-01-28 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8673899B2 (en) 2008-05-01 2014-03-18 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8680093B2 (en) 2009-04-30 2014-03-25 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8686149B2 (en) 2010-11-05 2014-04-01 Boehringer-Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
US8703765B2 (en) 2009-06-02 2014-04-22 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
US8735585B2 (en) 2011-08-17 2014-05-27 Boehringer Ingelheim International Gmbh Indenopyridine derivatives
US8748444B2 (en) 2007-12-11 2014-06-10 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
US8754076B2 (en) 2008-07-25 2014-06-17 Vitae Pharmaceuticals, Inc./Boehringer-Ingelheim Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8765744B2 (en) 2010-06-25 2014-07-01 Boehringer Ingelheim International Gmbh Azaspirohexanones
US8765780B2 (en) 2008-05-13 2014-07-01 Boehringer Ingelheim International Gmbh Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
US8835426B2 (en) 2007-02-26 2014-09-16 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11β-hydroxysteroid dehydrogenase 1
US8846613B2 (en) 2010-11-02 2014-09-30 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
US8846668B2 (en) 2008-07-25 2014-09-30 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8859580B2 (en) 2007-11-16 2014-10-14 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
US8883778B2 (en) 2009-07-01 2014-11-11 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
US8927539B2 (en) 2009-06-11 2015-01-06 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure
US8933072B2 (en) 2010-06-16 2015-01-13 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
US9079861B2 (en) 2007-11-07 2015-07-14 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
EP3351534A4 (en) * 2015-08-28 2019-03-13 Nippon Zoki Pharmaceutical Co., Ltd. Method for producing novel 4-benzazonine derivative
US11084807B2 (en) 2016-08-18 2021-08-10 Vidac Pharama Ltd. Piperazine derivatives, pharmaceutical compositions and methods of use thereof

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2697147A1 (en) 2007-07-26 2009-02-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
TW200934490A (en) 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
JP5490020B2 (en) * 2008-01-24 2014-05-14 ヴァイティー ファーマシューティカルズ，インコーポレイテッド Cyclic carbazate and semicarbazide inhibitors of 11β-hydroxysteroid dehydrogenase 1
WO2009102428A2 (en) * 2008-02-11 2009-08-20 Vitae Pharmaceuticals, Inc. 1,3-OXAZEPAN-2-ONE AND 1,3-DIAZEPAN-2-ONE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1
WO2009102460A2 (en) 2008-02-15 2009-08-20 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CA2718264A1 (en) * 2008-03-18 2009-09-24 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
EP2291373B1 (en) * 2008-05-01 2013-09-11 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5538365B2 (en) 2008-05-01 2014-07-02 ヴァイティー ファーマシューティカルズ，インコーポレイテッド Cyclic inhibitor of 11β-hydroxysteroid dehydrogenase 1
JP5696037B2 (en) 2008-05-01 2015-04-08 ヴァイティー ファーマシューティカルズ，インコーポレイテッド Cyclic inhibitor of 11β-hydroxysteroid dehydrogenase 1
EP2858976B1 (en) * 2012-05-11 2018-03-14 Purdue Pharma LP Benzomorphan compounds as opioid receptors modulators
WO2023225563A2 (en) * 2022-05-17 2023-11-23 Board Of Regents, The University Of Texas System Selective sigma-2 receptor ligands as modulators of tmem97

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1077711A (en) * 1963-12-20 1967-08-02 Geigy Ag J R Benzomorphans and process for their preparation
US3341538A (en) * 1965-06-18 1967-09-12 Geigy Chem Corp Certain 2, 6-methano-3-benzazocines
WO2006024628A1 (en) * 2004-08-30 2006-03-09 Janssen Pharmaceutica N.V. Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
WO2006040329A1 (en) * 2004-10-12 2006-04-20 Novo Nordisk A/S 1 ibeta- hydroxysteroid dehydrogenase type 1 active spiro compounds
WO2007051810A2 (en) * 2005-11-01 2007-05-10 Transtech Pharma Pharmaceutical use of substituted amides
WO2008000951A2 (en) * 2006-06-27 2008-01-03 Sanofi-Aventis Urea derivatives of tropane, their preparation and their therapeutic application

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3378587A (en) * 1963-03-14 1968-04-16 Du Pont 3, 3'-diaminomethyl-1, 1'-biadamantane
US3474106A (en) * 1966-11-16 1969-10-21 Hoffmann La Roche 3-lower-alkyl - 1,2,3,4,5,6 - hexahydro-6,11-di-lower-alkyl - 9-diethylaminomethyl-2,6-methano-3-benzazocin-8-ols
US3539637A (en) * 1967-04-10 1970-11-10 Geigy Chem Corp N-carbamyl and thiocarbamyl-2,3,4,5-tetrahydro - 1,4 - methano - 1h - 3-benzazepines
GB1304175A (en) * 1969-03-31 1973-01-24
CS166803B2 (en) * 1971-02-08 1976-03-29 Boehringer Sohn Ingelheim
US4043927A (en) * 1972-03-07 1977-08-23 Sun Ventures, Inc. Friction or tractive drive containing ethers of adamantanes
US3856795A (en) * 1972-04-25 1974-12-24 American Home Prod Process for preparation of secondary amines from tertiary amines
DE2229695A1 (en) * 1972-06-19 1974-01-31 Boehringer Sohn Ingelheim 2- (HETEROARYL-METHYL) -5,9 BETA-DIALKYL6,7-BENZOMORPHANES, THEIR ACID ADDITIONAL SALTS AND THE PROCESS FOR THEIR PRODUCTION
DE2338369A1 (en) * 1973-07-26 1975-02-13 Schering Ag MICROBIOLOGICAL HYDROXYLATION OF 2,6-METHANO-3-BENZAZOCINES
SU510999A3 (en) * 1973-10-27 1976-04-15 К.Х.Берингер Зон, (Фирма) Method for producing (methoxymethyl-furylmethyl) 6,7-benzomorphanes of morphinanes
US4009171A (en) * 1974-02-21 1977-02-22 Sterling Drug Inc. N-acylated-11-oxygenated-2,6-methano-3-benzazocine intermediates
GB1513961A (en) * 1975-02-25 1978-06-14 Acf Chemiefarma Nv 6,7-benzomorphans method for their preparation and intermediates
US4108857A (en) * 1975-08-18 1978-08-22 Sterling Drug Inc. Imidazolylmethyl methanobenzazocines
JPS5919542B2 (en) * 1976-06-24 1984-05-07 旭電化工業株式会社 Benzazosine derivative
US5607941A (en) * 1992-06-26 1997-03-04 Boehringer Ingelheim Kg Useful for treating neurodegenerative diseases
US5354758A (en) * 1992-12-16 1994-10-11 Japan Tobacco Inc. Benzomorphans useful as NMDA receptor antagonists
GB9517622D0 (en) * 1995-08-29 1995-11-01 Univ Edinburgh Regulation of intracellular glucocorticoid concentrations
US6145103A (en) * 1998-04-07 2000-11-07 Advanced Micro Devices, Inc. Emulator support mode for disabling and reconfiguring timeouts of a watchdog timer
CN1764458A (en) * 2003-03-26 2006-04-26 麦克公司 Bicyclic piperidine derivatives as the melanocortin-4 receptor agonist
US7700583B2 (en) * 2003-04-11 2010-04-20 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
TW200829171A (en) * 2006-11-17 2008-07-16 Nihon Nohyaku Co Ltd Haloalkyl sulfonanilide derivatives or salts thereof, herbicide using it as effective constituent and use-method thereof
CA2697147A1 (en) * 2007-07-26 2009-02-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
US8859580B2 (en) * 2007-11-16 2014-10-14 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
TW200944526A (en) * 2008-04-22 2009-11-01 Vitae Pharmaceuticals Inc Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
JP5538365B2 (en) * 2008-05-01 2014-07-02 ヴァイティー ファーマシューティカルズ，インコーポレイテッド Cyclic inhibitor of 11β-hydroxysteroid dehydrogenase 1
AR071719A1 (en) * 2008-05-13 2010-07-07 Boehringer Ingelheim Int ALICICLIC DERIVATIVES OF CARBOXILIC ACID OF BENZOMORPHANS AND RELATED STRUCTURES, MEDICINES CONTAINING THESE COMPOUNDS AND THEIR USE. OBTAINING PROCESSES
US8309597B2 (en) * 2008-07-25 2012-11-13 Boehringer Ingelheim International Gmbh 1,1′-diadamantyl carboxylic acids, medicaments containing such compounds and their use
US8609690B2 (en) * 2008-08-25 2013-12-17 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use
CA2738453C (en) * 2008-10-23 2017-07-04 Boehringer Ingelheim International Gmbh Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use
UA109255C2 (en) * 2009-04-30 2015-08-10 Берінгер Інгельхайм Інтернешнл Гмбх Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2438049B1 (en) * 2009-06-02 2014-05-14 Boehringer Ingelheim International GmbH Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
AR078887A1 (en) * 2009-11-06 2011-12-07 Boehringer Ingelheim Int ARILO AND HETEROARILCARBONILO DERIVATIVES OF HEXAHYDROINDENOPIRIDINE AND OCTAHYDROBENZOQUINOLINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US8735585B2 (en) * 2011-08-17 2014-05-27 Boehringer Ingelheim International Gmbh Indenopyridine derivatives

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1077711A (en) * 1963-12-20 1967-08-02 Geigy Ag J R Benzomorphans and process for their preparation
US3341538A (en) * 1965-06-18 1967-09-12 Geigy Chem Corp Certain 2, 6-methano-3-benzazocines
WO2006024628A1 (en) * 2004-08-30 2006-03-09 Janssen Pharmaceutica N.V. Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
WO2006040329A1 (en) * 2004-10-12 2006-04-20 Novo Nordisk A/S 1 ibeta- hydroxysteroid dehydrogenase type 1 active spiro compounds
WO2007051810A2 (en) * 2005-11-01 2007-05-10 Transtech Pharma Pharmaceutical use of substituted amides
WO2008000951A2 (en) * 2006-06-27 2008-01-03 Sanofi-Aventis Urea derivatives of tropane, their preparation and their therapeutic application

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835426B2 (en) 2007-02-26 2014-09-16 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11β-hydroxysteroid dehydrogenase 1
US9079861B2 (en) 2007-11-07 2015-07-14 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
US8859580B2 (en) 2007-11-16 2014-10-14 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
US8748444B2 (en) 2007-12-11 2014-06-10 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
US8673899B2 (en) 2008-05-01 2014-03-18 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US9073870B2 (en) 2008-05-13 2015-07-07 Boehringer Ingelheim International Gmbh Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
US8765780B2 (en) 2008-05-13 2014-07-01 Boehringer Ingelheim International Gmbh Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
US8846668B2 (en) 2008-07-25 2014-09-30 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8754076B2 (en) 2008-07-25 2014-06-17 Vitae Pharmaceuticals, Inc./Boehringer-Ingelheim Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP2012506405A (en) * 2008-10-23 2012-03-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Urea derivative of substituted nortropane, medicament containing the compound and use thereof
WO2010046445A2 (en) * 2008-10-23 2010-04-29 Boehringer Ingelheim International Gmbh Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use
US8829027B2 (en) 2008-10-23 2014-09-09 Boehringer Ingelheim International Gmbh Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use
WO2010046445A3 (en) * 2008-10-23 2010-07-01 Boehringer Ingelheim International Gmbh Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use
US8637505B2 (en) 2009-02-04 2014-01-28 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8680093B2 (en) 2009-04-30 2014-03-25 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8703765B2 (en) 2009-06-02 2014-04-22 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
US8927539B2 (en) 2009-06-11 2015-01-06 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure
US8883778B2 (en) 2009-07-01 2014-11-11 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
US9328072B2 (en) 2009-11-06 2016-05-03 Vitae Pharmaceuticals, Inc. Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
CN105037326A (en) * 2009-11-06 2015-11-11 生命医药公司 Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
CN102666491A (en) * 2009-11-06 2012-09-12 生命医药公司 Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
EA022323B1 (en) * 2009-11-06 2015-12-30 Вайтаи Фармасьютиклз, Инк. Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
US9663470B2 (en) 2009-11-06 2017-05-30 Vitae Pharmaceuticals, Inc. Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
CN102666491B (en) * 2009-11-06 2015-06-24 生命医药公司 Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
US20110136800A1 (en) * 2009-11-06 2011-06-09 Boehringer Ingelheim International GmbH Vitae Pharmaceuticals Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
WO2011057054A1 (en) * 2009-11-06 2011-05-12 Vitae Pharmaceuticals, Inc. Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
US8497281B2 (en) 2009-11-06 2013-07-30 Vitae Pharmaceuticals, Inc. Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
US8933072B2 (en) 2010-06-16 2015-01-13 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
US9090605B2 (en) 2010-06-16 2015-07-28 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
WO2011161030A1 (en) 2010-06-21 2011-12-29 Sanofi Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators
US8765744B2 (en) 2010-06-25 2014-07-01 Boehringer Ingelheim International Gmbh Azaspirohexanones
WO2012010413A1 (en) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament
WO2012004270A1 (en) 2010-07-05 2012-01-12 Sanofi Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament
WO2012004269A1 (en) 2010-07-05 2012-01-12 Sanofi (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals
US8846613B2 (en) 2010-11-02 2014-09-30 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
US8686149B2 (en) 2010-11-05 2014-04-01 Boehringer-Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
US9120769B2 (en) 2010-11-05 2015-09-01 Boehringer-Ingelheim International Gmbh Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
US8975405B2 (en) 2011-08-17 2015-03-10 Boehringer Ingelheim International Gmbh Indenopyridine derivatives
US8735585B2 (en) 2011-08-17 2014-05-27 Boehringer Ingelheim International Gmbh Indenopyridine derivatives
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP3351534A4 (en) * 2015-08-28 2019-03-13 Nippon Zoki Pharmaceutical Co., Ltd. Method for producing novel 4-benzazonine derivative
US10703725B2 (en) 2015-08-28 2020-07-07 Nippon Zoki Pharmaceutical Co., Ltd. Process for producing novel 4-benzoazonine derivatives
US11084807B2 (en) 2016-08-18 2021-08-10 Vidac Pharama Ltd. Piperazine derivatives, pharmaceutical compositions and methods of use thereof

Also Published As

Publication number Publication date
JP2011511817A (en) 2011-04-14
US20110028445A1 (en) 2011-02-03
WO2009100872A8 (en) 2010-08-05
ATE531696T1 (en) 2011-11-15
AR070526A1 (en) 2010-04-14
CA2711757A1 (en) 2009-08-20
JP5538239B2 (en) 2014-07-02
EP2245014B1 (en) 2011-11-02
EP2245014A1 (en) 2010-11-03
TW200938198A (en) 2009-09-16
CL2009000316A1 (en) 2010-04-09
CA2711757C (en) 2016-07-26

Similar Documents

Publication Publication Date Title
EP2245014B1 (en) Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
EP2220048B1 (en) Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
EP2288596B1 (en) Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
US8829027B2 (en) Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use
EP2318403B1 (en) Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use
EP2496559A1 (en) Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
US8686149B2 (en) Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
OA16619A (en) Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydro benzoquinoline.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09709660

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009709660

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2711757

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010546254

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12866125

Country of ref document: US